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Sickle cell anaemia (SCA) is a haemolytic anaemia that reduces life expectancy and places a 
great burden on healthcare systems worldwide. Despite being a monogenic disorder, the 
phenotypic severity varies greatly between patients, ranging from patients that experience 
multiple strokes and organ failure during childhood, to those that live largely unaffected lives. 
Some genetic variants that affect globin gene expression are known to influence phenotype 
severity, but most of this variation remains unaccounted for.    
We conducted whole exome sequencing analyses, comparing SCA patients with mild and 
severe clinical phenotypes, with the aim of identifying novel genetic modifiers of the disease. 
SCA patient exomes were sequenced from a cohort at King’s College Hospital, and combined 
with publicly available SCA exomes recruited in the United States. Nine candidate variants were 
identified in genes with plausible mechanisms to influence the pathophysiology of the disease. 
The genes identified in this study affected nitric oxide signalling, haematopoietic regulation, 
globin gene expression and recovery from ischaemic injury. 
In order to evaluate these variants, a CRISPR genomic editing pipeline was established and 
tested on two previously identified candidate modifiers of SCA, in the genes ASH1L and KLF1. 
These variants were successfully introduced into erythroleukaemic cells and provide a pathway 
for testing the novel modifier genes identified in the exome sequencing analysis. Preliminary 
studies indicate that both ASH1L and KLF1 variants alter globin gene expression. 
In addition to genetic factors, we also hypothesised that epigenetic factors affect the SCA 
phenotype, and play a role in the therapeutic mechanism of hydroxyurea treatment. We 
optimised a method for isolating CD45+CD71+GPA- nucleated erythroid progenitors from small 
volumes of SCA peripheral blood. This was undertaken to evaluate the role of the epigenome in 
SCA phenotype severity and drug action, but for which patient sample collection proved too 
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Figure 1.9: Figure from Mali et al. (2013)324. CRISPR Cas9 Type II System, showing the two 
distinct phases of bacterial ‘immune response’ and acquisition of resistance against invading 
viral DNA. Phase 1: Cas proteins (and Csn2) bind and recognise foreign DNA and cleave it into 
short 30bp ‘spacers’, and integrates these spacers into the host genome, at the 5’ end of the 
CRISPR array, separated by 36bp repeats. Phase 2: the CRISPR array is transcribed in full, 
and tracrRNA recognises and binds to the repeat regions, directing RNase III cleavage of the 
crRNA into sgRNA. tracrRNA-sgRNA complex recognise and bind to homologous sequence on 
foreign DNA. Cas9 is recruited by tracrRNA secondary structure, and cleaves the target DNA. 73 
Figure 1.10: Overview of the two main DSB repair pathways in humans. NHEJ – Non 
Homologous End Joining. HR – Homology Directed Repair. NHEJ involves the identification of 
DSB ends by Ku70/80, followed by non-specific end processing and ligation by Ligase IV. HDR 
pathway uses homologous sequence as a repair template to correct the damaged sequence. 
Image from Lans et al. (2012)336. ............................................................................................. 77 
Figure 2.1: Plasmid map of the 9kb pD1301 Cas9 plasmid provided by Horizon Discovery 
Group. Key features are highlighted: Cas9 is shown in red, self-cleaving GFP tag in green, 
kanamycin resistance gene in yellow, and gRNA target sequence and scaffold shown in blue. 87 
Figure 2.2: Diagram showing the cloning workflow to generate plasmids for introduction of 
specific genetic variants using the CRISPR-Cas9 system. Template sequence is indicated in 
purple, gRNA in blue, PAM site disruption in red, and SNP in yellow. ...................................... 89 
Figure 2.3: Diagrams of PCR amplicons used to clone K562 genomic DNA into CRISPR-Cas9 
plasmids to act as a template for Homology Directed Repair (HDR). Images are adapted from 
UCSC Genome Browser (http://genome.ucsc.edu - Assembly GRCh37/hg19380). A – 718bp 
amplicon from KLF1. B – 759bp amplicon from ASH1L. PCR amplicons are shown below the 
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genomic sequence, with BssHII restriction site tags at 5’ of primer in purple. In the genomic 
DNA sequence the targeted SNPs are indicated by red lines, with methionine residues and start 
codons indicated in green. gRNA target sequences are highlighted in blue. Also shown are 
single stranded oligodeoxynucleotides (ssODN), which were designed as an alternative 
technique to introduce the template sequence. In the ssODNs the SNP is shown in red, and the 
PAM site disruption in green. Full gene maps are shown in Appendix 1. .................................. 91 
Figure 3.1: Growth curves showing the progress of erythroid cultures from healthy blood 
PBMCs. A – Growth as total number of cells. B – Growth as a percentage of the starting cell 
number at P1D0. The black line at Day 6 indicates the transition from Phase 1 to Phase 2, and 
can be considered as both P1D6 & P2D0. Of the four cultures, only Culture 4 successfully 
recovered and expanded after switching to phase 2. Cultures 1-3 continued to experience large 
amounts of cell death, until being terminated early with only 1-2 million cells remaining, less 
than 10% of the starting culture. ............................................................................................ 104 
Figure 3.2: Flow Cytometry data from healthy PBMCs directly after isolation, compared to at 
P2D9 of a successful culture. Samples are from two separate healthy donors. A – Percentage 
of cells positive for each of the four cell surface markers: CD71, GPA, CD45 & cKit. CD71 & cKit 
are greatly enriched in the P2D9 cells compared to the PBMCs, increasing to 99.2% & 89.4% 
respectively. CD45+ cells are reduced to 26.6% in the cultured sample, making up 98.3% of the 
PBMCs.  B – CD71 & CD45 plots. CD45 & CD71 are co-expressed be some cell populations in 
both samples, although the majority of cells express either CD71 or CD45. C – GPA & CD45 
plots. There is no overlap in expression of GPA & CD45 in either sample, as is expected given 
the specificity of GPA as a late stage erythroid marker. D – CD71 & GPA plots. Two distinct but 
faint GPA+ populations are present in the PBMC sample; CD71+ and CD71-. Loss of CD71 
expression marks the transition to a later stage of erythroid progenitor development. In the 
cultured sample, only the CD71+ population is observed. E – Effect of FACS filtering gates on 
CD71 & GPA plot of P2D9 cultured cells. Red, blue & magenta represent CD45+, c-Kit+ and 
CD45-c-Kit- cells respectively. The position of the CD45-c-Kit- population shows that the culture 
is differentiating, as the CD71+ cells start to express GPA. .................................................... 106 
Figure 3.3: Photographs of cytospins showing in vitro culture of a healthy donor PBMC sample. 
Slides were stained with eosin & methylene blue. All photographs were taken at 40x 
magnification. The scale bar shown in P1D3 represents 50μm, and is the same for all 
photographs. A – Pro-erythroblasts, tightly packaged cells with no visible cytoplasm. B – Early 
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basophilic erythroblasts, larger than pro-erythroblasts, cytoplasm can be seen to be expanding 
away from the nucleus. C – Late basophilic erythroblasts, much more of the cytoplasm is visible 
compared to early basophilic cells. D – White blood cell populations, distinguishable from 
erythroid progenitors by lack of staining around the cell membrane. E – Macrophage cell. F – 
Polychromatic erythroblasts, nucleus stains lighter, and cytoplasm appears larger, with more 
white space. G – Orthochromatic erythroblasts, nucleus is more condensed, and cytoplasm is 
smaller, as cells prepare for enucleation. An early wave of basophilic erythroblasts can be seen 
to appear at P2D2, and is lost by P2D4. Subsequently the proerythroblast population that 
persists at this stage starts differentiating and progresses through the erythroid developmental 
stages until the orthochromatic stage at P2D10. .................................................................... 108 
Figure 3.4: Growth curves showing the progress of erythroid cultures from SCA HbSS blood 
PBMCs. A – Growth as total number of cells. B – Growth as a percentage of the starting cell 
number at P1D0. The black line at Day 6 indicates the transition from Phase 1 to Phase 2, and 
can be considered as both P1D6 & P2D0. Only Patient Culture 3 successfully recovered after 
entering Phase 2, and this recovery was delayed, with growth not occurring until P2D4. Patient 
Culture 2 expanded early during Phase 1, dropping to 77% of the starting culture at P1D1, 
before steadily recovering to 91% at P1D3, and then dropping to 39% by P1D4. Note that 
Patient Culture 1 was divided and cultured as three separate sub-cultures, under the same 
conditions. ............................................................................................................................ 109 
Figure 3.5: Growth curves showing the variability of erythroid cultures from SCA HbSS blood 
PBMCs. Patient Culture 1 from Figure 3.4 was divided into three sub-cultures at P1D0, and 
cultured concurrently in triplicate. A – Growth as a percentage of the starting cell number at 
P1D0. B – Mean of the growth curves shown in A, with error bars representing standard error. C 
– Mean of the growth curves shown in Figure 3.4.  The black line at Day 6 indicates the 
transition from Phase 1 to Phase 2, and can be considered as both P1D6 & P2D0. The variation 
observed in the growth of the sub-cultures is very low, and much greater variation is observed 
between the cultures from different patients, cultured at different times. ................................ 110 
Figure 3.6: Photographs taken of PBMC layers, visible after density separation with 
Histopaque® - 1077. A – Comparison of HbSS & Healthy blood samples, arrows indicate PBMC 
layer. In HbSS patient blood samples, this layer appears red. B – Three additional HbSS 
samples. Variation in the thickness and the intensity of this red layer varies between patients.
 ............................................................................................................................................. 111 
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Figure 3.7: Comparison of PBMCs from an HbSC patient and an HbSS patient. A – Photograph 
of PBMC layers after density separation. The PBMC layer from the less severe HbSC patient 
does not have the red layer that is observed in HbSS patients, and is indistinguishable from a 
healthy PBMC layer (Figure 3.6).  B – Flow Cytometry plots showing CD71 & GPA expression 
of the PBMC samples shown in A. The CD71+GPA+ cell population is present in both samples, 
but is more abundant in the HbSS PBMCs, making up 25.0% of cells, as opposed to 1.2% in 
HbSC. Both samples also have a high proportion of later stage CD71-GPA+ cells, 24.1% and 
20.0% for HbSS & HbSC respectively. .................................................................................. 112 
Figure 3.8: Flow cytometry analysis of three HbSS PBMC samples after <24 hours in culture. A 
– Numbers of CD71+GPA+ & CD71-GPA+ cells as a percentage of total PBMC layer, compared 
to a healthy PBMC sample. Levels of both populations vary between SCA patients, but are 
much higher than in the healthy blood sample. B – Flow cytometry plots of CD71 and GPA, after 
removal of CD45 and c-Kit, demonstrating the FACS gating used to collect each cell population. 
Magenta, maroon and blue represent CD45-CD14-, CD71+GPA+ & CD71-GPA+ cells 
respectively. .......................................................................................................................... 113 
Figure 3.9: Flow Cytometry data from CD71 BeadKit enrichment of three HbSS patient PBMCs. 
Both the CD71+ fraction (orange) and the CD71- fraction (grey) were analysed. A – CD71 
staining. CD71 is successfully enriched in the CD71+ fraction with a purity of 88.0 – 99.3%. B – 
CD45 staining. The CD45+ cells that make up the majority of PBMCs are successfully reduced 
in the CD71+ fraction, to <4% in HbSS 1 & 2, but only to 34.3% in HbSS 3. C – GPA staining.  
Similarly to CD71, GPA is successfully enriched in the CD71+ fraction, to >96% in HbSS 1 & 2, 
but only 65.3% in HbSS 3. .................................................................................................... 116 
Figure 3.10: Flow cytometry data from CD71 enrichment of nine HbSS patient PBMCs, following 
CD45 depletion. A – Flow diagram illustrating the process of isolating the different cell fractions. 
The CD71+ fraction (orange), the CD71- fraction (grey) and the CD45+ fraction (blue) were 
analysed. Sample HbSS 9 was from a patient undergoing HU therapy. Percentage of cells 
stained in each fraction is shown for B – CD45, C – CD71 and D – GPA. Processing of sample 
HbSS 7 appears to have failed, with the CD71+ fraction containing only 31.6% CD71+, 74.0% 
CD45+ & 13.8% GPA+ cells. Apart from HbSS 7, significant CD71 enrichment is observed in the 
CD71+ fraction for all samples, to between 80 – 99% purity. CD45 staining shows very low 
levels of CD45+ cells in the CD71+ fraction, of between 0.1 – 9.4% (excluding HbSS 7). GPA 
staining confirms that the cells isolated in the CD71+ and CD71- fractions are the CD71+GPA+ 
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and CD71-GPA+ cell populations respectively. E – Total cell counts of the CD71+ fraction from 
each sample, as estimated by haemocytometer counting. The total number of CD71+GPA+ cells 
isolated varied significantly between samples. ....................................................................... 118 
Figure 3.11: Photographs of cytospins taken from the three fractions of an HbSS patient blood 
sample isolated by Miltenyi BeadKit (CD45+, CD71- & CD71+). Slides were stained with eosin & 
methylene blue. Photographs were taken at 40x magnification, and scale bars represent 50μm. 
A – Red blood cell contamination in the CD45+ fraction. B – Nucleated CD45+ cells, nucleus 
stains as dark purple. C & D – Light purple staining indicates cytoplasm, but these cells are 
lacking a nucleus. E – Enucleated red cells. F – Sickling red cells. The CD45+ fraction mostly 
consists of nucleated PBMCs, with some red cell contamination. The CD71- fraction is densely 
packed with erythrocytes. The CD71+ fraction consists mostly of enucleated reticulocytes, 
staining slightly darker than in the other fractions. CD71+ & CD71- also contain larger 
enucleated cells, possibly post enucleation but prior to the reduction in volume that 
accompanies reticulocyte maturation401. ................................................................................ 121 
Figure 3.12: Flow Cytometry data from both fractions of an HbSS patient blood sample as 
isolated by BeadKit (CD34- & CD34+). A – Percentage of cells positive for each of the three cell 
surface markers: CD34, CD45 & GPA, as well as co-expression of each pair. CD34+ enrichment 
was successful with 97.8% purity in the CD34+ fraction, compared to 27.4% in the CD34- 
fraction. B – Composition of CD34+ population from both fractions. C – Graphs showing co-
expression of the cell surface markers. Pink indicates CD34+CD45+ cells, as defined by gate 
Q2. Results indicate two distinct cell populations within the CD34+ cells, with roughly 99% 
expressing either GPA or CD45, but <1% expressing both. ................................................... 123 
Figure 3.13: Photographs of cytospins taken from both fractions of an HbSS patient blood 
sample as isolated by BeadKit (CD34- & CD34+). Slides were stained with eosin & methylene 
blue. Photographs were taken at 40x magnification, and scale bars represent 50μm. A – Red 
blood cell contamination in the CD34- fraction. B – Nucleated CD34+ cells. As expected the 
CD34- fraction contains the majority of the PBMC sample. The CD34+ fraction is less densely 
packed, and contains some debris and dead cells, as well as some cells lacking a nucleus. 
Nucleated CD34+ cells are also visible. ................................................................................. 124 
Figure 3.14: Flow cytometry analyses of the three fractions (GPA+, GPA-CD71- & GPA-CD71+) 
isolated from three HBSS patient samples by GPA depletion and subsequent CD71 enrichment. 
Sample 2 was receiving HU treatment. A – Mean percentage of cells positive for GPA, CD45 & 
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CD71. Error bars represent standard error. GPA+ cells were successfully depleted, making up 
89.0% of the GPA+ fraction and 0.4% and 1.7% of the GPA- fractions. CD71+ cells were high in 
both the CD71- and CD71+ fractions, although higher in the enriched fraction, at 84.9%. B, C & 
D show individual expression as well as co-expression of markers for cells in each of the three 
fractions: B – GPA+. C – GPA-CD71-. D – GPA-CD71+. CD45+ cells made almost all of the 
GPA- fractions, and as was observed previously, very little co-expression of GPA and CD45 
was observed. CD71+ cells made up 84.9% of the GPA-CD71+ fraction, with 83.5% co-
expressing CD45. ................................................................................................................. 127 
Figure 3.15: Analysis of samples after depletion of GPA+ cells and enrichment for CD71+ cells. 
A – Flow cytometry plots for CD71 and CD45, comparing the GPA-CD71- and GPA-CD71+ 
fractions for all three samples tested. Intensity of CD71 is higher for some cells in the fraction 
enriched for CD71. Two distinct CD45+CD71+ populations are visible, distinguishable by high or 
low CD45 expression. B – Table summarising the DNA extracted from the GPA-CD71+ 
fractions of the three samples. Q-Micro – Qiagen QiaAMP DNA Micro Kit. Very low cell numbers 
were isolated, but total DNA yield is in the region of 400ng for all three samples, just below the 
500ng recommended for DNA methylation analysis395. .......................................................... 128 
Figure 4.1: Flow diagram outlining the three different analyses performed in this chapter in order 
to identify candidate genetic modifiers of SCA. Analysis 1 is presented in 4.3 and 4.4, with a 
detailed description of the various filtering steps provided in 4.3.1. Analysis 2 is presented in 
4.5.2, and Analysis 3 in 4.5.3. ............................................................................................... 133 
Figure 4.2: Summary of 649 SCA exomes downloaded from dbGaP (phs000691.v2.p1). 
Samples were checked for the SCA mutation (rs334), 10 were found to be heterozygous, and 1 
found to be homozygous for the wild type, these samples were excluded from further analyses. 
The majority of patients (411) were recruited from one of the three clinical trials – HUSTLE, 
SWiTCH or TWiTCH. ............................................................................................................ 138 
Figure 4.3: Summary of all 2,798,560 variants present in the mild group of patients, grouped by 
type of variant. Intergenic variants include those annotated as upstream or downstream. Coding 
variants also include those annotated as splicing variants. UTR – Untranslated Region. 93% of 
all annotated variants are either intergenic or intronic. ........................................................... 142 
Figure 4.4: Candidate variant filtering pipeline, describing the process of filtering the 2,798,560 
variants observed in the mild SCA patient group down to 11,419 for the gene burden analysis, 
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and 3,159 for the individual variant analysis. The full list of 11,419 variants is provided in 
Appendix 12. ......................................................................................................................... 143 
Figure 4.5: Summary of the 137,825 variants present in the mild group after filtering of 
intergenic and non-coding variants (other than splicing and ncRNA). ..................................... 144 
Figure 4.6: Summary of the candidate variants in the mild group after filtering for variants 
observed in the severe groups. A – Summary of the 26,810 variants after filtering by severe 
patients from KCH and SWiTCH clinical trial (KS). B – Summary of the 21,189 variants after 
filtering by severe patients from KCH, SWiTCH and TWiTCH clinical trials (KST). C – Change in 
proportion of variants for each variant type in A and B compared to before filtering for variants in 
the severe group (shown in Figure 4.5). ................................................................................ 146 
Figure 4.7: Summary of the trimming of the ncRNA dataset to include only variants in ncRNA 
covered by both the Agilent SureSelect and Roche NimbleGen exome capture kits. A – 
Summary of the number of ncRNA with annotated variants in each of the exome capture 
groups. Variants in the 336 ncRNA only present in the SureSelect group were excluded, and 
only variants in the 4988 that are shared were included in downstream analyses. B – Number of 
ncRNA variants before and after filtering for each of the candidate variant groups. ................ 147 
Figure 4.8: Filtering of splicing variants outside of the canonical 2bp splice site, for both the 
KCH and SWiTCH, and KCH, SWiTCH and TWiTCH filtered candidate variants. Approximately 
95% of splicing variants were removed by selecting for 20% of the splice site sequence. ...... 148 
Figure 4.9: Summary of the candidate variants after filtering for variants observed in the 
commonly mutated genes list. A – Summary of the 17,286 variants in the KCH and SWiTCH 
filtered group. B – Summary of the 14,346 variants in the KCH, SWiTCH and TWiTCH group. C 
– Number of each variant type removed by filtering out Commonly Mutated Genes for both the 
KCH & SWiTCH (KS), and the KCH, SWiTCH & TWiTCH (KST) filtered groups. ................... 150 
Figure 4.10: Summary of the candidate variants after filtering for variants observed in the 
haematopoietically silent genes list. A – Summary of the 15,199 variants in the KCH and 
SWiTCH filtered group. B – Summary of the 12,680 variants in the KCH, SWiTCH and TWiTCH 
group. C – Number of each variant type removed by filtering out haematopoietically silent genes 
for both the KCH & SWiTCH (KS), and the KCH, SWiTCH & TWiTCH (KST) filtered groups. . 152 
Figure 4.11: Summary of the candidate variants after exclusion of variants that occur only once, 
and in a gene that is not mutated in any other mild patient. A – Summary of the 11,419 variants 
in the KCH and SWiTCH (KS) filtered group. B – Summary of the 9,271 variants in the KCH, 
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SWiTCH and TWiTCH group (KST). C – Comparison of each variant type for the KS and KST 
filtered groups. ...................................................................................................................... 155 
Figure 4.12: Summary of the 3,159 and 2,597 candidate variants in the final lists for the KCH & 
SWiTCH (KS) and KCH, SWiTCH & TWiTCH (KST) filtered groups respectively. Loss of 
function variants (Splicing, Frameshift, Stopgain or Stoploss) were narrowed down to 24 and 18 
variants in the KS and KST lists. ........................................................................................... 156 
Figure 5.1: Figure showing the full length of the KLF1 gene as viewed in the UCSC Genome 
Browser (http://genome.ucsc.edu - Assembly GRCh37/hg19380). Transcription occurs on the 
negative strand, and the red line indicates the position of the KLF1 SNP (rs10407416) in intron 
1. The tracks below show ChIP-Seq signals for KDM5B, as well as two ZBTB7A replicates in 
K562 cells. It can be seen that there is a strong signal for KDM5B along the length of the gene, 
but that the signal for ZBTB7A is weak. This data was produced as part of the ENCODE 
Project474, and the tracks for KDM5B, and ZBTB7A have UCSC accession numbers 
wgEncodeEH002085 & wgEncodeEH001620, respectively. .................................................. 190 
Figure 5.2: Cas9 plasmid transfections in K562 cells. A – Percentage of cells GFP+ 48 hours 
after Lipofectamine transfection with different amounts of plasmid. Transfection rate increased 
with increasing concentrations of plasmid, but was very inefficient, reaching only 2% of live 
cells. B – Percentage of cells GFP+ 48 hours after transfection using the three different 
techniques. Due to differing restrictions on transfection reaction volume for each technique, 
different plasmid amounts were used: Lipofectamine - 6μg, Calcium Phosphate - 12μg and 
Nucleofection - 3μg. Nucleofection was by far the most successful, despite using the least 
amount of plasmid. Error bars indicate standard error, for each of the Lipofectamine 
transfections and the Nucleofection n = 3, for Calcium Phosphate n = 4. ............................... 194 
Figure 5.3: Summary of clonal expansions from 12 nucleofection reactions. 4 where only the 
Cas9-gRNA-Template plasmids were transfected, 6 with the plasmids and siRNA for 
knockdown of the NHEJ pathway, and 2 with the plasmids and additional ssODN templates. A – 
Summary of the 1,920 single cell cultures plated, of which only 190 survived. B – Percentage 
survival for each of the three nucleofection conditions. Survival was low for all experiments, but 
interestingly was lowest when transfected with the plasmid only. Error bars indicate Standard 
Error. .................................................................................................................................... 195 
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Figure 5.4: Summary of genetic analyses of K562 cell lines after transfection with CRISPR-Cas9 
Template containing plasmids only, after subsequent FACS and clonal expansion. A – 
Summarises the results for all plasmids. B – Shows the results for each plasmid individually. 
Plasmids used were for KLF1 gRNA 2, SNP and PAM only control (KS2 & KP2 respectively), 
and ASH1L gRNA 1, SNP and PAM only control (AS1 & AP1 respectively). Total refers to the 
number of cell lines that survived the single cell sorting stage. Cut refers to cell lines where any 
genetic changes have occurred, SNP refers to cell lines where the template mutations have 
been introduced on any allele, Hom Cut or SNP refers to cell lines defined as Cut or SNP that 
are homozygous. The results show that the gRNA-Cas9 plasmids cut with high efficiency, but 
introduction of the template is much less successful. Only one cell line was homozygous for a 
genetic variant, and none were homozygous for the SNPs of interest. ................................... 197 
Figure 5.5: rtPCR analysis of NHEJ knockdown by siRNA in K562 cells, normalised firstly to β-
actin expression, and then to the untransfected control. rtPCR analysis was performed on RNA 
extracted 48 hours after transfection with either scrambled siRNA or targeted siRNA. A – 
Knockdown using siRNA for XRCC6. B – Knockdown using siRNA for Ligase IV. Results show 
reduced expression for both XRCC6 and Ligase IV, 11.6% and 60.2% of untransfected K562 
expression respectively. Expression appears to have increased in the scrambled controls, 
although large variation was observed. Two sets of PCR primer pairs were used for each gene 
targeted, XRCC6-1 & 2 and Lig4-1 & 2, and results are consistent between each pair. Error bars 
indicate 95% confidence intervals, calculated from three biological replicates, each with two 
technical replicates. Knockdown of XRCC6 was statistically significant compared to scrambled, 
whereas Ligase IV was not, likely due to the variation observed between the samples 
transfected with scrambled siRNA. ........................................................................................ 198 
Figure 5.6: Summary of genetic analyses of K562 cell lines after transfection with CRISPR-Cas9 
Template containing plasmids and siRNA, after subsequent FACS and clonal expansion. Total 
refers to the number of cell lines that survived the single cell sorting stage. Cut refers to cell 
lines where any genetic changes have occurred, SNP refers to cell lines where the template 
mutations have been introduced on any allele, Hom Cut or SNP refers to cell lines defined as 
Cut or SNP that are homozygous. A – Summary of the cell lines transfected with each siRNA 
set: Scrambled, Ligase IV or XRCC6, as well as the cumulative counts for all three. B & C – 
Summary of the cell lines transfected with either KS2 or AS1 plasmids, B shows total counts, C 
shows percentage of total. Results show that co-transfection with siRNA for one of the target 
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genes does not appear to affect Cas9 cutting activity, which is consistent between the three 
groups. No homozygous variants were observed after transfection with scrambled siRNA, 
whereas three were observed with siRNA targeting Ligase IV, and one for XRCC6. Overall 
survival of cell lines past the single cell FACS stage is much higher for the KS2 plasmid than for 
AS1. One of the AS1 cell lines (KAX9) was found to be homozygous for the desired SNP. .... 200 
Figure 5.7: Summary of genetic analyses of K562 cell lines after transfection with CRISPR-Cas9 
Template containing plasmids and ssODN templates for KS2 or KP2 (ssKS2 or ssKP2), after 
subsequent FACS and clonal expansion. Total refers to the number of cell lines that survived 
the single cell sorting stage. Cut refers to cell lines where any sequence changes have 
occurred, SNP refers to cell lines where the template mutations have been introduced on any 
allele, Hom Cut or Hom SNP refers to cell lines defined as Cut or SNP that are homozygous. A 
– Total cell line counts. B – Percentage of total. Cleavage was observed in all cell lines, and 
SNP uptake was high. Number of homozygous cell lines remained low, however two ssKS2 cell 
lines were homozygous for the SNP of interest (ssKS2-10 & ssKS2-29). ............................... 202 
Figure 5.8: Sequence of the ASH1L SNP site of the K562 cell line that was homozygous for 
PAM disruption mutation and the SNP. K562 shows the wild type untransfected sequence. The 
green box/arrow shows the site of the C to T PAM disruption mutation. The red box/arrow 
shows the site of the A to G SNP of interest. A – MUSCLE alignment of the two sequences, with 
coding sequence displayed (antisense). The two SNPs can clearly be seen in the KAX9 
sequence, and it can be seen that the SNP results in an arginine to Glycine substitution, while 
the PAM disruption does not affect the coding sequence. One other polymorphism was 
identified, but by investigating the sequence traces was confirmed to be an artefact of the base 
calling algorithm. B & C – Forward and Reverse sequence traces respectively. Due to the 
presence of large Sanger sequencing artefacts, that persisted despite repeated sequencing, 
both forward and reverse sequence traces are shown, to confirm that the both the PAM 
disruption and SNP are present............................................................................................. 204 
Figure 5.9: rtPCR analyses of wt K562 and KAX9 cell lines. Graphs show relative expression of 
genes normalised to actin β, for A – β-globin (HBB), B – γ-globin (HBG), C – α-globin (HBA) and 
D – KLF1. Error bars indicate 95% confidence intervals, calculated from three technical 
replicates for each of the two cell lines. Expression of the globin genes is significantly increased 
in KAX9 compared to K562, and KLF1 expression is unchanged. .......................................... 206 
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Figure 5.10: rtPCR analyses of wt K562 and KAX9 cell lines, normalised to either α-globin or β-
globin expression. A – β-globin normalised to α-globin, B – γ-globin normalised to α-globin, C – 
γ-globin normalised to β-globin. Error bars indicate 95% confidence intervals, calculated from 
three technical replicates for each of the two cell lines. Results indicate that relative to α-globin, 
β-globin increased and γ-globin decreased in KAX9 compared to wt K562. The ratio of γ-globin 
to β-globin transcripts also decreased in KAX9 cells. ............................................................. 208 
Figure 5.11: Sanger sequencing trances of the KLF1 SNP site of K562 cell lines that 
incorporated the template sequence on at least one allele, and had no indel mutations on either 
allele. K562 shows the wild type untransfected sequence. ssKS2-10 and ssKS2-29 were 
homozygous for both the C to G PAM disruption (green box) and the C to G SNP of interest (red 
box). ssKS2-47 was heterozygous for both the PAM disruption and the KLF1 SNP. .............. 209 
Figure 5.12: Sanger sequencing trances of the KLF1 SNP site of three K562 cell lines that 
contained heterozygous indel mutations. K562 shows the wild type untransfected sequence. 
The green box shows the site of the C to G PAM disruption mutation. The red box shows the 
site of the C to G SNP of interest. Indel mutations prevent clear reading of the sequence from 
Sanger sequencing traces, since the two alleles are out of frame of each other. Therefore to 
fully characterise the genotypes of these cell lines, PCR amplicons were cloned and sequenced 
individually. (1) and (2) refer to two separate alleles for each cell line. ssKS2-3 and ssKS2-4 are 
both heterozygous for a dinucleotide insertion, and ssKS2-3 has the PAM disruption and SNP of 
interest on the other allele. ssKS2-45 is heterozygous for a 1bp deletion, and has the PAM 
disruption and SNP of interest on the other allele. ................................................................. 210 
Figure 5.13: Sequences of the KLF1 SNP site of three K562 cell lines that contained 
homozygous indel mutations. K562 shows the wild type untransfected sequence. The green 
box/arrow shows the site of the C to G PAM disruption mutation. The red box/arrow shows the 
site of the C to G SNP of interest. A – MUSCLE alignment of the 4 sequences. B – Sanger 
sequencing traces. KKL8 was homozygous for a 5bp deletion removing the SNP site. KKL11 
was homozygous for a 2bp insertion 2bp downstream of the SNP site. KKL17 was homozygous 
for a 41bp deletion covering the PAM site and the SNP. ........................................................ 211 
Figure 5.14: Sanger sequencing trances of the KLF1 SNP site of two candidate PAM disruption 
only controls. K562 shows the wild type untransfected sequence. The green box shows the site 
of the C to G PAM disruption mutation. Indel mutations prevent clear reading of the sequence 
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1.1 General Introduction 
This work aimed to investigate factors that affect the severity of the clinical phenotype 
presented by sickle cell anaemia (SCA) patients. Despite being well characterised as a 
monogenic disorder, the severity of symptoms, as well as the response to current treatments, 
varies greatly between SCA patients. 
 
This aim was investigated through three distinct research objectives: 
 
1. To optimise a non-invasive technique to isolate nucleated erythroid progenitors from the 
peripheral blood of SCA patients. There is a growing body of evidence to support the 
role of epigenetic factors in the pathology of SCA, both in terms of naturally occurring 
variation and in response to drug treatment. Due to the nature of erythrocytes and their 
lack of a nucleus, it is notoriously difficult to investigate epigenetic regulation in these 
cells in vivo, and most existing studies either focus on transcriptomic analyses of 
enucleated cells, or use in vitro treatment models. We set out to develop a protocol to 
allow investigation of both the epigenome & transcriptome of a nucleated erythrocyte 
progenitor population in a longitudinal manner (i.e. detecting changes in response to 
drug treatment in vivo). 
 
2. To conduct a whole exome sequencing (WES) study, comparing sequencing data from 
SCA patients with severe and mild clinical phenotypes. At one end of the phenotypic 
spectrum, some patients experience very few symptoms and live largely unaffected 
lives, while at the other end of the spectrum, some patients experience multiple strokes 
and organ damage at young age, and are frequently hospitalised. It has been shown 
that sequence variation in some genes (genetic modifiers) heavily influence the 
pathophysiology of the disease, and are known to affect symptomatic severity. 
However, much of this variation remains unaccounted for. We proposed to conduct a 
WES study investigating the extreme ends of the phenotypic spectrum, in order to 
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identify novel genetic modifiers that may be influencing the severity of symptoms in 
these patients. 
 
3. To use CRISPR genomic editing to replicate two previously identified candidate modifier 
SNPs in vitro. The aim of this work was to perform preliminary functional analyses to 
inform on the effect these SNPs have on gene function, as well as to set up a CRISPR 
genomic editing pipeline in our laboratory, to allow functional analyses of candidate 











1.2 Haemoglobin & SCA 
1.2.1 Healthy Haemoglobin 
Haemoglobin is a tetrameric protein expressed at high levels in erythrocytes, with the ability to 
bind oxygen molecules (O2) under conditions of high O2 concentration, and release them under 
conditions of low O2 concentration, allowing it to efficiently distribute O2 to tissues that need it. 
The affinity of haemoglobin for O2 binding is allosterically regulated by multiple small molecules, 
including 2,3-bisphosphoglycerate (BPG), Cl- and H+, allowing for tight regulation over the O2 
distribution process1–5. This is additionally regulated throughout development by the use of 
various isoforms of haemoglobin, controlled through the expression of different subunits. Since 
in the foetus O2 must be sourced from the mother’s blood through the placenta, where O2 
availability is much lower than in the lungs, a higher affinity for O2 binding is required for 
foetal/embryonic haemoglobin. This ensures that at the low concentration at which O2 
dissociates from the maternal haemoglobin, it still binds to the foetal/embryonic haemoglobin for 
transport through the foetal/embryonic body6–8. 
The haemoglobin tetramer is made up of two α-globin like subunits and two β-globin like 
subunits, which are encoded by two distinct gene clusters on chromosomes 16 and 11, 
respectively. The layout of the genes at these loci are shown in Figure 1.1, and the genes are 
positioned in the order in which they are expressed throughout development9. Two Gower 
haemoglobins are expressed during embryonic stages, HbGower I (ζ2ε2) and HbGower II (α2ε2), 
and during foetal development expression of ζ-globin is completely replaced by the two α-globin 
genes, and ε-globin is replaced by expression of the γ-globin genes, giving rise to the foetal 
haemoglobin (HbF: α2γ2)9,10. Shortly after birth, expression is switched from the γ-globins to β-
globin and δ-globin, producing adult haemoglobins HbA (α2β2) and HbA2 (α2δ2). HbA is the 
most abundant form of haemoglobin in healthy adults, making up >95% of total 
haemoglobin11,12. 
Each globin subunit folds around an aqueous pocket containing a protoporphyrin IX molecule, 
which has a negatively charged central ring that coordinates the binding of an Fe2+ ion13. Two 
histidine residues from the globin peptide interact with Fe2+, the first is situated below the plane 
of the porphyrin ring and is referred to as the proximal histidine, interacting directly with Fe2+, 
and the second is situated above the plane of the porphyrin ring, interacting with Fe2+ through 





Figure 1.1: Layout of the α-globin like gene locus on chromosome 16 and the β-globin like gene locus on 
chromosome 11. Genes are positioned in the order in which they are expressed during development. 
Embryonic haemoglobin – ζ2ε2, foetal haemoglobin – α2γ2, adult haemoglobin α2β2. Adapted from Kiefer et 
al. 20089. 
 
In the absence of O2 binding, Fe2+ sits just below the plane of the porphyrin ring, closer to the 
proximal histidine13. Upon O2 binding, electron rearrangements reduce the size of Fe2+ and it is 
pulled into the centre of the porphyrin ring, forming a more stable structure coordinated by six 
interactions13,16. This is illustrated in Figure 1.2. 
 
Figure 1.2: Oxygen binding stabilises the coordination of Fe2+ (Green) in the plane of the porphyrin ring, 
dragging the proximal histidine (and therefore the helix to which it is attached) closer, altering the structure 
of the globin subunit. Image is from Berg, Tymoczko & Stryer (2002)13. 
 
The conformational changes that occur upon binding of O2 to the globin subunits transition 
haemoglobin from the T (Tense, deoxygenated) state to the R (Relaxed, oxygenated 
state)2,13,15,17. The conformational changes in each globin subunit alter the interaction with the 
neighbouring subunits, allowing for the cooperative binding effect of O2 to haemoglobin. Upon 
O2 binding to one subunit, conformational changes make the R state of the other subunits more 
favourable, increasing O2 affinity17. This effect is additive, and when three of the four subunits 
are oxygenated, the affinity of the fourth subunit for oxygen is increased 20-fold13. The allosteric 
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regulators of haemoglobin oxygen affinity act by stabilising either the T or R state, e.g. there is a 
central cavity between the four subunits that closes upon transitioning to the R state, BPG binds 
this cavity, preventing the conformation changes required to transition to the R-state and 
therefore favouring the low oxygen affinity T-state13,18. 
 
1.2.2 Sickle Haemoglobin (HbS) & SCA Pathophysiology 
SCA is a recessive disorder caused by an aberrant haemoglobin variant, referred to as sickle 
haemoglobin (HbS). HbS is the result of a single nucleotide polymorphism (SNP) in the β-globin 
gene (HBB) on chromosome 11. The SNP is an A to T substitution, replacing the negatively 
charged glutamic acid at position 6 with a hydrophobic valine residue (E6V, OMIM: 
141900.0243). This substitution alters the conformation of haemoglobin; in the absence of Glu-6 
no intramolecular ionic interaction occurs with Lys-132, instead Val-6 forms intermolecular 
hydrophobic interaction with Phe-85 & Leu-88 of a neighbouring tetramer, resulting in HbS 
polymerisation19,20. 
Patients with SCA inherit two copies of this aberrant β-globin allele (βS), resulting in the 
production of sickle haemoglobin (HbS, α2βS2) rather than the wild type (HbA, α2β2). HbS has 
reduced solubility under low oxygen conditions, and in the deoxygenated T-state polymerises 
into long helical chains rather than free-floating globular tetramers19. These aberrant polymers 
aggregate and distort the shape of the erythrocyte cell membrane, forcing them from a 
biconcave structure to the eponymous sickle shape. Sickled erythrocytes are more rigid than 
wild type, and cannot pass through smaller capillaries as easily, slowing blood flow and 
resulting in vaso-occlusion and acute pain, commonly referred to as sickle crises21. The sickled 
cells are fragile, with an average survival time of 10-20 days compared to 110-120 days for wild 
type erythrocytes, leading to a chronic haemolytic anaemia22.  
High rates of haemolysis in SCA patients leads to increased levels of extra-cellular haemoglobin 
in the blood. The cell-free haemoglobin then binds and sequesters nitric oxide (NO), a 
vasodilatory signalling molecule. This reduction in NO bioavailability further increases 
susceptibility to frequent vaso-occlusive events and pulmonary hypertension. Recently however, 
the importance of the role of NO signalling in SCA pathology has been disputed, mostly due the 




1.2.3 Genotypes of Sickle Cell Disease 
A number of other β-globin genotypes result in a variety of sickle cell phenotypes when co-
inherited with at least one copy of the βS allele. Collectively these disorders are classified as 
Sickle Cell Disease (SCD), with SCA referring to homozygosity for the βS genotype. 
 
1.2.3.1 Alternative β-globin Genotypes 
The phenotype of SCD requires at least one βS mutation, the most common genotype being 
HbSS (homozygosity for βS), however there are a variety of rare alternative mutations that can 
give rise to the SCD phenotype when co-inherited with the βS allele, either passively through 
reduction of functional β-globin levels, or by acting cooperatively25. Haemoglobin C is the most 
common of these, and is discussed below in 1.2.3.2. 
 
1.2.3.2 Haemoglobin C 
An alternative substitution at the same position as the HbS mutation (HBB Glutamic acid 6), 
gives rise to a milder form of the SCA phenotype. This allele is referred to as HbC, and is 
characterised by Glutamic acid to Lysine substitution (rs33930165), rather than the Valine 
substitution that is associated with HbS. Similarly to HbS, both heterozygous and homozygous 
forms of HbC have been associated with protection from Malaria, and as such HbC is also most 
prevalent in populations of African descent26–29. 
Homozygosity for HbC presents as a mild haemolytic anaemia, less severe than that observed 
with HbSS patients30,31. Similarly to that observed with HbAS, coinheritance of HbC with the wild 
type HbA allele results in a mostly asymptomatic phenotype32. 
Coinheritance of HbC with HbS, results in a much more severe phenotype, although still with 




β-Thalassaemia is characterised by insufficient production of the β-globin component of adult 
haemoglobin, resulting in anaemia. The severity of the clinical symptoms of β-thalassaemia vary 
greatly, dependent on the levels of functional β-globin synthesised. Alleles that produce no 
functional transcripts, either due to early termination, frameshift mutations or large scale 
genomic deletions are classified as β0 genotype34–37, while alleles that contain polymorphisms 
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that reduce expression, typically by disrupting the promoter or other gene regulatory regions are 
classified as β+ genotype38–40. The β+ alleles display much more heterogeneity, based on the 
quantitative effect that the specific variant has on β-globin synthesis, and can be classified as 
severe, mild or silent41. 
Heterozygous β-thalassaemia patients (β/β+/0) are generally asymptomatic, and are referred to 
as carriers for the disease. Homozygous patients (β+/0/β+/0) lack a fully functional copy of the 
gene, and phenotypes range from thalassaemia major, suffering severe anaemia and requiring 
blood transfusions from shortly after birth, to thalassaemia intermedia, and the asymptomatic 
state41. Similarly to SCA, β-thalassaemia can be ameliorated by persistent expression of γ-
globin after birth (as discussed in 1.6.1), providing a functional alternative to β-globin42–44. 
In England roughly 44 per 1000 births are carriers of a β-thalassaemia allele, and coinheritance 
with a βS allele is common45. For both SCA and β-thalassaemia, heterozygosity for the 
pathogenic allele is mostly asymptomatic. However, compound heterozygotes where each of 
the disorders is co-inherited on separate β-globin alleles gives rise to a SCD phenotype46–48. In 
these cases the severity depends on the functionality of the β-thalassaemia allele. With 
decreasing expression from the functional allele, the ratio of βwt:βS shifts in favour of βS, and so 
levels of the pathogenic HbS increase48–51. Heterozygotes for βS/β0 produce no healthy β-globin, 





1.3 β-globin Locus Control 
The β-globin gene locus consists of five β-globin paralogues, as shown in Figure 1.1 as well as 
a β-globin pseudogene (HBBP1). The genes have a highly specific pattern of expression and 
are arranged in the order in which they are expressed throughout development, progressing 
from ε-globin at the 5’ end expressed in embryos to δ-globin and β-globin at the 3’ end 
expressed in adults. Expression of the genes in the locus is developmental stage and tissue 
specific, and is tightly regulated by a variety of factors, including long range chromatin 
interaction between individual promoters and an upstream locus control region (LCR). 




1.3.1 Transcription Factors 
Transcription factors play an important role in regulating gene expression, stabilising the 
chromatin state surrounding the transcription start site, recruiting and stabilising the 
transcription initiation complex and RNA polymerases (or destabilising in the case of 
repressors).  
The GATA family of transcription factors are key regulators of haematopoietic development52. 
GATA2 expression in haematopoietic stem cells (HSCs) is replaced by GATA1 expression at 
the proerythroblast stage52. GATA3 is also expressed at HSC stage, and is involved in the 
development of lymphoid lineages53. GATA1 is essential for globin gene expression, and 
knockdown in K562 cells results in chromatin reorganisation at the β-globin locus, forming 
transcriptionally repressive heterochromatin54. GATA1 upregulates expression of other erythroid 
transcription factors including KLF1 and TAL1, and binds with them at the β-globin locus 
stabilising long range chromatin interactions between CTCF/RAD21 binding sites55–57. 
TAL1 is an important haematopoietic transcription factor, critical for the establishment of 
haematopoietic lineages from mesodermal cells in early development, and is involved in 
maintenance of HSC renewal and quiescence in adults58–60. During haematopoiesis, expression 
of TAL1 is highly expressed in the myeloid lineages, and in erythroid cells associates with 
GATA1, LMO2 and Ldb1 at the β-globin locus, where it is required for chromatin looping58,61,62.    
Krüppel-like factor 1 (KLF1) is an erythroid specific transcription factor that plays a crucial role in 
the γ-globin to β-globin switch63,64. KLF1 directly activates β-globin expression by binding to the 
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promoter, and also silences transcription from the γ-globin genes through activation of 
BCL11A64–67. Interestingly, low levels of KLF1 expression are also required for ε and γ globin 
expression during early development, and it is thought to be required to stabilise the chromatin 
architecture of the β-globin locus with GATA157,68.  
BCL11A is required for the γ-globin to β-globin switch during erythroid development, repressing 
expression from the γ-globin genes by recruitment of the NuRD histone deacetylase complex to 
the promoter regions, mediated by interactions with SOX6, GATA1 and FOG169–72. Knock down 
of BCL11A reactivates γ-globin expression, and BCL11A polymorphisms have been associated 
with increased HbF levels in adults69,73–75. 
 
Figure 1.3: Figure illustrating the role of transcription factors during the  γ-globin to β-globin switch during 
erythroid development. MYB activated upregulation of KLF1 causes an increase in BCL11A, as well as 
ZBTB7A (LRF), and both of these form complexes recruiting the NuRD repressor to the γ-globin genes. 
Figure adapted from Cavazzana et al. (2017)76.  
 
MYB is a haematopoietic transcription factor, required during early haematopoiesis for 
commitment to the erythroid lineages, and activates transcription of both KLF1 and LMO277,78. 
MYB is activated by a distal enhancer in the MYB-HBS1L intergenic region upon binding by the 
transcriptional activation complex containing GATA1 and TAL1, as well as KLF1, resulting in a 
positive-feedback loop for transcriptional activation and commitment to the erythroid lineage79,80. 
Upregulation of KLF1 by MYB also provides a mechanism by which increased MYB promotes 
the γ-globin to β-globin switch. Sequence polymorphisms at the MYB-HBS1L intergenic region 
have been associated with increased HbF levels, and along with BCL11A and KLF1, MYB is 
downregulated in response to HU treatment73,75,81. 
ZBTB7A (aka LRF - Leukaemia/lymphoma-related factor) is a haematopoietic transcription 
factor, that is a downstream target of both GATA1 and KLF1, and plays a role in lineage 
determination in many haematopoietic cell populations, at both late and early stages82–84. 
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ZBTB7A is also involved in the repression of the γ-globin genes through recruitment of the 
NuRD histone deacetylase complex, and acts independently to BCL11A85. Since both ZBTB7A 
and BCL11A are upregulated by increased KLF1 expression, this means that KLF1 dependant 
repression of the γ-globin genes during the globin switch occurs through two parallel 
pathways82,85. 
 
1.3.2 Chromatin Looping 
Upstream of the β-globin gene locus is a cluster of 5 DNase I hypersensitivity sites (HS1-5, with 
HS5 being the furthest upstream), these are collectively known as the Locus Control Region 
(LCR), and play an important role in gene regulation. In addition to the LCR, the β-globin locus 
has a downstream hypersensitivity site (3’HS). HS5 and 3’HS contain CTCF binding sites in 
both mice and humans, and CTCF binding results in chromatin looping, bringing these two sites 
into close proximity, creating a chromatin domain and insulating from the effects of neighbouring 
enhancers (Figure 1.4A)86,87. 
Within this chromatin domain, the LCR acts as a distal enhancer, looping out into close 
proximity of the promoter of the specific gene being expressed (Figure 1.4B). This allows 
recruitment of chromatin remodelling machinery, transcriptional machinery and stabilisation of 
the transcription initiation complex. HS1-4 of the LCR are required for globin gene expression, 
and loss of HS5 does not affect expression levels, suggesting that its role is restricted to 
forming the chromatin domain with 3’HS88. 
The genes in both the α-globin and β-globin loci are arranged in the order in which they are 
expressed in development. Interestingly, the order of expression changes if the genes are 
rearranged, showing that the spatial organisation of the locus is important. This is thought to be 




Figure 1.4: Chromatin looping at the β-globin locus. A – Interactions between CTCFs (orange) at HS5 and 
3’HS (yellow) form a chromatin domain. B – Interactions between HS1, 2 & 4 and the γ-globin promoters 
result in histone acetylation and expression from those genes. C – Transcriptional activation complexes 
from the distal enhancer and the promoter dimerise through Ldb1 dimerisation domain. GATA1 and TAL1 
bind DNA, LMO2 stabilises this binding and recruits Ldb1. Images A & B from Kim & Kim (2013)90, C from 
Love et al. (2014)91. 
 
Chromatin looping at the β-globin locus is mediated by interaction between two transcriptional 
activation complexes, one forming at the LCR and the other at the promoter of the expressed 
gene. These complexes include GATA1, TAL1, LMO2 and Ldb1. Along with GATA1, which is 
required to maintain the open chromatin state at the locus, TAL1 binding is necessary to recruit 
LMO2 and Ldb1, and looping is lost when TAL1 is knocked down61,90. Although KLF1 is not a 
component of this complex, it is required to stabilise binding at the LCR57,92. 
Ldb1 and LMO2 are non DNA binding components of the complex, LMO2 is required for 
stabilisation of the complex, and for recruitment of Ldb1, with the LIM domain in LMO2 binding 
to the LIM-Interacting Domain in Ldb158,93,94. Ldb1 contains a self-association dimerisation 
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domain, and is the component of the complex responsible for mediating the interaction between 
the complexes at the two different genomic positions, directly binding to its counterpart in the 
other complex (Figure 1.4C)95,96. In Ldb1 knock out cells, chromatin looping can be rescued by 
fusion of the dimerisation domain to LMO295. If fused to an artificial zinc finger DNA binding 
protein, the dimerisation domain is capable of reactivating the transcriptionally silenced γ-globin 
gene, by induction of forced chromatin interactions97,98. Ldb1 mediated chromatin looping is also 
involved in transcriptional activation of other erythroid activated genes, including KLF1, GATA1, 
TAL1 and LMO291,96,99. 
 
1.3.3 DNA Methylation 
DNA methylation is a common epigenetic mark, and when located at promoters is often 
associated with transcriptional silencing; recruiting chromatin modifying complexes, or 
interfering with transcription factor to DNA interactions. 
While the β-globin locus has no bioinformatically predicted CpG islands, it has been found that 
in tissues expressing the globin genes, the promoters of the active genes have reduced CpG 
methylation, suggesting that DNA methylation is a relevant factor in the regulation of the 
locus100. This has also been shown in a transgenic mouse model, where DNA methylation was 
found to reduce expression of the foetal globin genes by 20 times101. Similarly, using a TALE-
TET1 construct, targeted demethylation of four CpG sites in the β-globin promoter region is 
enough to reactivate the gene in K562 cells102. The maintenance DNA methyltransferase 
DNMT1 associates with BCL11A, and is required to maintain transcriptional silencing of the 
repressed β-globin like genes103,104. 
 
1.3.4 Histone Modifications 
Histone modifications play a role in gene regulation, recruiting chromatin modifying complexes 
and signalling the transcriptional state of the gene. Histone marks are therefore very informative 
and useful to assay, especially in parallel with transcriptomic approaches such as RT-PCR or 
RNA-seq. They can be used to predict whether a gene is active or repressed, e.g. positive 
residues in the tail of histone H3 are commonly acetylated in euchromatin9,105. Methylation of 
lysine residues on histone tails indicates different states depending on which residue is 
methylated; H3K4 methylation is associated with active promoters, and H3K36 methylation is 
associated with actively transcribed regions, whereas H3K9, H3K27 and H4K20 methylation is 
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usually associated with inactive genes9. In the case of the β-globin locus it is important that the 
transitions between these marks by histone deactylases (HDACs) and acetyltransferases 
(HATs) as well as the methyltransferases and demethylases is controlled to regulate the 
complex expression pattern of the globin genes. 
The active genes at the β-globin locus have high levels of H3K27 acetylation, and low levels of 
H3K27 methylation, and this is reversed in the transcriptionally silent genes106. At the β-globin 
promoter, GATA1 recruits the histone acetyltransferase CBP and NF-E2 recruits the histone 
methyltransferase MLL2, promoting histone acetylation and H3K4 methylation and activating 
transcription54,107,108. 
GATA1 and KLF1 are also required to maintain the chromatin organisation at the β-globin locus, 
and knockdown of KLF1 in K562 cells reduces expression of the γ-globin genes, as well as 
H3K9ac, H3K14ac & H3K27ac histone marks at both the LCR and γ-globin, and disrupts 
chromatin looping between the two sites57. Chromatin looping was also lost upon knockdown of 
CBP in these cells, demonstrating the importance of histone modifications in regulating the 




1.4 Erythroid Development 
Haematopoiesis is a complex and tightly regulated process, by which a wide variety of cell types 
with highly specialised structures and functions are produced from a small pool of HSCs. Many 
haematopoietic cell types have a greatly reduced life span compared to other tissues, and this 
also varies greatly between the haematopoietic lineages. As a result, haematopoiesis is a 
continuous process, highly responsive to stimuli to allow coordination and maintenance of the 
many blood cell populations in the proportions required. 
Erythropoiesis is the developmental pathway within haematopoiesis that results in the 
production of erythrocytes, and in adults is responsible for the generation of approximately 
2x1011 red blood cells per day109. 
 
1.4.1 Normal Erythropoiesis 
The major sites of haematopoiesis change throughout development. The initial haematopoietic 
populations reside in the embryonic yolk sac, and during foetal development haematopoiesis 
occurs in the liver and spleen. After birth, HSCs migrate to the bone marrow, which remains the 
major site for haematopoiesis throughout adulthood109–111. 
Since SCA does not affect the embryonic or foetal stages of development, when alternative β-
globin paralogues are expressed, this section will focus on erythropoiesis in the bone marrow. 
 
 
1.4.1.1 Haematopoietic Stem Cells & Early Stage Progenitors 
A haematopoietic pool is maintained in the bone marrow, with self-renewal potential allowing 
expansion of the HSCs to replace those undergoing differentiation. Various cytokines in the 
bone marrow signal for quiescence of HSCs, as well as for their retention in the bone marrow 
through expression of adhesion molecules, including α4β1 integrin, which binds to VCAM1 
expressed on stromal cells in the bone marrow112–114. CXCL12 is one of the key cytokines in this 
process, binding to CXCR4 expressed on HSCs, and is essential for maintaining 
quiesence113,115,116. Several cytokines such as Granulocyte colony stimulating factor, Flt3 Ligand 




Figure 1.5: Simplified overview of haematopoietic development and terminally differentiated cell types 
produced from HSCs. MPP (Multipotent Progenitor), CLP (Common Lymphoid Progenitor), CMP (Common 
Myeloid Progenitor), MEP (Megakaryocyte-Erythroid Progenitor), GMP (Granulocyte-Macrophage 
Progenitor). Image adapted from Dzierzak & Philipsen (2013)109.  
 
The process of HSC development, and the potential cell types they can give rise to are 
summarised in Figure 1.5109. Upon haematopoietic stimulation, either as a result of natural 
blood homeostasis or in response to injury and blood loss, long-term HSCs divide 
asymmetrically, producing one long-term HSC and one short-term HSC, which no longer has 
capacity for self-renewal119,120. The short-term HSC develops into a Multipotent Progenitor 
(MPP), before committing as either a Common Myeloid Progenitor (CMP) or Common Lymphoid 
Progenitor (CLP)121,122. Before this stage the cells are capable of differentiating into any blood 
cell type, but CMPs are lineage restricted to myeloid cells, and CLPs can only produce the white 
blood cells119,122. 
CMPs develop into either Granulocyte-Macrophage Progenitors (GMPs), responsible for 
production of the granulocytes and macrophages, or Megakaryocyte-Erythroid Progenitors 
(MEPs). MEPs develop into either megakaryocytes, which produce platelets, or 





1.4.1.2 Erythroblast Development 
Erythroblast development occurs in the bone marrow at erythroblastic islands, where 
proerythroblasts cluster around central macrophages109,123,124. In humans this usually consists of 
10-30 erythroid progenitors per macrophage123. Proerythroblasts develop through three distinct 
stages identifiable through cytology, before enucleation and final erythrocyte maturation, all of 
which occurs at the erythroblastic island. 
 
Figure 1.6: Summary of erythroid development, showing the individual erythroblastic stages, as well as the 
enucleation step. A – Cell surface expression is shown for Kit, CD71 and GPA (Ter119 is the murine 
equivalent of GPA). Kit expression is a marker for early stage progenitors, and is lost by the 
proerythroblast stage. CD71 is expressed during erythroblast development and is lost by the enucleation 
of the orthochromatic erythroblast. GPA is a late stage erythroid marker, with increasing expression levels 
during erythroblastic development, and is expressed highly on terminally differentiated cells. B – Cytology 
of erythroblasts isolated from human bone marrow. Image A is from Dzierzak & Philipsen (2013)109. B is 
from Hu et al. (2013)125 
 
Proerythroblasts develop into basophilic erythroblasts, followed by polychromatic erythroblasts 
and finally orthochromatic erythroblasts before enucleation (Figure 1.6)109. Pro-erythroblasts 
have very little visible cytoplasm, and appear as small, tightly packaged cells. As they develop 
into basophilic erythroblasts the cytoplasm becomes visible, appearing to expand out from the 
nucleus. Basophilic staining in the cytoplasm is reduced as haemoglobin accumulates, and is 
accompanied by the appearance of large vesicles containing ferritin imported from the 







orthochromatic erythroblast stage stains very dark. Rapid division occurs during this process, 
and the cell size decreases throughout these terminal stages127,128. 
It is interesting to note that during erythroid development each cell goes through the process of 
globin switching observed during embryonic and foetal development, transitioning from HbF to 
HbA129–131. 
 
1.4.1.3 Enucleation & Reticulocyte Maturation 
The process of enucleation follows the orthochromatic erythroblast stage, and asymmetrically 
divides the cell into two products: a pyrenocyte, containing the condensed nucleus with a thin 
cytoplasmic shell, and a reticulocyte, consisting of the remaining organelles and the majority of 
the cytoplasm132,133. The pyrenocyte presents phosphatidylserine on the cell surface and is 
engulfed by the nearby macrophage at the erythroblastic island134,135, while the reticulocyte 
matures, developing into an erythrocyte. 
Enucleation is an important stage in erythropoiesis, and provides multiple structural advantages 
to the terminal erythrocyte, increasing flexibility and reducing both mass and volume, whilst 
maintaining its function as a haemoglobin rich oxygen transporter136–138. Enucleation also acts 
as an extremely effective developmental gate (there is no known mechanism by which a 
reticulocyte can re-absorb its nucleus), and given that erythrocytes are by far the most abundant 
cell type in the body, perhaps this irreversible block on cellular reprogramming is protective from 
an oncogenic perspective. It has been suggested that mitochondria are removed for a similar 
reason, since they have little influence over cell size or flexibility, but are a major source of 
oxidative stress136. 
 
1.4.2 Stress Erythropoiesis & Erythroid Progenitors in the Peripheral Blood 
Under conditions of hypoxic stress, stress erythropoiesis is triggered. The process of stress 
erythropoiesis is not fully understood, but it has long been linked to increased HbF levels139–142. 
It is thought to be alternative erythropoietic developmental pathway, resulting in the rapid 
production of immature erythrocytes. During this fast-tracked differentiation process, the globin 
switch from HbF to HbA does not occur, resulting in an increased proportion of F-cells in 
circulation143. Due to the demonstrated ability of hypoxic stress to trigger F-cell production, and 
the cytotoxic effects of HU treatment, induction of stress erythropoiesis has been suggested as 
a mechanism of action for HU143,144.  
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Stress erythropoiesis is triggered by a hypoxic response, mediated by the hypoxia induced 
transcription factor HIF2, which results in increased erythropoietin (EPO) production145. 
Induction of stress erythropoiesis is also dependent on functional EPO Receptor (EPOR) 
activation of STAT5146. Under stress erythropoietic conditions induced by phlebotomy in sheep, 
erythropoietin receptor (EPOR) levels are doubled, and mice haploinsufficient for EPOR are 
unable to elicit a stress erythropoietic response147,148. Stress response of dendritic cells has also 
been associated with activation of stress erythropoiesis, mediated through increased expression 
of Stem Cell Factor (SCF), the ligand for Kit149. 
SCA patients have increased levels of stress erythropoiesis as a result of hypoxia associated 
with the disease, and likely as a result of increased mobilisation, higher levels of stress erythroid 
progenitors have been observed in the peripheral blood150. 
 
1.4.3 In vitro Culturing of Erythroid Progenitors 
Erythroid progenitors primarily reside in the bone marrow, but small populations have been 
identified in the peripheral blood of healthy individuals, and can be isolated and expanded in 
culture. There are many variations of these culturing techniques, and they are widely used, 
presenting a source of erythroblasts more easily accessible than by invasive bone marrow 
sampling. 
In 1989 Fibach et al. demonstrated that it was possible to grow and differentiate erythroid 
progenitors isolated from the peripheral blood using a liquid in vitro culture151. Prior to this 
culturing was restricted to the establishment of macrophage dependent erythroblastic colonies 
on agar152. 
Human erythroid progenitors are commonly cultured from bone marrow, peripheral blood, cord 
blood and foetal livers, and in many protocols are enriched for CD34+ cells prior to culturing, 
with the aim of purifying the early stage progenitor population70,129,150,153–158. However the 
benefits of this are disputed, with evidence suggesting that most of the erythroblastic growth 
potential actually comes from the CD34- population159.  
The timeline of the cultures varies greatly between different protocols, with some lasting up to 
60 days153. This is mostly dependant on the design of the culture, with some single-phase 
cultures inducing differentiation from the start, two-phase cultures including an expansion phase 
before inducing differentiation, and three-phase cultures including two distinct expansion 
phases before differentiation153,154,159. 
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The in vitro culture technique tested in this project was a two-phase liquid culture, performed on 
Peripheral Blood Mononuclear Cells (PBMCs) that were not CD34+ enriched. 
 
1.4.3.1 Culture Components 
Various different media and serum are used in the in vitro culture systems, as well as a wide 
variety of different cytokines and growth hormones to stimulate proliferation and prevent 
apoptosis. All of these cultures include EPO, and the majority contain SCF, both of which have 
important proliferative and anti-apoptotic roles in erythropoiesis148,160–162. In addition, the culture 
tested in this project contains dexamethasone, Insulin-like Growth Factor 1 (IGF1) and 
Interleukin-3 (IL-3). 
Dexamethasone is a corticosteroid that acts as a ligand for the glucocorticoid receptor. It has 
been shown to increase the longevity of erythroid progenitors in culture, promoting self-renewal 
and preventing terminal differentiation in vitro161,163–165. IGF1 is a growth hormone with a similar 
structure to insulin, and binds to the IGF1 receptor on the cell surface, signalling for survival and 
proliferation. Under culture conditions, IGF1 has been shown to increase erythroblast numbers, 
and is required for later stages of differentiation166–168. 
IL-3 is a cytokine that stimulates both growth and differentiation in haematopoietic populations, 
and in combination with EPO stimulates early stage haematopoietic progenitors to commit to 
the myeloid lineage. However, if IL-3 is present in the media for the duration of the culture, a 
large proportion of these progenitors are stimulated to terminally differentiate into mast cells, 
rather than erythrocytes169. Therefore culture medium is only supplemented with IL-3 during the 
first phase (the expansion phase), and not during the second phase (the differentiation phase). 
 
1.4.3.2 Cell Surface Markers 
Cell surface markers can be used to accurately identify the developmental stage of erythroid 
progenitors, either directly from the peripheral blood, or after in vitro expansion and 
differentiation. 
CD71 and Glycophorin A (GPA) can be used to assess the stage of the erythroblasts. CD71 is a 
membrane receptor for transferrin and is expressed early on in development to allow iron 
accumulation prior to haemoglobin production. Expression is then lost towards the final stages 
of erythrocyte maturation109,129,170(Figure 1.6). GPA is an erythroid specific glycoprotein that is 
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transcriptionally silent during early haematopoiesis, and is expressed at high levels after the 
basophilic erythroblast stage109,129(Figure 1.6).  
c-Kit is the receptor for the ligand SCF and is expressed at high levels on HSCs, where SCF 
binding promotes self-renewal and expansion of the HSC pool171–173. c-Kit is negatively 
regulated by GATA1, so is lost shortly after the switch from GATA2 to GATA1 early in erythroid 
development173(Figure 1.6). CD34 is also an early HSC marker that is lost during 
haematopoietic development, before reaching  the proerythroblast stage174. 
CD45 (aka leukocyte common antigen) is expressed from an early stage during haematopoietic 
development, but is lost from the erythroid lineage, and can be used as a leukocyte specific 
marker125,175. CD14 is a marker expressed highly on monocytes, and was used since 






1.5 Sickle Cell Anaemia 
1.5.1 History of Sickle Cell Anaemia 
SCA was first recorded in the Western scientific literature by J. B. Herrick in 1910. The case 
was that of a patient from Grenada in the West Indies, with healthy parents and three healthy 
siblings, who presented “unusual blood findings” and red blood cells with a “large number of 
thin, elongated, sickle-shaped and crescent-shaped forms”177. Two additional cases were 
published in 1911 and 1915, and in 1922 a fourth patient was presented by V R Mason, with the 
first reference to the disease as “Sickle Cell Anaemia”178–180. 
The heritability of the disease was confirmed by two separate publications in 1949, where sickle 
trait (also referred to as sicklemia or drepanocytosis) was suggested to present in a dominant 
pattern in heterozygous carriers of the disease, while only homozygous cases had the full 
clinical presentation of SCA181,182. 
In 1949 Linus Pauling et al. noted a shift in the electrophoretic mobility of haemoglobin from 
SCA patients, correctly hypothesising that the sickle haemoglobin has a net positive charge of 
2-4 ions more than healthy haemoglobin183. He went on to hypothesise that these haemoglobin 
molecules “might be capable of interacting with one another at these sites sufficiently to cause 
at least a partial alignment of the molecules within the cell”, which remains the widely accepted 
hypothesis of SCA disease aetiology, more than 65 years after publication183. Pauling’s 1949 
paper is considered a landmark publication in the field of molecular medicine, being the first 
case of a disease being attributed to a specific molecular defect, and SCA became the first ever 
“Molecular Disease”183. 
Pauling’s discovery of the differing charge on the sickle haemoglobin molecules was confirmed 
in 1956, with the discovery of a substitution of a negatively charged glutamic acid residue for a 
neutral valine residue on each of the two β-globin subunits184. 
In 1978, a genetic association was identified between the sickle variant and a disrupted 
restriction digest site, 5kb downstream from the β-globin gene185. This formed the basis of using 
restriction fragment length polymorphisms (RFLPs) as a diagnostic tool, and led to antenatal 




1.5.2 Sickle Cell Disease Epidemiology and Malarial Resistance 
Due to the severity of SCD and the fact that it is a genetic disorder, it might have been expected 
that the disease would be less prevalent as a result of negative selection, since infant mortality 
is high without early intervention. The prevalence of the sickle genotype is increased because 
individuals who are heterozygous for the HbS allele have increased resistance to severe 
malaria from Plasmodium falciparum188,189. It is therefore likely that the prevalence of the sickle 
cell genotype is maintained in part by a balance of the positive selection for heterozygosity 
against the negative selection for homozygosity. This also explains why the disease is most 
prevalent in tropical and sub-tropical regions where malaria is endemic, including sub-Saharan 
Africa, the Mediterranean, the Middle East and India (Figure 1.7)190. The global frequency of the 
HbS allele as estimated by the 1000 Genomes Project is 0.03, this is increased to 0.10 in 
African populations, and 0.14 in the Yoruban subpopulation in Nigeria191. 
Individuals who are heterozygous for the HbS allele do not present with the SCA phenotype, but 
do have an increased protection from the symptoms of malaria. However, patients homozygous 
for the sickle HbS allele do not have this protective effect, they experience the severe anaemia 
and autosplenectomy associated with SCA, and are actually predisposed to an increased risk of 
death from malarial infection192,193. 
Carriers of the HbS allele are not actually protected from the malarial infection, but from the 
symptoms. The proportion of erythrocytes infected with P. falciparum appears to be reduced in 
these individuals, believed to be at least partially due to increased rates of sickling in infected 
erythrocytes, and the subsequent clearance of these cells from the bloodstream by 
phagocytosis193–195. It has also been shown that cytoskeletal disruption in erythrocytes of HbS 
carriers prevents correct trafficking of the malarial proteins to the cell membrane, which are 
required for endothelial adhesion and thought to increase parasite survival29,193,196. 
The sickle mutation is believed to have arisen independently multiple times, in different 
populations under strong selective pressure by malarial infection. This is demonstrated by the 
different genetic haplotypes that associate with the βS mutation, as shown in Figure 1.8187. 
Malaria is not endemic to Northern Europe, and so the selective advantages of the sickle 
mutation are minimised in these countries. However, likely as a result of increased global 
migration over the last century, SCD is the most common severe genetic disorder in the UK, 
and affects approximately 13,000 individuals197–199. 140-175 babies are born with SCD in 
England each year, equating to 0.22-0.28 per 1000 births, this is increased to 5.6 and 14.7 in 
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patients with Caribbean and African ancestry respectively45. A published analysis of SCD 
treatments and sickle related hospitalisations in 2010-2011 estimated that SCD costs the NHS 




Figure 1.7: Diagram illustrating the global distribution of (A & B) HbS allele, (C) Plasmodium falciparum 





Figure 1.8: Map showing the distribution of different haplotypes that associate with sickle globin alleles. 
The sickle globin mutation is believed to have arisen independently multiple times across malaria affected 
countries in Africa and Southern Asia. Image from Gabriel & Przybylski (2010)187.  
 
1.5.3 Sickle Cell Anaemia Symptoms 
The major symptoms of SCA arise from severe chronic haemolytic anaemia and acute vaso-
occlusive events. Hypoxia due to anaemia causes cell death in organs and peripheral tissues, 
while recurrent episodes of vaso-occlusion prevent blood flow to large areas of tissue, causing 
increased cell death, and resulting in many symptoms, including chronic and acute pain, stroke, 
chronic lung disease, osteonecrosis, renal failure and retinopathies25,200. 
Sickle cell crisis is an inflammatory response triggered by vaso-occlusion, and is the most 
common reason for hospitalisation of SCA patients198. Evidence suggests that damage caused 
to the endothelium by rigid cells triggers this response, and activated endothelial cells, as well 
as neutrophil extracellular traps (NETs) are involved in this process201–203. 
Autosplenectomy is a common occurrence in SCA patients, with splenic function often severely 
impaired from a young age (<12 months), due to damage caused by vaso-occlusive events and 
continuous filtering of abnormal sickled cells from the blood204,205. Loss of splenic function 
leaves SCA patients susceptible to infections206.  
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Current risk categories for stroke in SCA children are assessed by measuring blood flow in the 
brain using transcranial Doppler ultrasonography (TCD), and patients with a flow of <170cm/s 
are considered at low risk, however a study found a significantly high incidence of intracranial 
stenosis as well as silent cerebral infarcts in these patients, both of which are predictive markers 
of future stroke. This shows that the current methods used to predict severity of SCA symptoms 
can be improved207. 
Despite the well-characterised genotype and the classification as a classical Mendelian 
recessive disorder, SCA pathology varies greatly between patients, both in terms of severity 
and symptoms observed. Patients with the same β-globin mutation will in some cases have high 
incidence of stroke and clotting from an early age, and others will be largely unaffected, 
reaching old age without incident; this implies that there is an additional component to the 
disease200,208. 
 
Symptoms observed in a longitudinal study of 1056 patients 
     Acute Clinical Events 
 
Irreversible Organ Damage 
Symptom % Patients 
 
Symptom % Patients 
Hospitalisation: 76 
 
Gall Bladder Disease 28 
Sickle Related 73 
 
Avascular Necrosis 21 
Painful Sickle Crisis 70 
 
Sickle Chronic Lung Disease 16 
Associated Sickle Crisis 51 
 
Leg Ulcer 14 
Acute Chest Syndrome 48 
 
Priapism (<17 yrs) 14 
Hypersplenism 20 
 
Renal Failure 12 
Bone Infarction 15 
 
Cerebrovascular Accident 11 




   Meningitis/Septicaemia 12 
 
Death 232 Total 
Neurologic Disorder 12 
 
Sickle Caused 170 (73%) 
Dactylitis <4 years 4 
 
<20 years 46 (20%) 
 
Table 1.1: Table showing data from a longitudinal study of 1056 SCA patients over 40 years, adapted from 
Powars et al. (2005)200. A large variety of symptoms are presented, and the percentage of patients that 
presented with each clinical event is shown, the study found that patients that present a chronic clinical 
event are more likely to have future events as well. 
 
A longitudinal study of 1056 patients over 40 years is summarised in Table 1.1. The table shows 
the variety of symptoms, and the study found that many of the chronic clinical events were risk 
factors for future clinical events, further demonstrating that the severity of symptoms varies from 
patient to patient, despite sharing the same sickle-globin mutation200. This wide variety of 
symptoms provides a challenge in clearly defining boundaries between severe and mild patients 
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for our analyses, since phenotypic severity is a sliding scale. For this study, patients that suffer 
a stroke or serious clinical incident before the age of 18 are considered as severe, and patients 
that reach 30 years without serious incident as mild. In addition to this, onset of symptoms 




Due to the variation in phenotype severity observed, there is no ‘one size fits all’ treatment for 
SCA. A variety of treatment options are available, with different advantages and disadvantages, 
and a specific treatment plan is generally decided on a case by case basis depending on the 
frequency and severity of the symptoms observed. 
Bone marrow transplant remains the most comprehensive treatment option, at least partially 
replacing the host’s sickle HSC population with that from a healthy donor, leading to increased 
production of healthy erythrocytes209–211. However, bone marrow transplantation is an invasive 
procedure, requiring the availability of an HLA-matched sibling, and risks severe complications 
such as graft versus host disease212–214. As a result, very few SCA patients receive this 
treatment. 
Blood transfusions are an effective temporary treatment option for SCA patients, increasing the 
proportion of healthy erythrocytes circulating in the peripheral blood. These can either be 
administered as treatment in response to an acute clinical event, to alleviate symptoms and 
assist in recovery, or they can be used as a preventative measure for patients at risk of stroke, 
as identified by severe clinical history or TCD215–218. The STOP (Stroke Prevention in Sickle Cell 
Anaemia) trial demonstrated that regular transfusions as a long-term treatment plan was able to 
reduce incidence of primary stroke in children with SCA218.  
Patients receiving regular blood transfusions require frequent hospital visits, and risk long term 
complications. Regular blood infusions increases the risk of alloimmunisation, triggering an 
adaptive immune response to donor erythrocytes and resulting in haemolysis of transfused 
blood, reducing the effectiveness of treatment and increasing the burden of clearing already 
high levels of haemolytic debris from the bloodstream219. Interestingly the rates of 
alloimmunisation vary between countries, and is thought to be linked to the shared genetic 
ancestry of the donor and the recipient, i.e. patients of African or Asian ancestry treated in 
countries with a majority of white donors experience higher rates of alloimmunisation219–221. 
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As well as increased risk of blood borne infections, regular blood transfusions increase levels of 
iron, which is released from erythrocytes upon haemolysis, and over time can result in iron 
overload218. Due to the redox activity of unbound iron, iron overload results in increased free 
radical production and higher levels of oxidative stress and inflammatory response to the 
damage caused222. Excess iron that cannot be excreted builds up in hepatocytes and eventually 
cardiomyocytes, and can lead to cirrhosis and heart failure222,223. Iron overload as a result of 
regular transfusions is a significant cause of death among SCA patients, and the monitoring of 
iron levels is important to minimise risks, and to ensure that the need for chelation therapy is 
identified at an early stage222,224,225. 
Hydroxyurea (HU, also referred to as hydroxycarbamide) is the most commonly prescribed drug 
for treatment of SCA, and significantly reduces frequency of sickle cell crises and 
hospitalisations, increases overall survival and is preventative of strokes and other vaso-
occlusive events226–230. HU has been used as a chemotherapy drug to treat myeloproliferative 
neoplasms (MPNs) since the early 1960s, and was first tested for use in SCA patients in 1984, 
having being shown to increase foetal haemoglobin levels in anaemic monkeys231–233. MPNs are 
myeloid lineage cancers that result in uncontrolled expansion of blood cell populations, and HU 
was used for treatment since it disrupts DNA replication, and inhibits proliferation of the 
malignant cell types231,234,235. It is now known that HU blocks DNA synthesis through inhibition of 
Ribonucleotide Reductase (RNR), which catalyses the reduction of ribonucleotides to the 
deoxyribonucleotides required for DNA strand elongation, either during replication or DNA 
repair236,237. 
In SCA patients this cytotoxic effect of HU treatment results in a reduction of reticulocyte and 
white blood cell counts22. However, rates of haemolysis are decreased and a greater proportion 
of these reticulocytes survive, and the reduction in white blood cells may be beneficial in 
improving blood flow through narrow blood vessels238. 
The main benefit of HU treatment in SCA patients is mediated through the increase in foetal 
haemoglobin (HbF) levels; increased HbF provides a functional alternative to the sickle globin, 
as well as diluting the intracellular HbS concentration, competing for binding and forming hybrid 
tetramers (a2gbS). This is mediated through repression of the MYB, BCL11A, KLF1 and TAL1 
regulatory pathways, although how this is achieved is not fully understood81,239,240. Evidence 
supports the involvement of miRNA as well as the nitric oxide (NO) and cGMP signalling 
pathway, with HU treatment known to increase NO production either through signalling or as a 
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by-product of its degradation239,241–245. This increase is also caused by an increase in the 
proportion of F cells (erythrocytes with high HbF) in the peripheral blood, which occurs as a 
result of increased stress erythropoiesis in response to the cytotoxic effects of HU (1.4.2)246,247. 
Various other processes are also thought to be involved in the mechanism of action of HU, 
including increasing the oxygen affinity of haemoglobin (only the deoxygenated state of 
haemoglobin polymerises), mediated through a reduction in adenosine signalling248. Another 
proposed mechanism is through altering the expression of cell surface adhesion molecules, 
reducing rates of vaso-occlusion249. 
Because of the many processes and pathways that HU appears to affect, it is difficult to identify 
distinct mechanisms of action, since it is not clear which of these changes occur as a direct 
result of HU interaction, and which occur as a secondary response to either the cytotoxic stress 
of HU treatment, or to the general improvement in disease phenotype. For this reason it is 
important that reliable protocols are in place to investigate the epigenetic and transcriptional 
changes that occur in specific homogenous erythroid populations from SCA patients in vivo, 
since the additional stress of in vitro culturing further masks the pathways being influenced by 
HU treatment. While most current studies either use mouse models or in vitro culturing 
techniques (discussed in 1.4.3), a study by Walker et al. used a magnetic bead separation 
technique to isolate both DNA and RNA from erythroid progenitors in patients undergoing HU 
therapy245.  
Trials comparing HU treatment and phlebotomy to chronic blood transfusions and chelation 
therapy have been conducted in the USA, looking to prevent complications such as iron 
overload as a result of regular transfusions. The SWiTCH (Stroke With Transfusions Changing 
to Hydroxyurea) study was carried out in SCA patients that had experienced stroke at a young 
age (<18), and were receiving regular transfusions to prevent a secondary stroke250,251. TWiTCH 
(TCD With Transfusions Changing to Hydroxyurea) was a similar study, investigating SCA 
patients receiving regular transfusions to prevent initial stroke, having been identified as at risk 
by TCD252. SWiTCH was terminated early when HU was shown to be inferior to transfusions in 
preventing adverse effects, and did not alter liver iron levels250. TWiTCH however did 
demonstrate that liver iron levels were reduced in the HU treatment arm, and showed non-
inferiority to transfusions in terms of effect on TCD velocity and risk for stroke252. 
Prior to HU, other drugs had been used to re-activate expression of foetal haemoglobin, 
including butyrate and 5-azacytidine253–256. 5-azacytidine is incorporated into the genome as a 
65 
 
homologue of cytosine that cannot be methylated, inhibiting DNA methylation. This was thought 
to reactivate γ-globin by removing repressive DNA methylation marks at the promoter, 
highlighting a role for epigenetic factors in the pathology of SCA254,256. The study by Walker et 
al. found that HbF induction in response to HU was not accompanied by hypomethylation at the 
γ-globin promoter245. Interestingly butyrate is thought to increase translation efficiency of γ-
globin mRNA, suggesting the role of post-transcriptional regulators257. More recently, novel HbF 
inducers have been proposed, including rapamycin and pomalidomide258,259.  
Anti-sickling agents such as 5-hydroxymethyfurfural (5-HMF) has also been suggested as a 
potential treatment option, increasing the oxygen affinity of haemoglobin, and therefore reducing 
sickling260,261. 
The vasodilatory effect of NO signalling has been identified as a potential mechanism by which 
HU may ameliorate SCA symptoms severity, and arginine treatment has been shown to reduce 
pain during sickle cell crises through the same mechanism242,262,263. NO is a vasodilatory 
signalling molecule that is synthesised from L-arginine by NO synthases, and supplementing 
arginine levels was suggested as a way to increase NO levels262,264. However the importance of 
the role of NO in SCA is disputed23, and the study that found arginine therapy to relieve pain 
during sickle crises also observed that low arginine in these patients didn’t always correlate with 
low NO, and suggested that the benefits of arginine therapy may also be conferred through NO 
independent pathways262. 
As a result of autosplenectomy, SCA patients have an increased susceptibility to infections, and 
preventative measures are started at an early age, with patients receiving additional 
vaccinations for Streptococcus pneumoniae, Influenza and Hepatitis B, as well as prophylactic 





1.6 Known Genetic Modifiers of SCA Phenotype Severity 
Haplotype analysis of the β-globin locus in SCA patients in Africa and Southern Asia has 
revealed a correlation between haplotype and severity of symptoms, highlighting that genetic 
factors outside of the βS mutation play a role in disease pathology187,269. 
Genetic variants in genes and pathways influencing the pathophysiology of SCA can account 
for some of the variation in severity that is observed. The two best characterised mechanisms of 
action for these genetic modifiers are those that increase HbF production, and those that cause 
α-thalassaemia. Both of these play a role in ameliorating the severity of the SCA phenotype. 
 
1.6.1 Foetal Haemoglobin 
Foetal haemoglobin (HbF) is expressed during foetal development, with a switch to HbA 
occurring shortly after birth. HbF is made up of two α subunits and two γ subunits (α2γ2), with β-
globin transcriptionally silent at this stage. This explains why there are no in utero complications 
of SCA (other than those caused by SCA in the mother270,271), and why symptoms are not 
observed until several months after birth272. Even moderately increased γ-globin levels in an 
erythrocyte leads to competition for α-globin binding, reducing HbS formation, and 
polymerisation. 
Errors can occur in the regulatory switch from γ-globin to β-globin, and in healthy adults 
individual erythrocytes may contain high HbF, these are referred to as F cells, and generally 
account for <1% of total blood haemoglobin273,274. Genetic variants have been identified that 
result in much higher levels of HbF in adults, collectively these are characterised as Hereditary 
Persistence of Foetal Haemoglobin (HPFH) syndromes. In HPFH patients, HbF expression is 
not limited to F-cells, but is expressed universally across erythrocytes, since rather than being a 
stochastic phenomenon caused by dysregulation on a cell by cell basis, every cell contains the 
same genetic variant, which will affect HbF γ-globin expression in the same way269. 
HPFH can be caused by genetic variants at the β-globin locus that directly influence gene 
expression. These include variants that disrupt the β-globin promoter, variants in the promoter 
or intronic regions of the γ-globin genes that are associated with transcriptional repression, and 




Alternatively genetic variants causative of HPFH can disrupt genes in pathways that regulate 
expression from the β-globin locus, these include genes such as BCL11A and KLF163,74,276,277. 
Another mechanism for HPFH is through variants that result in increased haematopoiesis276. 
Under hypoxic conditions stress erythropoiesis can occur, stimulating an increased rate of 
erythrocyte production, achieved by the release of premature erythroid progenitor cells from the 
bone marrow141,142. Since the γ-globin to β-globin switch occurs during erythroid maturation, 
these premature erythrocytes still synthesise γ-globin, leading to an overall increase in blood 
HbF levels139,143,278 (discussed in more detail in 1.4.2). MYB is haematopoietic regulator that is 
required for cell cycle progression of erythroid progenitors and HSCs, playing a crucial role in 
proliferation and differentiation78. As a result of this MYB has oncogenic potential, and variants 
up-regulating the function of MYB are implicated in various cancers, including leukaemia279,280.  
MYB acts as a transcriptional activator of key erythroid transcription factors KLF1 & LMO2, 
which both play a role in transcriptional regulation at the β-globin locus77. Variants in the 
intergenic region between MYB and HBS1L, have been linked to high HbF levels by GWAS, 
and ChIP-seq combined with Chromosome Conformation Capture (3C) shows a distal enhancer 
interaction with the MYB promoter79,80,281. 
Elevated HbF levels in healthy individuals is mostly asymptomatic. However, in patients with 
SCA or any other β-globinopathy, coinheritance of HPFH provides a functional alternative to βS 
and results in a less severe disease phenotype.  
HbF levels in SCA patients vary greatly, and associate with the different sickle globin 
haplotypes (Figure 1.8). Individuals with the Senegal or Saudi Arabia/India haplotypes generally 
have higher levels of HbF, and present a milder disease phenotype than those with the Bantu or 
Cameroon haplotype, while patients with the Central African Republic haplotype generally have 
the lowest HbF levels and present the most severe symptoms269,282.  
Additional genetic studies have identified three quantitative trait loci (XmnI-Gγ on chromosome 
11p, BCL11A on 2p and the HBS1L-MYB intergenic region on 6q) that have been attributed to 
up to 50% of common HbF variation in SCA patients74,283. 
 
1.6.2 α-Thalassaemia 
Α-Thalassaemia is defined by insufficient production of the α-globin component of adult 
haemoglobin, resulting in a haemolytic anaemia. Similarly to γ-globin, α-globin is encoded by 
two paralogous genes (HBA1 & HBA2) both of which are situated in the α-globin like gene locus 
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(referred to as α-globin locus), shown in Figure 1.1. As is observed at the β-globin locus, 
developmental stage specific regulation results in a switch from the embryonic ζ-globin to adult 
α-globin, further adding to the repertoire of haemoglobin variants encountered during healthy 
development. Interestingly, it has been shown that ζ2βs2 haemoglobin does not polymerise in 
vitro, and expression of ζ-globin in a SCD mouse model reversed the phenotype, suggesting 
that similarly to γ-globin, persistent expression of ζ-globin could have a therapeutic effect on the 
SCA phenotypes. 
The expression of four functional α-globin genes in adults makes α-thalassaemia a particularly 
variable disease, both in terms of genotype and phenotype. Expression levels from each 
individual gene vary with genetic polymorphisms in their regulatory regions, while frameshift and 
stop gain mutations prevent the translation of functional products, however the most common 
genetic cause is the large scale deletion of an entire α-globin paralogue284,285. Disease severity 
varies with the amount of functional α-globin, which depends on a combination of gene copy 
number and functional expression level from each gene present285,286. 
Loss of a single α-globin gene (αα/α-) is asymptomatic and is classified as being a silent carrier, 
and loss of two copies (α-/α- or αα/--) is referred to as α-thalassaemia trait, only presenting a 
mild phenotype (mild anaemia). In the presence of less than two functional α-globin genes, the 
symptoms become much more severe, resulting in symptoms including severe haemolytic 
anaemia, oedema, jaundice and skeletal/cardiovascular malformations285,286. 
Similarly to SCD, α-thalassaemia has been associated with protection against malaria, and in α-
thalassaemia patients this effect is observed in both the heterozygous and homozygous 
forms287–289. This is contrary to what is observed in SCD, where the protective effect is limited to 
the heterozygous patients193. 
As a result of both disease phenotypes being evolutionarily advantageous in malaria rich 
regions, the global distributions of both SCA anaemia and α-thalassaemia are very similar, and 
they are often co-inherited, with 30-35% of SCA patients from an African ethnic background 
also having α-thalassaemia290–293. When co-inherited with even the silent carrier state of α-
thalassaemia, HbSS patients have reduced sickling, resulting in reduced haemolysis and 
increased erythrocyte lifespan. As such, some of the major symptoms of SCA are ameliorated, 
including risk of stroke and acute chest syndrome, however reduced haemolysis in these 
patients also leads to increased blood viscosity and been associated with increased vaso-
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occlusive crises and osteonecrosis294–300. These patients also have a reduced response to 
treatment with HU301. 
This effect on disease severity is most likely caused by a reduction in formation of the 
haemoglobin tetramer (α2βS2) due to a lack of α-globin. This results in lower intracellular HbS 
levels, and since βS-globin is only pathogenic when incorporated into haemoglobin, there is a 
reduction in the likelihood of polymerisation reaching the threshold required to distort the 
erythrocyte membrane. 
 
1.6.3 Epigenetic Modifiers 
As well as variation in severity between individuals of different genotypes, it has been observed 
that the SCA phenotype can vary between monozygotic twins302–304. Since these individuals are 
genetically identical, it can be assumed that any variation is due to epigenetic or environmental 






1.7 Genetic Editing: CRISPR-Cas9 
Recent advances in genomic editing techniques now present exciting opportunities for 
researchers investigating genetic disorders, not only for possible applications in the laboratory, 
but also for the potential to correct disease causing mutations in patients, which would become 
the pinnacle of personalised medicine. Unfortunately however, in addition to the ethical issues 
that will almost certainly be raised, there are technical obstacles that need to be overcome 
before this can become a reality.  
Firstly, from a practical viewpoint, an effective delivery system is needed, capable of introducing 
the CRISPR machinery into all cells of a target tissue. This is more achievable for tissues with a 
high turnover rate such as the haematopoietic lineages, where the desired mutation only has to 
be introduced into the HSC pool in bone marrow. However, in developed tissues with low 
turnover rates a much larger number of cells will need to be targeted directly. For the majority of 
cases, genomic correction may need to be carried out at early developmental stages to be 
effective, either to correct a progenitor population before the tissue becomes established, or 
because correcting the genotype may not reverse any damage already caused by deleterious 
mutations in developed tissues. 
Also, as is clearly demonstrated by the results in this study, the technique is not yet 100% 
accurate, especially when it relies on the use of the host’s endogenous DNA repair machinery. 
While directed cleavage of DNA by CRISPR is efficient, the genomic integration of template 
sequences is less so, often resulting in introduction of small insertion or deletions around the 
target site. Off target effects as well as these aberrant on target effects of CRISPR therapy 
could be catastrophic and unpredictable, and unlike the majority of non-surgical medical 
treatments, irreversible. Ideally cells need to be isolated, edited, rigorously tested and replaced. 
Bone marrow is one of the few tissues that can realistically fill all these criteria: blood cells have 
a high turnover rate, and therefore editing could potentially be done at any stage. Cells are 
repopulated from an easily isolatable stem cell population. Bone marrow transplants are already 
a commonly performed technique in severe haemoglobinopathies, and the dangers of host 




1.7.1 CRISPR-Cas9 Discovery 
The name ‘CRISPR’ (Clustered Regularly InterSpaced Palindromic Repeats), has no relevance 
to either the structure or mechanism of the CRISPR-Cas9 systems used in laboratories today, 
but instead refers to the structure of a highly repetitive locus that was initially identified in E. coli 
by Ishino in 1987, and was later observed in many other prokaryotes, often occurring at multiple 
sites in the genome305–307. The term ‘CRISPR’ was first coined by Jansen in 2002, along with 
the Cas (CRISPR-associated) family of genes that co-localised with the CRISPR loci307. 
In early 2005, both Mojica and Pourcel independently published that the non-repetitive regions 
separating these repeats (protospacer regions) were homologous to DNA sequences found in 
bacteriophages and other transmissible genetic elements, and they hypothesised that CRISPR 
loci play a role in protecting prokaryotes from pathogenic foreign DNA308,309. 
Also in 2005, Bolotin identified a variation in Streptococcus thermophilus and Streptococcus 
vestibularis, where Cas1-4 from previously investigated bacterial strains were absent, but had 
been replaced by a Cas1 homologue and two additional genes, one of these genes was Cas9 
(although referred to in this paper as Cas5)310. This was the first discovery of what would later 
become known as the Type II CRISPR System, the system currently used in laboratories 
around the world310,311. 
In 2007 Barrangou et al. confirmed the theory that CRISPR functions as a bacterial immune 
system, demonstrating in S. thermophilus that when cultured in the presence of bacteriophages, 
some cultures acquired resistance, and that this correlated with the incorporation of 
bacteriophage genomic DNA sequence into new protospacer elements in the bacterial 
genome312. Additionally, creating knockout strains of Cas7 and Cas9 (referred to as Cas5 in the 
paper) they showed that Cas7 was required for incorporation of new protospacer elements, and 
therefore acquisition of resistance, and that Cas9 was required for the resistance to be 
effected312. The papers by Bolotin & Barrangou also both mention that Cas9 contains nuclease 
activity, and that it is likely important for its function310,312. 
In 2008, van der Oost et al. found that the entire CRISPR loci of repeating elements was 
transcribed as one long CRISPR RNA (crRNA), and that this was cleaved by a complex of Cas 
proteins into short guide RNA (sgRNA), each containing one of the protospacer sequences313. 
They cloned components from a Type I CRISPR system from E. coli into a CRISPR negative E. 
coli strain, and designed an artificial crRNA to target λ phage. This was the first example of a 
CRISPR system being artificially targeted for a specific sequence of interest313.  Using this 
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system Oost et al. demonstrated that the CRISPR system was driven by sgRNA, cleaved from 
the longer crRNA transcript, and that this works for both sense and antisense RNA sequences, 
suggesting that dsDNA is the target. This theory was confirmed later on 2008 by Marraffini & 
Sontheimer, targeting an untranslated region of a conjugation plasmid, in the summary of this 
paper they go on to postulate that if the functionality of CRISPR is not limited to its use in 
bacterial systems, then it would have many potential uses, including its use in the clinic314. 
In 2010 it was shown that the cleavage site is not random, and that a double strand break is 
introduced 3bp upstream of the Protospacer Adjacent Motif (PAM), a sequence in the target 
DNA immediately at the 3’ of the protospacer sequence315. 
In 2011, performing RNA-seq on Streptococcus pyogenes, Deltcheva et al. came across a small 
non-coding RNA adjacent to the CRISPR locus316. This tracrRNA (trans-activating CRISPR 
RNA) was found to be required for crRNA processing into sgRNA, and has a 24bp sequence 
complementary to the CRISPR repeating region, suggesting a mechanism where the crRNA 
cleavage is directed by binding of tracrRNA316. It was shown in 2012 that this tracrRNA also 
interacts with Cas9 through its secondary structure, and therefore acts as the link that physically 
connects the sequence targeting sgRNA to the nuclease activity of Cas9311,317. 
In 2012 two separate papers were published demonstrating significant optimisation in the use of 
the CRISPR-Cas9 System, Gasiunas et al. demonstrated that by purifying the individual 
components they were able to perform CRISPR mediated cleavage in vitro, directed by 20bp 
protospacer sequences in the crRNA318. Jinek et al. (published as a collaboration between the 
Doudna and Charpentier laboratories) demonstrated that the tracrRNA was required to interact 
with Cas9, and that it was possible to fuse the sgRNA and the tracrRNA into a single gRNA 
molecule, streamlining the process for use outside of bacterial systems319. 
In January 2013 the first examples of CRISPR use in human cells were published, initially by 
Zhang and Church separately (in the same issue of Science)320,321, and then a few weeks later 
separately by Doudna and Kim322,323. All four of these papers used systems based on the S. 
pyogenes Type II CRISPR System, and the authors of all four papers have separately applied 




1.7.2 Mechanism: Bacterial ‘Immune System’ 
 
Figure 1.9: Figure from Mali et al. (2013)324. CRISPR Cas9 Type II System, showing the two distinct 
phases of bacterial ‘immune response’ and acquisition of resistance against invading viral DNA. Phase 1: 
Cas proteins (and Csn2) bind and recognise foreign DNA and cleave it into short 30bp ‘spacers’, and 
integrates these spacers into the host genome, at the 5’ end of the CRISPR array, separated by 36bp 
repeats. Phase 2: the CRISPR array is transcribed in full, and tracrRNA recognises and binds to the repeat 
regions, directing RNase III cleavage of the crRNA into sgRNA. tracrRNA-sgRNA complex recognise and 
bind to homologous sequence on foreign DNA. Cas9 is recruited by tracrRNA secondary structure, and 
cleaves the target DNA. 
 
 
The S. pyogenes Type II CRISPR system is shown in Figure 1.9, demonstrating how CRISPR 
works in bacteria to protect the cell from infection by previously encountered foreign DNA. Viral 
DNA that enters the cell is recognised and cleaved into short 30bp ‘protospacer’ DNA 
fragments. This process is not fully understood, but Cas9 is known to play a crucial role, and 
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interestingly the HNH and RuvC nuclease domains of Cas9 are not required, suggesting that its 
role in creating protospacer DNA does not include cleavage325. Disruption of the PAM site 
recognition domain, which specifies the ‘NGG’ sequence required at the 3’ of the target 
sequence for efficient cleavage, results in the creation of protospacer sequences with no PAM 
site specificity326. This suggests that the role of Cas9 at this stage is to identify eligible 
protospacer sequences upstream of potential PAM sites, to allow efficient cleavage when the 
same sequence is encountered upon re-infection. The requirement of a PAM site outside of the 
protospacer target sequence is an important feature that prevents Cas9 cleavage of the 
CRISPR array, which will contain an exact sequence match for each sgRNA produced. 
While the mechanism for initial recognition of foreign DNA is not fully understood, presumably it 
is relatively inefficient, or there would be no requirement for the adaptive immune response 
element of CRISPR. It has been observed that protospacers matching the bacterial host 
genome are sometimes incorporated into CRISPR arrays, resulting in severe genomic 
instability325. This suggests that this initial recognition may not be efficiently targeted against 
foreign DNA, and would explain the necessity of acquired immunity, with cells targeting self 
undergoing negative selection, and cells targeting pathogens undergoing positive selection. 
This is similar to the selection processes applied to mammalian T-cells during development in 
the thymus327. 
After the recognition and cleavage of foreign DNA, Cas1, Cas2 and Csn2 are then required for 
the integration of the 30bp protospacer into the CRISPR array325,326,328. Cas1 forms a complex 
with Cas2, and has nuclease activity, able to target a specific sequence at the 5’ end of the 
CRISPR array328. During this process, the new 30bp protospacer is inserted at the 5’ end of the 
CRISPR array, and the 36bp repeating unit is duplicated, so that it flanks either side of the new 
protospacer. 
The second phase of the CRISPR-Cas9 immune system, is the recognition and cleavage of 
foreign DNA upon reinfection. The entire CRISPR array is transcribed as one long crRNA, which 
is then broken down into sgRNAs, in a process coordinated by tracrRNA. tracrRNA have a 24bp 
region of sequence homology to the CRISPR array repeats, and recruit RNase III to these sites 
along the crRNA316. Cleavage occurs in both the protospacer sequence and the repeat region, 
leaving a sgRNA of 39-42bp, consisting of 20bp of protospacer target sequence at the 5’, and 
19-22bp of the repeat region at the 3’ 316. The subsequent sgRNA:tracrRNA complex binds to 
Cas9, and directs it to any sites matching the 20bp target sequence, which will be cleaved if a 
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PAM site (NGG) is situated immediately downstream of the target sequence. The secondary 
structure formed by the tracrRNA plays a key role in this process, and is required for Cas9 
activity, both in identifying potential protospacer sequences in the first phase, and for the 
cleavage of them in the second phase319,326. 
 
1.7.3 CRISPR-Cas9 as a Laboratory Tool 
For use in a laboratory setting, typically only the effector part of the CRISPR pathway is desired, 
and the Cas genes responsible for identifying novel foreign DNA elements, cleaving them and 
incorporating them into the host genome in the form of a CRISPR array, are omitted. The only 
components that are required are the sequence specific sgRNA, the tracrRNA and the effector 
complex. Typically, rather using two RNA components, the single fused gRNA model 
demonstrated by Doudna & Charpentier is used319. The most commonly used effector is based 
on Cas9, of the Class II Type II CRISPR System found in S. pyogenes. 
 
1.7.3.1 Other CRISPR Systems and Cas9 Variations 
There are two main classes of CRISPR system that have been identified in prokaryotes, defined 
by the component of the pathway responsible for binding to the tracrRNA, and introducing 
double strand breaks into the bound target DNA. Class I systems include Type I, Type III-A, 
Type III-B and Type IV CRISPR Systems, and rely on multiple subunits assembling to form one 
large complex, referred to as Cascade (CRISPR-associated Complex for Antiviral Defence) in 
Type I systems, Csm in Type III-A and Cmr in Type III-B329. The function and mechanism of 
Type IV systems are not fully understood, but have been identified based on sequence 
homology. Interestingly the Cas genes in Type IV are not always situated adjacent to a CRISPR 
array329. 
Class II includes Type II and Type V CRISPR Systems, these systems have one large gene that 
codes for the entire effector complex, that binds the tracrRNA and has the nuclease function, in 
Type II systems this is Cas9, and in Type V this is Cpf1329.  
Class II systems rather than Class I have been isolated and optimised for use in the laboratory, 
since it is much more efficient to clone and express a single gene than to dissect the Cas 
operon and clone several individual subunits. As was mentioned in 1.7.1, the initial four papers 
describing the use of CRISPR in human cells all used a Type II system based on Cas9 from S. 
pyogenes, optimised for human codon usage. This remains the most commonly used CRISPR 
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method in laboratories today, and various modified versions are now available, allowing 
researchers to tailor the Cas9 function to suit the requirements of their experiments. 
Modified Cas9 variants are now available, including versions in which one of the nuclease 
domains is inactivated, either the HNH domain, which cleaves the strand bound by the gRNA or 
the RuvC domain, which cleaves the non-complementary strand319. The resultant Cas9 variants 
only cleave one strand, and are referred to as Cas9 ‘nickases’, these only introduce double 
strand breaks if two gRNA are used in parallel on opposite strands, and greatly increase 
cleavage specificity, since if only one gRNA binds within a region, a nick rather than a double 
strand break is introduced, reducing off-target effects330,331. Other variants harbour mutations 
disrupting both nuclease domains; these Cas9Null variants do not have any nuclease activity, but 
can be tagged to another protein or domain with a regulatory function. In these cases CRISPR 
is used as a molecular delivery system, with Cas9-directed recruitment of a transcription factor 
or epigenetic modifier to a specific locus332–334. 
The Type V system is now also being used in laboratories, and is considered to have several 
advantages over the Type II system. Type V is still a Class II System, and so still only requires a 
single molecule effector (Cpf1), and Cpf1 is smaller than Cas9, and can therefore be introduced 
into cells more easily. Endogenous Cpf1 from Francisella novicida is 3,900bp, while Cas9 from 
the same strain (F. novicida has both systems) is 4,887bp, and the commercially available 
optimised Cas9 from S. pyogenes is 4,101bp335. The sgRNA produced after processing of the 
crRNA in the Type V system interact directly with Cpf1, and no tracrRNA is required, similarly to 
the gRNA system designed by Doudna & Charpentier for the Type II system319,335. The PAM site 
required for cutting by Cpf1 is ‘TTN’ at the 5’ of the target sequence335. The fact that this is 
different from the ‘NGG’ favoured by Cas9 provides additional flexibility in gRNA design, which 
is limited by presence of a PAM site in the target region, e.g. if the region of interest has a low 
abundance of ‘GG’ dinucleotide, the Cpf1 system can be used instead (and vice versa). 
Additionally, while Cas9 produces blunt ends, Cpf1 cleavage leaves a 5-nucleotide overhang at 
the 5’ end, this can be used for efficient template insertion if an artificial template with the same 
overhangs is generated335. Since the cleavage sites are not palindromic like the sequences 
typically targeted by restriction endonucleases, the overhangs produced are not identical 




1.7.3.2 Endogenous Repair Machinery 
While the gRNA directed cleavage of DNA by Cas9 is highly specific and efficient, the 
subsequent Double Strand Break (DSB) repair relies on the host’s endogenous repair 
machinery, and is less predictable. 
 
Figure 1.10: Overview of the two main DSB repair pathways in humans. NHEJ – Non Homologous End 
Joining. HR – Homology Directed Repair. NHEJ involves the identification of DSB ends by Ku70/80, 
followed by non-specific end processing and ligation by Ligase IV. HDR pathway uses homologous 
sequence as a repair template to correct the damaged sequence. Image from Lans et al. (2012)336. 
 
Two main pathways repair DSBs in humans, Non-Homologous End Joining (NHEJ) or 
Homology Directed Repair (HDR), as summarised in Figure 1.10. NHEJ is non-specific, with 
ku70/80 recognising two dsDNA ends, and Ligase IV ligating them, often resulting in 
introduction of short insertions or deletions.  
HDR relies on the identification of a homologous sequence to use as a template to repair the 
gap between the two ends, which would usually be the other allele. In HDR, the MRN complex 
recognises and binds to the DSBs, and recruits other factors including StIP, which is required 
for trimming the 5’ strand, leaving a 3’ overhang at the DSB site337,338. RAD51 displaces the 
bound RPA, and enables the 3’ overhang to ‘invade’ nearby dsDNA. When a region of 
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sequence homology is found, the overhang acts as a primer, and polymerases extend the 
sequence, reading off the template strand338. This continues until the junction between the two 
sister chromosomes is resolved, which can occur by a variety of different methods, and may 
result in recombination and genomic crossover338.  
For gene knockouts or introduction of non-specific deletions to disrupt a DNA motif, the NHEJ 
pathway is sufficient, and produces a variety of different genotypes with differing lengths of 
insertions or deletions as a result of end processing. However, for precise gene editing, where a 
specific sequence is desired, the HDR pathway is relied on. Under normal conditions, the HDR 
pathway uses the undamaged allele as the template for repair, but an artificial DNA repair 
template can be provided, containing a modified sequence for incorporation into the genome. 
Artificial DNA repair templates can either be incorporated into a plasmid, or introduced as 
independent DNA fragments, which can be either double stranded or single stranded339,340.  
Utilisation of HDR as a mechanism to incorporate template DNA into the genome after 
introduction of DSB is well established341,342. This was initially developed through the use of 
older techniques such as meganucleases, which bind and cleave specifically at long target 
sequences, which could be modified for sequences of interest342,343. More recently, this has 
developed into the use of fusion proteins, such as Zinc Finger Nuclease (ZFNs) and 
Transcription Activator Like Effector Nucleases TALENs, fusing nuclease domains to DNA 
binding domains with high sequence specificity, essentially allowing modular construction of a 
nuclease that targets a desired site342,344–346. This is very similar to the principle of CRISPR-
Cas9 targeted cleavage, but the ease with which gRNA can be substituted enables Cas9 based 
approaches to be more efficiently applied in practice, compared to fusion proteins which require 
construction of a new specific protein for each target site342. 
Template DNA for HDR can be either single or double stranded, and can be introduced to the 
cell directly, or incorporated into a vector such as a plasmid or virus347–349. When introducing the 
template sequence in the form of Single Stranded Oligodeoxynucleotides (ssODNs), efficient 
incorporation can be observed with sequence homology arms of >40bp flanking the targeted 
DSB site347. However, when using dsDNA, longer homology arms are required, typically ranging 
from 500-800bp either side of the target site, and linearised DNA is more efficient than a circular 
plasmid340,350,351.  
In order to improve the efficiency of cleavage directed genomic editing techniques such as 
CRIPSR, which rely on the incorporation of a template sequence into the host genome, the 
79 
 
HDR pathway is preferred over NHEJ. There are several techniques that have been suggested 
as a way to promote HDR over NHEJ in cells, including both transitory changes, such as siRNA 
knockdown of NHEJ components, as well as permanent changes, such as gene knock outs352–
354. While knock outs are more efficient, and would effectively silence the NHEJ pathway, they 
risk substantial genomic instability in any subsequent cell lines generated354–356. Transitory 
silencing is therefore preferable, since the loss of NHEJ function can be limited to a short time 
frame during which genome editing is taking place. 
Alternative methods to promote rates of HDR over NHEJ include small molecule inhibitors of the 
NHEJ pathway, such as the Ligase IV inhibitor SCR7357,358, as well as taking advantage of the 
differences in activity observed during different phases of the cell cycle. NHEJ is active 
throughout the cell cycle, whereas HDR activity is mostly active during S-Phase359. It has 
recently been shown that the use of modulators of the cell cycle, such as Cyclin D1, can 
increase HDR efficiency by promoting transition to S-Phase351. Modified versions of Cas9 fused 
to a Geminin, a protein that is targeted for degradation during G1 have also been shown to 
increase efficiency, allowing temporal regulation of Cas9 machinery to ensure that cleavage 
occurs at a time when HDR is most efficient360,361. 
 
1.7.3.3 Off-Target Activity of CRISPR-Cas9 
 
The off-target effects of CRISPR-Cas9 directed cleavage of DNA are well documented. ChIP-
Seq experiments have demonstrated Cas9 occupancy at off-target sites, and while this is 
believed to overestimate off-target effects, since Cas9 occupancy does not necessarily correlate 
with actual cleavage, whole genome sequencing analyses identify a large number of indel 
mutations and SNPs at loci across the genome, in both coding and non-coding regions362–366. 
This off-target activity is mostly unpredictable, and could severely restrict the conclusions that 
are able to be drawn from experiments replicating mutations using this technique. To verify that 
any observed effects are caused by the mutation of interest rather than secondary mutations 
introduced at other genomic loci, it may be necessary to carry out costly genomewide analyses 
to document all the specific off-target effects for each clonal cell population generated. 
The majority of off-target activity appears to arise as a result of S. pyogenes Cas9 tolerating 
some mismatches between the gRNA and the bound DNA, with increased tolerance further 
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away from the PAM site, and frequency of cleavage at these off target sites also increases at 
higher Cas9 concentrations367,368. 
While the off target effects can be mediated to a certain extent by selecting gRNA with the 
fewest predicted off-target sites, based on sequence similarity in the target host genome, there 
is only limited scope for this, especially when introducing specific mutations, since the gRNA 
need to be as close to the target site as possible to maximise efficiency for HDR. Instead, 
specificity may be improved through the use of other Cas9 variants, such as the Cas9 nickases 
described in .1.7.3.1, where two different Cas9 molecules must bind on opposite strands and in 
close proximity to cleave DNA324. Modified versions of Cas9 have now also been generated 
specifically for their improved specificity and reduction in off-target activity, these include High 
Fidelity Cas9 (spCas9-HF1), Enhanced Specificity Cas9 (eSpCas9) & Hyper Accurate Cas9 
(HypaCas9)369–371. Interestingly, truncated gRNA (tru-gRNA) with target sequences shorter than 
the usual 20bp have also been demonstrated to reduce Cas9 off-target activity372. 
 
1.7.4 Current Clinical Work 
The development of accurate genomic editing techniques such as CRISPR-Cas9 present many 
therapeutic opportunities, particularly for monogenic blood disorders such as SCA. The sickle 
cell mutation has already been corrected using CRISPR-Cas9 in human erythroid progenitors in 
vitro, although with a very low efficiency, highlighting the issue of relying on the endogenous 
HDR machinery373. 
An alternative strategy has been to introduce large scale deletions at the β-globin locus, 
mimicking a naturally occurring 13kb deletion that causes HPFH, increasing γ-globin 
expression374.  Introducing genomic deletions relies on the NHEJ pathway rather than HDR and 
is much more efficient, correction of the sickle mutation requires a highly specific gene-edited 
product, whereas the lack of specificity of the large deletion allows for more sequence variation 
surrounding the deletion site after the DSB repair. 
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 Materials & Methods 
2.1 Isolation of Erythroid Progenitors 
2.1.1 Blood Samples & PBMC Isolation 
Peripheral blood samples were collected from either healthy donors, or anonymised SCA 
patients, recruited from Guy’s Hospital or King’s College Hospital to participate in projects IRAS 
ID - 128238 or IRAS ID - 35853. 
9 – 27ml blood were collected in vacuum tubes containing EDTA. Samples were centrifuged at 
3000rpm for 10 minutes, and the Buffy Layer collected using a Pasteur pipette. The Buffy Layer 
was diluted 1:1 in Dulbecco’s Phosphate-Buffered Saline (PBS), gently layered onto 2/3 by 
volume of pre-warmed Histopaque®-1077 (Sigma-Aldrich – 10771) in polystyrene culture tubes 
(Corning - 430172). Samples were centrifuged at 1900rpm for 30min with no brake, and the 
PBMC layer was collected using a Pasteur pipette. 
PBMC samples were then washed three times in PBS before progressing to downstream steps. 
 
2.1.2 Culture Conditions 
Phase 1: PBMCs were plated at 107 cells per ml, in StemSpan™ media (Stem Cell 
Technologies - 09650), supplemented with 1 nM Dexamethasone (Sigma-Aldrich – D4902), 2 
U/ml Erythropoietin (Eprex), 40 ng/μl Insulin-like Growth Factor 1 (R&D Systems – 291-G1-
200), 2 ng/ml Interleukin-3 (Stem Cell Technologies - 02603), 2 mM L-Glutamine (Sigma-Aldrich 
– G7513), 1% Penicillin & Streptomycin (Sigma-Aldrich – P4333), 40 ng/μl Stem Cell Factor 
(Sigma – S7901) and 0.2% Synthechol (Sigma-Aldrich – S5442). The cultures were transferred 
to new plates daily, in order to remove adherent cells. The medium was refreshed on Phase 1 
Day 3 (P1D3), when cells were diluted to 2 x 106 cells per ml, and Interleukin-3 concentration 
was reduced to 1 ng/ml. 
Phase 2: Phase two was initiated on either P1D6 or P1D7, depending on the health of the 
culture as assessed by cytospin. The medium was fully replaced, without Interleukin-3, and cells 
were diluted to 106 cells per ml, and maintained at this concentration for the remainder of the 





Aliquots were concentrated onto microscope slide by centrifugation at 1000rpm for 3min in a 
cytocentrifuge (Thermo Scientific™ Cytospin™ 4). Slides were incubated for one minute in each 
of methanol fixation solution, eosin solution, and methylene blue solution (Thermo Fisher 
Scientific - 10435310). Stained cells were air-dried before addition of DPX Mountant and cover 
slip. 
 
2.1.4 Flow Cytometry & Cell Sorting 
Cells were re-suspended in 80μl PBS and incubated for 20min at room temperature with 20μl 
Human Fc Receptor Binding Inhibitor (eBioscience - 14-9161-73). 5μl of antibody was added, 
and cells were incubated for 30min at room temperature in the dark and washed with PBS prior 
to analysis or sorting. 
Flow cytometry analysis was carried out using BD Accuri™, BD FACSCalibur™ or BD 
FACSCanto II™ cytometers. Fluorescence-Activated Cell Sorting (FACS) was carried out on BD 
FACSAria™ cell sorters, as a service provided by the BRC Flow Cytometry Core Facility at 
Guy’s Hospital. The FACS service was unavailable outside of working hours, and so for direct 
sorting of SCA patient PBMCs, cells were plated in the culture medium overnight before sorting 
the following day, at P1D1. 
Fluorescent antibodies used for flow cytometry: anti-CD71-APC (eBioscience - 17-0719-42), 
anti-Glycophorin A-FITC (eBioscience - 11-9886-42), anti-CD45-eFluor® 450 (eBioscience - 48-
9459-42), anti-CD34-PE (Miltenyi Biotec - 130-098-140), anti-CD14-PE-Cy7 (eBioscience - 
9025-0149-120) and anti-c-Kit-PE-Cy7 (eBioscience - 25-1178-42). 
 
2.1.5 Antibody-MicroBead Cell Isolation 
For CD71+ cell isolation, freshly extracted PBMCs were depleted of CD45+ cells using Human 
CD45 MicroBead kit (Miltenyi Biotec - 130-045-801) using LD columns. The CD45- fraction was 
then enriched for CD71+ cells using Human CD71 MicroBead Kit (Miltenyi Biotec - 130-046-201) 
using MS columns. 
CD34+ cells were isolated from freshly extracted PBMCs using Human CD34 MicroBead Kit 
UltraPure (Miltenyi Biotec - 130-100-453) using MS columns, the protocol was repeated with an 
additional column, for increased purity. 
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For isolation of GPA-CD71+ cells, freshly extracted PBMCs were depleted of GPA+ cells using 
Human CD235a (Glycophorin A) MicroBead Kit (Miltenyi Biotec – 130-050-501) using LD 
columns. The GPA- fraction was then enriched for CD71+ cells using Human CD71 MicroBead 
Kit (Miltenyi Biotec - 130-046-201) using MS columns. 
 
2.1.6 DNA & RNA extractions 
DNA & RNA were extracted simultaneously from isolated erythroid progenitor cells either after 
storage in TRIzol® Reagent (Thermo Fisher Scientific - 15596018) at -80°C, or immediately 
after isolation using a Qiagen AllPrep DNA/RNA/Protein Mini Kit (Qiagen - 80004), in 
conjunction with a QIAshredder (Qiagen - 79654) for homogenisation. Where DNA & RNA were 
extracted from cells separately, DNA was extracted using a Qiagen DNeasy Blood & Tissue Kit 
(Qiagen - 69504), Qiagen Puregene Blood Core Kit A (Qiagen - 158445), or a Qiagen QiaAMP 
DNA Micro Kit (Qiagen - 56304), and RNA was extracted using a Qiagen RNeasy Mini Kit 
(Qiagen - 74104). Concentrations were analysed by NanoDrop Spectrophotometer (NanoDrop 
2000 or NanoDrop One) or by Qubit using Qubit® dsDNA HS Assay Kit (Thermo Fisher 
Scientific - Q32854) and Qubit® RNA HS Assay Kit (Thermo Fisher Scientific - Q32852) for 





2.2 Whole Exome Sequencing 
2.2.1 SCA Patient WES Data 
2.2.1.1 SCA Patients from King’s College Hospital 
Samples were selected from a collection of >700 SCA patients managed by Professor Swee 
Lay Thein and her team at King’s College Hospital. These patients had been recruited for 
participation in genetic research, under projects LREC 01-083, 07/H0606/165 or 12/LO/1610. 
Patients were classified as either mild or severe in consultation with Professor Thein & Dr 
Catherine Gardner. 
Genomic DNA (gDNA) samples of >1.5µg were submitted to the NIHR Biomedical Research 
Centre Genomics Core Facility at Guy’s and St Thomas’ NHS Foundation Trust, for Whole 
Exome Sequencing (WES) library preparation and sequencing. Exome capture was carried out 
using Agilent SureSelectXT Human All Exon v5 kit (Agilent – 5190-6210), and samples were 
sequenced on an Illumina HiSeq2000. Sequence reads were mapped to the reference genome 
(GRCh37/hg19), assessed for read quality and variant calls were annotated, this was carried 
out using an in-house analytical pipeline developed by Professor Michael Simpson. 
 
2.2.1.2 SCA Data from dbGaP Dataset 
Exome sequencing data from clinical trials investigating response to HU therapy in SCA 
patients were obtained through dbGaP (Study Accession ID: phs000691.v2.p1)375. Analyses of 
the data generated in this study were initially published by Sheehan et al. in 2014376.  
These samples were sequenced in the Human Genome Sequencing Center at Baylor College 
of Medicine, exome capture was carried out using Roche SeqCap EZ HGSC VCRome 2.1 kit 
(Roche NimbleGen - 06465587001), and samples were sequenced on an Illumina HiSeq2000. 
651 patients were included in the study data, of which 143 were recruited as part of the Long 
Term Effects of Hydroxyurea Therapy in Children With Sickle Cell Disease clinical trial 
(HUSTLE - NCT00305175), 132 of the Stroke With Transfusions Changing to Hydroxyurea 
clinical trial (SWiTCH - NCT00122980) and 139 of the Transcranial Doppler (TCD) With 
Transfusions Changing to Hydroxyurea clinical trial (TWiTCH - NCT01425307), the remaining 
237 had no annotated source. 
Short read archive files were downloaded from dbGaP (phs000691.v2.p1), converted into 
FASTQ format, and then processed through the same alignment, quality control and variant 
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calling pipeline as the in-house exomes, in order to minimise variation between the two data 
sources. 
 
2.2.2 Filtering of ANNOVAR Annotated Variants & Statistical Testing 
Bioinformatic tools were used to identify relevant candidate variants, and to perform statistical 
tests for significance between the mild and severe SCA patient groups. 
 
2.2.2.1 Computational Tools for Filtering 
Details of the individual variant filtering criteria used for each specific analysis performed is 
described in full in 4.3.1. Variant filtering steps were performed on the British Research 
Council’s Athena-Apollo High Performance Computing Cluster at KCL, using Python v2.7.12. 
 
2.2.2.2 Fisher’s Exact Test 
Fisher’s exact test was performed using the SciPy Python for Scientific Computing Toolkit377. 
 
2.2.2.3 CADD Phred-Like Variant Scoring 
Combined Annotation Dependant Depletion (CADD) Phred-like scores were obtained for coding 
variants and loss of function mutations from http://cadd.gs.washington.edu378. 
 
2.2.3 Manual Assessment of Variants 
Top candidate variants were assessed individually based on the proximity of the variant to any 
annotated structures within the gene, and their inclusion in any alternative splicing isoforms. 
 
2.2.3.1 Identification of Gene Features 
Information regarding annotated protein domains and conserved regions as well as structural 
information was accessed from the neXtProt knowledgebase on human proteins379. 
 
2.2.3.2 Identification of Alternative Isoforms 
Alternative splicing isoforms were investigated using the University of California Santa Cruz 




2.3 CRSIPR-Cas9 Plasmid 
CRISPR-Cas9 plasmids were provided by Horizon Discovery Group, as part of a programme to 
test their gUIDEbook™ gRNA design platform set up through a partnership with Desktop 
Genetics Ltd.  The plasmids provided were derived from pD1301, and key features include a 
kanamycin resistance gene, a chimeric gRNA scaffold and a Cas9 tagged with a self-cleavable 
linker to DasherGFP. 
The gRNA consists of a 20bp target sequence, identical to the region of interest in the host 
genome, coupled to a 76bp gRNA scaffold that forms a secondary structure to interact with 
Cas9. Expression of the gRNA is controlled by the P_hU6.1-human RNA expression promoter 
containing a TATA box.  
The Cas9 is derived from that found in Streptococcus pyogenes, and has nuclease activity 
capable of introducing double strand breaks in mammalian DNA, directed by interactions with 
the gRNA. Expression of Cas9 is controlled by E_CMV, a cytomegalovirus enhancer element, 
and P_CMV, a constitutive mammalian promoter with strong expression. Cas9 is tagged at both 
the 5’ and 3’ ends with nuclear localisation signals (NLS), which direct proteins for nuclear 
import, ends. Downstream of the 3’NLS is a CHYSEL_TAV linker connecting to DasherGFP. 
CHYSEL (cis-acting hydrolase element) will self-cleave in the cytoplasm after translation, 
leaving cytosolic GFP as a marker for expression, while Cas9 is targeted to the nucleus. 
Downstream of DasherGFP is pA_GH-bovine(min), a polyadenylation signal. 
The kanamycin resistance gene encodes Neomycin phosphotransferase II and allows survival 
in medium containing kanamycin. Expression is controlled by bacterial promoter P_Amp. 
Ori_pUC is an origin of replication sequence derived from E. coli, allowing the plasmid to 
replicate when transformed into competent bacteria. 
Bacterial transcriptional termination cites Term_rpoC & Term_bla are included upstream of the 
human expression promoter, to prevent read through and unregulated expression of gRNA & 
Cas9 in bacterial cells. 
The full plasmid map is shown in Figure 2.1 and the full sequence is provided in Appendix 2, 




Figure 2.1: Plasmid map of the 9kb pD1301 Cas9 plasmid provided by Horizon Discovery Group. Key 
features are highlighted: Cas9 is shown in red, self-cleaving GFP tag in green, kanamycin resistance gene 





2.4 CRIPSR-Cas9 Genomic Editing 
2.4.1 gRNA Design 
gRNA to target the SNP sites in the ASH1L and KLF1 genes were designed using the online 
tool DESKGEN381. Five candidate gRNA were initially selected for each SNP based on proximity 
of the cleavage site to the SNP, and the ‘on-target score’, a scoring mechanism designed to 
estimate the likelihood of Cas9 cleavage382,383.  
 
         
     PAM Site 
Disrupted PAM 
Site 
 gRNA Off Target 
On 
Target Distance Protein DNA Protein DNA 
K1 GATCTCAGCTTAGTCTGGCA 89 62 22bp n/a GGG n/a GCG 
K2 AGGTACGCTCAGTCCAGGAG 87 61 3bp n/a AGG n/a AGC 
K3 AGTCTGGCAGGGGGTGAGGA 50 51 34bp n/a GGG n/a GCG 
K4 TAAGCTGAGATCTCCTCTCC 79 51 1bp n/a TGG n/a TGC 
K5 AAGAGACTTAACCAGGACTG 73 68 23bp n/a AGG n/a ACG 
         





A2 CAAACCCTAACTCCAGTGGC 88 57 24bp R CGG R CGA 
A3 GTTTCAAACCCTAACTCCAG 61 70 20bp G GGC 
Not 
Possible - 
A4 AACCTTTTCACAAGTGCAAT 77 50 14bp G GGC 
Not 
Possible - 




Table 2.1: Five candidate gRNAs for both the KLF1 (K1-5) and ASH1L (A1-5) SNPs. The on-target and 
off-target scores are shown, along with the gRNA sequence and distance between the target SNP and the 
cleavage site. The codons in which the endogenous PAM sites are situated are shown, with the GG 
dinucleotide in bold. Red indicates proposed changes to disrupt the PAM site. K1 & K2 were selected for 
KLF1, due to high off-target scores, which were considered more important. A1 & A2 were selected for 
ASH1L, since they were the only gRNAs with PAM sites that could be silently disrupted, they also have 
high off-target scores. 
 
The five gRNAs are shown in Table 2.1, of these five, two gRNA were selected for use for each 
SNP, these were chosen based on the ‘off-target score’, an inverse scoring mechanism to 
predict the likelihood of Cas9 cleaving non-targeted regions of the host genome with a similar 
sequence to the gRNA368. The ability to introduce a silent mutation to disrupt the PAM site was 
also investigated at this stage. Due to the fact that the KLF1 SNP is intronic, and thought to 
disrupt transcription factor binding, any disruption of the PAM site may also influence 
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transcription factor binding, making it difficult to distinguish which of the two mutations is the 
cause of any effect observed. Therefore for the KLF1 SNP, a negative control was carried out, 
introducing only the PAM mutation. 
 
2.4.2 Plasmid Design & Cloning 
A DNA sequence containing the target SNP and the PAM site disruption was cloned into each 
plasmid. This sequence acts as a template, and is incorporated into the host by Homology 
Directed Repair (HDR) after cleavage of the genomic DNA target sequence by Cas9. Including 
the PAM site disruption in the template sequence not only prevents Cas9 from repeatedly 
cutting the genomic DNA once the sequence has been incorporated, but also prevents cleavage 
of the template DNA in the plasmid. 
Initially, unmodified template DNA (containing the wild type sequence) was cloned into each 
plasmid. A 20bp gRNA target sequence was then substituted in by Site Directed Mutagenesis 
(SDM). A PAM site disruption mutation was then introduced to the template DNA in each of 
these plasmids, specific to the gRNA target sequence. This was also achieved by SDM. 
Aliquots of plasmids at this stage were kept for use as PAM site only controls. The SNPs of 
interest were then introduced to the template DNA, also by SDM. This process is outlined in 
Figure 2.2. 
 
Figure 2.2: Diagram showing the cloning workflow to generate plasmids for introduction of specific genetic 
variants using the CRISPR-Cas9 system. Template sequence is indicated in purple, gRNA in blue, PAM 




2.4.2.1 Unmodified Template DNA Insertion 
Template DNA was inserted into the CRISPR-Cas9 plasmids at a BssHII restriction site, 
situated between the kanamycin resistance gene and the origin of replication sequence. 
Unmodified template DNA was amplified from K562 genomic DNA by PCR, using primers 
tagged with a 6bp spacer and a 6bp BssHII restriction site at the 5’ end. PCR products were 
Sanger sequenced to confirm that the K562 sequence matched that of the reference genome, 
since cancer cell lines typically carry high levels of genetic variation. Sequences of the primers 
used for amplification are shown in Table 2.2 and the KLF1 & ASH1L regions amplified are 
shown in Figure 2.3. Full gene maps are provided in Appendix 1. 
The whole 20µl PCR reaction was run on an agarose gel, and bands were excised and DNA 
extracted as described in 2.5.4.2. Plasmids and PCR products were digested with BssHII (NEB 
– R0199S). 1µg plasmid, or up to 1µg of PCR product were added to 5µl 10X NEB CutSmart® 
Buffer and 1µl BssHII, and made up to a total reaction volume of 50µl with nuclease free H2O. 
Digests were run at 50°C for 1 hour, and then 65°C for 20 minutes to heat inactivate the 
enzyme. 
Products of the 50µl digest were run on an agarose gel, excised and extracted. Ligation was 
then performed using T4 DNA Ligase (NEB – M202S). 50ng of digested and purified plasmid 
was added to 2µl 10X T4 DNA Ligase Buffer and 1µl T4 DNA Ligase, the remainder of the 20µl 
reaction volume was then made up with the digested and purified PCR product. The reaction 
was incubated at 4°C overnight. 
10µl of the ligation reaction was transformed into competent cells and plated on agar with 
kanamycin (as described in 2.5.8). Colonies were screened for successful template insertion by 







Table 2.2: Table showing primer sequences used for amplification of KLF1 & ASH1L template DNA. 






Figure 2.3: Diagrams of PCR amplicons used to clone K562 genomic DNA into CRISPR-Cas9 plasmids to 
act as a template for Homology Directed Repair (HDR). Images are adapted from UCSC Genome Browser 
(http://genome.ucsc.edu - Assembly GRCh37/hg19380). A – 718bp amplicon from KLF1. B – 759bp 
amplicon from ASH1L. PCR amplicons are shown below the genomic sequence, with BssHII restriction 
site tags at 5’ of primer in purple. In the genomic DNA sequence the targeted SNPs are indicated by red 
lines, with methionine residues and start codons indicated in green. gRNA target sequences are 
highlighted in blue. Also shown are single stranded oligodeoxynucleotides (ssODN), which were designed 
as an alternative technique to introduce the template sequence. In the ssODNs the SNP is shown in red, 
and the PAM site disruption in green. Full gene maps are shown in Appendix 1. 
  
2.4.2.2 gRNA Sequence Substitution 
gRNA sequences were introduced to plasmids with successful template insertion. This was 
done using Site Directed Mutagenesis (SDM), performing a substitution of the initial 20bp gRNA 
sequence for one of those designed in 2.4.1. Primer sequences used for SDM are shown in 
Appendix 3, the 10bp at the 5’ of both forward and reverse primers contain the variable gRNA 
sequence, and the 3’ ends anneal to the sequences flanking the insertion site. Therefore all 
forward primers follow the pattern NNNNNNNNNN-GTTTTAGAGCTAGAAATAGCAAG, where 
N10 represents the last 10bp of the target sequence, and all reverse primers follow the pattern 
NNNNNNNNNN-CGGTGTTTCGTCCTTTCC, where N10 represents the reverse complement of 
the first 10bp of the target sequence. 
After the SDM reaction and plating of transformed DH5α on kanamycin plates (as described in 
2.5.6), colonies were screened by Sanger sequencing for incorporation of the new sequence. 




2.4.2.3 PAM Site Disruption & SNP Introduction in Template Sequence 
Plasmids containing the template insertion and the gRNA substitution underwent sequential 
rounds of SDM, transformation and cloning to introduce firstly a PAM site disruption mutation, 
as designed for each gRNA and shown in Table 2.1, and secondly the SNP of interest. The 
sequences for the SDM primers are shown in Table 2.3. 
Primer Sequence 



















Table 2.3: SDM primer sequences for PAM site disruption and SNP introduction to the template sequence 
in the CRISPR-Cas9 plasmid. PAM site disruption SNPs are highlighted in green, with targeted SNPs in 
red. In cases where the gRNA target sequence is close to the SNP, the PAM site is also close, in these 
cases both the PAM site disruption and the SNP must be included in the second SDM reaction, to prevent 
the SNP introduction SDM reversing the PAM site disruption. The possibility of using a single SDM 
reaction to introduce both variants was considered for these cases, this was rejected since it would not 
enable production of PAM only controls.  
 
 
2.4.3 siRNA Knock Down of Non-Homologous End Joining Pathway 
The first and last components of the NHEJ pathway, XRCC6 and LIG4, were targeted for knock 
down using siRNA. 
siRNA were ordered for both XRCC6 (OriGene - SR301689) and LIG4 (OriGene - SR302689), 
with three separate siRNAs provided for each target gene, as well as one vial of Universal 
Scrambled siRNA as a negative control (OriGene – SR30004). siRNAs were 27 ribonucleotides 
long, and were provided as 2nmol of lyophilised powder, which were resuspended in 100µl of 
RNAse free siRNA duplex resuspension buffer (OriGene – SR30005) to a final concentration of 
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20µM, and incubated at 94°C for 2 minutes before first use. Sequences of the siRNA, as well as 
the primers used for rtPCR analysis of knockdowns are shown in Appendix 4. 
siRNA were transfected alongside CRISPR plasmids by nucleofection, with 1.5µl (30pmol) of 
each of the three siRNA for either target gene, or 4.5µl (90pmol) scrambled siRNA, and up to 
5µg of CRISPR-Cas9 plasmid. 
 
2.4.4 Single Stranded Oligodeoxynucleotide (ssODN) Templates  
As an alternative to the template sequence incorporated into the plasmid, 110bp ssODNs with 
55bp sequence homology either side of the SNP were designed, and ordered from Eurofins 
Genomics. The ssODN templates also contained the PAM site disruption. This was done for 
gRNA A2 for ASH1L, and gRNA K3 with the corresponding PAM only template, for KLF1. 
Templates were designed antisense to transcription, since this has been shown to increase 
incorporation into the genome384. The ssODN sequences are shown in Table 2.4. ssODN 
alignments for gRNAs A2 and K3 against the ASH1L gene and KLF1 gene respectively are 
shown in Figure 2.3. ssODNs were transfected alongside the plasmids containing the relevant 
gRNA by nucleofection, with 30µg ssODN and up to 5µg plasmid. 
 
ssODN Target 
Gene & SNPs ssODN Sequence 













Table 2.4: Sequences for 110bp ssODN templates used. PAM only control was used in parallel for KLF1 
but not ASH1L, due to the fact that the PAM disruption is translationally silent. PAM disruptions are 





2.5 Molecular Biology & Cloning Tools 
2.5.1 Oligonucleotide Primers 
Oligonucleotide primers for PCR, Sanger sequencing and rtPCR were designed using 
Primer3Plus Version 2.4.0385. Primers for Site Directed Mutagenesis were designed using the 
online tool NEBaseChanger™386. All primers were ordered from Eurofins Genomics. 
 
2.5.2 Polymerase Chain Reaction (PCR) 
Unless otherwise specified, PCR was performed using ThermoPrime 2X ReddyMix PCR Master 
Mix (Thermo Scientific - AB0575DCLDB), and run on an MJ Research PTC-200 thermal cycler. 
The standard reaction mix for a 20µl reaction, and the standard PCR programme are shown 
below in Table 2.5. 
PCR Reaction Mix   PCR Thermal Cycling Programme 
Reagent Volume   Step Temp Time Cycle 
2X ReddyMix 10µl   Initial Denaturation 96°C 2 min - 
Forward Primer 20µM 0.5µl   Denaturation 96°C 30 sec 
Repeat 29x Reverse Primer 20µM 0.5µl   Annealing 58°C* 30 sec 
Nuclease Free H2O 8µl   Extension 67°C 1 min 
Template DNA 1µl   Final Extension 67°C 5 min - 
Total 20µl   Rest 4°C ∞ - 
 
Table 2.5: Tables Showing PCR reaction mix and Thermal Cycling programme for a standard PCR 
reaction. *Annealing temperature varies depending on the primers used, and was adjusted to 0.5-1.0°C 
below the lowest primer melting temperature. 
 
2.5.3 Agarose Gel Electrophoresis 
To check the size of dsDNA fragments generated e.g. by PCR or Restriction Endonuclease 
Digest, samples were run on an agarose gel. 
Gels aimed to target fragments >1kb or <1kb were made with either 1% or 1.5% respectively of 
UltraPure™ Agarose (Invitrogen – 16500-500) in TAE Buffer (40mM Tris acetate, 1mM EDTA 
pH 8.0). The solution was heated for roughly 2 minutes in a microwave and allowed to cool 
before adding 0.2µg/ml Ethidium Bromide (Sigma – E1510) and pouring into a gel cast. 
Gels were placed in a gel tank with TAE Buffer, and samples were diluted 5:6 with Purple Gel 
Loading Dye (NEB – B7025) before loading. Samples prepared using ReddyMix PCR Master 
Mix (as described in 2.5.2), already contained loading dye, and so no more was added. A DNA 
ladder of either 100bp (NEB – N3231) or 1kb (NEB – N3232) was also loaded as a marker of 
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fragment size. Gels were run at 100mV for 1 hour, or until sufficient size separation was 
observed. Gels were visualised using a UVP BioDoc-It™ Imaging System. 
  
2.5.4 PCR Clean-Up 
Prior to downstream processing of PCR products, it is frequently required to perform a ‘clean-
up’, removing any remaining primers and dNTPs. For Sanger sequencing reactions, residual 
primers can cause bidirectional sequencing, resulting in overlapping sequence traces that are 
unreadable. The Sanger sequencing reaction mixture contains a specific ratio of dNTPs to 
ddNTPs, which would be altered by residual dNTPs from the PCR reaction. 
In the case of TA cloning systems, primer dimer products can insert themselves into the 
plasmid, reducing cloning efficiency. 
 
2.5.4.1 ExoSAP-IT 
For Sanger sequencing of PCR products, 2.5µl of PCR product was added to 1µl ExoSAP-IT® 
PCR Product Cleanup (Affymetrix – 782011) and 11.5µl nuclease free H2O to a final reaction 
volume of 15µl. The reaction mixture was run on an MJ Research PTC-200 thermal cycler at 
37°C for 15 minutes, and then 94°C for 15 minutes to denature the enzymes. 
 
2.5.4.2 Gel Extraction 
For cloning of PCR products, gel extraction was used to clean up the PCR reaction. This allows 
size selection of the PCR product based on the section of the gel that is excised. Cloning 
efficiency improves as insert size decreases, and so smaller PCR products that may be present 
in quantities too low to observe on a gel, could still influence overall cloning efficiency, 
particularly when trying to insert large fragments. 
For gel extraction, gels were made with Low Melting Point (LMP) Agarose (Promega – V3841), 
which is more efficient for DNA extraction, and the gel tanks were run on ice to prevent the gels 
from melting in the heat generated by the current. 
Bands were excised from the gels using a scalpel, and DNA was extracted using a QIAquick 




2.5.5 Sanger Sequencing 
Sanger sequencing was performed on PCR products after clean up, or on plasmid DNA after 
extraction. Due to the high copy numbers of plasmids after extraction, amplification by PCR is 
not required prior to sequencing. The sequencing reaction was performed using BigDye 
Terminator v2.1/v3.1 Cycle Sequencing Kit (Thermo Fisher Scientific - 4337455). The reaction 
mix and the standard PCR programme are shown below in  
Table 2.6. Each sample requires two reactions, one containing the forward primer, and one 
containing the reverse. 
Sequencing Reaction Mix   PCR Thermal Cycling Programme 
Reagent Volume   Step Temp Time Cycle 
5X Sequencing Buffer 2µl   Initial Denaturation 96°C 1 min  
Sequencing Primer 20µM 0.4µl   Denaturation 96°C 30 sec 
Repeat 29x BigDye Reaction Mix 0.5µl   Annealing 58°C* 15 sec 
Nuclease Free H2O 4.6µl   Extension 62°C 1 min 
Template DNA 2.5µl   Rest 4°C ∞  
Total 10µl   
   
 
 
Table 2.6: Tables Showing Sanger sequencing reaction mix and Thermal Cycling programme for a 
standard sequencing reaction. *Annealing temperature varies depending on the primer used, and was 
adjusted to 0.5-1.0°C below the primer melting temperature. 
 
After the sequencing reaction, DNA was purified by ethanol precipitation. 30µl of 100% ethanol 
and 100mM Sodium Acetate was added to each reaction, samples were then incubated at 4°C 
for 20 minutes before being centrifuged at 3060xg at 4°C for 20 minutes. The supernatant was 
tipped off, and 30µl 70% Ethanol was added. Samples were then incubated at 4°C for 5 
minutes, before being centrifuged at 3060xg at 4°C for 10 minutes. The supernatant was tipped 
off again, and samples were left to air-dry at room temperature for 20 minutes. 
Samples were then resuspended in 10µl Hi-Di™ Formamide (Thermo Fisher Scientific - 
4404307) and incubated at 94°C for 2 minutes, before being analysed on a 3730xl DNA 
Analyzer. 
Sequencing traces were analysed manually using SnapGene Viewer387, and multiple sequence 
alignment analysis was performed using the online tool MUltiple Sequence Comparison by Log-




2.5.6 Site Directed Mutagenesis (SDM) 
SDM is an efficient technique for introducing small changes into plasmid DNA, and is 
particularly useful for regions with no restriction enzyme cleavage sites, or where there is no 
available template DNA for the desired sequence. It also allows greater flexibility when inserting 
new genetic features, and can even be used to insert new cleavage sites to ensure that 
subsequent cloning steps are kept in frame with the rest of the gene. 
SDM was performed using the Q5® Site-Directed Mutagenesis Kit (NEB – E0554S). The 
reaction mix and the standard PCR programme are shown below in Table 2.7. 
SDM PCR Reaction Mix  SDM PCR Thermal Cycling Programme 
Reagent Volume  Step Temp Time Cycle 
2X Q5 Hot Start 
Master Mix 12.5µl  Initial Denaturation 98°C 30 sec  
Forward Primer 10µM 1.25µl  Denaturation 98°C 10 sec Repeat 
24x 
Reverse Primer 10µM 1.25µl  Annealing 60°C* 30 sec 
Template Plasmid 10-20ng  Extension 72°C 30 sec/kb 
Nuclease Free H2O Up to 10µl  Final Extension 72°C 2 min  
Total 25µl  Rest 4°C ∞  
 
Table 2.7: Tables Showing SDM PCR reaction mix and Thermal Cycling programme. *Annealing 
temperature varies depending on the primer used, and was adjusted to that recommended by 
NEBaseChanger386 when the primers were designed. The extension time was calculated based on the 
size of the plasmid, with 30 seconds per 1000bp. 
 
After amplification of the new plasmid sequence by PCR, a KLD reaction is used to circularise 
the product. 1µl of PCR product was added to 5µl of 2x KLD Buffer, with 3µl of nuclease free 
H2O and 1µl of 10X KLD Enzyme Mix. The KLD reaction is incubated for 5 minutes at room 
temperature, before being transformed into competent cells for screening (as described in 
2.5.8). 
 
2.5.7 TA Cloning 
Many of the polymerases used for PCR add leave a single 3’-A overhang, allowing easy ligation 
into plasmids with a 5’-T overhang. This is known as TA cloning, and is a useful tool to allow 
sequencing of individual DNA molecules from a pool of amplified fragments, this is useful for 
sequencing of genomic DNA where frameshift insertions or deletions make it difficult to 
determine the exact sequence, or for haplotyping of multiple SNPs observed within the same 
amplicon. It is also useful for locus specific bisulphite sequencing, where due to inaccuracies in 
the bisulphite conversion process, a percentage of methylation at each CpG is estimated based 
on the sequences of multiple bisulphite converted DNA molecules from the same sample. 
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TA cloning was performed using the pGEM®-T Easy Vector System I (Promega – A1360). 
pGEM®-T Easy Vector comes as a linearised plasmid with 5’-T overhangs, the plasmid 
contains an ampicillin resistance gene allowing for positive selection by ampicillin. The insertion 
site is within a lacZ operon that is disrupted if a fragment is successfully inserted, allowing for 
blue/white colony selection on agar plates containing IPTG & X-gal. 
PCR products for ligation were purified by gel extraction (as described in 2.5.4.2), and then 3µl 
were added to 5µl of 2X Rapid Ligation Buffer, 1µl pGEM®-T Easy Vector and 1µl T4 DNA 
Ligase for a final ligation reaction volume of 10µl. The ligation reaction was incubated at 4°C 
overnight, and transformed into competent cells for screening (as described in 2.5.8). 
 
2.5.8 Bacterial Transformation for Plasmid Expansion, Colony Separation & Glycerol 
Stocks 
Plasmids were transformed into E. coli DH5α competent cells from stocks maintained by our 
laboratory group. 5 – 10µl of plasmid solution were added to 50µl DH5α, and incubated on ice 
for 30 minutes, before heat shock at 42°C for 45 seconds, and were then immediately returned 
to ice for 5 minutes. 100µl S.O.C media (Invitrogen 15544034) was added, and cells were 
shaken at 37°C for 1 hour. 
For plasmid extraction by maxiprep, cultures were then added to 50ml of LB broth containing 
either 50µg/ml Kanamycin or 20µg/ml Ampicillin, depending on the antibiotic resistance gene 
contained within the plasmid. Cultures were then shaken at 37°C overnight.  
To generate glycerol stocks for long term storage, the S.O.C cultures were added to 5ml LB 
broth containing either 50µg/ml Kanamycin or 20µg/ml Ampicillin, and shaken at 37°C overnight. 
For each stock, 500µl was mixed with 500µl of 50% glycerol (autoclaved), to a final 
concentration of 25% glycerol, and stored at -80°C. 
For individual colony separation, S.O.C cultures were plated on LB agar plates, containing 
either 20µg/ml Ampicillin, 84µM IPTG & 40µg/ml X-Gal, or 50µg/ml Kanamycin. Plates were 
then incubated at 37°C overnight. 
 
2.5.9 Colony PCR 
Successful colonies were identified on agar plates after overnight culture, screened by 
resistance against the antibiotic. For the pGEM-T Easy plasmids, white/blue colony selection 
was used to screen for successful disruption of the lacZ gene (as described in 0).  
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Picked colonies were added to 50µl LB broth containing either 50µg/ml Kanamycin or 20µg/ml 
Ampicillin and incubated at 37°C for 3 hours. 1µl of the culture was then used as the DNA input 
for PCR (as described in 2.5.2), with an initial step of 96°C for 6 minutes. 
The remaining culture was stored at 4°C until after screening by Sanger sequencing. 
 
2.5.10 Plasmid Extraction from Bacterial Cultures 
For plasmids to be used for transfections, large quantities of DNA are required. These plasmids 
were extracted from 50ml overnight cultures (as described in 2.5.8) using a QIAGEN Plasmid 
Maxi Kit (Qiagen - 12163), following the standard protocol. 
For plasmids undergoing multiple cloning steps during plasmid construction, only a small 
amount of DNA is required from successful colonies to progress to the next stage. For these 
colonies screened by colony PCR, the 50µl stock at 4°C (as described in 2.5.9) was added to 
10ml LB broth containing either 50µg/ml Kanamycin or 20µg/ml Ampicillin and shaken overnight 
at 37°C. Plasmids were then extracted using Wizard® Plus SV Minipreps DNA Purification 
System (Promega – A1330), using the centrifugation protocol. 
Concentrations were analysed by NanoDrop Spectrophotometer (NanoDrop 2000 or NanoDrop 
One). 
 
2.5.11 cDNA Conversion & Analysis 
1µg of RNA was converted to cDNA using either SuperScript™ II Reverse Transcriptase 
(Thermo Fisher Scientific - 18064014) or ProtoScript® First Strand cDNA Synthesis Kit (NEB – 
E6300S), following the recommended protocols for using poly(T) primers. Each sample was 
also run with a negative control tube lacking the Reverse Transcriptase enzyme (RT negative). 
For real-time PCR (rt-PCR) analysis, Power SYBR Green PCR Master Mix (Thermo Fisher 
Scientific - 4368702) was used, with a 50µl reaction mix containing 1µl sample cDNA, 0.5µl of 
each 20µM primer, 23µl nuclease free H2O and 25µl SYBR Green Master Mix. Reactions were 
run with β-actin as an endogenous control, and both H2O and RT negative samples as negative 
controls. Where possible, triplicate biological replicates were used, and each individual cDNA 
sample was run in duplicate as a technical replicate. 
Reactions were set up on MicroAmp® Fast Optical 96-Well Reaction Plates (Thermo Fisher 
Scientific - 4346906), and were run on an ABI 7900HT Real Time PCR System. The primers 
used for rtPCR analysis are shown in Appendix 4.  
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2.6 Cell Culture Conditions 
2.6.1 K562 Growth Conditions 
K562 is a human erythroleukaemic cell line, derived from a female chronic myelogenous 
leukaemia patient in 1970390. K562 cells were generously provided by Professor Thein’s 
laboratory. 
K562 cells were grown at a concentration of between 2x105 – 1x106 cells per ml or medium, 
roughly doubling each day, and splitting every 2-3 days. Cells were grown in RPMI 1640 
Medium (Thermo Fisher Scientific - 21875091) with 10% FBS (Thermo Fisher Scientific - 
10270106) and 1% Penicillin/Streptomycin (Thermo Fisher Scientific - 15140122), at 37°C with 
5% CO2. 
 
2.6.2 Freezing & Thawing 
Aliquots of 1x106 cells were frozen for storage in 1ml of freezing solution. Freezing solution 
consisted of 90% FBS (Thermo Fisher Scientific - 10270106) & 10% DMSO (Santa Cruz 
Biotechnology – sc-202581). Vials were then transferred to a Mr. Frosty™ Freezing Container 
(Thermo Fisher Scientific – 5100-0001) filled with Isopropanol, and incubated at -80°C for 1 – 3 
days, before being transferred to liquid nitrogen for long term storage. 
Frozen aliquots were thawed by warming rapidly in a 37°C water bath, and immediately diluting 
with 10ml pre-warmed growth media in a drop-wise manner. Cells were then centrifuged at 
1800rpm for 5 minutes, and the medium fully replace before plating. 
 
2.6.3 DNA & RNA Extractions 
DNA was extracted from K562 cell culture using a Qiagen DNeasy Blood & Tissue Kit (Qiagen - 
69504), ideally using >2x106 cells. In the case of cells that had been sorted by FACS, the 
number of cells was typically lower than this, and a Qiagen QiaAMP DNA Micro Kit (Qiagen - 
56304) was used. 
RNA was extracted using a Qiagen RNeasy Mini Kit (Qiagen - 74104), performing the optional 
DNase treatment step using RNase-Free DNase Set (Qiagen - 79254). Both DNA & RNA 
concentrations were assessed by either NanoDrop Spectrophotometer (NanoDrop 2000 or 
NanoDrop One) or by Qubit using Qubit® dsDNA HS Assay Kit (Thermo Fisher Scientific - 
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Three different transfection techniques were tested, with varying success in terms of 
transfection efficiency. 
 
2.6.4.1 Lipofectamine 2000 
2x106 cells were seeded in a 6-well plate in 2ml growth medium (without antibiotics) and 
incubated overnight. Between 2-10µg plasmid DNA was mixed with 250µg RPMI 1640 (without 
antibiotics or FBS), in a separate tube 10µl Lipofectamine 2000 (Thermo Fisher Scientific - 
11668027) was mixed with 250µl RPMI 1640 (also without antibiotics or FBS). Mixtures were 
incubated at room temperature for 5 minutes, and then combined to make a transfection 
solution of 500µl, which was incubated at room temperature for 20 minutes. 
The transfection was then added to the cells in the 6-well plate, and then returned to the 
incubator. After 5 hours, cells were washed and replated in fresh growth medium, complete with 
both antibiotics and FBS. 
 
2.6.4.2 Calcium Phosphate  
Transfections were performed using the Calcium Phosphate Transfection Kit (Sigma-Aldrich - 
CAPHOS). 4x105 cells were seeded in a 6-well plate in 2ml of complete growth medium and 
incubated overnight. A full media change was then performed two hours before transfection. 
12µg plasmid DNA was added to 15µl 2.5M Calcium Chloride, and made up to 150µl with 
nuclease free water and mixed thoroughly by pipetting. 
150µl 2X HEPES buffered saline pH 7.05 was added to a separate tube, and the 150µl Calcium 
Chloride:DNA solution was added in a drop-wise manner, whilst the HEPES solution was gently 
agitated by passing air through it with a 1ml pipette. This transfection solution was then 
incubated at room temperature for 20 minutes, before being added to the cells in the 6-well 
plate and gently mixed. Plates were then returned to the incubator for 16 hours, after which cells 





Nucleofection was performed using Amaxa® Cell Line Nucleofector® Kit V (Lonza – VCA-
1003), and was run on a Nucleofector™ 2b Device (Lonza – AAB-1001). 
Cells were split 24 hours in advance of nucleofection, to ensure that they were in growth phase. 
1x106 cells were resuspended in 100µl Nucleofector® Solution, and 1-5µg plasmid DNA, 30µg 
ssODN or 30pmol siRNA were added either individually or in combination, in a maximum 
volume of 10µl (10% of Nucleofector® Solution). This reaction mix was immediately transferred 
to a cuvette, ensuring that the solution completely covered the gap between the metal plates, 
before placing in the nucleofector and running on programme T-016. 
Upon completion of the programme, 500µl of complete growth medium was added to the 
cuvette, and the cell suspension was immediately transferred to a 6-well plate, containing 
another 2ml of medium. 
 
2.6.5 Positive Selection for Plasmid Uptake & Clonal Expansion 
48 hours after transfection, cultures were sorted based on GFP expression by FACS. FACS 
was carried out on BD FACSAria™ cell sorters, as a service provided by the BRC Flow 
Cytometry Core Facility at Guy’s Hospital. Cells were sorted onto 96-well culture plates, with 
one cell per well in 200µl of complete culture medium, to allow clonal expansion of gene edited 
cell lines. 
From the seventh day after FACS, cultures were checked every two days, looking for signs of 
colony growth. Identified cultures were transferred to 6-well culture plates and grown until they 
reached a concentration of approximately 1x106 cells per ml, after which they were cultured 
under the standard K562 culture conditions described in 2.6.1, with DNA and RNA extracted as 
described in 2.6.3. 
Cells were screened for the SNPs of interest by Sanger sequencing following PCR amplification 




 Results: Erythroid Progenitor Isolation 
3.1 In vitro Culturing of Erythroid Progenitors 
The rationale for this part of the thesis work was to use an in vitro culture system to develop 
erythroid progenitor cells from the peripheral blood of SCA patients, to allow us to isolate a late 
stage progenitor population prior to enucleation. This would allow investigation into DNA 
methylation and other epigenetic marks with important roles in gene regulation in these cells, 
conducting longitudinal studies to investigate how these marks are affected by different 
treatments, such as HU therapy.  
As discussed in 1.4.3, there are a variety of different in vitro culture techniques currently used 
for expansion and differentiation of erythroid cells from PBMCs in vitro. The technique outlined 
in 2.1.2 is based on a culture system that has been demonstrated to maximise the number of 
cells, and does not rely on the expensive pre-selection of CD34+ cells159. This technique was 
routinely used by Professor Thein’s laboratory group, and they had extensive experience using 
this culture system to grow cells from healthy donors. 
 
3.1.1 Healthy Donor Blood Culturing 
Initially, PBMCs were cultured from healthy blood donors. This approach was chosen because 
the erythroid precursors in the culture are particularly sensitive, and it was important to 
demonstrate that the culturing process was robust and reproducible before attempting to culture 
SCA blood samples collected from consenting patients in clinic.  
This was especially important since much smaller volumes of blood were available from the 
SCA patients than the 50ml that was routinely used for this culturing process. Since SCA is a 
haemolytic disorder, the volume of blood collected from patients in the clinic has to be 
minimised, and only between 9 – 27 ml was available for culturing, as dictated by the study 
protocol. It was anticipated that a reduced starting cell number would compromise the viability of 
the culture. 
During Phase 1 of the culture, the number of cells decreased rapidly as expected, with the 
majority of the cell populations that make up the PBMC layer undergoing cell death while the 
erythroid precursor population expanded. By P1D6, this resulted in a relatively pure cell culture 




After the switch to Phase 2 at P1D6, the majority of cultures did not recover, and the cell count 
remained in decline, although some signs of differentiation were visible. Figure 3.1 shows 
growth curves of four of these cultures, only one of which was successfully expanded after 
entering Phase 2, yielding more cells than were plated at P1D0. As expected, successful 
cultures differentiated while expanding, resulting in a population that was relatively homogenous 
in terms of both cell lineage and developmental stage (Figure 3.2 & Figure 3.3). Isolation of this 
population would allow for much more sensitive analyses than is possible when working on the 
mixture of PBMCs that were initially isolated from the blood sample.  
 
Figure 3.1: Growth curves showing the progress of erythroid cultures from healthy blood PBMCs. A – 
Growth as total number of cells. B – Growth as a percentage of the starting cell number at P1D0. The 
black line at Day 6 indicates the transition from Phase 1 to Phase 2, and can be considered as both P1D6 
& P2D0. Of the four cultures, only Culture 4 successfully recovered and expanded after switching to phase 
2. Cultures 1-3 continued to experience large amounts of cell death, until being terminated early with only 
1-2 million cells remaining, less than 10% of the starting culture. 
 
Contrary to our expectations, the four cultures shown in Figure 3.1 are representative of the 
poor success rate that was experienced when culturing these cells, which appeared to vary both 
between individuals, as well as over time. Interestingly, the rate of reduction in cell number as 
erythroid precursors expand and other blood populations are lost during phase 1, seems to bear 
no indication as to the likelihood of success of the culture. In Figure 3.1, the successful culture 
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actually experienced the greatest reduction, down to roughly 20% of the initial starting 
population. 
It is worth noting that the cultures appeared to be sensitive to the age of the reagents used, and 
to SCF in particular. While this data was not recorded, cultures performed with freshly ordered 
SCF appeared to be healthier than those using aliquots a couple of months after delivery. This 
is despite the fact that these had been divided into small aliquots and stored at -20°C upon 
arrival, to minimise the number of freezing and thawing cycles that each aliquot experienced. It 
is not clear why this occurred, but it is thought that it may be the result of a faulty freezer, and 
that perhaps storage temperature was not as consistent as was expected. Upon noticing this 
effect, SCF aliquots were replaced more often, although the frequency at which new vials were 
ordered was limited by the fact that SCF is by far the most expensive reagent of the culture.  
The progress of each culture was assayed by cytospin daily throughout Phase 2, as shown in 
Figure 3.3. When cells reached the polychromatic erythroblast stage of development (typically 
around P2D7 - P2D10), CD71+GPA+ cells were isolated by FACS (Figure 3.2) in order to 
guarantee the purity of the population in terms of developmental stage. FACS also ensured 
removal of any monocyte populations that frequently persisted to this stage, and were the main 
source of contamination by non-target cells. 
Figure 3.2 shows flow cytometry data of a successful culture at P2D9 compared to freshly 
isolated PBMCs. Although some variation in cellular composition would be expected, since the 
samples are from two different individuals, it is clear that the cultured cells have been greatly 
enriched for CD71+ erythroid progenitors, and that the CD45+ leukocyte populations have been 
reduced. CD71 & GPA expression from these data can be used to assess the developmental 
stage, and while the majority of cells are still CD71+GPA-, some GPA expression is observed, 
and it would be expected that shortly after this the majority of cells would have entered the 






Figure 3.2: Flow Cytometry data from healthy PBMCs directly after isolation, compared to at P2D9 of a 
successful culture. Samples are from two separate healthy donors. A – Percentage of cells positive for 
each of the four cell surface markers: CD71, GPA, CD45 & cKit. CD71 & cKit are greatly enriched in the 
P2D9 cells compared to the PBMCs, increasing to 99.2% & 89.4% respectively. CD45+ cells are reduced 
to 26.6% in the cultured sample, making up 98.3% of the PBMCs.  B – CD71 & CD45 plots. CD45 & CD71 
are co-expressed be some cell populations in both samples, although the majority of cells express either 
CD71 or CD45. C – GPA & CD45 plots. There is no overlap in expression of GPA & CD45 in either 
sample, as is expected given the specificity of GPA as a late stage erythroid marker. D – CD71 & GPA 
plots. Two distinct but faint GPA+ populations are present in the PBMC sample; CD71+ and CD71-. Loss of 
CD71 expression marks the transition to a later stage of erythroid progenitor development. In the cultured 
sample, only the CD71+ population is observed. E – Effect of FACS filtering gates on CD71 & GPA plot of 
P2D9 cultured cells. Red, blue & magenta represent CD45+, c-Kit+ and CD45-c-Kit- cells respectively. The 




Interestingly, c-Kit also seems to be enriched in the cultured cells. c-Kit is typically a marker of 
early stage erythroid development, with a key role HSC self-renewal and quiescence, and 
expression is lost during erythroid maturation160,391–393. It is likely that this is an artefact of the 
culture system, since persistent expression of c-Kit has previously been associated with stress 
erythropoiesis, and has been observed both in vivo and in vitro159,394. If the biological activity of 
the SCF in the culture was in fact impaired, as was mentioned previously, this could also 
partially explain the increase of c-Kit in the cell surface, since SCF is the ligand for the c-Kit 
receptor. 
The negative filtering of CD45 & c-Kit expressing cells is shown in Figure 3.2, demonstrating 
that the selection of CD45-c-Kit-CD71+GPA+ cells by FACS allows isolation of a homogenous 
population, and provides data for accurate developmental staging of the progenitors isolated. 
Figure 3.3 shows the successful culture of erythroid progenitor cells. Two waves of 
differentiation are observed, the first occurring shortly after transition into phase 2, where a 
population of basophilic erythroblasts appears and is subsequently lost. The second wave of 
differentiation comes from a population of pro-erythroblasts that is maintained during the 
development of the first wave. This second wave of differentiation progresses further through 
the developmental pathway, and is responsible for the increase in cell numbers observed during 
the latter stages of the culture. It is thought that the early wave of differentiation is triggered by 
the increased concentration of pro-erythroblasts accumulated towards the end of Phase 1, in 
the absence of later stage erythroblasts. Mechanisms to address any imbalance between early 
and late stage erythroblasts would be expected as a normal part of erythropoietic homeostasis 
in vivo. 
While it was shown that nucleated erythroid progenitors could be isolated from successful in 
vitro culture of healthy blood, the success rate of these cultures survival after transition to phase 





Figure 3.3: Photographs of cytospins showing in vitro culture of a healthy donor PBMC sample. Slides 
were stained with eosin & methylene blue. All photographs were taken at 40x magnification. The scale bar 
shown in P1D3 represents 50μm, and is the same for all photographs. A – Pro-erythroblasts, tightly 
packaged cells with no visible cytoplasm. B – Early basophilic erythroblasts, larger than pro-erythroblasts, 
cytoplasm can be seen to be expanding away from the nucleus. C – Late basophilic erythroblasts, much 
more of the cytoplasm is visible compared to early basophilic cells. D – White blood cell populations, 
distinguishable from erythroid progenitors by lack of staining around the cell membrane. E – Macrophage 
cell. F – Polychromatic erythroblasts, nucleus stains lighter, and cytoplasm appears larger, with more white 
space. G – Orthochromatic erythroblasts, nucleus is more condensed, and cytoplasm is smaller, as cells 
prepare for enucleation. An early wave of basophilic erythroblasts can be seen to appear at P2D2, and is 
lost by P2D4. Subsequently the proerythroblast population that persists at this stage starts differentiating 
and progresses through the erythroid developmental stages until the orthochromatic stage at P2D10.   
 
3.1.2 SCA Patient Blood Culturing 
The survival rate of erythroid progenitor cultures from healthy blood donors was unreliable, and 
sensitive to a variety of external factors. SCA patients experience increased stress 
erythropoiesis, with more early stage erythroid progenitor cells released into the peripheral 
blood. Therefore, it was thought that cells isolated from SCA blood samples might be more 
stable under culture conditions than blood from healthy donors. To test this, the technique was 




Figure 3.4: Growth curves showing the progress of erythroid cultures from SCA HbSS blood PBMCs. A – 
Growth as total number of cells. B – Growth as a percentage of the starting cell number at P1D0. The 
black line at Day 6 indicates the transition from Phase 1 to Phase 2, and can be considered as both P1D6 
& P2D0. Only Patient Culture 3 successfully recovered after entering Phase 2, and this recovery was 
delayed, with growth not occurring until P2D4. Patient Culture 2 expanded early during Phase 1, dropping 
to 77% of the starting culture at P1D1, before steadily recovering to 91% at P1D3, and then dropping to 
39% by P1D4. Note that Patient Culture 1 was divided and cultured as three separate sub-cultures, under 
the same conditions. 
 
Survival rates of cells isolated from SCA (HbSS) patient blood were found to be just as 
unpredictable as healthy blood. Figure 3.4 shows growth curves for three patient blood sample 
cultures, and like the healthy blood samples shown in Figure 3.1, two out of the three cultures 






Figure 3.5: Growth curves showing the variability of erythroid cultures from SCA HbSS blood PBMCs. 
Patient Culture 1 from Figure 3.4 was divided into three sub-cultures at P1D0, and cultured concurrently in 
triplicate. A – Growth as a percentage of the starting cell number at P1D0. B – Mean of the growth curves 
shown in A, with error bars representing standard error. C – Mean of the growth curves shown in Figure 
3.4.  The black line at Day 6 indicates the transition from Phase 1 to Phase 2, and can be considered as 
both P1D6 & P2D0. The variation observed in the growth of the sub-cultures is very low, and much greater 









In order to investigate the issue of reproducibility, the sample from Patient 1 in Figure 3.4, was 
divided into three sub-cultures at P1D0, and these were grown separately throughout the time 
course of the culture, the results of this are shown in Figure 3.5. The variation between the 
three cultures isolated from the same individual and grown concurrently show much less 
variation than is observed between the three separate HbSS patients cultured at different times. 
This difference in variation was to be expected during Phase 2, given that one of the samples 
eventually recovered, whilst the other two failed. More surprising was the difference in variation 
observed during Phase 1, with the triplicate cultures reducing in number at almost exactly the 
same rate. This suggests that rather than the non-erythroid lineages undergoing random cell 
death, the specific cellular composition of the PBMC sample and the cytokines produced by 
these cells determines a highly reproducible rate of decline. 
 
Figure 3.6: Photographs taken of PBMC layers, visible after density separation with Histopaque® - 1077. A 
– Comparison of HbSS & Healthy blood samples, arrows indicate PBMC layer. In HbSS patient blood 
samples, this layer appears red. B – Three additional HbSS samples. Variation in the thickness and the 
intensity of this red layer varies between patients. 
 
Interestingly, the patient samples did behave differently under culture conditions compared to 
healthy donor blood. There is an additional population of cells that appears to be present in the 
HbSS blood samples, but not in healthy blood. These are believed to be a late stage erythroid 
population, present in the peripheral blood as the product of stress erythropoiesis. This 
population was quite unpredictable, and was maintained throughout phase 1, alongside the 
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erythroid precursors, while the other blood cells were lost. In Culture 2 of Figure 3.4 this 
nucleated red cell population appeared to expand rapidly during phase 1, and may be the cause 
of the growth in cell number observed at a stage when the culture was expected to reduce.  
The presence of these cells was clearly visible after the separation of the Buffy Coat (Figure 
3.6), with the PBMC layer appearing bright red, or with red layers rather than the white colour 
that is usually observed when processing healthy blood samples. The size and intensity of this 
red layer appears to vary between patients, and if these cells are a product of stress 
erythropoiesis occurring in the peripheral blood, then it would be expected that the presence of 
this population would be influenced by the severity of the SCA phenotype in each individual. 
This variation is observed in Figure 3.7, where blood from the milder HBSC genotype appears 
indistinguishable from a healthy blood sample. 
Figure 3.7 shows the comparison between two patient samples, an HbSS genotype patient and 
a patient with the HbSC genotype, resulting in a milder form of the disease (discussed in 
1.2.3.2). The flow cytometry analysis of the PBMC layer in the HbSS patient shows the 
presence of a large cell population that is available directly from peripheral blood and does not 
require in vitro culturing. Since this population is only present in the HbSS patient sample, it is 
thought to be the cell population that is visible as the red layer in HbSS PBMCs. 
 
 
Figure 3.7: Comparison of PBMCs from an HbSC patient and an HbSS patient. A – Photograph of PBMC 
layers after density separation. The PBMC layer from the less severe HbSC patient does not have the red 
layer that is observed in HbSS patients, and is indistinguishable from a healthy PBMC layer (Figure 3.6).  
B – Flow Cytometry plots showing CD71 & GPA expression of the PBMC samples shown in A. The 
CD71+GPA+ cell population is present in both samples, but is more abundant in the HbSS PBMCs, making 
up 25.0% of cells, as opposed to 1.2% in HbSC. Both samples also have a high proportion of later stage 
CD71-GPA+ cells, 24.1% and 20.0% for HbSS & HbSC respectively. 
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3.2 FACS Isolation of Progenitors Directly from PBMCs 
Due to the unreliability of the in vitro culture method for erythroid progenitor expansion, and the 
discovery of an erythroid progenitor population present in HbSS peripheral blood, sorting 
directly from PBMCs by FACS was tested. 
 
3.2.1 FACS of Patient Blood Samples 
Due to the logistics of collecting the sample from the clinic, and the FACS service only being 
available during working hours, PBMCs were not sorted directly after isolation from peripheral 
blood, but were kept in culture overnight, and sorted the following day at P1D1. It was thought 
that with such a short exposure to culture conditions, any influence on DNA methylation or 
transcription would be minimal, and any cell death induced in the immune cells would be 
beneficial, increasing the efficiency of the FACS process.  
 
 
Figure 3.8: Flow cytometry analysis of three HbSS PBMC samples after <24 hours in culture. A – Numbers 
of CD71+GPA+ & CD71-GPA+ cells as a percentage of total PBMC layer, compared to a healthy PBMC 
sample. Levels of both populations vary between SCA patients, but are much higher than in the healthy 
blood sample. B – Flow cytometry plots of CD71 and GPA, after removal of CD45 and c-Kit, demonstrating 
the FACS gating used to collect each cell population. Magenta, maroon and blue represent CD45-CD14-, 
CD71+GPA+ & CD71-GPA+ cells respectively. 
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Figure 3.8 shows the flow cytometry analysis of cells collected from three HbSS patients. While 
the proportion of CD71+GPA+ & CD71-GPA+ cells varies between the HbSS samples, it is again 
clear that the CD71+GPA+ populations are specific to HbSS samples. Sufficient numbers of cells 
were acquired from the FACS process, with the CD71+GPA+ output reliably reaching more than 
1x106 cells. Given that only 500ng of DNA is required for the Infinium® HumanMethylation450 
BeadChip to assay for genome-wide DNA methylation395, and between 0.1-4.0μg of RNA is 
recommended for TruSeq Stranded mRNA Library Prep Kit for RNA-seq396, these cell numbers 
were much higher than required. 
 
3.2.2 DNA & RNA Extractions 
Initially, it was intended that CD71+GPA+ cells would be stored in TRIzol Reagent at -80°C after 
isolation by FACS, with the aim of performing all DNA and RNA extractions in parallel after all 
the samples had been collected, so as to minimise variation. DNA & RNA extraction was tested 
for Sample 1 in Table 3.1, after storage in TRIzol for two months, and negligible amounts of 
both were obtained. Given that 6.5x106 cells were originally collected, this was unexpected. For 
samples 2 & 3, cells were instead extracted immediately after sorting, using the Qiagen AllPrep 
Kit. Samples isolated immediately after extraction yielded measurable amounts of DNA & RNA, 
despite having less than half the input of Sample 1. 
 Sample 1 Sample 2 Sample 3 
Cell number 6.5 x 106 3.1 x 106 2.8 x 106 
Extraction Method TRIzol Q-All Q-All 
RNA Concentration (ng/µl) <5.0 11.2 13.0 
DNA Concentration (ng/µl) <0.2 4.5 <0.2 
RNA Total Yield (µg) <0.15 0.34 0.39 
DNA Total Yield (µg) <0.02 0.45 <0.02 
 
Table 3.1: Three HbSS PBMC samples sorted on P1D1 by FACS. Q-All – Qiagen AllPrep 
DNA/RNA/Protein Mini Kit. Table shows the number of sorted cells, the method used to extract DNA & 
RNA, and the concentrations as assayed by Qubit. Sample 1 stored in TRIzol yielded negligible amounts 
of DNA & RNA, despite having the highest input cell number. DNA was also very low in samples 2 & 3. 
 
While the extracted RNA is within the recommended range for RNAseq, the DNA fell below the 
0.5μg recommended for the DNA Methylation array. While Sample 2 was close to this 
boundary, and may have still been successfully assayed, Sample 3 had negligible amounts of 
DNA. Most concerning was the fact that both the DNA & RNA were far below the yields 
expected. 1 x 106 cells from cell lines typically yield >5μg and >10μg for DNA & RNA 
respectively397, and although cell lines have different properties, and extractions typically have 
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higher yields than from primary tissue samples, this does not account for roughly 30 fold and 80 
fold disparities for DNA & RNA concentrations respectively. 
During the sample processing, after centrifugation of the samples post-FACS, it was observed 
that the cell pellets appeared smaller than expected for the given cell number. This, in 
combination with the low DNA & RNA yields, led to the conclusion that the majority of cells were 
not surviving the cell sorting process. FACS requires forcing cells through capillaries at high 
pressure, and dropping them into a collection tube one cell at a time. Both of these stages can 
lead to rupturing of the cell, and it is possible that the erythroid progenitors are too sensitive for 
this process to be used efficiently, even when run at the lowest pressure available on the FACS 
machine398. 
While it has been demonstrated in the literature that FACS can be used to isolate erythroid 
progenitors, for the most part this has been demonstrated in bone marrow or cord blood 
samples, which have a higher concentration of these progenitor cells125,131. A study that 
successfully isolated erythroid progenitors by FACS targeted cells at earlier stages (BFU & 
CFU, which are both CD45+) and enriched the samples for CD45+ cells using magnetic beads 
prior to sorting. They also observed that the cells isolated from peripheral blood had reduced 




3.3 Miltenyi BeadKit Isolation of CD71+GPA+ Progenitors from 
PBMCs 
Due to the harsh conditions and high rate of cell death associated with FACS, isolation by 
Miltenyi BeadKit was tested. This technique relies on antibody-magnetic bead conjugates, and 
while it does not have the same specificity as FACS, where the sorting process occurs after 
analysis of each cell and so 100% purity is expected, it is a more gentle isolation process. 
Isolation of erythroid progenitors using the magnetic bead separation technique had previously 
been demonstrated by Walker et al.245. 
 
3.3.1 Enrichment for CD71+ Cells 
 
Figure 3.9: Flow Cytometry data from CD71 BeadKit enrichment of three HbSS patient PBMCs. Both the 
CD71+ fraction (orange) and the CD71- fraction (grey) were analysed. A – CD71 staining. CD71 is 
successfully enriched in the CD71+ fraction with a purity of 88.0 – 99.3%. B – CD45 staining. The CD45+ 
cells that make up the majority of PBMCs are successfully reduced in the CD71+ fraction, to <4% in HbSS 
1 & 2, but only to 34.3% in HbSS 3. C – GPA staining.  Similarly to CD71, GPA is successfully enriched in 
the CD71+ fraction, to >96% in HbSS 1 & 2, but only 65.3% in HbSS 3. 
 
Figure 3.9 shows successful enrichment for CD71+ cells by Miltenyi BeadKit for three HbSS 
patient samples. The purity of the CD71+ fraction was high for all samples, varying between 88 
- 99%. The GPA+ & CD45+ cells were enriched and depleted respectively, and interestingly 
these cell populations appear to be complementary to each other in the CD71+ fraction. This 
suggests that two distinct erythroid progenitor populations are being isolated, the CD71+GPA+, 
as well as the CD45+CD71+. The CD45+CD71+ population represents an earlier stage of 
erythroid development, since CD45 is expressed on HSCs and is lost shortly after erythroid 
lineage determination399, which was confirmed by the absence of co-expression with GPA, since 
CD45 is lost from the cell surface significantly in advance of GPA expression, although co-
expression has been observed under some in vitro culture conditions169. 
While this CD45+CD71+ population appears to be low in HbSS 1 & 2 (<4%) it was much higher 
in HbSS 3 (34.3%), significantly reducing the homogeneity of the sample. These early stage 
progenitors had been observed previously, both in the cultured cells and PBMCs (Figure 3.2). In 
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these cases, the presence of the CD45+CD71+ cells was not a concern, since the FACS 
selection process included negative selection for CD45. It was therefore decided to use a CD45 
Miltenyi BeadKit as a depletion step prior to enrichment for CD71. 
 
3.3.2 CD45 Depletion Prior to Enrichment for CD71+ Cells  
Figure 3.10 shows successful depletion of CD45+ cells from the CD71+ fraction, and suggests 
that a reasonably reliable process for isolating the CD71+GPA+ cell fraction has been achieved. 
These results also stress the importance of testing purity of the isolated cell population from 
each sample by flow cytometry, since the failed enrichment of sample HbSS 7 would otherwise 
have gone unnoticed. Errors in the isolation process result in a completely different cellular 
composition of the enriched sample, and if these samples are not identified and removed from 
the study, they would identify cell-type specific differences in DNA methylation and transcription, 
as opposed to differences caused by drug treatment. 
CD71+ cells were more abundant in the CD45+ fraction than the CD71- fraction, this is likely 
due to the CD45+CD71+ cells that were observed in the CD71+ fractions in Figure 3.9, that are 
now being successfully removed by the CD45 depletion step. 
Sample HbSS 9 in Figure 3.10 was from a SCA patient being treated with HU. There were 
concerns that if these erythroid progenitors were present in the peripheral blood as a result of 
the clinical severity of SCA, then it might be expected that this population would disappear in 
patients undergoing treatment. There is no apparent variation in cell surface markers, and 3.7 
million CD71+GPA+ cells were collected (Table 3.2), more than in most of the untreated 
samples. Although this is only one sample, an increase rather than a decrease in CD71+GPA+ 
cells may be expected in patients undergoing HU therapy, since HU has been linked to 





Figure 3.10: Flow cytometry data from CD71 enrichment of nine HbSS patient PBMCs, following CD45 
depletion. A – Flow diagram illustrating the process of isolating the different cell fractions. The CD71+ 
fraction (orange), the CD71- fraction (grey) and the CD45+ fraction (blue) were analysed. Sample HbSS 9 
was from a patient undergoing HU therapy. Percentage of cells stained in each fraction is shown for B – 
CD45, C – CD71 and D – GPA. Processing of sample HbSS 7 appears to have failed, with the CD71+ 
fraction containing only 31.6% CD71+, 74.0% CD45+ & 13.8% GPA+ cells. Apart from HbSS 7, significant 
CD71 enrichment is observed in the CD71+ fraction for all samples, to between 80 – 99% purity. CD45 
staining shows very low levels of CD45+ cells in the CD71+ fraction, of between 0.1 – 9.4% (excluding 
HbSS 7). GPA staining confirms that the cells isolated in the CD71+ and CD71- fractions are the 
CD71+GPA+ and CD71-GPA+ cell populations respectively. E – Total cell counts of the CD71+ fraction 
from each sample, as estimated by haemocytometer counting. The total number of CD71+GPA+ cells 
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CD71+ 0.3 0.1 2.0 0.4 0.2 9.4 74.0 1.3 3.0
CD71- 0.1 14.0 0.8 0.5 3.6 34.4 4.0 3.2 8.0











































CD71+ 94.7 99.4 90.4 98.7 99.7 96.8 31.6 98.3 83.4
CD71- 0.8 5.9 0.1 0.1 3.4 26.8 18.7 2.8 3.4











































CD71+ 99.7 99.9 97.5 99.8 99.8 87.6 13.8 99.2 95.9
CD71- 100.0 81.0 98.3 99.5 96.4 60.3 76.8 96.4 84.4


































































3.3.3 DNA & RNA Extractions 
 HbSS 1 HbSS 2 HbSS 3 HbSS 4 HbSS 5 HbSS 6 HbSS 7 HbSS 8 HbSS 9 
Cell number 1.0 x 106 1.4 x 106 0.3 x 106 0.5 x 106 1.7 x 106 1.2 x 106 0.5 x 106 10.0 x 106 
3.7 x 
106 
Extraction Q-All Q-All Q-All Q-All Q-All Q-All Q-All Q-All Q-Pure 
RNA (ng/µl) <5.0 166.0 11.1 45.6 92.4 17.4 <5.0 >2000.0 DNA Only 
DNA (ng/µl) <0.2 0.2 <0.2 <0.2 <0.2 0.9 2.3 0.8 <0.2 
RNA Yield 




(µg) <0.02 0.02 <0.02 <0.02 <0.02 0.09 0.23 0.08 <0.02 
 
Table 3.2: Summary DNA & RNA extractions of the nine HbSS PBMC samples from Figure 3.10. Q-All – 
Qiagen AllPrep DNA/RNA/Protein Mini Kit. Q-Pure – Qiagen Puregene Blood Core Kit A. Table shows the 
number of sorted cells, the method used to extract DNA & RNA, and the concentrations as assayed by 
Qubit. <5.0 & <0.2 represent the lower limits of Qubit detection for RNA & DNA respectively, while >2000.0 
represents the upper limit of RNA detection. RNA extraction was generally successful, and for sample 
HbSS 8, yielded more than was measureable by Qubit. Both DNA & RNA extraction failed for sample 1, 
and RNA extraction failed for HbSS 7. DNA extraction was unsuccessful, even in sample HbSS 8, with an 
input of 10.0 x 106 cells, which yielded >60.0µg of RNA. For HbSS 9, an alternative DNA extraction 
technique was tested with the entire sample of isolated cells, and was also unsuccessful. 
 
Table 3.2 shows the total DNA and RNA isolated from the samples shown in Figure 3.10. RNA 
yields from the samples isolated by Miltenyi BeadKit was improved compared to the samples 
isolated using FACS, and larger cell pellets were observed after isolation, despite having a 
lower cell number. This suggests that less cell death is occurring during the isolation process, 
as is expected when avoiding the harsh conditions of FACS398. 
However, the DNA yield was very low, even in the sample that yielded >60µg RNA. The highest 
DNA output from the nine samples was only 230ng, roughly half of the recommended input for 
the DNA methylation analysis395. This came from sample HbSS 7, which had a high 
contamination of CD45+ cells (Figure 3.10). 
For HbSS 9, an alternative DNA extraction kit was tested (Qiagen Puregene Blood Core Kit A), 
this was used in Walker et al. for erythroid progenitor isolation, where they obtained sufficient 
DNA for locus specific bisulphite-sequencing to assess DNA methylation state. This was also 
unsuccessful, despite using the entire isolated sample as input for the DNA extraction, with no 
RNA extraction being performed. 
 
3.3.4 Cytology: CD71+GPA+ Cells in HbSS Patients Are Enucleated 
Due to the extremely low DNA yield from these cells, cytospins were prepared of the three 
fractions of an HbSS sample isolated by Miltenyi BeadKit, to allow visual identification of the 
stage of erythroid development, and to confirm that the cells were nucleated. These cytospins 
are shown in Figure 3.11, and demonstrate that the CD71+ cells being isolated are at a later 
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stage of development than anticipated, and mostly consist of enucleated reticulocytes. This 






Figure 3.11: Photographs of cytospins taken from the three fractions of an HbSS patient blood sample 
isolated by Miltenyi BeadKit (CD45+, CD71- & CD71+). Slides were stained with eosin & methylene blue. 
Photographs were taken at 40x magnification, and scale bars represent 50μm. A – Red blood cell 
contamination in the CD45+ fraction. B – Nucleated CD45+ cells, nucleus stains as dark purple. C & D – 
Light purple staining indicates cytoplasm, but these cells are lacking a nucleus. E – Enucleated red cells. F 
– Sickling red cells. The CD45+ fraction mostly consists of nucleated PBMCs, with some red cell 
contamination. The CD71- fraction is densely packed with erythrocytes. The CD71+ fraction consists 
mostly of enucleated reticulocytes, staining slightly darker than in the other fractions. CD71+ & CD71- also 
contain larger enucleated cells, possibly post enucleation but prior to the reduction in volume that 
accompanies reticulocyte maturation401.  
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3.4 Miltenyi BeadKit Isolation of Early Stage Progenitors from 
PBMCs 
It is clear that the CD71+GPA+ cells isolated from peripheral blood have advanced to a later 
developmental stage than was anticipated, and in order to investigate epigenetic markers in the 
erythroid lineage, cells must be isolated at an earlier stage. It was therefore decided to attempt 
to isolate CD34+ cells from peripheral blood, as has been successfully shown in the literature, 
and is routinely used to provide a pure erythroid precursor population for some of the in vitro 
culturing techniques150,157,158,175. CD34+ progenitors are at an earlier stage of haematopoietic 
development, and would almost certainly be nucleated399. 
 
3.4.1 Enrichment for CD34+ Cells 
CD34+ cells were isolated from peripheral blood by Miltenyi BeadKit, the same technique used 
to isolate CD45-CD71+ cells. Figure 3.12 shows CD34+ cells from an HbSS patient that were 
successfully enriched to 97% in the CD34+ fraction. Similar to the CD71+ fractions isolated 
previously (3.3.1), there appear to be two distinct CD34+ populations present, expressing either 
CD45 or GPA. As was observed previously, there was very little co-expression of GPA and 
CD45, which is expected given that CD45 expression is lost after the HSC stage in the erythroid 
lineage, and that GPA is a late stage erythroid developmental marker399,402. Interestingly, Figure 
3.12C shows that CD34+ isolation appears to enrich for the CD34+CD45+ subpopulation rather 
than CD34+GPA+, possibly due to higher cell surface expression of CD34 on these cells, 






Figure 3.12: Flow Cytometry data from both fractions of an HbSS patient blood sample as isolated by 
BeadKit (CD34- & CD34+). A – Percentage of cells positive for each of the three cell surface markers: 
CD34, CD45 & GPA, as well as co-expression of each pair. CD34+ enrichment was successful with 97.8% 
purity in the CD34+ fraction, compared to 27.4% in the CD34- fraction. B – Composition of CD34+ 
population from both fractions. C – Graphs showing co-expression of the cell surface markers. Pink 
indicates CD34+CD45+ cells, as defined by gate Q2. Results indicate two distinct cell populations within 




Figure 3.13 shows cytospins of the CD34+ and CD34- fractions of an HbSS sample. Successful 
isolation of nucleated CD34+ cells can be seen, and it is anticipated that these are the 




Figure 3.13: Photographs of cytospins taken from both fractions of an HbSS patient blood sample as 
isolated by BeadKit (CD34- & CD34+). Slides were stained with eosin & methylene blue. Photographs 
were taken at 40x magnification, and scale bars represent 50μm. A – Red blood cell contamination in the 
CD34- fraction. B – Nucleated CD34+ cells. As expected the CD34- fraction contains the majority of the 
PBMC sample. The CD34+ fraction is less densely packed, and contains some debris and dead cells, as 
well as some cells lacking a nucleus. Nucleated CD34+ cells are also visible. 
 
3.4.3 DNA & RNA Extractions 
Very low cell numbers were isolated in the CD34+ fraction of these samples, fewer than could 
be counted accurately by haemocytometer. Even when resuspended in 500µl of PBS, only one 
or two cells were visible in the counting chamber, suggesting that the cell number was in the 
order of 1x104. 
In order to obtain the results shown in Figure 3.12 and Figure 3.13, an entire sample was used 
for either flow cytometry or cytospin respectively. Even when a whole sample was used for DNA 




3.5 Miltenyi BeadKit Isolation of GPA-CD71+ Erythroid Progenitors 
Since the number of CD34+ cells in circulation was found to be prohibitively low, another early 
stage population was investigated. Since the GPA+CD71+ cells were found to be enucleated, it 
was decided to deplete GPA+ cells, prior to a CD71+ selection, with the aim of isolating GPA-
CD71+ erythroid progenitors, which while less abundant would be expected to be nucleated. 
The flow cytometry analyses of the populations isolated by GPA depletion and CD71 
enrichment are shown in Figure 3.14. 
GPA+ cells were successfully removed from the sample, making up 89.0% of the GPA+ fraction, 
but only 0.4% and 1.7% of the GPA-CD71- and GPA-CD71+ fractions respectively. As had 
been observed previously, CD71+ cells also expressed either CD45 or GPA, but minimal co-
expression of CD45 & GPA was observed. As a result of this, almost all of the CD71+ cells in 
the GPA- fractions also expressed CD45, making the target cell population CD45+CD71+GPA- 
erythroid progenitors, which made up between 79.7-88.7% of the GPA-CD71+ fraction. 
While CD71 enrichment was successful, increasing the CD71+ population in the GPA-CD71+ 
fraction to 84.9%, it appears as though a large number of CD45+CD71+ cells did not bind the 
column, and made up an average of 57.9% of cells in the GPA-CD71- fraction, rising to as high 
as 79.8% for Sample 3. It is unclear what caused this, since given the low cell numbers involved 
it is unlikely that the column was saturated.  
It is possible that CD71 is expressed at low levels on the cells in the GPA-CD71- fraction, which 
could be due to their being at an earlier stage of development. CD71LOW cells may not have 
reached the magnetic bead binding threshold for effective enrichment, but might still have been 
detectable by flow cytometry. 
While there is some observable variation in the intensity of the CD71 staining between the two 
GPA- fractions, it is not clear whether this would be sufficient to account for different binding 
affinities to the column (Figure 3.15). Interestingly, two distinct CD45+ populations with different 
CD45 staining intensities are observed in both the GPA-CD71- and GPA-CD71+ fractions. 
CD71 expression does not appear to be specifically associated with either CD45HIGH or 
CD45LOW in either fraction, but higher intensity of CD71 expression does appear to be more 




It has also been suggested that the retention of a significant population of CD71 expressing 
cells in the CD71- fractions may be due to the fact that a different antibody was used for the 
flow cytometric analysis than that used for the purification. The two different antibody clones 
recognise different epitopes, and since CD71 is glycosylated, it is possible that the specificity for 
CD71 glycosylation variants is not the same for the two antibodies403. This could lead to specific 
isoforms of CD71 identified in the flow cytometric analysis not being bound to the column during 
the purification step, which would explain the observed results. This could be tested by using 
alternative antibodies for the flow cytometric analyses, however it is not advisable to use the 
same antibody for the two different experiments, since if binding sites are saturated during the 
purification process, then the fluorescent antibody could be blocked from binding, and cells will 




Figure 3.14: Flow cytometry analyses of the three fractions (GPA+, GPA-CD71- & GPA-CD71+) isolated 
from three HBSS patient samples by GPA depletion and subsequent CD71 enrichment. Sample 2 was 
receiving HU treatment. A – Mean percentage of cells positive for GPA, CD45 & CD71. Error bars 
represent standard error. GPA+ cells were successfully depleted, making up 89.0% of the GPA+ fraction 
and 0.4% and 1.7% of the GPA- fractions. CD71+ cells were high in both the CD71- and CD71+ fractions, 
although higher in the enriched fraction, at 84.9%. B, C & D show individual expression as well as co-
expression of markers for cells in each of the three fractions: B – GPA+. C – GPA-CD71-. D – GPA-
CD71+. CD45+ cells made almost all of the GPA- fractions, and as was observed previously, very little co-
expression of GPA and CD45 was observed. CD71+ cells made up 84.9% of the GPA-CD71+ fraction, with 
83.5% co-expressing CD45. 
 
Approximately 400ng of DNA was extracted from the GPA-CD71+ fractions of each of the three 
samples tested (Figure 3.15). While this is still below the 500ng recommended for genome-wide 
A      B 
 





% GPA+ 89.0 0.4 1.7
% CD45+ 11.0 96.7 98.0














































Sample 1 97.8 3.7 36.4 35 1.4 2.6
Sample 2 98.8 2.8 18.7 17.6 1.6 1.6














































Sample 1 0.7 99.6 47.4 0.6 0.4 46.8
Sample 2 0.4 98.6 47.5 0.1 0.2 47.2


















































Sample 1 2.4 98.5 89.3 2.4 1.5 88.7
Sample 2 0.6 99.3 79.7 0.6 0.4 79.7










































DNA methylation analysis using the Infinium Infinium® HumanMethylation450 BeadChip, it is a 
much higher yield than was obtained using any of the other techniques, and would hopefully be 
sufficient to generate informative data on patterns of DNA methylation in these cells395. 
 
Figure 3.15: Analysis of samples after depletion of GPA+ cells and enrichment for CD71+ cells. A – Flow 
cytometry plots for CD71 and CD45, comparing the GPA-CD71- and GPA-CD71+ fractions for all three 
samples tested. Intensity of CD71 is higher for some cells in the fraction enriched for CD71. Two distinct 
CD45+CD71+ populations are visible, distinguishable by high or low CD45 expression. B – Table 
summarising the DNA extracted from the GPA-CD71+ fractions of the three samples. Q-Micro – Qiagen 
QiaAMP DNA Micro Kit. Very low cell numbers were isolated, but total DNA yield is in the region of 400ng 






 Sample 1 Sample 2 Sample 3 
Cell number 150,000 200,000 60,000 
Extraction Method Q-Micro Q-Micro Q-Micro 
DNA Concentration (ng/µl) 8.28 8.50 8.56 




3.6 Summary of Erythroid Progenitor Isolation Results 
The identification of a non-invasive technique that allows reliable and reproducible study of 
erythroblasts from the peripheral blood of SCA patients will be highly valuable, and will allow 
longitudinal studies of patients undergoing treatment. This will be especially useful for 
investigation into the mechanism of action of HU, and how response varies between patients. 
As was described in 1.5.4, the mechanism by which HU results in the upregulation of HbF in 
SCA patients is not fully understood, but appears to involve targeted regulatory changes in key 
erythroid transcription factors, such as MYB, BCL11A, KLF1 and TAL1, rather than merely as a 
result of increased stress erythropoiesis in response to the cytotoxic effect of the 
drug81,239,240,246,247.  
Since this change in HbF levels has also been observed in response to treatment with 5-
azacytidine, a potent inhibitor of DNA methylation which also has cytotoxic effects, we 
hypothesised that there could be a role for epigenetic regulation, and specifically DNA 
methylation in the mechanism of action of HU254,256.  
The importance of DNA methylation at the γ-globin promoter in the silencing of γ-globin is well 
established, and therefore presents itself as an obvious target for DNA demethylation70,101,102,104. 
This has previously been investigated by Walker et al. who found that HbF induction in 
response to HU was not accompanied by hypomethylation at the γ-globin promoter245. However, 
the absence of changes in DNA methylation at one promoter is not sufficient to rule out the 
possibility of it playing an important role in another part of the complex regulatory pathway. We 
hypothesise that performing genome-wide methylation analysis as part of a longitudinal study in 
SCA patients undergoing HU therapy will provide important insight into the global epigenetic 
changes that occur, and when coupled with RNA-seq will inform on specific regulatory changes 
that may be causing the observed increase in HbF expression. 
However, the results presented in this chapter demonstrate that using the in vitro culturing 
technique as we initially proposed, we were unable to reliably obtain an erythroid progenitor 
population for analysis in longitudinal studies. As a result of this, we were unable to investigate 
the effect that HU treatment has on the epigenome of SCA patients. The combined unreliability 
of the culture technique along with the difficulty in obtaining longitudinal blood samples from 
patients on HU meant that this approach would not have provided sufficient data points for a 
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statistically reliable study. Therefore we took the decision to change tack at this point in the 
research plan. 
We demonstrated that a CD71+GPA+ cell population exclusive to the peripheral blood of SCA 
patients, that we had thought represented late stage nucleated progenitors, actually 
represented enucleated reticulocytes, presumably as a result of increased stress erythropoiesis 
in these patients. Through further investigation of erythroid progenitors at an earlier 
developmental stage, we identified a CD45+CD71+GPA- nucleated cell population that we were 
able to successfully isolate. 
As such, we propose a method of GPA depletion, followed by CD71 enrichment to obtain an 
early stage erythroid progenitor population from small volumes of peripheral blood from SCA 
patients. DNA extracted from this population should be sufficient to perform genome-wide DNA 
methylation analyses, and this technique will be used to conduct future longitudinal studies on 
the effect of drug treatment on the methylome of SCA patients, should they become accessible 




 Results: Whole Exome Sequencing Analysis of 
Sickle Cell Anaemia Patients 
4.1 WES Study Rationale 
This work was undertaken to identify novel genetic modifiers of SCA phenotype severity. We 
hypothesised that a large number of these modifiers remain undetected, and could cause the 
large amount of variation in disease severity that is currently unaccounted for.  
As described previously, there is a huge variation in the severity of phenotype of SCA patients, 
despite the fact that the disease is considered to be a monogenic disorder, manifesting in a 
simple Mendelian recessive manner. While in simplistic terms this is the case, there have also 
been shown to be a variety of contributing factors that influence how the disease is presented. 
Heterozygous carriers of the HbS allele are not always asymptomatic, and some homozygous 
patients have a phenotype mild enough to be considered healthy. 
A range of genetic modifiers have been identified, and these are discussed in 1.6. However, 
most of the variation observed remains unaccounted for, and we hypothesised that additional 
genetic factors modifying the phenotype remain to be discovered.  
WES is a powerful and cost-effective tool for identifying genetic variants in case-control studies, 
and although not able to detect variants in the non-coding regions e.g. mutations that disrupt 
long range promoter-enhancer interactions, it has been estimated that 85% of the known 
disease casing mutations fall into the 1% of the genome that is covered by exome capture 
kits404,405. 
In this study, WES is used to interrogate groups of phenotypically mild and severe SCA 
patients, with the aim of identifying novel genetic modifiers of the disease. We sequenced 21 
mild and 5 severe SCA exomes from a collection at King’s College Hospital (KCH), and 
downloaded 651 publicly available exomes from dbGaP (phs000691.v2.p1). This included 132, 
139 and 140 exomes from patients recruited to the SWiTCH, TWiTCH and HUSTLE clinical 
trials, respectively. Three different strategies were used to analyse these datasets to achieve 
our aims:  
 
1. Analysis 1: We aimed to identify individual variants that are protective of the severe 
SCA phenotype. This was achieved by identifying SNPs with high frequency in the mild 
patient group that were absent from the severe group, and applying a series of filtering 
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criteria to remove variants that are less likely to affect the pathophysiology of the 
disease. Each of these filtering steps introduces an inherent bias into the candidate 
variant list generated, and are discussed in detail in 4.3.1. 
 
2. Analysis 1: Using the candidate variant lists generated, a gene burden test was 
performed. This aimed to identify genes that contained candidate variants in as many of 
the mild patients as possible. 
 
3. Analyses 2 & 3: A series of purely statistical analyses were performed. Using Fisher’s 
Exact Tests to identify variant enrichment between either the mild and severe SCA 
patient groups, or between the SWiTCH and HUSTLE groups. Unlike in the previous 
tests, the only bias introduced is the selection for variants that occur in the coding 
region. 
 
The implementation of these aims is summarised in Figure 4.1, which demonstrates how the 
exome data generated from the KCH mild and severe cohorts, as well as the US SCA datasets 






Figure 4.1: Flow diagram outlining the three different analyses performed in this chapter in order to identify 
candidate genetic modifiers of SCA. Analysis 1 is presented in 4.3 and 4.4, with a detailed description of 
the various filtering steps provided in 4.3.1. Analysis 2 is presented in 4.5.2, and Analysis 3 in 4.5.3. 
 
4.1.1 Stratification by Clinical Phenotypes 
When WES is combined with detailed clinical information, it allows for powerful in depth analysis 
of genotype:phenotype relationships within patient cohorts. In studies with sufficient numbers of 
patients, the patient population can be broken down into sub-populations, defined by highly 
specific clinical characteristics. In the case of severe SCA patients, this could include frequency 
of sickle cell pain crises, sickle-related organ damage, and different types of stroke. 
In the case of stroke, the inclusion criteria used in this study simply required overt clinical stroke, 
as opposed to silent infarctions, which do not present with strong clinical symptoms, and are 
diagnosed retrospectively, such as by MRI scans406. With a large enough sample size, overt 
clinical stroke could be stratified into sub-groups of ischaemic or haemorrhagic stroke, which 
have different patterns of occurrence between different SCA patient age groups407,408. 
Ischaemic strokes occur as a result of vaso-occlusion or narrowing of blood vessels in the brain, 
and a study has shown that SCA patients are at the highest risk below the age of 19, and above 
the age of 30407. Conversely, haemorrhagic strokes are caused by rupturing of blood vessels in 
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the brain, and SCA patients were shown to be most at risk between the ages of 20-30407,409. 
Due to the difference between these types of strokes, and the difference in the age at which 
they occur, it is likely that different pathophysiological pathways could be involved, with different 
underlying genetic modifiers. Stratifying these two groups would therefore allow more sensitive 
analyses. Of the four SCA patients recruited from King’s College Hospital that had experienced 
a stroke before the age of 18 (Table 4.1), each of these included at least one ischaemic stroke, 
and two had subsequently had haemorrhagic strokes. 
In this project, due to the limited size of both the mild and severe SCA groups, and the fact that 
no individual phenotype information was available for the US SCA exome dataset, stratification 
of the populations on specific symptoms was not performed. In the future, if the sample size of 
the study is substantially expanded, this could provide valuable insight into the underlying 
mechanisms that result in the wide range of symptoms presented by SCA patients. While it 
would be more complicated to incorporate into the variant filtering pipeline performed for 
Analysis 1, it would be relatively straightforward to perform this sort of stratification for Analyses 
2 & 3, which would allow identification of variants not just associated with mild or severe forms 




4.2 SCA Patient Data Summary 
4.2.1 SCA Patients from King’s College Hospital 
DNA samples from 26 SCA patients stored at King’s College Hospital were Whole Exome 
Sequenced for this study. Patients with the HbSS genotype were selected to avoid any 
phenotypic variation associated with other forms of SCD. Patients were selected from the 
extreme ends of the phenotypic range, with the aim of comparing severe and mild patients to 
identify novel genetic variants influencing the severity of the SCA phenotype. Of the 26 patients, 
five were categorised as severe, and 21 as mild. Fewer severe patients were selected than 
mild, since there are data from a US WES study that is publicly available through dbGaP 
(phs000691.v2.p1), which included severe SCA patients376. 
 
4.2.1.1 Severe Patients 
Severe patients were selected based on the severity of clinical symptoms presented at a young 
age, these are summarised in Table 4.1. One major indicator used was having an ischaemic 
stroke in childhood, which was experienced by four out of the five patients selected, and in one 
extreme case three strokes had occurred by age 6. One patient had not experienced stroke, but 
presented a wide range of other symptoms, and while these symptoms are not rare 
complications of SCA (many can be observed in the mild patients in Table 4.2), they are often 
associated with older patients, and it is rare to experience all of them at a young age. This 
patient is also undergoing HU therapy, which may have prevented stroke from occurring. 
Patient 









001 30 F 
Blood 
Transfusion HbSS αα/α- 
Not 
Known 13, 23* 
Retinopathy, Pulmonary 
Hypertension, Gallstones, Fe 
Overload 
GMKH 
042 29 M 
Blood 
Transfusion HbSS αα/αα 
Not 
Known 3, 4, 6, 20 
Abnormal Proteinuria, Acute 
Chest Syndrome, Parvovirus 
Infection, Fe Overload 
GMKH 
063 25 F 
Blood 
Transfusion HbSS αα/αα 6.9 (11) 18 




234 31 F 
Blood 
Transfusion HbSS αα/α- 
Not 
Known 8, 23* 
Abnormal Proteinuria, Gall 
Bladder Removed, Fe 
Overload 
GMKH 
249 24 M Hydroxyurea HbSS αα/αα 3.1 (22) None 
Abnormal Proteinuria, 
Pulmonary Hypertension, 
Acute Chest Syndrome, Leg 
Ulcers, Hyperhaemolysis, 
Deep Vein Thrombosis, 
Osteomyelitis 
 
Table 4.1: Patient data for the 5 severe phenotype SCA patients that were sequenced. Samples GMKH 
001, 042, 063 & 234 all had a stroke at ≤18 years old. Patient GMKH 249 did not have a history of stroke, 
but was classified as severe due to the severity of other symptoms experienced at a young age. Stroke 




Two of the severe patients have the silent carrier genotype of α-thalassaemia, this is interesting 
since it has been shown that the carrier state can contribute to a reduction of severity of some 
SCA complications294–296,298. HbF% is not reported for all patients on blood transfusions, since 
contamination with the donor blood prevents accurate detection while undergoing regular 
treatment. 
 
4.2.1.2 Mild Patients 
Mild patients were selected on the basis of not having experienced a stroke or any other severe 
complication of SCA by the age of 30, the clinical information regarding these patients is 
summarised in Table 4.2. 
It was discovered that two of these patients had previously been found to have concurrent α-
thalassaemia. Although these were only αα/α- & α-/α- genotypes, representing silent carrier and 
α-thalassaemia trait respectively, they would still be expected to modify the SCA phenotype. 
Due to having an already identified causative variant, these patients were excluded from the 
study. 
One patient was heterozygous for the sickle cell mutation and a β0-thalassaemia allele, and was 
included due to this genotype’s similarity to HbSS in terms of both disease pathology and 
clinical severity. Despite being heterozygous, HbS is the only form of haemoglobin expressed in 
HbS/β0 patients (as described in 1.2.3.3). 
While mild patients with concurrent α-thalassaemia were excluded, patients with abnormally 
high percentage HbF were not. This is because the diagnosis of α-thalassaemia is confirmed by 
genetic testing to identify the genotype, and therefore has a known cause. In the case of HPFH 
disorders however, HbF is measured by High Performance Liquid Chromatography (HPLC) as a 
percentage of total haemoglobin, and so is measured as a phenotype, the cause of which is not 
necessarily explained. As described in 1.6.1 there are a variety of genetic factors known to 
influence HbF levels, and the SCA patient collection at King’s College Hospital has previously 
been screened for these common variants. Only the patients with no known cause for HPFH 












(Age) Other Symptoms 
GMKH 
169 33 F None HbSS αα/αα 20.0 (20) None Abnormal Proteinuria 
GMKH 
171 38 F None HbSS αα/αα 8.4 (25) None 
Gall Bladder Removed, Spleen 
Removed 
GMKH 




HbSS αα/αα 6.4 (41) None 
Retinopathy, Abnormal 
Proteinuria, Gall Bladder 
Removed, Asymptomatic Acute 
Chest Syndrome 
SCD 178 45 F None HbSS αα/αα 17.7 (32) None Asymptomatic Acute Chest Syndrome 
GMKH 
138 55 F None HbSS αα/αα 19.3 (51) None 
Abnormal Proteinuria, Gall 
Bladder Removed, Avascular 
Necrosis, Carcinoid, Deep Vein 
Thrombosis 
SCD 213 74 F None HbSS αα/αα 29.5 (62) None Abnormal Proteinuria, Osteoarthritis 
SCD 215 55 F None HbS/ β° αα/αα 9.2 (49) None Retinopathy, Abnormal Proteinuria 
GMKH 
016 43 F None HbSS αα/αα 8.3 (28) None 
High Proteinuria, Asymptomatic 
Acute Chest Syndrome, Hepatitis 
B 
HFKH 
063 45 F None HbSS αα/αα 10.5 (33) None 
High Proteinuria, Small Distal ICA 
Aneurisms 
GMKH 
056 62 F None HbSS αα/αα 1.3 (50) None 
NK, Gallbladder Removed, 
Avascular Necrosis, 
Asymptomatic Acute Chest 
Syndrome, Thromboembolism 
SCD 278 54 M None HbSS αα/αα 13.4 (45) None 
Retinopathy, Abnormal 
Proteinuria, Avascular Necrosis, 
Priapism 
SCD 146 54 F None HbSS αα/αα 16.3 (53) None 
Gall Bladder Removed, Avascular 
Necrosis, Asymptomatic Acute 
Chest Syndrome 
GMKH 
317 59 M None HbSS αα/αα 1.8 (57) None 
Retinopathy, Abnormal 
Proteinuria, Gall Bladder 
Removed, Mild Acute Chest 
Syndrome, Leg Ulcers 
GMKH 
052 49 F Hydroxyurea HbSS αα/αα 15.2 (42) None NK, Gallstones 
GMKH 
084 38 F None HbSS αα/α- 9.5 (32) None Pes Planus 
GMKH 
143 62 F Hydroxyurea HbSS αα/αα 22.3 (56) None 
Abnormal Proteinuria, Mild 
Pulmonary Hypertension, Acute 
Chest Syndrome, Pulmonary 
Embolism, Abdominal Hernia, 
Hypertension, Pes Planus 
GMKH 
175 69 F None HbSS α-/α- 7.9 (64) None 
Abnormal Proteinuria, Borderline 
Pulmonary Hypertension, Gall 
Bladder Removed, Hypertension, 
Cataracts, Hepatitis B 
GMKH 
290 64 F None HbSS αα/αα 11.4 (59) None 
Borderline Pulmonary 
Hypertension, Gall Bladder 
Removed 
GMKH 
036 63 M None HbSS αα/αα 7.1 (58) None 
Abnormal Proteinuria, Borderline 
Pulmonary Hypertension, Gall 
Bladder Removed, Avascular 
Necrosis 
GMKH 
179 69 M None HbSS αα/αα 20.3 (63) None 
Prostate Cancer, Osteomyelitis, 
Inguinal Hernia 
SCD 131 52 F None HbSS αα/αα 16.1 (45) None Bilateral Carpel Tunnel Syndrome 
 
Table 4.2: Patient information for the 21 mild phenotype SCA patients that were sequenced. None of the 
samples had had a stroke by age 33, and the majority are not on any form of treatment. Patients GMKH 
084 & GMKH 175 both have concurrent α-thalassaemia and were excluded. Patient SCD 215 was 





4.2.2 SCA Exome Data from dbGaP 
651 SCA patient WES datasets were acquired from dbGaP (phs000691.v2.p1). Data for two of 
these patients were unable to be correctly downloaded, despite multiple attempts and so are not 
included. A summary of the source of the remaining 649 samples is shown in Figure 4.2. 
411 of these patients were recruited from one of three clinical studies investigating the outcome 
of HU treatment in SCA patients in the USA. Other than sex, age at start of HU treatment, and 
HbF percentage before and after treatment, no individual clinical information is available for 
these patients.  
For the patients that can be identified as being recruited through one of the clinical trials 
(HUSTLE, SWiTCH251 & TWiTCH252), it is possible to categorise them based on the specific 
inclusion criteria for each trial. These inclusion criteria are summarised in Table 4.3. 
 
 
Figure 4.2: Summary of 649 SCA exomes downloaded from dbGaP (phs000691.v2.p1). Samples were 
checked for the SCA mutation (rs334), 10 were found to be heterozygous, and 1 found to be homozygous 
for the wild type, these samples were excluded from further analyses. The majority of patients (411) were 


















 HUSTLE SWiTCH TWiTCH 
Age 
(years) <30 5 - 18 4 – 15 




receiving or about to 
receive Hydroxyurea 
therapy*. 
Overt clinical stroke >1 year 
old, documented by CT or 
MRI. >18 months of chronic 
erythrocyte transfusions 
since primary stroke. 
Transfusional iron overload. 
Adequate monthly 
erythrocyte transfusions with 
average HbS <45% in the 6 
months prior to study entry. 
Documented index (pre-
treatment) abnormally high 
TCD Velocity by Transcranial 
Doppler ultrasonography. >12 
months of chronic erythrocyte 
transfusions since abnormal 
TCD. Adequate monthly 
erythrocyte transfusions with 
average HbS <45% in the 6 
months prior to study entry. 
Exclusion 
Criteria n/a 
Inability to receive RBC 
transfusion therapy. Inability 
to take daily oral 
hydroxyurea. Clinical and 
laboratory evidence of 
hypersplenism. A sibling 
enrolled in SWiTCH. 
Overt clinical stroke or TIA. 
Known severe vasculopathy or 
moyamoya disease on brain 
MRA. Inability to receive 
chronic RBC transfusion 
therapy. Inability to take daily 
oral hydroxyurea. Clinical and 
laboratory evidence of 
hypersplenism. A sibling 
enrolled in TWiTCH. 
Non-SCA 
Controls? No No No 
Patients 
Recruited 260 134 159 
 
Table 4.3: Table summarising recruitment criteria for the three clinical studies – HUSTLE, SWiTCH & 
TWiTCH. Information is obtained from clinicaltrials.gov website, and is correct as of November 2016. * - 
Inclusion criteria for HUSTLE only require patients to be taking HU, additional information on the criteria for 
prescribing treatment at St. Jude’s Children’s Hospital, the trial centre, is described by Nottage et al. 
2014205. 
 
4.2.2.1 Stroke with Transfusions Changing to Hydroxyurea (SWiTCH) 
SWiTCH was a study of SCA patients that had suffered a stroke at a young age and were 
receiving regular blood transfusions. The trial investigated the benefits of switching these 
patients to HU treatment in an attempt to avoid the side effects of long-term blood transfusion 
therapy. The trial was ultimately stopped when liver iron levels, one of the primary outcomes, 
was found not to be improved in the HU treatment arm, and an increase in the frequency of 
adverse effects was observed222,250,251.   
Based on the study inclusion criteria shown in Table 4.3, it is clear that all patients recruited 
through SWiTCH must have had at least one stroke before the age of 17.5 (to allow at least 18 
months of blood transfusions before the age of 19), this is in line with the criteria used for 
definition of severe patients that were sequenced from King’s College Hospital. As such the 132 




4.2.2.2 Transcranial Doppler (TCD) With Transfusions Changing to Hydroxyurea 
(TWiTCH) 
TWiTCH was a study of SCA patients that had not suffered a stroke, but were identified as 
having abnormally high Transcranial Doppler velocities (TCDv), one of the key indicators for risk 
of stroke, and had been receiving regular transfusions as a preventative treatment215,216. The 
trial investigated the benefits of switching these patients to HU therapy, to avoid the side effects 
of long-term blood transfusion therapy, similar to the SWiTCH trial. TWiTCH demonstrated that 
the HU treatment arm was non-inferior to blood transfusions in terms of reducing TCDv, and 
showed a significant decrease in liver iron levels compared to those in the transfusion treatment 
arm, which increased252. 
Although abnormal TCDv is an indicator for risk of stroke, and regular blood transfusions would 
be expected to prevent stroke occurring, it is not possible to categorise all of these patients as 
severe by the same criteria used for the patients recruited from King’s College Hospital. 
Additionally, of the 159 patients recruited, only 121 passed the initial screening stages, meaning 
that up to 38 of the 139 downloaded TWiTCH exomes didn’t fully meet the inclusion criteria252. 
Although, 29 out of the 38 were either excluded for severe vasculopathy, or chose to withdraw, 
and would still have the same clinical definition as the included patients252.  
Due to concerns about the clinical definition of this ‘high risk’ group, the 139 exomes from the 
TWiTCH study are only used in combination with the severe dataset in some parallel analyses, 
with a lower threshold for definition of severe patients. 
 
4.2.2.3 Long Term Effects of Hydroxyurea Therapy in Children with Sickle Cell Disease 
(HUSTLE) 
HUSTLE is an on-going observational study, aiming to investigate the long-term effects of HU 
therapy in SCD. It is not possible to categorise the severity of these patients based on the 
inclusion criteria alone (Table 4.3), since any patient under the age of 30 being treated with HU 
could be included. More information is available regarding the clinical criteria for starting 
patients on HU at St. Jude’s Children’s Research Hospital, where patients were recruited205. 
These criteria are as follows: ‘frequent vaso-occlusive pain, acute chest syndrome, chronic 
hypoxemia, haemoglobin level less than 7.0 g/dL, HbF less than 8% after 24 months of age, 
WBC count greater than 20 x 109/L, and LDH more than twice the upper limit of normal’205,410. 
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Even with this additional information, the clinical severity of the HUSTLE participants is difficult 
to define without individual information for each patient. As such, the HUSTLE participant data 
is not included in the comparison of mild and severe SCA patients. However, these data are 
used as a control group when investigating variant enrichment in the severe SWiTCH group. 
This analysis is based on the assumption that HUSTLE is representative of the SCA population 





4.3 Analysis 1: Identification of Coding SNPs Protective of the 
Severe SCA Phenotype 
In order to identify genetic variants that are protective of the severe phenotype of SCA, coding 
variants that are present in the mild group, but completely absent from the severe group were 
investigated.  In this model, any variants identified are assumed to be completely protective, 
and both recessive and dominant models are taken into account. 
 
4.3.1 Variant Filtering 
This section describes the various filtering criteria used to generate a list of candidate variants 
and the assumptions that accompany these criteria. An overview of the filtering process is 
demonstrated in Figure 4.4. Figure 4.3 shows the total number of variants in the mild group, and 
the proportions of these based on type. 48% of all variants are intergenic, and 45% intronic, with 
only 4% representing coding mutations.  
 
Figure 4.3: Summary of all 2,798,560 variants present in the mild group of patients, grouped by type of 
variant. Intergenic variants include those annotated as upstream or downstream. Coding variants also 
include those annotated as splicing variants. UTR – Untranslated Region. 93% of all annotated variants 














Figure 4.4: Candidate variant filtering pipeline, describing the process of filtering the 2,798,560 variants 
observed in the mild SCA patient group down to 11,419 for the gene burden analysis, and 3,159 for the 
individual variant analysis. The full list of 11,419 variants is provided in Appendix 12. 
 
4.3.1.1 Intergenic Variants 
When annotating variants with ANNOVAR, intergenic refers to variants found more than 1kb 
upstream or downstream of gene. While these variants can influence transcriptional regulation 
through long-range enhancer-promoter interaction, they are situated at the edge of the targeted 
capture area, and coverage of these regions is inconsistent. Intergenic variants are therefore 
excluded from the analysis. As well as the intergenic variants, this includes variants <1kb 
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upstream or downstream of genes, which are annotated by ANNOVAR as ‘upstream’ or 
‘downstream’.  
 
4.3.1.2 Non-Coding Variants 
The design of this analysis is targeted towards detecting coding variants, since these are the 
most likely to have a phenotypic effect. Non-coding variants also play an important role in 
regulation of gene expression, and there are many documented examples of mutations in non-
coding regions influencing disease phenotype, including one of the SNPs investigated in 
Chapter 5. However, since non-coding regions are generally much more tolerant of genetic 
disruption, it is more difficult to identify variants that are eliciting a true effect. This, combined 
with the relatively small sample sizes used in this study, means that the analysis will exclude the 
non-coding variants. As well as the intergenic variants, this includes variants in the untranslated 
regions (UTRs) of transcripts, and intronic variants. 
There are some exceptions to this, and intronic variants near the intron/exon boundary are 
annotated as splicing variants and retained, similarly UTR variants that span translational 
initiation or termination codons are also retained. Also variants in ncRNA exons are not 
excluded. 
 
Figure 4.5: Summary of the 137,825 variants present in the mild group after filtering of intergenic and non-
coding variants (other than splicing and ncRNA). 
 
Figure 4.5 shows a summary of the candidate variants in the mild group after filtering of non-


















nonsynonymous substitutions and nonframeshift insertions or deletions (37.4%). These are 
variants that either have no impact on the amino acid sequence (in the case of synonymous 
SNPs), or only affect the residue in which the mutation is located, without disrupting the overall 
sequence or structure of the gene, as is the case in splicing variants, frameshift insertions or 
deletions and stopgain or stoploss mutations. 
  
4.3.1.3 Removal of Severe Variants 
Variants that are present in one of the severe groups were filtered out, with recessive and 
dominant models taken into account. For the dominant model, any variant that was only 
heterozygous in the mild group must be completely absent from the severe group. For the 
recessive model, if a variant was homozygous in the mild group, it was filtered out if 
homozygous in the severe group as well, however heterozygous variants in the severe group 
were tolerated. 
Two separate filtering criteria were used in parallel, one with variants from the severe patients 
from King’s College Hospital and from the SWiTCH trial, and the second additionally excluding 
variants from the TWiTCH trial, with a less strict definition of severe. The variants after filtering 
for both of these are summarised in Figure 4.6. 
Filtering of variants found in the severe patient group greatly reduced the number of candidate 
variants, from 137,825 before filtering to 26,810 and 21,189 for the severe and SWiTCH and the 
severe, SWiTCH and TWiTCH filtered groups respectively. Interestingly the proportion of 
synonymous SNP variants is reduced from 36.2% of all variants to 21.4% and 18.6%, 
suggesting that more of these variants are shared between the groups than of the other coding 
variant types. Presumably this is due to the increased tolerance for variants that don’t affect the 
protein sequence. At the same time the proportion of ncRNA variants increased from 15.2% to 
37.9% and 42.9%, suggesting that fewer of these variants are shared, possibly due to the 
different exome capture kits used, Figure 4.6C summarises the changes in proportion of the 




Figure 4.6: Summary of the candidate variants in the mild group after filtering for variants observed in the 
severe groups. A – Summary of the 26,810 variants after filtering by severe patients from KCH and 
SWiTCH clinical trial (KS). B – Summary of the 21,189 variants after filtering by severe patients from KCH, 
SWiTCH and TWiTCH clinical trials (KST). C – Change in proportion of variants for each variant type in A 
and B compared to before filtering for variants in the severe group (shown in Figure 4.5). 
 
4.3.1.4 Restriction of ncRNA to those targeted by both SureSelect and NimbleGen 
Due to the difference in exome capture target areas between the Agilent SureSelect and Roche 











































Pre-Filtering 15.2 1.2 9.1 37.4 0.9 36.2
KS 37.9 1.0 6.4 32.1 1.3 21.4























NimbleGen exome data. This list was generated using the assumption that each ncRNA will 
contain at least one variant in one individual for each of the capture kits used. This list is the 
same as the one used for the analysis in 4.5.2.3 and the complete list is available in Appendix 
7. Figure 4.7 summarises the ncRNA filtering step, 4988 ncRNA had variants observed in both 
the SureSelect and NimbleGen groups, with 336 and 790 respectively expressed exclusively in 
either group. 
 
Figure 4.7: Summary of the trimming of the ncRNA dataset to include only variants in ncRNA covered by 
both the Agilent SureSelect and Roche NimbleGen exome capture kits. A – Summary of the number of 
ncRNA with annotated variants in each of the exome capture groups. Variants in the 336 ncRNA only 
present in the SureSelect group were excluded, and only variants in the 4988 that are shared were 
included in downstream analyses. B – Number of ncRNA variants before and after filtering for each of the 
candidate variant groups. 
 
4.3.1.5 Splicing Variants 
Intronic variants within 10bp of the intron/exon boundary are annotated by ANNOVAR as 
splicing variants. A degree of variation is permitted within splice site sequences without severely 
impacting on splicing, there are multiple scoring tools available, but there is still a degree of 






























Dinucleotide pairs both upstream and downstream of each exon are strongly conserved in 
mammalian splice sites, with over 98% featuring a GT downstream and AG upstream412. 
Disruptions of these dinucleotide sites have been shown to have serious effects on splicing 
efficiency, and when disrupted can lead to exon skipping, alternative exon usage, alternative 
polyadenylation site usage or intron retention, any of which can significantly impair gene 
function413–417. Due to the strength of the conservation of these canonical dinucleotide splice 
sites, and the uncertainty of splice site scoring for variants further away, splicing variants were 
filtered out if situated >2bp up or downstream of the exon. Figure 4.8 shows the number of 
splicing variants before and after filtering. Filtering based on the variant position within the splice 
site greatly reduces the number of variants, and confirms that fewer variants are tolerated in the 
2bp adjacent to an exon than in the rest of the 10bp sequence. If variants were randomly 
distributed throughout the 10bp, an 80% reduction would be expected, whereas in Figure 4.8 
94.8% and 94.4% reductions are observed respectively for the KCH and SWiTCH and the KCH, 
SWiTCH and TWiTCH candidate variants. 
 
Figure 4.8: Filtering of splicing variants outside of the canonical 2bp splice site, for both the KCH and 
SWiTCH, and KCH, SWiTCH and TWiTCH filtered candidate variants. Approximately 95% of splicing 
variants were removed by selecting for 20% of the splice site sequence. 
 
4.3.1.6 Synonymous Variants 
Due to redundancies in codon usage, it is possible for nucleotide substitutions to have no effect 
on the subsequent amino acid sequence. These substitutions are referred to as synonymous, 





























were filtered out of the candidate variant lists. All 5,728 and 3,941 synonymous SNPs were 
removed from the KCH and SWiTCH, and the KCH, SWiTCH and TWiTCH filtered candidate 
variant lists respectively. 
 
4.3.1.7 Commonly Mutated Genes 
Some genes are more commonly mutated than others, and frequently harbour many variants 
without affecting gene function. This can be due to gene size, if the rate of mutations across 
coding regions is uniform and considered in the format of SNPs/kb, then it would be expected 
that for larger genes, more SNPs would be indentified418. Additionally, some genes have a 
higher tolerance for genetic aberration, these typically tend to be genes with a degree of 
redundancy, or that perform functions that are not particularly dependant on the specific amino 
acid sequence as much as the overall structure, these include structural proteins and large 
secreted proteins such as those encoded by the MUC family of mucin genes419. These genes 
are commonly identified in next generation sequencing studies as false positive results.  
To remove variants found in commonly mutated genes, a list was compiled of genes identified 
by two published studies420,421.  The first list is of 2,157 genes and loci from Fuentes et al. 
(2012) that includes 1,580 pseudogenes, 435 genes commonly identified in exome sequencing 
studies, as well as 142 genes with more than 10 rare nonsynonymous coding variants in more 
than 3 families from a cohort of 29420. The second list is the top 100 genes identified by Shyr et 
al. (2014), in a study investigating FrequentLy mutAted GeneS (FLAGS), being the genes most 
commonly found to contain rare coding variants (minor allele frequency <1%) in published 
exome sequencing studies421. The complete list of 2,256 commonly mutated genes is provided 
in Appendix 10. 
A summary of the candidate variants after removal of commonly mutated genes is shown in 
Figure 4.9. 1,882 and 1,418 variants were removed from the KCH and SWiTCH filtered, and the 
KCH SWiTCH and TWiTCH filtered groups respectively. The proportion of the variants that 
occur in ncRNA is increasing, and at this stage make up more than half of the remaining 





Figure 4.9: Summary of the candidate variants after filtering for variants observed in the commonly 
mutated genes list. A – Summary of the 17,286 variants in the KCH and SWiTCH filtered group. B – 
Summary of the 14,346 variants in the KCH, SWiTCH and TWiTCH group. C – Number of each variant 
type removed by filtering out Commonly Mutated Genes for both the KCH & SWiTCH (KS), and the KCH, 
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4.3.1.8 Haematopoiesis Associated Genes 
This study aimed to identify variants that influence the severity of symptoms in SCA, as such, it 
was decided to narrow down the list of genes to those involved in erythroid development and 
function, as well as the immune response, which is known to play an important role in SCA 
disease pathology. 
To achieve this, a list of 7,420 ‘haematopoietically silent’ genes was compiled, based on data 
from the FANTOM5 Consortium422. The FANTOM5 Consortium have a large collection of 
RNAseq data, from many tissues and cell lines in both mice and humans. The human tissues 
that were used to compile the haematopoietically silent gene list are shown in Appendix 6, and 
the full list of 7,420 genes and transcripts is provided in Appendix 11. Genes were defined as 
transcriptionally silent if they had an RNA expression level of <1tpm (transcripts per million) in 
all 11 of the tissues analysed.  
The remaining candidate variants after removal of the haematopoietically silent genes are 
summarised in Figure 4.10. 2,087 and 1,666 variants were removed from the KCH and SWiTCH 
filtered, and the KCH SWiTCH and TWiTCH filtered groups, respectively. As was observed after 
removal of commonly mutated genes, the proportion of ncRNA variants was also increased 
after removal of haematopoietically silent genes, making up 33.8% and 30.4% of variants 




Figure 4.10: Summary of the candidate variants after filtering for variants observed in the 
haematopoietically silent genes list. A – Summary of the 15,199 variants in the KCH and SWiTCH filtered 
group. B – Summary of the 12,680 variants in the KCH, SWiTCH and TWiTCH group. C – Number of each 
variant type removed by filtering out haematopoietically silent genes for both the KCH & SWiTCH (KS), 
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4.3.1.9 Unknown Variants 
Variants designated as ‘UNKNOWN’ by ANNOVAR are caused by errors in the transcript 
annotation and alignment process, and the 203 & 150 variants from the KCH and SWiTCH, and 
the KCH, SWiTCH and TWiTCH candidates respectively were excluded.  
 
4.3.1.10 Allele Frequency – Rare Variants 
In WES studies, it is common to filter for variants based on allele frequency in the general 
population, e.g. using data from the 1000 genomes project423, with variants with a MAF >1% 
excluded. For studies aiming to identify variants causative of a disease phenotype, this is 
appropriate, since it is safe to assume that a mutation causing a disease will not be present in 
more than 1% of the population, unless 1% of the population are affected. This can be altered to 
10% for recessive disorders, providing a homozygous genotype frequency of 1%, e.g. the βS-
globin SNP has a frequency of 3% in the 1000 genomes project data (10% in African 
populations), and so would be excluded by analyses looking for variants with a MAF <1%423. 
Since this study is aiming to identify modifiers of SCA, not the disease itself, it was decided that 
filtering based on allele frequency would not be appropriate, and any SNPs influencing disease 
severity may be relatively common in the rest of the population, with no observable phenotype. 
This is similar to what is observed in HPFH disorders, which are frequently asymptomatic and 
often only diagnosed in conjunction with a β-globinopathy. 
 
4.3.1.11 CADD Phred-like Scores 
CADD (Combined Annotation-Dependent Depletion) scoring is a predictive measure of the 
likelihood of a variant to be deleterious to the function of the host gene, as modelled based on 
data from many different sources, including data regarding sequence conservation, GC content, 
CpG sites, transcription factor binding and other epigenetic data from the ENCODE project, 
transcript annotation and pre-existing amino acid change scoring tools378. The scores generated 
by CADD are converted to a Phred-like score, a scaled logarithmic ranking metric, where scores 
higher than 10 represent the top 10% most deleterious mutations, and higher than 20 
represents the top 1%, 30 the top 0.1% etc. CADD Phred-like scoring was not used to filter 
variants in the initial analysis, but were used in conjunction with information about gene function 




4.3.1.12 Removal of Single Occurrence Genes 
Any variants that occurred in only one patient were removed if the gene in which it was 
observed contained no other variants in the rest of the mild patients. This was because if a 
variant is not shared, nor the gene mutated in another mild patient, then an association cannot 
be shown. A summary of the two candidate groups is shown in Figure 4.11. 11,419 and 9,271 
variants remain in the candidate gene list for the KCH and SWiTCH, and the KCH, SWiTCH and 
TWiTCH filtered groups, respectively, and are again enriched for ncRNA variants, which now 
represent more than two thirds of all remaining variants. 
The candidate variant lists at this stage were used as the input for the gene burden test 




Figure 4.11: Summary of the candidate variants after exclusion of variants that occur only once, and in a 
gene that is not mutated in any other mild patient. A – Summary of the 11,419 variants in the KCH and 
SWiTCH (KS) filtered group. B – Summary of the 9,271 variants in the KCH, SWiTCH and TWiTCH group 
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4.3.2 Exome variants exclusive to mild patients 
To identify individual variants with a high frequency in the mild patient group, variants that only 
occurred once in the mild patient group were excluded. Variants that were heterozygous in one 
of the severe groups could only be relevant under a recessive model, and so were excluded if 
not homozygous in at least two of the mild SCA patient group, even if heterozygous in multiple 
patients. The full list of 11,419 filtered variants is provided in Appendix 12. 
The results of this final filtering step are shown in Figure 4.12, and demonstrate a significant 
reduction in the size of the candidate variant lists, suggesting that most of these variants were 
specific to one patient. The ncRNA still harbour the majority of variants, now representing 
81.1% and 84.6% of all remaining variants. 
 
Figure 4.12: Summary of the 3,159 and 2,597 candidate variants in the final lists for the KCH & SWiTCH 
(KS) and KCH, SWiTCH & TWiTCH (KST) filtered groups respectively. Loss of function variants (Splicing, 
Frameshift, Stopgain or Stoploss) were narrowed down to 24 and 18 variants in the KS and KST lists.  
 
CADD Phred-like scores were obtained for candidate loss of function and coding mutations, and 
are displayed alongside the candidate variants in 4.3.2.1 & 4.3.2.2. 
 
4.3.2.1 Nonsense: Loss of Function Candidate Variants 
After the removal of variants that occurred only once in the dataset, there were eight remaining 
variants that affected splicing, ten that resulted in a frameshift, four that resulted in the gain of a 
stop codon, and two that resulted in the loss of a stop codon. All 24 of these variants are shown 
in Table 4.4, ranked by frequency within the mild group. The variants that were present in the 
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       Mild Group Severe 




Hom Het Het 
KCH, SWiTCH & TWiTCH Filtered Candidate Loss of Function Variants 
11 124972553 C:T TMEM218 Stopgain W3X 5.18 0 9 0 
4 53611484 C:T ERVMER34-1 Stopgain W68X 35.00 0 5 0 
7 99269397 T:C CYP3A5 Stoploss X141W 2.43 0 5 0 
4 2721759 T:C FAM193A Stoploss X1212R 5.47 0 4 0 
15 101550877 A:- LRRK1 Splicing ex9 -2 26.30 2 1 0 
7 44112998 C:- POLM Frameshift Del R397fs 3.04 2 1 47 
2 234474229 -:A USP40 Frameshift Ins L3fs 19.40 1 2 0 
17 80755631 A:- TBCD Splicing ex8 -2 26.00 1 2 0 
11 704605 A:- TMEM80 Frameshift Del T271fs 0.41 0 3 0 
12 133698497 A:- ZNF891 Frameshift Del V3fs 14.57 0 3 0 
2 165657066 T:C COBLL1 Splicing ex4 -2 10.05 0 3 0 
8 74169207 C:A C8orf89 Splicing ex3 +1 11.68 0 3 0 
13 114059901 T:- LOC101928841 Frameshift Del T868fs 1.31 0 2 0 
10 6010779 -:G IL15RA Frameshift Ins C102fs 0.26 0 2 0 
1 168105586 -:G GPR161 Frameshift Ins P17fs 10.29 0 2 0 
19 17397478 -:TT ANKLE1 Frameshift Ins V637fs 9.29 0 2 0 
3 46305948 T:G CCR3 Splicing ex2 +2 6.22 0 2 0 
12 92382871 A:G C12orf79 Splicing ex4 +2 1.80 0 2 0 
          
KCH & SWiTCH Filtered Candidate Loss of Function Variants – Not present in KST 
8 21966711 G:- NUDT18 Frameshift Del P35fs 13.01 5 0 0 





GALR2 Frameshift Del P370fs 26.50 0 3 0 
16 4414415 C:G CORO7 Splicing ex13 -1 25.30 0 2 0 
16 4519398 G:A NMRAL1 Stopgain R37X 35.00 0 2 0 
7 99758145 C:T GAL3ST4 Stopgain W289X 38.00 0 2 0 
Table 4.4: 24 variants resulting in splice site disruption, frameshift, stoploss or stopgain in the mild SCA 
patient group after filtering. 6 of these were absent from the SWiTCH group but observed in the TWiTCH 
group. fs indicates frameshift, and splice variants are annotated as exN +/- 1/2, where the variant is either 
one or two nucleotides upstream (-) or downstream (+) of exon N.   
 
One of the stopgain mutations shown in Table 4.4 occurs in NMRAL1, and is heterozygous in 
two mild patients. NMRAL1 detects changes in the NADPH/NADP+ ratio, and regulates 
downstream signalling pathways, including NO synthesis, with signalling modulated through 
interaction with argininosuccinate synthetase, and also regulates apoptosis through the NF-κB 
pathway424,425. The variant in NMRAL1 substitutes arginine at position 37 for a stop codon, in an 
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exon included in all three annotated transcripts. This results in a truncated version of the 299 
residue peptide, and the variant has a high CADD Phred-like score of 35.00.  
The 24 loss of function variants occur in genes involved in a broad range of biological pathways 
and processes, some of which present a plausible biological mechanism to affect the 
pathophysiology of SCA. The most interesting candidate from this point of view is NMRAL1, 
which regulates synthesis of NO, a signalling molecule that has already been associated with 
the disease. This variant was predicted to effect gene function, as indicated by a high CADD 
Phred-like score, and is expected to completely remove functionality from all transcripts on the 
affected allele. 
Loss of function variants affect the amount of gene product produced in the cell, and an 
important factor to consider when investigating these variants is whether or not the cell can 
rescue these levels by compensating with increased expression of other isoforms, or from other 
alleles. Many of the variants identified in this analysis occurred in a limited proportion of splicing 
variants, and depending on the individual roles of each these isoforms, and any redundancy in 
function shared between them, any effect on gene function in the cell may be mediated. 
Similarly, most of the variants shown in Table 4.4 are heterozygous, including the stopgain 
mutation in the candidate gene NMRAL1. 
 
4.3.2.2 Missense: Nonsynonymous Substitutions and Nonframeshift Insertions/Deletions 
After the removal of variants that occurred only once in the dataset, there were 509 
nonsynonymous substitutions remaining, as well as 27 nonframeshift deletions and 35 
nonframeshift insertions. Nonframeshift insertions or deletions are characterised by addition or 
removal of a sequence fragment consisting only of complete codons (i.e. with sequence length 
being a multiple of three), with the result that in the protein sequence individual amino acids are 
added or lost, but the downstream sequence does not change. These sequence changes are 
generally considered to be less deleterious to gene function than frameshift mutations, which 
change the reading frame of the downstream sequence, essentially resulting in a nonsense 
protein sequence that can result in the use of a premature translational termination site, or is 
disposed of at the mRNA level by nonsense mediated decay426. 
The 20 of the 572 nonsynonymous and nonframeshift candidate variants with the highest 





       Mild Group Severe 




Hom Het Het 
KCH, SWiTCH & TWiTCH Filtered Candidate Nonsynonymous & Non-Frameshift Variants 
19 7293898 G:C INSR Nonsyn. SNP A2G 0.50 16 0 0 





MMP17 Non-FS Ins P24LPLP 3.28 13 2 0 
6 1313952 A:G FOXQ1 Nonsyn. SNP E338G 0.01 9 6 0 
1 2126139 C:G C1orf86 Nonsyn. SNP R17P 13.23 13 1 0 
13 28674628 T:C FLT3 Nonsyn. SNP D7G 16.24 7 7 0 
20 60640315 AGGGCC:- TAF4 
Non-FS 
Del 183:184del 9.84 10 2 0 
19 50155387 CGCTCC:- SCAF1 
Non-FS 
Del 581:582del 5.98 11 0 0 
14 70039824 GGCGGC:- CCDC177 
Non-FS 
Del 171:172del 7.26 10 1 0 
2 231902471 C:G C2orf72 Nonsyn. SNP A64G 0.01 4 7 0 
21 40178042 A:G ETS2 Nonsyn. SNP R140G 11.38 4 7 0 
21 40178043 G:C ETS2 Nonsyn. SNP R140T 8.96 4 7 0 
6 24797815 A:T C6orf229 Nonsyn. SNP F172L 23.90 3 8 0 
22 19137658 G:A GSC2 Nonsyn. SNP R47C 15.68 3 8 0 
9 139972219 G:T UAP1L1 Nonsyn. SNP V79L 0.00 2 9 0 
17 73512653 G:T TSEN54 Nonsyn. SNP E4D 0.06 5 5 0 
4 107279482 T:A GIMD1 Nonsyn. SNP K171I 3.72 0 10 0 
19 55525508 G:A GP6 Nonsyn. SNP T602M 21.50 0 10 0 
          





IGFBP2 Non-FS Ins L22PLLL 12.54 14 0 0 
1 33430102 T:G RNF19B Nonsyn. SNP Q62P 6.34 13 1 0 
Table 4.5: Summary of the top 20 candidate variants from the Nonsynonymous and non-frameshift 
substitutions after filtering. Ranked by frequency in the mild SCA patient group. Table shows 18 variants 
after filtering by the KCH, SWiTCH and TWiTCH groups, and 2 that  were present in TWiTCH but absent 
from the KCH and SWiTCH severe exome datasets. 
 
A non-frameshift insertion of three amino acid residues was observed in IGFBP2. This variant in 
was homozygous in 14 of the mild patients and results in insertion of proline-leucine-leucine 
before a leucine residue at position 22, and has a higher CADD Phred-like score of 12.54. This 
variant occurs in the signalling peptide sequence and is likely lost during post-translational 
processing of the protein. IGFBP2 encodes insulin-like growth factor binding protein 2, a 
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signalling molecule that promotes cell proliferation and differentiation, and has been associated 
with cancer progression427,428. IGFBP2 promotes HSC survival and expansion in bone marrow, 
as well as in cell culture conditions, and one of its targets (insulin-like growth factor 1) is used 
for the in vitro expansion of erythroid progenitors described in Chapter 30172,429,430. 
Substitutions were also observed in FOXQ1 (homozygous in 9, heterozygous in 6) and FLT3 
(homozygous in 7, heterozygous in 7). FOXQ1 is a transcription factor activated by TGF-β/Wnt 
signalling, and is associated with colorectal cancer progression and metastasis431–433. 
Expression of FOXQ1 has been shown to be lost during the γ-globin to β-globin switch, and it is 
thought to transcriptionally repress BCL11A, one of the master regulators of this switch434,435. 
This variant causes the substitution of glutamic acid at position 338 for glycine, and has a very 
low CADD Phred-like score of 0.01. FLT3 is a receptor tyrosine kinase that stimulates the 
expansion of HSCs and erythroid progenitors in the bone marrow, and is commonly associated 
with blood cancers436–438. The variant in FLT3 results in an aspartic acid to glycine substitution 
at position 7, situated in the signal peptide. The substitutions in FLT3 has a CADD Phred-like 
score of 16.24, and is included in both isoforms of the protein. 
A non-frameshift deletion of two amino acids was observed in TAF4, and which occurred in 12 
mild SCA patients (10 homozygous and 2 heterozygous). TAF4 is a component of the 
transcription initiation complex, and interacts with the transcription factor CREB, which is 
thought to be capable of γ-globin re-activation439,440. The deletion in TAF4 results in the loss of a 
glycine-proline repeat at positions 183-184, with a CADD Phred-like score of 9.84. 
Two variants were present adjacent to each other in ETS2, causing substitution of arginine at 
position 140 for either glycine or threonine. ETS2 is a transcription factor required for the 
formation of cardiac progenitor cells from fibroblasts during development, and is involved in the 
triggering of angiogenesis in endothelial cells441,442. Overexpression of ETS2 in K562 cells has 
also been shown to affect several important erythroid genes, reducing expression levels of 
KLF1, β-globin and α-globin443. Upon further investigation it was discovered that the two 
variants co-localised, and were observed in the same patients (four homozygous and seven 
heterozygous each). The fact that these were identified as two separate variants is due to mis-
annotation, and rather than being two separate SNPs resulting in substitution of arginine to 
either glycine or threonine, this is a dinucleotide variant causing an arginine to alanine 
substitution. The CADD Phred-like scores for glycine and threonine substitutions were 11.38 




       Mild Group Severe 




Hom Het Het 
KCH, SWiTCH & TWiTCH CADD Filtered Candidate Nonsynonymous & Non-Frameshift Variants 
1 2126139 C:G C1orf86 Nonsyn. SNP R17P 13.23 13 1 0 
13 28674628 T:C FLT3 Nonsyn. SNP D7G 16.24 7 7 0 
21 40178042 A:G ETS2 Nonsyn. SNP R140G 11.38 4 7 0 
6 24797815 A:T C6orf229 Nonsyn. SNP F172L 23.90 3 8 0 
22 19137658 G:A GSC2 Nonsyn. SNP R47C 15.68 3 8 0 
19 55525508 G:A GP6 Nonsyn. SNP T602M 21.50 0 10 0 
11 94261280 G:A C11orf97 Nonsyn. SNP R94K 16.30 2 7 0 
9 131580998 C:T ENDOG Nonsyn. SNP S12L 16.34 0 9 0 
10 102770278 T:C PDZD7 Nonsyn. SNP K790E 12.36 1 6 0 
X 100749038 C:T ARMCX4 Nonsyn. SNP A1821V 22.70 2 4 0 
12 29936626 C:A TMTC1 Nonsyn. SNP R20L 12.65 1 5 0 
11 22881002 C:T CCDC179 Nonsyn. SNP R29Q 10.45 5 6 4 
3 113052314 G:C CFAP44 Nonsyn. SNP P1185R 26.90 1 4 0 
12 55968284 T:C OR2AP1 Nonsyn. SNP L29P 24.60 1 4 0 
4 107279518 T:C GIMD1 Nonsyn. SNP E159G 11.45 0 5 0 
          





IGFBP2 Non-FS Ins L22PLLL 12.54 14 0 0 
16 2077090 G:C SLC9A3R2 Nonsyn. SNP E28D 24.90 0 7 0 
11 46369267 G:A DGKZ Nonsyn. SNP A20T 23.40 0 6 0 
19 1000785 C:T GRIN3B Nonsyn. SNP H117Y 19.19 1 4 0 
X 153707209 C:T LAGE3 Nonsyn. SNP D16N 10.78 1 4 0 
Table 4.6: Summary of the top 20 candidate variants from the Nonsynonymous and non-frameshift 
substitutions after filtering, as in Table 4.5, with additional filtering of variants with CADD Phred-like scores 
<10. Variants are ranked by frequency in the mild SCA patient group. Table shows 15 variants after 
filtering by the KCH, SWiTCH & TWiTCH groups, and 5 that  were present in TWiTCH but absent from the 
KCH and SWiTCH severe exome datasets. Seven candidate variants from Table 4.5 passed the CADD 
Phred-like score filtering. 
 
Some of these candidate variants occur in genes with biologically plausible mechanisms to 
affect the SCA pathophysiology, but have very low CADD Phred-like scores, and are unlikely to 
affect gene function e.g. the variant in FOXQ1, which has been associated with repression of 
BCL11A, but has CADD Phred-like score of 0.01. To avoid this, it was decided to apply a CADD 
Phred-like score cut-off of 10.00 to the list of top candidate variants, to ensure that only those 
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predicted to affect gene function would be considered, the results of this are shown in Table 4.6. 
CADD Phred-like scores of >10.00 represent the top 10% of CADD scored variants, and are the 
most likely to be deleterious to gene function.  
After the exclusion of candidate variants with CADD Phred-like scores of <10 from Table 4.5, 
only the variants in C1orf86, FLT3, ETS2, C6orf229, GSC2, GP6 and IGFBP2 were retained. 
Table 4.6 shows the updated candidate variant table after filtering by CADD Phred-like score, 
containing the new list of top candidates. 
Of the variants identified by the analyses performed in this section, five candidates with 
biologically plausible mechanisms were observed. These are the variants in IGFBP2, FOXQ1, 
FLT3, TAF4 and ETS2. However, the variants in FOXQ1 and TAF4 had CADD Phred-like 
scores below the threshold of 10.00, and so were not predicted to be deleterious to gene 
function. 
 
4.3.2.3 Non Protein Coding: ncRNA Candidate Variants 
After the removal of variants that occurred only once in the dataset, there were 2,563 ncRNA 
variants remaining. The 20 ncRNA candidate variants with the highest frequency in the mild 
SCA patient group after filtering are shown in Table 4.7. It is worth noting that while CADD 
scoring is available for ncRNA variants, these scores are not included in Table 4.7, and were 
not used for assessment of ncRNA variants. Due to a the relative lack of annotated ncRNA data 















     Mild Severe 
Chr POS Var Gene Type Hom Het Het 
KCH, SWiTCH & TWiTCH Filtered ncRNA Variants 
8 29779220 T:C FAM183CP ncRNA exonic 15 0 0 
20 61667631 T:C LINC00029 ncRNA exonic 10 4 0 
20 25658484 A:G ZNF337-AS1 ncRNA exonic 12 1 0 
17 68063631 G:A LINC01028 ncRNA exonic 11 2 0 
8 11618998 G:C C8orf49 ncRNA exonic 12 2 1 
8 73663426 T:A LOC101926908 ncRNA exonic 5 7 0 
19 38042410 C:G ZNF571-AS1 ncRNA exonic 2 10 0 
1 149576483 G:A LINC00623,LINC00869,LOC103091866 ncRNA exonic 2 10 0 
3 156392191 T:C TIPARP-AS1 ncRNA exonic 11 0 0 
10 17428971 T:A ST8SIA6-AS1 ncRNA exonic 10 1 0 
14 95999998 G:C SNHG10 ncRNA exonic 4 7 0 
12 104260287 T:C GNN ncRNA exonic 3 8 0 
10 91597426 T:C LINC00865 ncRNA exonic 3 8 0 
20 25834293 C:T LOC101926935 ncRNA exonic 1 10 0 
11 65272383 C:T MALAT1 ncRNA exonic 1 10 0 
13 22849324 C:T LINC00540 ncRNA exonic 10 0 0 
2 67313607 T:C LOC102800447 ncRNA exonic 8 2 0 
7 1201192 A:T LOC101927021 ncRNA exonic 5 5 0 
        
KCH & SWiTCH Filtered ncRNA Variants – Not present in KST 
13 114452024 A:G LINC00552 ncRNA exonic 9 3 0 
19 51398377 G:A KLKP1 ncRNA exonic 7 5 0 
 
Table 4.7: Summary of the top 20 candidate variants from the ncRNA candidate variants after filtering. 
Variants are ranked by frequency in the mild SCA patient group. Table shows 18 variants after filtering by 
the KCH, SWiTCH & TWiTCH groups, and two that were present in TWiTCH but absent from the KCH & 
SWiTCH severe exome datasets. 
 
Of the 20 ncRNA variants shown in Table 4.7, 19 have no characterised function, this 
demonstrates the vast gap in our current knowledge about the individual function of these non-
coding transcripts. 
MALAT1 is the only ncRNA in Table 4.7 with a characterised function, and presents a plausible 
biological mechanism to influence the severity of SCA. MALAT1 is a long ncRNA that regulates 
serine/arginine splicing factors and is associated with cancer progression, negatively regulating 
the tumour suppressor gene p53, as well as B-MYB444,445. B-MYB is a key regulator of HSC 
proliferation, and when depleted results in a reduction of haematopoietic potential. Through this 
interaction, MALAT1 regulates early haematopoietic development446,447. 
All of these variants are exonic SNPs, which are unlikely to affect transcriptional interference, 
and without more information regarding the function and mechanism of action of these ncRNA, 
it is difficult to predict how their function would be affected. SNPs could affect the formation of 
secondary structures required for the ncRNA function, and any ncRNA that work by sequence 
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specific binding could be affected, but may also have a degree of tolerance for short 
mismatches448. 
 
4.3.3 Variants in Known Modifier Genes 
Genes that had previously been associated with the SCA phenotype were screened for variants 
in the mild SCA patient population. This was performed using the list of 14,996 KCH and 
SWiTCH filtered candidate variants generated after removal of ‘unknown’ variants in 4.3.1. 
These include genes from both the α-globin-like and β-globin-like gene loci, as well as some 
known regulators of globin locus expression (MYB, BCL11A, KLF1, ASH1L, GATA1, LMO2, and 
LDB1). The results of this search are shown in Table 4.8. 
The only variant observed in one of the β-globin-like genes occurred in β-globin (HBB), and was 
confirmed to correspond to the β0 thalassaemia mutation in patient SCD 215. It is reassuring 
that this variant made it through the filtering process, and also that it has a very high CADD 
Phred-like score of 33.00, since it is known to have a severe effect on gene function. 
 
       Mild Group 





1 155327167 A:T ASH1L Nonsyn. SNP I2332N 12.82 0 1 
1 155491102 T:C ASH1L Nonsyn. SNP Q70R 24.60 0 1 
1 155449342 T:C ASH1L Nonsyn. SNP I1107V 0.63 0 1 
1 155531805 T:A ASH1L-AS1 ncRNA n/a 13.62 0 1 
1 155533060 G:T ASH1L-AS1 ncRNA n/a 3.86 0 1 
1 155532525 C:G ASH1L-AS1 ncRNA n/a 7.98 0 1 
1 155532696 -:C ASH1L-AS1 ncRNA n/a 5.19 0 3 
11 5247979 -:T HBB Frameshift Ins D48fs 33.00 0 1 
16 230574 T:C HBQ1 Nonsyn. SNP L30P 24.70 0 1 
19 12995802 T:C KLF1 Nonsyn. SNP H329R 27.50 0 1 
Table 4.8: Results of a search for variants in the candidate gene list that occur in known modifier genes for 
SCA phenotype severity. 10 variants were identified, all of which were heterozygous. One variant occurs in 
the β-globin gene (HBB) in patient SCD 215, who was heterozygous for both HbS and β0 thalassaemia, as 
described in Table 4.2. This frameshift variant is the β0 mutation, since it prevents any functional β-globin 
expression from this allele. 
 
There was also only one variant observed in the α-globin–like genes, which occurred in θ-globin 
(HBQ1). This variant resulted in a single amino acid substitution of leucine to proline at position 
30, and also had a high CADD Phred-like score of 24.70. θ-globin is an α-globin homologue that 
is highly conserved, but is only transcribed at very low levels449,450. Given the protective effect of 
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persistent ζ-globin expression in SCA, it is feasible that any SNP that increases expression of θ-
globin could also ameliorate the severity of the SCA phenotype. 
A SNP was observed in KLF1, substituting histidine for arginine at position 329 in the second of 
three zinc finger domains, with a very high CADD Phred-like score of 27.50. As described in 
1.6.1, variants affecting the function of KLF1 could impair the γ-globin to β-globin switch during 
erythroid development. This variant was observed in patient SCD 213, which had the highest 
HbF level observed in the mild patient group, of 29.5%. 
Three SNPs were also identified in the histone methyltransferase ASH1L, with CADD Phred-like 
scores of 24.60, 12.82 and 0.63, and a further four variants were observed in ASH1L-AS1, an 





4.4 Analysis 1: Gene Burden Analysis 
It is possible that individual variants protective for the SCA severe phenotype are not shared 
between the patients in the SCA mild group, but occur in the same genes. To investigate this 
model, a simple gene burden test was performed. 
This was carried out using the list of 11,419 candidate variants generated after filtering of genes 
with one variant in one patient as described in 4.3.1.12, rather than the list of 3,159 generated 
after removal of single occurrence variants generated in 4.3.2, since many variants that occur 
only once in the Mild SCA patient group would still be relevant if additional variants are 
observed in that gene in other patients. 
For each candidate variant, a list of the mild SCA patients in which that SNP is observed was 
generated, these were then collated for each gene, giving information on how many of the 19 
patients contained a candidate variant in each gene, and how many different variants were 
observed in that gene. Results were ranked firstly by the number of the mild SCA patients 
affected, and secondly by the fewest number of variants. Genes with fewer variants were 
prioritised since it was expected that the most variable genes have a higher tolerance for 
sequence polymorphisms, as is the case for the ‘Commonly Mutated Gene’ list described in 
4.3.1.7. 
The top 20 candidate genes from this analysis are shown in Table 4.9, firstly showing the list 
inclusive of ncRNA, which are shown to be highly variable, with many mutated in most of the 
patients, and with many variants. An additional candidate gene list was generated with the 
ncRNAs removed. Candidate genes that contained only one variant were also excluded, since 
individual variants with a high frequency in the mild SCA patient group had already been 
investigated by the analyses in 4.3.2.  
The majority of genes identified by the gene burden test were observed in ncRNA, this is 
probably at least partially due to the fact that ncRNA made up the majority of the candidate 
variant list, accounting for 66.8% of the 11,419 variants analysed from the KCH and SWiTCH 
filtered group in Figure 4.11. The results in Table 4.9 also show that the ncRNA generally 
harbour far more variants than the coding genes, and the average number of variants per 
ncRNA is 19.2, compared to 6.7 in the coding genes. This is to be expected given that ncRNA 
function is generally more tolerant of individual sequence variation448. However there are some 
exceptions to this, for example, the ncRNA LOC100287944 has only two variants that affect 18 
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of the 19 patients, whereas the MUC22 coding gene has 31 variants. MUC22 is a member of 
the mucin gene family, the majority of which were filtered out by the ‘Commonly Mutated Gene’ 
list described in 4.3.1.7. 
 
















MRGPRG-AS1 19 6 ncRNA  MUC22 19 31 
SLC6A10P 19 6 ncRNA  MST1L 18 2 
FAM215A 19 7 ncRNA  LOC100129697 18 14 
LINC00955 19 19 ncRNA  TUBGCP3 17 3 
GUCY2EP 19 24 ncRNA  MMP17 16 2 
MUC22 19 31 Coding  C11orf97 16 2 
LOC101926935 19 47 ncRNA  IGFBP2 16 3 
LOC401357 19 51 ncRNA  C1orf86 16 3 
MST1L 18 2 Coding  DSPP 16 11 
LOC100287944 18 2 ncRNA  LOC100129520 16 12 
LOC100133077 18 7 ncRNA  SUCLG2 15 3 
ESPNP 18 8 ncRNA  FOXQ1 15 4 
LINC00469 18 9 ncRNA  BEAN1 14 2 
LINC00940 18 12 ncRNA  RNF225 14 2 
LINC01262 18 13 ncRNA  OR1D5 14 3 
LINC00552 18 13 ncRNA  GIMD1 14 4 
LOC100129697 18 14 Coding  ARMCX4 14 7 
LINC00937 18 14 ncRNA  RALGDS 14 7 
KCNQ1OT1 18 43 ncRNA  GOLGA8H 14 9 
PRKXP1 18 45 ncRNA  STARD9 14 10 
 
Table 4.9: Top 20 candidate genes identified by the gene burden test, ranked by the number of mild 
patients containing a variant in each gene, and by the total number of variants observed in the gene. Table 
on the left shows the list including ncRNA, and on the right shows only protein coding genes. 
 
Of the 17 ncRNA shown in Table 4.9, only one has any characterised function. KCNQ1OT1 is a 
chromatin interacting ncRNA, it binds to the KCNQ1 locus and recruits chromatin modifying 
complexes, promoting formation of heterochromatin and transcriptionally silencing the 
surrounding genes451,452. Dysregulation of at the KCNQ1 locus has previously been associated 
with Beckwith-Wiedemann syndrome and Silver Russell Syndrome453,454. 
Of the 20 protein coding genes, seven have no known function (MST1L, LOC100129697, 
C11orf97, LOC100129520, RNF225, ARMCX4 and GOLGA8H). Variants in MMP17, IGFBP2 
and C1orf86 were previously identified in the analysis shown in 4.3.2.2, with individual variants 
accounting for 15, 14 and 14 of the mild patients respectively. A variant in FOXQ1 was 
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previously identified in 4.3.2.2, with this variant found in 15 patients, three of these patients also 
harbour an extra variant in the FOXQ1 gene.  
Of the top candidate genes identified by the gene burden test, the only gene that presents a 
biologically plausible mechanism to affect the SCA disease pathophysiology is the BCL11A 
repressor FOXQ1. However, the most frequent variant in this gene (E338G) was investigated in 
4.3.2.2, and was not predicted to affect gene function, with a very low CADD Phred-like score of 






4.5 Fisher’s Exact Tests 
Statistical analyses were used to test for associations of individual variants with the SCA patient 
groups outlined in 4.2. These were performed independently of the variant filtering pipeline, so 
as to not introduce inherent biases based on the filtering criteria. 
After the removal of low quality variant calls, as defined by the ANNOVAR variant calling 
pipeline, the number of occurrences of each variant within each patient group was counted. 
These counts were used to test the statistical significance of the frequency of each variant in 
these groups, using three separate Fisher’s exact tests:  
1. Firstly, a simple patient count test was performed, testing for the number of patients 
carrying each variant within the group, disregarding whether they are homozygous or 
heterozygous. 
2. The second test was for allele frequency, considering each patient as two alleles with 0, 
1 or 2 copies of the variant. This investigates whether there is an imbalance in the 
distribution of these alleles between the investigated groups.   
3. The third test was for homozygous counts. This was to account for a model where the 
effect of the variant is recessive, and only the homozygous patients would be affected. 
In this case the heterozygous cases in either group were ignored. 
 
4.5.1 P-Values & Multiple Testing Correction 
For most scientific experiments, a p-value cut off of <0.05 is used to test for statistical 
significance. This threshold signifies a 5% probability of the observed difference occurring 
purely by chance, resulting in a false positive rejection of the null hypothesis. Therefore, if 
performing a test on twenty different variables, it would be expected that at least one of them 
would incorrectly reject the null hypothesis, regardless of whether there is a true effect or not. 
For studies where multiple variables are investigated, it is common practice to adjust the p-
value cut-off to account for this multiple testing. The Bonferroni correction is a simple 
conversion of this value, where the desired p-value threshold is divided by the number of tests, 
e.g. if testing 20 variables with a p-value cut off of 0.05, the Bonferroni correction would be 
0.05/20, giving a p-value threshold of <0.0025 455. For studies investigating genome-wide 
datasets, every base pair sequenced could potentially be considered an additional variable, 
although this is generally considered to be prohibitively conservative, and it is common practice 
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for genome-wide studies to Bonferroni correct using the number of common SNPs covered by 
the sequencing area (with common SNPs defined as having a MAF of >5%). An estimate of this 
for whole genome sequencing is 4,152,114, and for exome sequencing using the Agilent 
SureSelect capture kit is 58,091, resulting in adjusted p-value thresholds of p<1.2x108 and 
p<8.6x107 respectively456. For the Roche NimbleGen capture kit, this estimation is 50,000 
common variants, resulting in a cut-off of p<1.0x106 456. 
Table 4.10 shows the number of common variants identified in our own datasets, for both the 
Agilent SureSelect and Roche NimbleGen kits respectively, compared to those estimated by 
Lacey et al.456. 
Group Total Variants 
Common 






Mild 2,798,560 2,180,113 2.29x108 Agilent SureSelect 58,091 8.61x107 
Severe 566,010 449,433 1.11x107 Agilent SureSelect 58,091 8.61x107 
SWiTCH 1,712,023 1,089,120 4.59x108 Roche NimbleGen 50,000 1.00x106 
TWiTCH 2,036,852 1,378,096 3.63x108 Roche NimbleGen 50,000 1.00x106 
HUSTLE 1,966,311 1,310,841 3.81x108 Roche NimbleGen 50,000 1.00x106 
Unknown 3,808,700 2,829,713 1.77x108 Roche NimbleGen 50,000 1.00x106 
 
Table 4.10: Table summarising the number of common variants (minor allele frequency >5% in the 1000 
Genomes Project data191) for each of the SCA patient groups, and comparing to those estimated for the 
same exome capture kits by Lacey et al. 456. The numbers of common variants are much higher than 
expected, resulting in much stricter Bonferroni corrected p-value thresholds. 
 
The total number of common variants annotated from both the Roche and Agilent exome 
capture kits is drastically higher than suggested by Lacey et al. and subsequently the 
corresponding p-value thresholds are lower456,457. Due to this discrepancy, rather than using 
these estimates for the Bonferroni correction for each exome capture kit, a new correction factor 
will be calculated for each analysis performed, corresponding to the number of variants being 
tested. 
 
4.5.2 Analysis 2: Statistical Comparison of Mild & Severe SCA Patient Groups 
To identify variants associated with either the mild or severe SCA patient phenotype, variants 
from the group of 19 mild SCA patients were compared to those in the severe group, firstly 
including just the five KCH severe patients, and secondly including the data from the 132 




4.5.2.1 Mild and severe SCA patients from King’s College Hospital 
The initial analyses performed considered only the patients from King’s College Hospital, the 
ten most significant results from the 2,922,494 variants tested are shown for each of the three 
Fisher’s Exact Tests in Table 4.11, Table 4.12 & Table 4.13. The difference in p-values between 
the different tests demonstrate that the most significant results were identified by the allele 
frequency test, although this is likely due to the fact that each patient is considered as two 
separate alleles, effectively doubling the sample number. 
      Mild Severe 
Chr Position Var Gene Type P Value Hom Het Hom Het 
3 153725251 T:C C3orf79, ARHGEF26-AS1 Intergenic 2.35E-05 16 3 0 0 
16 13359272 C:T SHISA9, ERCC4 Intergenic 2.35E-05 14 5 0 0 




Intergenic 2.35E-05 4 15 0 0 
21 10935167 TG:- TPTE Intronic 2.35E-05 0 19 0 0 
4 190544967 A:G LINC01060, LINC01262 Intergenic 0.000141 1 0 5 0 
15 90172474 A:G KIF7 Intronic 0.000141 1 0 5 0 
10 42400172 A:T LOC441666 Intergenic 0.000141 0 1 0 5 
10 70139112 T:G RUFY2 Intronic 0.000141 0 1 0 5 
8 43094814 C:G HGSNAT, POTEA Intergenic 0.000141 0 1 0 5 
8 43094823 C:T HGSNAT, POTEA Intergenic 0.000141 0 1 0 5 
Table 4.11: Patient count test. The ten variants with the lowest p-values as tested by Fisher’s Exact Test 
for patient counts between the mild and severe SCA groups. Analysis includes all variants annotated in 
patients from King’s College London only. The lowest p-value is 2.35x10-5, and does not reach the 
threshold of 1.71x10-8 required for statistical significance after Bonferroni Correction. Hom and Het refer to 
the number of patients found to be homozygous or heterozygous respectively, within the mild or severe 
patient groups. 
 
None of the variants in the mild or severe patient groups reached statistical significance when 
tested for significance by the patient count test in Table 4.11, or the homozygous count test in 
Table 4.13.  
However, statistical significance was reached using the allele frequency test in Table 4.12, 
finding variants significantly enriched in both the severe group compared to the mild, and vice 
versa. The ten most significant variants from the allele frequency test are shown in Table 4.12, 








      Mild Severe 
Chr Position Var Gene Type P Value Hom Het Hom Het 
4 190544967 A:G LINC01060, LINC01262 Intergenic 1.01E-08 1 0 5 0 
15 90172474 A:G KIF7 Intronic 1.01E-08 1 0 5 0 
1 246677104 A:C SMYD3, LOC255654 Intergenic 1.01E-08 18 0 0 0 
2 54885314 A:T SPTBN1 Intronic 1.01E-08 18 0 0 0 
2 64881017 C:G SERTAD2 UTR5 1.01E-08 18 0 0 0 
2 64881018 G:C SERTAD2 UTR5 1.01E-08 18 0 0 0 
2 71148045 C:T VAX2 Intronic 1.01E-08 18 0 0 0 
12 63073959 G:T PPM1H Intronic 4.37E-08 17 1 0 0 
2 74856123 C:T M1AP Intronic 4.37E-08 17 1 0 0 
7 81358712 G:A HGF Intronic 4.37E-08 17 1 0 0 
Table 4.12: Allele frequency test. The ten variants with the lowest p-values as tested by Fisher’s Exact 
Test for allele frequency between the mild and severe SCA groups. Analysis includes all variants 
annotated in patients from King’s College London only. Only p-values for the first seven variants fall below 
the Bonferroni corrected threshold of 1.71x10-8 for statistical significance. Hom and Het refer to the number 
of patients found to be homozygous or heterozygous respectively, within the mild or severe patient groups. 
 
Comparing the most significant results of the allele frequency test to those of the homozygous 
count test (Table 4.12 & Table 4.13 respectively), it is clear that there is a lot of overlap. This is 
expected given that the variants with the highest allele frequency will often be those that are 
homozygous in the most patients. Interestingly those variants that reach statistical significance 
in the allele frequency test are far above the threshold in the homozygous count test, 
presumably due to the doubling of the sample number in the former. This demonstrates how the 
technique used in the analyses can artificially alter the significance of the findings. 
 
      Mild Severe 
Chr Position Var Gene Type P Value Hom Het Hom Het 
4 190544967 A:G LINC01060, LINC01262 Intergenic 0.000141 1 0 5 0 
15 90172474 A:G KIF7 Intronic 0.000141 1 0 5 0 
1 246677104 A:C SMYD3, LOC255654 Intergenic 0.000141 18 0 0 0 
2 54885314 A:T SPTBN1 Intronic 0.000141 18 0 0 0 
2 64881017 C:G SERTAD2 UTR5 0.000141 18 0 0 0 
2 64881018 G:C SERTAD2 UTR5 0.000141 18 0 0 0 
2 71148045 C:T VAX2 Intronic 0.000141 18 0 0 0 
2 92315552 T:A ACTR3BP2 Intergenic 0.000471 0 0 4 0 
10 125622253 A:- CPXM2 Intronic 0.000471 19 0 1 3 
12 126517773 G:A LINC00939, LOC101927464 Intergenic 0.000471 0 11 4 1 
Table 4.13: Homozygous count test. The ten variants with the lowest p-values as tested by Fisher’s Exact 
Test for homozygous patient count between the mild and severe SCA groups. Analysis includes all 
variants annotated in patients from King’s College London only. The lowest p-value is 0.000141, and does 
not reach the threshold of 1.71x10-8 required for statistical significance after Bonferroni Correction. Hom 
and Het refer to the number of patients found to be homozygous or heterozygous respectively, within the 




4.5.2.2 Mild and Severe including SWiTCH Trial Exomes 
Patient count, allele frequency and homozygous count tests for variants enriched in either the 
mild or severe SCA patient groups were repeated, with the SWiTCH trial patients included in the 
severe group. The top ten most significant of the 3,860,685 variants tested are shown for each 
these tests in Table 4.14, Table 4.15 and Table 4.16.  
Seven of the ten most significant variants from the patient count test in Table 4.14 are 
intergenic.  
      Mild Severe 
Chr Position Var Gene Type P Value Hom Het Hom Het 
16 13359272 C:T SHISA9, ERCC4 Intergenic 8.16E-25 14 5 0 0 
12 48418556 G:T COL2A1, SENP1 Intergenic 1.63E-23 15 4 1 0 
5 137024472 C:T KLHL3 Intronic 1.63E-23 15 4 1 0 
2 91694185 T:C LOC654342 Intergenic 1.63E-23 1 18 1 0 




Intergenic 1.63E-23 16 3 1 0 
6 31336926 -:TT HLA-B, MICA Intergenic 1.63E-23 15 4 0 1 
4 45615916 T:G GNPDA2, GABRG1 Intergenic 1.63E-23 17 2 1 0 
11 71140156 C:T FLJ42102, DHCR7 Intergenic 1.63E-23 9 10 1 0 
14 57116979 A:G TMEM260 Downstream 1.63E-23 18 1 1 0 
3 96712868 A:T EPHA6 Intronic 1.63E-23 6 13 0 1 
Table 4.14: Patient count test. 10 most significant variants from Fisher’s Exact Test for patient count 
between Mild and Severe groups, including 132 severe patients from SWiTCH. The lowest p value is 
8.16x10-25, and all ten of these variants reach the significance threshold of 1.30x10-8. Hom and Het refer to 




      Mild Severe 
Chr Position Var Gene Type P Value Hom Het Hom Het 
18 8336695 -:GAAGGG PTPRM Intronic 7.13E-47 19 0 1 0 
13 42017682 T:G OR7E37P ncRNA 1.02E-44 19 0 2 0 
19 48564545 A:G PLA2G4C Intronic 1.02E-44 19 0 2 0 
4 8790898 G:A CPZ, HMX1 Intergenic 1.02E-44 19 0 2 0 
14 57116979 A:G TMEM260 Downstream 1.85E-44 18 1 1 0 
12 63073959 G:T PPM1H Intronic 3.2E-43 17 1 0 0 
12 125670964 A:C AACS, TMEM132B Intergenic 6.45E-43 19 0 3 0 
12 125670970 A:C AACS, TMEM132B Intergenic 6.45E-43 19 0 3 0 
15 91590948 A:T LOC101926911, SV2B Intergenic 6.45E-43 19 0 3 0 
15 95111778 A:G MCTP2, LOC440311 Intergenic 6.45E-43 19 0 3 0 
Table 4.15: Allele Frequency Test. 10 most significant variants from Fisher’s Exact Test for allele 
frequency between Mild and Severe groups, including 132 severe patients from SWiTCH. The lowest p 
value is 7.13x10-47, and all ten of these variants reach the significance threshold of 1.30x10-8. Hom and 
Het refer to the number of patients found to be homozygous or heterozygous respectively, within the mild 




Table 4.15 shows the most significant variants from the allele frequency test, one SNP, the 
downstream mutation in TMEM260 was also present in the patient count and homozygous 
count tests in Table 4.14 and Table 4.16. 
      Mild Severe 
Chr Position Var Gene Type P Value Hom Het Hom Het 
18 8336695 -:GAAGGG PTPRM Intronic 1.63E-23 19 0 1 0 
13 42017682 T:G OR7E37P ncRNA 1.71E-22 19 0 2 0 
19 48564545 A:G PLA2G4C Intronic 1.71E-22 19 0 2 0 
4 8790898 G:A CPZ, HMX1 Intergenic 1.71E-22 19 0 2 0 
12 125670964 A:C AACS, TMEM132B Intergenic 1.26E-21 19 0 3 0 
12 125670970 A:C AACS, TMEM132B Intergenic 1.26E-21 19 0 3 0 
12 2039690 A:G LINC00940 ncRNA 1.26E-21 19 0 3 2 
15 91590948 A:T LOC101926911, SV2B Intergenic 1.26E-21 19 0 3 0 
15 95111778 A:G MCTP2, LOC440311 Intergenic 1.26E-21 19 0 3 0 
17 33307703 C:- LIG3 Intronic 1.26E-21 19 0 3 1 
Table 4.16: Homozygous count test. 10 most significant variants from Fisher’s Exact Test for homozygous 
patient count between Mild and Severe groups, including 132 severe patients from SWiTCH. The lowest p 
value is 1.63x10-23, and all ten of these variants reach the significance threshold of 1.30x10-8. Hom and 
Het refer to the number of patients found to be homozygous or heterozygous respectively, within the mild 
or severe patient groups. 
 
The ten most significant results from the homozygous count test are shown in Table 4.16. As 
was observed previously in 4.5.2.1, there was a large overlap between the most significant 
variants from the allele frequency test and the homozygous count test. Only two of the variants 
in Table 4.16 were absent from Table 4.15. 
These results present interesting, statistically significant candidate variants located at gene loci 
that could have a biologically plausible effect on the SCA phenotype, e.g. SMYD3, SENP1, 
KLHL3 and TMEM123B. However, in these cases it seems very unlikely that any of the variants 
are able to influence the gene function, being mostly intergenic or intronic, and not disrupting 
annotated transcription factor binding sites. In contrast, some variants have a plausible 
mechanism for disruption of gene regulation, e.g. being situated in a densely populated 
transcription factor binding site, or deletion of CG dinucleotides from a CpG island, but affect 
genes with functions that seem very unlikely to influence the SCA phenotype. 
The ten most significant variants for each of the three analyses all reach the Bonferroni 
corrected p-value threshold required for statistical significance. This shows that including the 
exome data for the US SCA patients from the SWiTCH clinical trial greatly increases the power 
to identify statistically significant differences between the two groups. However, due to the size 
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of the SWiTCH dataset, and the fact that it is made up of SCA patients recruited from the US, 
the two groups being compared are no longer separated solely by SCA phenotype severity, but 
also by geographic location and ethnic ancestry. 
Of the variants presented in these results, none occur in the coding region. Intergenic, intronic 
and other non-coding regions have a much higher tolerance for genetic variation, since they are 
less likely to have a serious impact on gene function, and therefore are not strongly selected for 
or against. This genetic variation therefore accumulates in the non-coding areas of the genome 
over time, and can produce a lot of ‘noise’ when performing genome-wide analyses. It is worth 
noting that this is not always the case, and that there are some important non-coding regulatory 
elements associated with SCA and the Beta globin locus e.g. the ‘Corfu’ deletion in an 
intergenic region at the β-globin locus, that results in dysregulation and increased HBF 
expression (described in more detail in 1.3)458. 
 
4.5.2.3 Mild and Severe including SWiTCH, with non-coding variants removed  
In order to avoid the noise generated by the large number of non-coding variants, the analyses 
performed in 4.5.2.2 were repeated, but this time with the intergenic, intronic, upstream and 
downstream mutations removed.  
As described in 2.2.1.1 and 2.2.1.2, two different exome capture kits were used for library 
preparation. Agilent SureSelect was used for all 19 mild patients, as well as the 5 severe 
patients from King’s College Hospital, while Roche NimbleGen was used for the US dataset that 
makes up the rest of the severe patient group. The coverage of the genome varies between 
different capture kits, especially in the non-coding regions, and could therefore identify false-
positive associations purely due to the sampling technique used for each group.  
To account for any discrepancies in the ncRNA targeted, lists of ncRNA were generated for 
both the SureSelect and NimbleGen groups, and each ncRNA was only included in the study if 
at least one variant in one sample was observed in both the SureSelect and the NimbleGen 
groups. 4988 ncRNA were found to be shared between the groups, out of a total of 5324 and 
5778 for SureSelect and NimbleGen datasets respectively, the full list is shown in Appendix 7, 
and is summarised in 4.3.1.4. 
The results of the analyses are shown in Table 4.17, Table 4.18 and Table 4.19, for the patient 
count test, allele frequency test, and homozygous count test respectively. A full list of the 2,442 
significant variants is included in Appendix 8. 
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       Mild Severe 




P Value Hom Het Hom Het 
7 77326410 T:C APTR ncRNA 6.86 1.71E-22 15 4 2 0 
13 42017682 T:G OR7E37P ncRNA 0.06 1.71E-22 19 0 2 0 
X 6975782 C:G HDHD1 Exonic SNP 1.77 1.26E-21 10 9 1 2 
18 77440128 T:G CTDP1 Exonic SNP 0.00 2.13E-21 12 6 1 0 
5 150311858 T:- ZNF300P1 ncRNA splicing 8.19 7.23E-21 10 9 4 0 
1 31973125 GAGTCTGTCTG:- LINC01225 ncRNA 9.51 7.23E-21 7 12 1 3 
1 31973409 G:A LINC01225 ncRNA 7.15 7.23E-21 7 12 1 3 
21 15646397 A:G ABCC13 ncRNA 2.64 7.23E-21 12 7 4 0 
5 150311622 A:G ZNF300P1 ncRNA 1.68 7.23E-21 12 7 4 0 
5 150311678 A:G ZNF300P1 ncRNA 0.11 7.23E-21 12 7 4 0 
Table 4.17: Filtered patient count test. 10 most significant variants from Fisher’s Exact Test for patient 
count between Mild and Severe groups, including 132 severe patients from SWiTCH. The lowest p value is 
1.71x10-22, and all ten of these variants reach the significance threshold of 2.29x10-8. Hom and Het refer to 
the number of patients found to be homozygous or heterozygous respectively, within the mild or severe 
patient groups. Intergenic, intronic, downstream and upstream variants have been removed, along with 
ncRNA exclusive to one exome capture kit. 
 
After the removal of the non-coding variants, variants that affect amino acid sequence are 
observed among the most significant results, such as the SNP in HDHD1, a pseudouridine-5’-
phosphatase that is active in erythrocytes, and is involved in the processing of by-products of 
RNA degradation459. 
       Mild Severe 




P Value Hom Het Hom Het 
13 42017682 T:G OR7E37P ncRNA 0.06 1.02E-44 19 0 2 0 
12 2039690 A:G LINC00940 ncRNA 0.57 2.38E-41 19 0 3 2 
2 186655726 G:A FSIP2 Exonic SNP 6.58 2.38E-41 19 0 3 2 
7 128294446 A:G LINC01000 ncRNA 2.16 2.38E-41 19 0 4 0 
17 41961451 T:C MPP2 Splicing 0.70 1.25E-40 19 0 4 1 
4 156706482 G:A GUCY1B3 Splicing 2.79 1.25E-40 19 0 4 1 
X 65382685 T:C HEPH Exonic SNP 0.00 1.25E-40 19 0 4 1 
3 149376058 T:G WWTR1-AS1 ncRNA 5.76 3.08E-40 18 0 2 0 
3 51990119 A:C GPR62 Exonic SNP 5.20 3.08E-40 18 0 2 0 
1 221507141 C:T C1orf140 ncRNA 5.12 5.98E-40 19 0 5 0 
Table 4.18: Filtered allele frequency test. 10 most significant variants from Fisher’s Exact Test for allele 
frequency between Mild and Severe groups, including 132 severe patients from SWiTCH. The lowest p 
value is 1.02x10-44, and all ten of these variants reach the significance threshold of 2.29x10-8. Hom and 
Het refer to the number of patients found to be homozygous or heterozygous respectively, within the mild 
or severe patient groups. Intergenic, intronic, downstream and upstream variants have been removed, 
along with ncRNA exclusive to one exome capture kit. 
 
The most significant results from the filtered allele frequency and homozygous count tests are 
shown in Table 4.18 and Table 4.19. The ten variants identified are the same for the two tests, 
differing only in the order in which the significance is ranked e.g. MPP2 has a lower ranking in 
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the allele frequency test than the homozygous count test, since it is observed in a heterozygous 
severe patient as well as the four homozygous severe patients, whereas this is ignored in the 
homozygous count test. 
       Mild Severe 




P Value Hom Het Hom Het 
13 42017682 T:G OR7E37P ncRNA 0.06 1.71E-22 19 0 2 0 
12 2039690 A:G LINC00940 ncRNA 0.57 1.26E-21 19 0 3 2 
2 186655726 G:A FSIP2 Exonic SNP 6.58 1.26E-21 19 0 3 2 
17 41961451 T:C MPP2 Splicing 0.70 7.23E-21 19 0 4 1 
4 156706482 G:A GUCY1B3 Splicing 2.79 7.23E-21 19 0 4 1 
7 128294446 A:G LINC01000 ncRNA 2.16 7.23E-21 19 0 4 0 
X 65382685 T:C HEPH Exonic SNP 0.00 7.23E-21 19 0 4 1 
3 149376058 T:G WWTR1-AS1 ncRNA 5.76 2.11E-20 18 0 2 0 
3 51990119 A:C GPR62 Exonic SNP 5.20 2.11E-20 18 0 2 0 
1 221507141 C:T C1orf140 ncRNA 5.12 3.47E-20 19 0 5 0 
Table 4.19: Filtered homozygous count test. 10 most significant variants from Fisher’s Exact Test for 
homozygous patient count between Mild and Severe groups, including 132 severe patients from SWiTCH. 
The lowest p value is 1.71x10-22, and all ten of these variants reach the significance threshold of 2.29x10-8. 
Hom and Het refer to the number of patients found to be homozygous or heterozygous respectively, within 
the mild or severe patient groups. Intergenic, intronic, downstream and upstream variants have been 
removed, along with ncRNA exclusive to one exome capture kit. 
 
A coding variant was observed in HEPH. HEPH encodes Hephaestin, a ferroxidase involved in 
the processing of iron in intestinal cells, and delivery into the blood460. This provides an obvious 
biological mechanism by which sickle cell severity could be affected, lower blood iron levels 
would limit haemoglobin production, perhaps to below the threshold required to aggregate and 
distort the erythrocyte membrane. This would alleviate the symptoms caused by vaso-occlusive 
events, but severe anaemia would still be observed. 
Two splicing variants were identified in MPP2 and GUCY1B3, both of which are homozygous in 
all 19 mild patients and four severe patients, as well as being heterozygous in one severe 
patient. GUCY1B3 is a subunit of guanylate cyclase, which acts as the receptor for the NO 
signalling pathway, it directly recognises NO and is then activated to convert GTP to cGMP, 
triggering the downstream signalling cascade461. Mutations at this locus have previously been 
associated with hypertension and cardiovascular disease462. Impaired guanylate cyclase could 
either reduce response to NO signalling, or even leave it constitutively active. NO is a 
vasodilator that has previously been linked to the pathophysiology of SCA and pulmonary 
hypertension, and is thought to contribute to the mechanism of action of HU24,241,244,463. 
Some of these variants occur in genes that have a plausible biological mechanism for 
influencing SCA phenotype, including HDHD1, HEPH and GUCY1B3. However, many others 
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can be excluded based on their expression patterns, these include FSIP2, which is expressed 
exclusively in spermatocytes, and is therefore unlikely to affect SCA disease pathophysiology. 
Table 4.17, Table 4.18 and Table 4.19 also include the CADD Phred-like score for each of the 
variants identified. None of the variants have a CADD Phred-like score higher than 10.00, and 
so do not fall within the top 10% of variants predicted to affect gene function. The variants in 
HDHD1, HEPH and GUCY1B3 have particularly low CADD Phred-like scores of 1.77, 0.001 and 
2.79 respectively, and are not predicted to affect gene function. 
 
4.5.2.4 Most of the significant variants associate with ancestry, not disease severity 
Many of the variants highlighted as being statistically significant between the groups are likely to 
be due to the difference in ancestry of the UK SCA patients compared to the USA SCA patients. 
In this study, all 19 mild patients were recruited from SCA patients living in London, whereas the 
severe group consists of 132 patients recruited from the USA, plus an additional 5 from London. 
Of the variants shown in Table 4.17, Table 4.18 and Table 4.19, the SNPs are present in either 
18 or 19 of the 19 mild patients, and no more than 5 of the severe patients. This sort of 
imbalance is to be expected given that the tests are looking to identify imbalances between the 
two groups. However, upon further investigation it was discovered that apart from the variant in 
CTDP1, the candidate variants present in the severe group were only observed in the five 
patients that were recruited from the UK. In the case of CTDP1, the homozygous severe case 
was from the US dataset. 
For example, the ncRNA SNP in C1orf140 was statistically significant due to the fact that it is 
homozygous in all 19 patients from the mild group, and is homozygous in only 5 out of the 137 
severe patients. However this can also be viewed as being homozygous in all 24 of the UK SCA 
patients, and completely absent from the 132 US patients. It is unlikely that this is due to the 
difference in the capture kits used between the two datasets, since the ncRNA filtering step that 
was applied ensures that only ncRNA with variants present in the data from both capture kits 
are included. 
 
4.5.3 Analysis 3: Statistical Comparison of SWiTCH and HUSTLE SCA Patient Groups 
The analyses described previously focus on the identification of variants either protective or 
causative of the severe SCA phenotype, by identifying imbalances in frequency in our mild SCA 
patient group from KCH compared to a severe group made up of mostly US patients. 
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Taking a different approach, it was decided to investigate variants enriched in either the 
SWiTCH or HUSTLE patient groups within the US dataset. As described in 4.2.2, the SWiTCH 
group contains severe SCA patients, having had a stroke before the age of 17.5, whereas the 
HUSTLE group shows no particular bias for severity, and any SCA patient receiving HU therapy 
at St Jude’s Children’s Research Hospital could be included. Based on these assumptions, a 
comparison of these groups could inform on any variants enriched (or depleted) in the stroke 
group compared to the general SCA population. 
 
4.5.3.1 SWiTCH and HUSTLE Fisher’s Exact Tests 
Three Fisher’s Exact Tests were performed on the variants identified in SWiTCH and HUSTLE 
exome groups, testing for patient count, allele frequency and homozygous count, as was 
performed for the mild and severe groups described in 4.5.2. The results of these analyses are 
shown in Table 4.20, Table 4.21 and Table 4.22 respectively, and it can be seen that the 
majority of the most significant variants are non-coding, similar to the observations in the mild vs 
severe patient tests in 4.5.2.1 and 4.5.2.2. A total of 2,673,201 variants were tested, giving a 
Bonferroni corrected p-value threshold for statistical significance of 1.87x10-8. 
      
SWiTCH HUSTLE 
Chr Position Var Gene Type P Value Hom Het Hom Het 
16 12009279 A:G GSPT1 Exonic SNP 8.26E-17 91 4 30 1 
4 151177432 A:C DCLK2 UTR3 4.35E-16 60 21 17 3 
2 166810373 A:G TTC21B Upstream 4.35E-16 81 0 20 0 
11 209002 A:G RIC8A Intronic 4.99E-16 75 15 25 3 
5 101596078 TATAT:- SLCO4C1 Intronic 6.59E-16 51 24 12 4 
14 88852283 G:- SPATA7 Intronic 7.95E-16 96 0 34 0 
9 33264540 C:G BAG1 Exonic SNP 8.08E-16 69 10 17 2 
21 38081577 C:G SIM2 Intronic 8.08E-16 61 18 12 7 
19 56041255 C:G SBK2 Exonic SNP 8.08E-16 78 1 19 0 
1 2518186 A:G FAM213B Upstream 8.77E-16 86 0 25 0 
Table 4.20: Patient count test. The ten variants with the lowest p-values as tested by Fisher’s Exact Test 
for patient counts between the SWiTCH and HUSTLE SCA groups. The lowest p-value is 8.26x10-17, and 
all ten variants reach the threshold of 1.87x10-8 required for statistical significance after Bonferroni 
Correction. Hom and Het refer to the number of patients found to be homozygous or heterozygous 
respectively, within the SWiTCH or HUSTLE patient groups. 
 
Three protein coding variants were identified in Table 4.20, including a SNP in BAG1. BAG1 is a 
cell cycle regulator that upregulates anti-apoptotic factors, including BCL2, and has been shown 
to be essential for healthy development of both haematopoietic and neuronal cells in mice464,465.  
 




Chr Position Var Gene Type P Value Hom Het Hom Het 
16 12009279 A:G GSPT1 Exonic SNP 4.37E-31 91 4 30 1 
2 166810373 A:G TTC21B Upstream 4.66E-31 81 0 20 0 
14 88852283 G:- SPATA7 Intronic 1.65E-30 96 0 34 0 
1 2518186 A:G FAM213B Upstream 3.39E-30 86 0 25 0 
19 56041255 C:G SBK2 Exonic SNP 4.43E-30 78 1 19 0 
1 1229680 G:T ACAP3 Intronic 5.61E-30 101 0 40 0 
1 115631924 C:T TSPAN2 Intronic 1.51E-29 74 5 16 4 
22 31687142 G:C PIK3IP1 Intronic 2.16E-29 79 0 20 0 
1 246670281 G:C SMYD3 Intronic 6.96E-29 81 0 22 0 
5 149737221 T:G TCOF1 UTR5 7.55E-29 77 0 19 0 
Table 4.21: Allele frequency test. The ten variants with the lowest p-values as tested by Fisher’s Exact 
Test for allele frequency between the SWiTCH and HUSTLE SCA groups. The lowest p-value is 4.37x10-
31, and all ten variants reach the threshold of 1.87x10-8 required for statistical significance after Bonferroni 
Correction. Hom and Het refer to the number of patients found to be homozygous or heterozygous 
respectively, within the SWiTCH or HUSTLE patient groups. 
 
      SWITCH HUSTLE 
Chr Position Var Gene Type P Value Hom Het Hom Het 
2 166810373 A:G TTC21B Upstream 4.35E-16 81 0 20 0 
14 88852283 G:- SPATA7 Intronic 7.95E-16 96 0 34 0 
1 2518186 A:G FAM213B Upstream 8.77E-16 86 0 25 0 
1 1229680 G:T ACAP3 Intronic 1.11E-15 101 0 40 0 
1 115631924 C:T TSPAN2 Intronic 1.69E-15 74 5 16 4 
16 12009279 A:G GSPT1 Exonic SNP 1.69E-15 91 4 30 1 
19 56041255 C:G SBK2 Exonic SNP 2.08E-15 78 1 19 0 
22 31687142 G:C PIK3IP1 Intronic 2.91E-15 79 0 20 0 
5 149737221 T:G TCOF1 UTR5 5.30E-15 77 0 19 0 
1 246670281 G:C SMYD3 Intronic 5.36E-15 81 0 22 0 
Table 4.22: Homozygous count test. The ten variants with the lowest p-values as tested by Fisher’s Exact 
Test for homozygous patients between the SWiTCH and HUSTLE SCA groups. The lowest p-value is 
4.35x10-16, and all ten variants reach the threshold of 1.87x10-8 required for statistical significance after 
Bonferroni Correction. Hom and Het refer to the number of patients found to be homozygous or 
heterozygous respectively, within the SWiTCH or HUSTLE patient groups. 
 
As was observed in the mild vs severe Fisher’s Exact Tests performed in 4.5.2.1 and 4.5.2.2, 
the majority of the most significant variants occur in the non-coding region. In these previous 
tests no coding variants were identified, however in the SWiTCH vs HUSTLE tests, three exonic 
SNPs were observed, in GSPT1, SBK2, and BAG1, which has been linked to healthy regulation 
of haematopoietic cells465. 
 
4.5.3.2 SWiTCH and HUSTLE Fisher’s Exact Test with Non-Coding Variants Removed 
Table 4.23, Table 4.24 and Table 4.25 show the most significant results from the three Fisher’s 
Exact Tests shown in 4.5.3.1, with the non-coding variants removed. CADD Phred-like scores 
are also included in these tables. A full list of the 236 significant variants is included in Appendix 
9. Three of these coding variants (in GSPT1, BAG1 and SBK2) were described in the previous 
section. The variants observed in GSPT1 and SBK2 had very low CADD Phred-like scores of 
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0.001 and 0.02 respectively, and are not predicted to affect gene function. The variant in BAG1 
however had a high CADD Phred-like score of 16.29. 
        SWiTCH HUSTLE 




P Value Hom Het Hom Het 
16 12009279 A:G GSPT1 Nonsyn. SNP V100A 0.00 8.26E-17 91 4 30 1 
9 33264540 C:G BAG1 Nonsyn. SNP G45R 16.29 8.08E-16 69 10 17 2 
19 56041255 C:G SBK2 Nonsyn. SNP A298P 0.02 8.08E-16 78 1 19 0 
19 10676681 T:C KRI1 Nonsyn. SNP T5A 0.00 3.99E-15 54 26 15 6 
7 6193521 G:C USP42 Nonsyn. SNP R779P 11.14 5.30E-15 56 21 12 7 
5 140537363 C:T PCDHB17P ncRNA n/a 19.17 1.01E-14 76 3 20 1 
19 51015404 T:C ASPDH Nonsyn. SNP Q266R 9.60 2.19E-14 75 10 24 3 
1 1361641 C:T TMEM88B Nonsyn. SNP P45L 5.81 2.66E-14 62 36 32 8 
19 4670313 C:G MYDGF Nonsyn. SNP G12R 22.90 2.74E-14 31 37 4 10 
5 54830295 T:G RNF138P1 ncRNA n/a 0.53 3.29E-14 51 24 16 3 
Table 4.23: Patient count test. The ten variants with the lowest p-values as tested by Fisher’s Exact Test 
for patient counts between the SWiTCH and HUSTLE SCA groups, with non-coding variants removed. The 
lowest p-value is 8.26x10-17, and all ten variants reach the threshold of 1.87x10-8 required for statistical 
significance after Bonferroni Correction. Hom and Het refer to the number of patients found to be 
homozygous or heterozygous respectively, within the SWiTCH or HUSTLE patient groups. 
 
A variant with a high CADD Phred-like score of 22.90 was observed in MYDGF, resulting in the 
substitution of glycine to arginine at position 12 in the signal peptide. MYDGF is a myeloid 
derived growth factor, produced by monocytes and macrophages in response to ischaemic 
tissue damage in the heart, preventing apoptosis by activating the PI3K signalling pathway, as 
well as stimulating endothelial cell growth and angiogenesis in the damaged tissue466. MYDGF 
has been proposed as a therapeutic treatment to repair cardiac tissues after ischaemic injuries, 
and if its ability to minimise tissue damage and reperfusion injury are observed in other tissues 
as well, MYDGF could have an important role in modulating the severity of SCA symptoms 












        SWiTCH HUSTLE 




P Value Hom Het Hom Het 
16 12009279 A:G GSPT1 Nonsyn. SNP V100A 0.00 4.37E-31 91 4 30 1 
19 56041255 C:G SBK2 Nonsyn. SNP A298P 0.02 4.43E-30 78 1 19 0 
5 140537363 C:T PCDHB17P ncRNA n/a 19.17 1.21E-27 76 3 20 1 
9 33264540 C:G BAG1 Nonsyn. SNP G45R 16.29 2.75E-27 69 10 17 2 
5 132149684 G:C SOWAHA Nonsyn. SNP R124P 9.51 2.42E-26 76 1 21 0 
8 120220779 G:- MAL2 Frameshift Del V23fs 24.90 3.56E-26 91 0 34 0 
7 140396475 -:G NDUFB2-AS1 ncRNA n/a 8.17 4.20E-26 94 0 37 0 
16 25704145 A:G HS3ST4 Nonsyn. SNP Q136R 7.82 6.80E-26 65 7 14 3 
1 151881885 A:C THEM4 Nonsyn. SNP L17R 0.09 9.36E-26 62 5 12 2 
8 145106943 CC:- OPLAH Frameshift Del R1166fs 23.90 1.07E-25 73 0 19 0 
Table 4.24: Allele frequency test. The ten variants with the lowest p-values as tested by Fisher’s Exact 
Test for allele frequency between the SWiTCH and HUSTLE SCA groups, with non-coding variants 
removed. The lowest p-value is 4.31x10-31, and all ten variants reach the threshold of 1.87x10-8 required 
for statistical significance after Bonferroni Correction. Hom and Het refer to the number of patients found to 
be homozygous or heterozygous respectively, within the SWiTCH or HUSTLE patient groups. 
 
        SWiTCH HUSTLE 




P Value Hom Het Hom Het 
16 12009279 A:G GSPT1 Nonsyn. SNP V100A 0.00 1.70E-15 91 4 30 1 
19 56041255 C:G SBK2 Nonsyn. SNP A298P 0.02 2.08E-15 78 1 19 0 
5 140537363 C:T PCDHB17P ncRNA n/a 19.17 4.56E-14 76 3 20 1 
8 120220779 G:- MAL2 Frameshift Del V23fs 24.90 1.12E-13 91 0 34 0 
7 140396475 -:G NDUFB2-AS1 ncRNA n/a 8.17 1.27E-13 94 0 37 0 
5 132149684 G:C SOWAHA Nonsyn. SNP R124P 9.51 1.5E-13 76 1 21 0 
8 145106943 CC:- OPLAH Frameshift Del R1166fs 23.9 1.94E-13 73 0 19 0 
4 48492434 G:C ZAR1 Nonsyn. SNP Q42H 0.01 2.3E-13 70 3 17 2 
16 25704145 A:G HS3ST4 Nonsyn. SNP Q136R 7.82 3.82E-13 65 7 14 3 
9 33264540 C:G BAG1 Nonsyn. SNP G45R 16.29 5.45E-13 69 10 17 2 
Table 4.25: Homozygous count test. The ten variants with the lowest p-values as tested by Fisher’s Exact 
Test for homozygous patient counts between the SWiTCH and HUSTLE SCA groups, with non-coding 
variants removed. The lowest p-value is 1.70x10-15, and all ten variants reach the threshold of 1.87x10-8 
required for statistical significance after Bonferroni Correction. Hom and Het refer to the number of patients 
found to be homozygous or heterozygous respectively, within the SWiTCH or HUSTLE patient groups. 
 
Table 4.25 shows the most significant variants identified by the homozygous count test. Nine of 
the variants shown were also identified in the allele frequency test in Table 4.24, likely due to 
the fact that the allele frequency test favours homozygous variants. 
Of the variants identified by these analyses, two SNPs in BAG1 and MYDGF present plausible 
biological mechanisms for influencing the severity of the SCA phenotype. Both of these variants 
have CADD Phred-like scores >10.00 (16.29 and 22.90 respectively), and are significantly 
enriched in the SWiTCH severe patient group compared to the HUSTLE group. The G45R 
variant in BAG1 was among the most significant variants for all three tests, being present in 79 
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of 132 SWiTCH patients (69 homozygous and ten heterozygous), and 19 of 140 HUSTLE 
patients (17 homozygous and two heterozygous). The G12R variant in MYDGF was observed in 
68 of the 132 SWiTCH patients (31 homozygous and 37 heterozygous), and 14 of the 140 
HUSTLE patients (four homozygous and ten heterozygous), and was only included among the 
most significant variants for the patient count test, not the allele frequency of homozygous count 
tests, since the majority of the patients were heterozygous. This MYDGF variant had a p-value 
of 1.80x10-19 for the allele frequency test, reaching the threshold of p<1.87x10-8 required for 
significance. However for the homozygous count test the p-value was 2.5x10-7, and was not 
significant, suggesting that if this SNP is affecting the SCA phenotype, it is acting under a 




4.6 Summary of the SCA WES Results 
Using WES data generated by this study and in combination with publicly available datasets, we 
were able to identify nine potential modifiers of the SCA disease phenotype (Table 4.26). These 
nine candidates occur in genes with biologically plausible mechanisms to influence the 
pathophysiology of the disease, and warrant further testing in vitro through the use of CRISPR 
genomic editing. 
       
Mild Severe  




Hom Het Het  
Analysis 1: Variants in known modifier genes  
16 230574 T:C HBQ1 Nonsyn. SNP L30P 24.7 0 1 0  
19 12995802 T:C KLF1 Nonsyn. SNP H329R 27.5 0 1 0  
Analysis 1: Loss of function variants  
16 4519398 G:A NMRAL1 Stopgain R37X 35.00 0 2 0  





IGFBP2 Non-FS Ins L22PLLL 12.54 14 0 0  
13 28674628 T:C FLT3 Nonsyn. SNP D7G 16.24 7 7 0  
2 40178042 AG:GC ETS2 Nonsyn. SNP R140A 10.57 4 7 0  
Analysis 1: ncRNA variants  
11 65272383 C:T MALAT1 ncRNA exonic n/a n/a 1 10 0  
 
       SWiTCH HUSTLE 




Hom Het Hom Het 
Analysis 3: Variants enriched in SWiTCH or HUSTLE patients 
9 33264540 C:G BAG1 Nonsyn. SNP G45R 16.29 69 10 17 2 
19 4670313 C:G MYDGF Nonsyn. SNP G12R 22.9 31 37 4 10 
 
Table 4.26: Table summarising the nine candidate modifier variants identified by the different exome 
sequencing analysis strategies used. 7 of these variants were identified in the mild SCA patient group from 
KCH using the variant filtering pipeline developed in Analysis 1. Two variants in BAG1 and MYDGF were 
identified by Fisher’s Exact Tests for enrichment in either the SWiTCH or HUSTLE SCA exome groups. 
 
Seven of these modifier variants were identified in the Mild SCA patient group and are predicted 
to protect patients from the severe SCA phenotype, whilst two were identified as being enriched 




The two variants in KLF1 & HBQ1 were identified by searching for variants in known modifier 
genes that had made it through the variant filtering pathway, and both would be expected to 
elicit their effect on the SCA phenotype by de-repressing early stage globin genes (g-globin and 
q-globin respectively). 
Five other candidate variants were identified by Analysis 1, and are present in more than one of 
the mild SCA patients at KCH, and absent from the severe SCA groups from KCH and 
SWiTCH, having made it through the variant filtering pipeline. These five variants include a loss 
of function mutation in NMRAL1, three missense mutations in IGFBP2, FLT3 and ETS2, and 
one variant in the ncRNA MALAT1. The variant in NMRAL1 would be expected to affect nitric 
oxide signalling, while IGFBP2, FLT3, ETS2 and MALAT1 have all previously been associated 
with haematopoietic regulation. 
Two candidate variants in BAG1 and MYDGF were identified by Analysis 3, being significantly 
enriched in the severe SWiTCH cohort compared to the HUSTLE cohort, which is 
representative of the general SCA population. Therefore, these variants are predicted to 
increase rather than ameliorate the severity of the SCA phenotype. The variant in BAG1 is 
expected to affect haematopoietic regulation, while MYDGF has previously been associated 
with recovery from ischaemic injury. 
The potential mechanisms by which these mutations may affect the SCA phenotype, and how 
they could be functionally analysed in future work, are discussed in more detail in 6.2.4. 
If the predicted impact of these candidates on gene function is confirmed in vitro, this will 
demonstrate the power of WES and our variant filtering pipeline as a tool for identification of 
phenotype altering variants, especially given the small sample size of the mild SCA patient 
group. This would also support our hypothesis that many candidate genetic modifiers of SCA 
remain to be identified, and would demonstrate the importance of carrying out genome-wide 
sequencing studies on a larger scale to identify additional genetic factors influencing phenotype 





 Results: CRISPR Genomic Editing - Functional 
Analysis of SNPs in vitro 
WES provides a powerful tool for identification of variants associated with disease phenotypes. 
However, after in silico identification, functional analyses must be conducted to determine 
whether candidate variants are actually causative of the phenotype, or whether the observed 
association is coincidental. The advent of CRISPR genomic editing has greatly improved our 
ability to introduce specific mutations into the genome, and is a powerful tool for analysing the 
effect that specific variants have on gene function in vitro. 
We plan to use CRISPR genomic editing to functionally assess the candidate variants that were 
identified by the WES study performed in Chapter 4. Prior to identification of these variants, we 
set out to familiarise ourselves with the CRISPR-Cas9 system, and to set up a pipeline in our 
laboratory to allow efficient introduction of candidate variants into cell lines in vitro. 
This part of the thesis work aimed to test and optimise the CRISPR pipeline by investigating two 
previously identified variants that are thought to affect regulation of the β-globin locus. These 
two variants affect ASH1L and KLF1, and their discovery and proposed mechanisms of action 
are described below. We aimed to introduce these variants into a K562 cell line, and to perform 
preliminary functional analyses to determine what effect the mutations have on globin gene 
expression. K562 is an erythroleukaemic cell line, and is commonly used as a model for the 
erythroid lineages. The reasons for selecting K562 cells is described in more detail below, in 
5.2.3. 
Cas9 plasmids containing gRNAs designed to target the regions of interest were constructed as 
described in 2.4.2, initially using DNA repair templates incorporated into the Cas9 plasmids. As 
is described below in 5.1, this technique was chosen for simplicity, to allow transfection of a 
single plasmid that contained all three of the components for our CRISPR-Cas9 system. 
 
5.1 CRISPR-Cas9 Strategy and Design 
As described in 1.7.3, there are now a wide variety of CRISPR-based techniques and 
methodologies routinely used in laboratories around the world, that can be tailored and 
implemented according to the specific requirements of the intended experiments. While this 
makes CRISPR-Cas9 a powerful and versatile tool for laboratory research, the wealth of 
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information available also makes it very complex when initially establishing a CRISPR based 
protocol in a laboratory, due to the numerous options available.  
 
5.1.1 gRNA & Template Sequence Design 
When targeting the introduction of specific mutations, the options for gRNA design are quite 
limited, since the distance between the DSB and the target is a key factor for determining  
successful incorporation rates of the mutation467. gRNA design therefore involved a compromise 
between distance from the SNP site, computationally predicted cleavage efficiency, and number 
of predicted off-target binding sites (described in detail in 2.4.1). 
Design of the template sequence is obviously restricted regarding the target SNP, but is less 
specific regarding disruption of the PAM site. Disruption of the PAM site prevents repeated 
cleavage of the target sequence once the template is correctly incorporated, and so increases 
efficiency. However, introducing additional sequence changes may also affect gene function 
independently of the SNP of interest. Since the KLF1 SNP is intronic, and hypothesised to affect 
transcription factor binding, it is therefore possible that the PAM disruption mutation could also 
affect the transcription factor binding at that site. In the case of the ASH1L SNP, the sequence 
allows the disruption of the PAM site without altering the amino acid sequence of the protein, 
but could potentially have an impact on protein levels as a result of altered codon usage. For 
the chosen PAM disruptions, asparagine AAC to AAT have usage frequencies of 0.54 and 0.46 
respectively, while arginine CGG to CGA have 0.21 and 0.11468. 
It was decided that the benefits of increased efficiency outweighed these risks, and PAM 
disruption mutations were included in the template sequence. Additional PAM disruption only 
controls were also designed, in order to assay the effects that the PAM disruption mutations 
themselves have on gene function. 
 
5.1.2 Delivery Methods for gRNA, Cas9 & Template Sequence 
A straightforward approach was initially chosen for this project, where all three components of 
the system (Cas9, gRNA and template DNA) were included in a single plasmid (Figure 2.1). 
Plasmid transfection of K562 cells is well established, and this allowed the use of a single GFP 
reporter to confirm that all the necessary components had been successfully introduced into the 
cell. The use of a plasmid for the source of each of the components also makes the technique 
more cost-effective, since once constructed, the plasmid can be cloned and modified with 
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minimal additional cost in the laboratory, rather than purchasing each of the individual 
components for each experiment. 
The main disadvantage of this technique was that it required a relatively large plasmid 
(approximately 10kb), which had adverse effects on transfection efficiency, (as described in 
5.3.1). While it can be seen that this did not have a significant impact on cleavage efficiency in 
cells that had been successfully transfected, it was believed that the low copy number of the 
template DNA had an adverse effect on HDR rates. In response to this, the protocol was 
subsequently modified, and co-transfection with siRNA to knock down key components of the 
NHEJ pathway (Ku70 and Ligase IV), as well as separate introduction of the template sequence 
in the form of ssODNs were tested. Each of these techniques had previously been 
demonstrated to increase template uptake353,469. 
Template sequences for insertion into the plasmid were designed with approximately 350bp 
homology arms either side of the target mutation. This may also have affected the efficiency of 
template incorporation, since it is recommended that longer flanking sequences of 500-800bp 
are used for optimal HDR340,350,351. The shorter arms were chosen in this case in order to try to 
reduce the size of the plasmid, and also to facilitate the cloning process, with PCR fragments of 
750bp much easier to clone into the plasmids than fragments of 1,600bp. 
For the design of the ssODN template sequences, the homology arms were reduced to 50bp 
flanking the target sequence, which had previously been demonstrated to enable efficient 
HDR469. Other factors associated with ssODN design, such as using as asymmetric homology 
arms, could also be used to increase HDR efficiency in the future470. These, as well as other 
possible techniques to improve HDR efficiency are described in more detail in 6.3.3.  
 
5.2 Candidate SNPs Modifying Expression from the β-globin Locus 
Two candidate SNPs in KLF1 and ASH1L had previously been identified by Professor Thein’s 
laboratory group. These were identified by independent genetic analyses looking for SNPs 
causative of an altered pattern of expression from the β-globin locus. This project aimed to 
establish a CRISPR-Cas9 system for genomic editing in the laboratory, and to use this system 
to replicate the KLF1 & ASH1L SNPs in the erythroleukaemic K562 cell line. This will allow 
future functional analysis of each variant in vitro, providing insight to any effect that these 




5.2.1 KLF1 SNP 
This SNP was identified in a currently unpublished genetic study performed by Professor 
Thein’s laboratory. The study performed Sanger sequencing across the full length of the KLF1 
gene, including introns, in selected patients from their collection of >800 SCA DNA samples. 50 
patients were selected, 25 for having abnormally high HbF, and 25 for having abnormally low 
HbF, with no known cause. The study hypothesised that as a key regulator of the γ-globin to β-
globin switch, novel KLF1 mutations could be causing this strong phenotypic effect. The SNP 
(rs10407416) was overrepresented in the high HbF group (9/25) compared to the low HbF 
group (1/25), and is hypothesised to result in the downregulation of KLF1. 
This candidate SNP (rs10407416) is an intronic C to G substitution, situated 135bp downstream 
of exon 1, in an intron of approximately 900bp. This first intron of KLF1 has previously been 
suggested as a potential downstream regulatory element, and contains highly conserved GATA 
and SMAD5 binding sites, although these are situated approximately 500bp downstream of the 
candidate SNP471. Reporter assays have also demonstrated that inclusion of intron 1 is required 
for optimal expression from the KLF1 promoter471. The site of the KLF1 candidate SNP  
The SNP falls within possible DNA binding sites for transcription factors ZBTB7A and KDM5B 
(as annotated by data from the ENCODE Consortium472,473, Figure 5.1), and it is hypothesised 
that the SNP may disrupt KLF1 expression by interfering with transcription factor binding, 
resulting in de-repression of γ-globin expression. However, upon further inspection of the ChIP-
Seq tracks (Figure 5.1), the signal strength underlying the predicted ZBTB7A binding is 
relatively weak in K562 cells. KDM5B appears to be strongly associated with the full length of 
the KLF1 gene in K562 cells, which suggests a strong involvement with the repression of KLF1 
in these cells. It is not clear whether binding at the specific site of the SNP would be required to 
maintain this pattern. 
Despite the lack of reliable evidence form the ChIP-Seq data that a specific transcription factor 
binding at this intronic site significantly affects KLF1 expression, it was decided that the location 
of a known regulatory element 500bp downstream, as the well as the well-established role that 
KLF1 plays in globin gene expression, was sufficient to warrant further investigation. 
Loss of function of KLF1 has previously been linked to increased HbF levels, and its role in 
regulation of erythropoiesis and the switch from γ-globin to β-globin expression is well 
established, and is described more fully in 1.6.1 and 1.3. As such, we hypothesised that this 
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intronic SNP would reduce KLF1 expression levels, and as a result prevent the efficient switch 
to β-globin expression, accounting for the increased HbF levels observed in this patient. 
 
 
Figure 5.1: Figure showing the full length of the KLF1 gene as viewed in the UCSC Genome Browser 
(http://genome.ucsc.edu - Assembly GRCh37/hg19380). Transcription occurs on the negative strand, and 
the red line indicates the position of the KLF1 SNP (rs10407416) in intron 1. The tracks below show ChIP-
Seq signals for KDM5B, as well as two ZBTB7A replicates in K562 cells. It can be seen that there is a 
strong signal for KDM5B along the length of the gene, but that the signal for ZBTB7A is weak. This data 
was produced as part of the ENCODE Project474, and the tracks for KDM5B, and ZBTB7A have UCSC 
accession numbers wgEncodeEH002085 & wgEncodeEH001620, respectively.  
 
 
5.2.2 ASH1L SNP 
This SNP was identified by a study investigating a large family with heterozygous cases of β-
thalassaemia affecting three generations, that did not associate with genetic haplotype at either 
β-globin or α-globin loci475,476. The study had used Whole Genome Sequencing to analyses two 
affected and two unaffected family members, and identified 15 variants that were then 
sequenced in the remaining 25 family members476. Of these 15 variants, four were present in all 
seven of the affected family members. Two of these genes were found to be expressed in 
human erythroid progenitor cells. LRIG2 was expressed at low levels throughout differentiation, 
whereas increased ASH1L expression occurred shortly before the increase in globin gene 
expression476. The SNP in ASH1L was therefore identified as the most likely candidate to cause 
the b-thalassaemia phenotype. 
 
ASH1L is a histone methyltransferase that tri-methylates H3K4 at actively transcribed genes, 
some evidence also suggests that it mono-methylates and di-methylates H3K36477,478. 
Methylated H3K4 and H3K36 act as positive markers for active transcription, and prevent the 
addition of repressive histone markers such as tri-methylation at H3K27479. ASH1L has 
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previously been shown to occupy promoters at both the α-globin and β-globin like loci, and 
ASH1L shRNA knock down results in loss of H3K4 tri-methylation and transcription at these 
promoters in human erythroid progenitors in an in vitro culture476,480. This suggests a 
mechanism by which ASH1L is recruited to the promoter and gene body of the b-globin gene, 
and tri-methylates H3K4, to respectively initiate and protect active transcription478. It is therefore 
plausible that any mutation impairing either the recruitment or catalytic activity of ASH1L would 
adversely affect b-globin expression, and could cause the observed phenotype. 
ASH1L consists of a SET domain, which performs the methyltransferase function, as well as 
four AT hook motifs, a Bromo-domain and a PHD motif478,481. AT hook motifs bind to DNA, while 
Bromo-domains and PHD motifs are thought to be involved in recognising specific histone 
modifications (acetylated lysine and methylated lysine respectively), suggesting that ASH1L 
activity may also be regulated by the chromatin state482–484. The candidate SNP identified in 
ASH1L (rs151028549) is a T to C substitution, that results in Arginine at position 1615 being 
replaced by Glycine, in a serine rich region. While the SNP is not in close proximity to any of the 
domains previously associated with recruitment or catalytic function, it was selected for further 
investigation due to the strength of the evidence for its involvement in b-thalassaemia, as 
identified by the study.  
Since the ASH1L SNP appears to be the strongest candidate for causing b-thalassaemia in this 
family, we hypothesised that when introduced into K562 cells, this SNP would present a similar 
effect, and would significantly reduce β-globin expression. 
 
5.2.3 K562 Cells as a model for the KLF1 & ASH1L SNPs 
There are several cell systems available for the study of erythropoiesis and globin expression, 
ranging from primary human erythroid cells extracted from peripheral blood or bone marrow, to 
established cell lines such as K562. For this project, K562 cells were chosen for the initial 
functional analyses, since they are well established as a laboratory model, and were thought to 
be less sensitive to the stressful conditions associated with the CRISPR-Cas9 system. This was 
a particularly important consideration, since the main aim of this project was to optimise a 
CRISPR pipeline in the laboratory. 
As was described in detail in 1.4.3 and 3.1, it is possible to culture primary erythroid cells from 
tissue including peripheral blood and bone marrow, and to induce them to differentiate in vitro. 
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While the use of CRISPR-Cas9 to introduce loss of function mutations to these cells has 
subsequently been demonstrated, this results in a genetically heterogeneous population of cells 
with a limited lifespan485. This would not have been appropriate for this project, and it was 
anticipated that the length of time required to introduce specific mutations, rather than targeted 
deletions, would have presented a particular challenge for a short-lived culture. Additionally, 
given our experience of the sensitivity of these cultures (3.1), it was thought that expansion of 
clonal cultures from single cells would have been unlikely to be successful. 
Induced Pluripotent Stem Cells (iPSCs) expressing the globin genes can be derived from 
erythroblasts, and would provide a more stable alternative to working with primary cell 
cultures486,487. This would be especially valuable if we were able to generate iPSCs from the 
erythroblasts of the individual patients themselves, as has recently been demonstrated for a b-
thalassaemia patient, where the causative mutation was subsequently corrected in vitro using 
CRSIPR-Cas9488. This technique would likely be the most informative on the impact of the 
SNPs of interest on globin gene expression, and would be worth pursuing in the future. 
However, due to the technical difficulties associated with generating iPSCs, as well as the high 
stress associated with the CRISPR-Cas9 system, it was decided that the technique should be 
optimised in a less sensitive model initially. 
Another alternative would be the use of already established immortalised erythroblast lines such 
as HUDEP-2, and more recently BEL-A, which retain an erythroblast phenotype, and can be 
induced to differentiate all the way through to terminal erythrocytes489,490. Over the last few 
years, HUDEP-2 has become widely used as an in vitro model of globin regulation and 
erythropoiesis82,85,491. HUDEP-2 cells were investigated as a potential model for use in this 
project, however at the time, our collaborators in Professor Thein’s laboratory were 
experiencing difficulty in reliably culturing these cells, particularly in low cell numbers. It was 
therefore decided, as with iPSCs, that while this would be very informative, and worth pursuing 
in the future, the fact that the CRISPR-Cas9 pipeline had not been used in our laboratory before 
meant that a simpler model should be used first, to optimise the process. 
K562 erythroleukaemic cells were chosen as a robust and easy to culture cell line, with active 
expression form the globin gene loci. K562 is a less accurate model than those discussed 
above, for example due to the fact that KLF1 expression is very low, and expression of g-globin 
is much higher than b-globin, which is more similar to the foetal pattern of globin expression, 
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that our SNPs of interest are hypothesised to replicate67,492,493. Haemoglobin production also low 
in these cells, however can be increased by induction of differentiation, where the cells acquire 
a red/pink colour494. As a cancer cell line that was generated over 40 years ago, K562 also has 
an abnormal karyotype, being triploid for most chromosomes (although this karyotyping may not 
be accurate for our cells, and should be updated), and the relevance of it as a model for 
erythroid tissues is questionable390,495. 
While KLF1 expression is very low in these cells, it was hypothesised that KLF1 expression may 
still change in response to disruption of the putative regulatory region. For investigation of the 
ASH1L SNP, K562 is more appropriate. It had been previously shown that ASH1L binds to the 
both the a-globin and b-globin promoters in K562 cells, and that this correlates with H3K4me3 
at these regions. It was therefore hypothesised that introduction of the ASH1L SNP would 
disrupt either the recruitment or catalytic activity of ASH1L. 
 
5.3 Transfections & Single Cell Sorting 
5.3.1 Nucleofection is the most efficient transfection technique for K562 cells 
Three different transfection techniques were tested for efficiency; Lipofectamine, Calcium 
Phosphate and Nucleofection (2.6.4). K562 cells were sorted into single cell cultures 48 hours 
after transfection, using GFP as the positive marker for successful transfection. A comparison of 
the three transfection techniques is shown in Figure 5.2. Efficiency for the Lipofectamine and 
Calcium Phosphate transfections was very low, ranging from 0.2% to 2.1%. Transfection by 
Nucleofection was also low, but was comparatively higher with a mean efficiency of 15.2% 
despite using half the amount of plasmid of the Lipofectamine transfections, and a quarter of 
that used for the Calcium Phosphate transfections. Different amounts of plasmid were used as a 
result of the different restrictions on reaction volume for each technique. 
All subsequent transfections were therefore performed using the Nucleofection method. 
Because successfully transfected cells were sorted into single cell cultures for clonal expansion, 
the low transfection efficiency did not affect the experimental outcome, since a maximum of 288 
cultures were grown from each transfection reaction (3 x 96 well plates), and even 0.2% of the 




Figure 5.2: Cas9 plasmid transfections in K562 cells. A – Percentage of cells GFP+ 48 hours after 
Lipofectamine transfection with different amounts of plasmid. Transfection rate increased with increasing 
concentrations of plasmid, but was very inefficient, reaching only 2% of live cells. B – Percentage of cells 
GFP+ 48 hours after transfection using the three different techniques. Due to differing restrictions on 
transfection reaction volume for each technique, different plasmid amounts were used: Lipofectamine - 
6μg, Calcium Phosphate - 12μg and Nucleofection - 3μg. Nucleofection was by far the most successful, 
despite using the least amount of plasmid. Error bars indicate standard error, for each of the Lipofectamine 
transfections and the Nucleofection n = 3, for Calcium Phosphate n = 4.  
 
5.3.2 Low K562 viability from single cell cultures 
After the sorting of GFP+ cells into separate wells by FACS, less than 10% of the clonal cultures 
survived. This is shown in Figure 5.3, which summarise survival rates from eight different 
nucleofection experiments, which resulted in the plating of 1,920 single cell sorted cultures, of 
which only 170 survived and were expanded into clonal cell cultures. 
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Figure 5.3: Summary of clonal expansions from 12 nucleofection reactions. 4 where only the Cas9-gRNA-
Template plasmids were transfected, 6 with the plasmids and siRNA for knockdown of the NHEJ pathway, 
and 2 with the plasmids and additional ssODN templates. A – Summary of the 1,920 single cell cultures 
plated, of which only 190 survived. B – Percentage survival for each of the three nucleofection conditions. 
Survival was low for all experiments, but interestingly was lowest when transfected with the plasmid only. 
Error bars indicate Standard Error. 
  
This loss in viability could be due to the hydrodynamic stress associated with the FACS 
process, or as a result of the isolated culture itself, growing in the absence of the growth factors 
usually secreted into the culture medium when cultured in larger numbers398,496,497. The latter 
could be accounted for by culturing in ‘conditioned’ medium, whereby the medium from an 
untransfected K562 culture is removed after 24 hours, filtered to prevent contamination, and 
then used to grow the single cell cultures. 
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5.4 Template Incorporation into Genome 
5.4.1 CRISPR-Cas9 Cleavage Activity is High, but Template Uptake is Low in K562 Cells 
CRISPR-Cas9 experiments were designed to provide the optimal environment for the intended 
outcome, using PAM site disruptions to prevent repeated cutting once the correct variant has 
been introduced, and ensuring that the artificial template was more abundant in the cell than the 
endogenous template, of which there should only be two copies. Despite this, the editing 
process relies on the stochastic action of Cas9 and the endogenous repair machinery within 
each cell, and with one million cells per transfection reaction, a variety of genotypes are 
produced. The broad range of observed genotypes confirms the need to isolate individual cells 
and culture clonal cell lines that can be analysed individually, rather than producing a 
heterogeneous mixture of cells with different genotypes.  
It is difficult to determine the exact mechanism by which any given genotype has been 
introduced into a cell using CRISPR. For example, a cell line homozygous for the desired 
variant may have undergone successful cleavage and template introduction independently on 
both alleles, or only on one allele which then acted as a template for the second. Similarly, for 
cell lines homozygous for the wild type allele, it is possible that no cleavage took place at all, or 
that one allele was cleaved, but that the other allele was used as the HDR template. 
In order to assess the efficiency of the CRISPR-Cas9 experiments based on the genotypes 
produced, some assumptions were made. Firstly, that any cell line with the wild type genotype 
experienced no Cas9 cleavage. Secondly, any cell lines homozygous for a variant underwent 
HDR. And thirdly, any allele other than the wild type or the template was produced as a result of 
NHEJ.  
The results of the genetic screening for successful CRISPR cell lines after transfection with the 
CRISPR-Cas9 plasmids and expansion from single cell cultures are shown in Figure 5.4. These 
results illustrate that Cas9 is being directed to the correct genomic loci and cleaving efficiently, 
with genetic variants introduced in 79.5% of the cell lines screened. However, introduction of the 
SNPs of interest was much less successful, with only 25.8% of these variants including an allele 





Figure 5.4: Summary of genetic analyses of K562 cell lines after transfection with CRISPR-Cas9 Template 
containing plasmids only, after subsequent FACS and clonal expansion. A – Summarises the results for all 
plasmids. B – Shows the results for each plasmid individually. Plasmids used were for KLF1 gRNA 2, SNP 
and PAM only control (KS2 & KP2 respectively), and ASH1L gRNA 1, SNP and PAM only control (AS1 & 
AP1 respectively). Total refers to the number of cell lines that survived the single cell sorting stage. Cut 
refers to cell lines where any genetic changes have occurred, SNP refers to cell lines where the template 
mutations have been introduced on any allele, Hom Cut or SNP refers to cell lines defined as Cut or SNP 
that are homozygous. The results show that the gRNA-Cas9 plasmids cut with high efficiency, but 
introduction of the template is much less successful. Only one cell line was homozygous for a genetic 
variant, and none were homozygous for the SNPs of interest. 
 
Only one cell line was homozygous for a genetic modification introduced by CRISPR, equating 
to 2.6% of all the cell lines screened. This variant was a 10bp deletion at the gRNA cleavage 
site, and the majority of variants observed in all cell lines were also short insertions or deletions. 
These variants are presumably the result of the NHEJ pathway, and are likely so prevalent due 
to the fact that the products are very stable. Using the same rationale as for the PAM site 
disruption mutations, these insertions or deletions either disrupt the PAM site or remove it 
completely. Some deletions also result in the removal of the gRNA target sequence, and are 
very efficient at preventing repeated cleavage by Cas9. 
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The results suggest that NHEJ is occurring much more frequently than HDR in K562 cells, this 
is demonstrated not only by the frequency of insertions and deletions, but by how few of the cell 
lines had homozygous mutations, suggesting that it is rare for the already modified allele to be 
used as a template. 
This highlights one of the main limitations of using the CRISPR machinery for targeted genetic 
editing. While the introduction of DSB by Cas9 is efficient, the endogenous repair machinery is 
relied on to introduce the target mutations, and the efficiency of this varies between cell types 
depending on the activity of the NHEJ and HDR pathways. 
 
5.4.2 siRNA Mediated Knockdown of NHEJ pathway 
Template sequence uptake in K562 cell lines after cleavage by Cas9 was very low. This was 
thought to be due to high activity of the NHEJ pathway, with fewer double strand breaks being 
repaired by the HDR pathway that is required to incorporate the repair template into the 
genome. It was hypothesised that by inhibiting the NHEJ pathway, increased repair through the 
HDR pathway would be observed. This was tested by siRNA mediated knockdown of 
components of the NHEJ machinery, with siRNA transfected simultaneously with the CRISPR-
Cas9 and template containing plasmid. 
 
 
Figure 5.5: rtPCR analysis of NHEJ knockdown by siRNA in K562 cells, normalised firstly to β-actin 
expression, and then to the untransfected control. rtPCR analysis was performed on RNA extracted 48 
hours after transfection with either scrambled siRNA or targeted siRNA. A – Knockdown using siRNA for 
XRCC6. B – Knockdown using siRNA for Ligase IV. Results show reduced expression for both XRCC6 
and Ligase IV, 11.6% and 60.2% of untransfected K562 expression respectively. Expression appears to 
have increased in the scrambled controls, although large variation was observed. Two sets of PCR primer 
pairs were used for each gene targeted, XRCC6-1 & 2 and Lig4-1 & 2, and results are consistent between 
each pair. Error bars indicate 95% confidence intervals, calculated from three biological replicates, each 
with two technical replicates. Knockdown of XRCC6 was statistically significant compared to scrambled, 





In order to inhibit the NHEJ pathway, either the first or the last component of the pathway were 
knocked down, (XRCC6 or Ligase IV respectively). XRCC6 (X-Ray Repair Cross 
Complementing 6, aka Ku70) forms a dimer with Ku80, and this complex recognises and binds 
the dsDNA ends and acts as a scaffold to recruit the other factors of the NHEJ pathway498–502. 
Ligase IV is recruited to the NHEJ complex at the double strand break through interaction with 
XRCC4, and performs the ligation step, re-joining the two ends of the double strand break502,503. 
The results in Figure 5.5 show that knockdown of XRCC6 & Ligase IV by siRNA was successful 
in K562 cells. Cells transfected with siRNA targeting XRCC6 demonstrated a roughly 90% 
reduction in XRCC6 expression, while cells transfected with siRNA targeting Ligase IV had a 
less efficient knockdown of roughly 40%, and did not reach statistical significance. The 
scrambled siRNA controls showed were highly variable for both genes assayed. 
Having tested and confirmed the successful knockdown of XRCC6 and Ligase IV by siRNA, the 
CRISPR-Cas9 plasmids containing the SNP templates were co-transfected with XRCC6, Ligase 
IV or scrambled siRNA. The results of the genetic screening of clonal cell lines arising from 
these transfections are summarised in Figure 5.6. 
It is not clear why the error associated with the scrambled siRNA transfected controls in Figure 
5.5 is so high. Given the small degree of variation observed in the targeted siRNA cultures, and 
the fact that two pairs of target primers were used, it seems unlikely that this is an artefact of the 
rt-PCR itself. It has been shown that non-targeting siRNA can trigger a stress response within 
the cell, which may account for some of the variation that is observed504. If these siRNA 
experiments are used to reduces NHEJ activity in the future, western blotting analysis should be 
run in parallel with the rt-PCR to investigate this variation and confirm that the changes in 
expression are observed at the protein level. 
The results in Figure 5.6 show that Cas9 cleavage activity is not reduced in cell lines co-
transfected with siRNA targeting either Ligase IV or XRCC6, with 75.0% containing a genetic 
variant when transfected with scrambled siRNA, 80.1% for Ligase IV and 88% for XRCC6, with 
an average efficiency of 81.3%. Compared to the 79.5% observed for the data shown in Figure 
5.4 for cells transfected with the CRISPR-Cas9 plasmid only, this demonstrates that siRNA 
transfection does not alter Cas9 activity, despite the fact that limitations to the transfection 
volume mean that half as much plasmid is used during the co-transfection experiments. This 
shows that while the amount of plasmid used for transfection is important for transfection 
efficiency, it has a limited effect on Cas9 activity within the cell. 
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This is important to take into consideration when designing experiments to generate clonal cell 
lines, where only a few hundred individual cells are positively selected for downstream culturing, 
making transfection efficiency largely irrelevant. 
 
Figure 5.6: Summary of genetic analyses of K562 cell lines after transfection with CRISPR-Cas9 Template 
containing plasmids and siRNA, after subsequent FACS and clonal expansion. Total refers to the number 
of cell lines that survived the single cell sorting stage. Cut refers to cell lines where any genetic changes 
have occurred, SNP refers to cell lines where the template mutations have been introduced on any allele, 
Hom Cut or SNP refers to cell lines defined as Cut or SNP that are homozygous. A – Summary of the cell 
lines transfected with each siRNA set: Scrambled, Ligase IV or XRCC6, as well as the cumulative counts 
for all three. B & C – Summary of the cell lines transfected with either KS2 or AS1 plasmids, B shows total 
counts, C shows percentage of total. Results show that co-transfection with siRNA for one of the target 
genes does not appear to affect Cas9 cutting activity, which is consistent between the three groups. No 
homozygous variants were observed after transfection with scrambled siRNA, whereas three were 
observed with siRNA targeting Ligase IV, and one for XRCC6. Overall survival of cell lines past the single 
cell FACS stage is much higher for the KS2 plasmid than for AS1. One of the AS1 cell lines (KAX9) was 
found to be homozygous for the desired SNP. 
 
Interestingly, it appears that cells transfected with the AS1 plasmid have a much lower survival 
rate than for the KS2 plasmid, with 6.3% and 19.8% of single cell sorted cultures surviving 
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respectively. This was also observed in the plasmid only transfections shown in Figure 5.4, 
where the two K2 gRNA containing plasmids, KS2 & KP2 had survival rates of 7.3% and 5.7% 
respectively, compared to the A2 gRNA containing plasmids, which both had 3.6% survival. 
Similarly, a higher percentage of KS2 cell lines showed Cas9 activity (89.5% vs 55.6% for AS2), 
however this was not observed in the plasmid only transfections. 
 
 
While it was shown that siRNA did not impair Cas9 activity, it remains unclear as to whether or 
not knocking down the Ligase IV or XRCC6 influenced the number of homozygous variants that 
were produced, since the success rate was still extremely low. No homozygous variants were 
generated using the scrambled siRNA, compared to 3 for the Ligase IV siRNA and 1 for the 
XRCC6 siRNA, making the HDR rates for each 0.0%, 11.5% and 4.0% respectively, compared 
to 2.6% for the plasmid only transfections from Figure 5.4. A Poisson Test was performed on 
these success rates, using 0.026 (from the plasmid only transfections) as the expected mean. 
The results of this test are shown in Table 5.1, and indicate that siRNA mediated knockdown of 
Ligase IV resulted in a significant increase in the success rate of generating homozygous 
genetic variants in K562 cells. However, due to the extremely low numbers involved in 
calculation of the mean success rates, these tests may not be reliable 
 
Null Hypothesis: λ = 0.026 Scrambled Ligase IV XRCC6 
Number of Cell Lines (n) 24 26 25 
Expected Successes (X = n x λ) 0.624 0.676 0.65 
Observed Successes (O) 0 3 1 
P(O = X) 0.5358 0.0262 0.3393 
 
Table 5.1: Poisson test for significance for the increase in success rate when generating homozygous 
genetic variants using siRNA for Ligase IV or XRCC6. Probability was calculated using the Poisson 
Distribution Calculator made available online at ncalculators.com505. K562 cells transfected with siRNA 
targeting Ligase IV were the only group able to reject the null hypothesis at the significance threshold of 
p<0.05. 
 
Knocking down Ligase IV yielded three homozygous variants for the KS2 plasmid, however 
these were all deletions, and did not contain the SNP of interest. Knocking down XRCC6 
yielded one homozygous variant for the AS1 plasmid, which was found to be homozygous for 
the variant of interest, and therefore can be confirmed to be a successful introduction of the 




5.4.3 ssODN to Increase Template Copy Number in the Cell 
While the results of knocking down Ligase IV may have shown a significant increase in the 
number of homologous genetic variants generated, the success rate was still very low, and the 
rate of successful template incorporation into the genome was even lower. It was thought that 
this was possibly due to the low copy number of the template in the cell, as a result of the low 
transfection efficiency.  
Reducing the amount of plasmid used for transfection was shown to not affect Cas9 activity, but 
reducing the amount of template may affect HDR efficiency. Having the template incorporated 
into the CRISPR-Cas9 plasmid allows selection for successful transfection using GFP 
expression, however it limits the intracellular levels of template to a ratio of 1:1 with the larger 
plasmid. 
 
Figure 5.7: Summary of genetic analyses of K562 cell lines after transfection with CRISPR-Cas9 Template 
containing plasmids and ssODN templates for KS2 or KP2 (ssKS2 or ssKP2), after subsequent FACS and 
clonal expansion. Total refers to the number of cell lines that survived the single cell sorting stage. Cut 
refers to cell lines where any sequence changes have occurred, SNP refers to cell lines where the 
template mutations have been introduced on any allele, Hom Cut or Hom SNP refers to cell lines defined 
as Cut or SNP that are homozygous. A – Total cell line counts. B – Percentage of total. Cleavage was 
observed in all cell lines, and SNP uptake was high. Number of homozygous cell lines remained low, 
however two ssKS2 cell lines were homozygous for the SNP of interest (ssKS2-10 & ssKS2-29). 
 
It was hypothesised that introducing more copies of the template may increase HDR efficiency. 
Short 110bp ssODN templates were used to test this, and were transfected alongside the 
CRISPR-Cas9 plasmids which also contained the template sequences. These short ssODNs 
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have previously been used as a template for HDR alongside Zinc Finger Nuclease (ZFN) 
genomic editing techniques339,347, as well as with the CRISPR-Cas9 system384. 
Since a successful K562 cell line containing the ASH1L SNP had already been generated by 
this stage, only transfections targeting the generation of the KLF1 SNP were carried out. A 
summary of the cell lines generated by these transfections is shown in Figure 5.7, and shows 
that very low viability was observed for the ssODN + KP2 plasmid (ssKP2) transfections 
compared to ssODN + KS2 plasmid (ssKS2), with only 4 of 288 single cell cultures surviving 
compared to 41 of 288 for ssKS2. Interestingly, there was a 100% cleavage rate for the cell 
lines co-transfected with ssODN, and template uptake was observed in 36.6% and 50.0% of 
clones for ssKS2 and ssKP2 respectively.  
Homozygous variant introduction was still low, with only two homozygous clones. However 
these two clones were homozygous for the SNP of interest, and confirmed successful 




5.5 ASH1L mutant K562 cell line KAX9 
5.5.1 Genotype of the K562 ASH1L mutant KAX9 
The cell lines that survived the single cell sorting process were screened by Sanger sequencing 
over the ASH1L SNP site. One successful homozygous cell line was generated for the ASH1L 
SNP (KAX9, Figure 5.8), which was produced by co-transfection of the AS1 plasmid with the 
siRNA for XRCC6. 
 
Figure 5.8: Sequence of the ASH1L SNP site of the K562 cell line that was homozygous for PAM 
disruption mutation and the SNP. K562 shows the wild type untransfected sequence. The green box/arrow 
shows the site of the C to T PAM disruption mutation. The red box/arrow shows the site of the A to G SNP 
of interest. A – MUSCLE alignment of the two sequences, with coding sequence displayed (antisense). 
The two SNPs can clearly be seen in the KAX9 sequence, and it can be seen that the SNP results in an 
arginine to Glycine substitution, while the PAM disruption does not affect the coding sequence. One other 
polymorphism was identified, but by investigating the sequence traces was confirmed to be an artefact of 
the base calling algorithm. B & C – Forward and Reverse sequence traces respectively. Due to the 
presence of large Sanger sequencing artefacts, that persisted despite repeated sequencing, both forward 
and reverse sequence traces are shown, to confirm that the both the PAM disruption and SNP are present. 
 
Sequencing artefacts like those in Figure 5.8 are often seen near the start of sequence traces, 
where large amounts of unbound fluorescent ddNTPs can cause large distortions, however this 
is not believed to be the case here. The site shown is approximately 80bp downstream from 
each sequencing primer, and the sequences both upstream and downstream of this region are 
free from these artefacts for both forward and reverse traces. The fact that these artefacts were 
observed when sequencing was repeated suggests that this is specific to the sequence and 
region, and the fact that it was observed in all cell lines assayed, including the K562 wild type 
controls, confirms that it is not a result of genomic disruption caused by Cas9 cleavage. While it 
is possible that it could be possible to generate cleaner chromatograms by testing different 
primer pairs, it is not necessary, and the clear presence of both the SNP and PAM disruption 
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mutation when sequenced in both directions (Figure 5.8) is sufficient to confirm correct 
incorporation of the template sequence. 
  
5.5.2 rtPCR Analysis of the K562 ASH1L mutant KAX9 
Expression of α-globin, β-globin and γ-globin were found to be significantly increased in the 
KAX9 cell line containing the ASH1L SNP compared to the wild type K562 cells (Figure 5.9). 
This was unexpected, given that the SNP was believed to be causative of β-thalassaemia, and 
it was predicted that K562 cells harbouring the mutation would show reduced expression of β-
globin. KLF1 expression remained unchanged in KAX9 compared to K562, suggesting that this 
global upregulation of globin gene expression was independent of the KLF1 regulatory pathway. 
A previous study investigating shRNA mediated knockdown of ASH1L in human erythroid 
progenitors demonstrated a decrease in globin gene expression, having the opposite effect of 
what was observed in the K562 experiments476. This decrease in globin expression correlated 
with reduced occupancy of ASH1L at the β-globin and α-globin promoters, and a reduction in 
H3K4 tri-methylation at these regions476. 
It is possible that the change in globin expression occurred as the result of the stressful 
CRISPR-Cas9 modification process, which involves high pressure FACS, single cell culturing 
and the introduction of double strand breaks into the genome. The stress involved in these 
processes is demonstrated by the low survival rates observed in 5.3.2, and it has been shown 
that K562 cells can be induced to differentiate under conditions of stress506,507. During stress 
induced differentiation, upregulation of all the globin genes is known to occur. However, this 
increase in globin expression is also accompanied by an increase in KLF1, which was not 
observed in the KAX9 cells (Figure 5.9)506. Similarly, there was no observed change in the 
colour of the KAX9 cell pellet, which for K562 cells turns a pink/red colour when differentiation is 
induced, as a result of increased haemoglobin production494. Due to the absence of these 
established markers of K562 differentiation, it is possible that the observed changes in globin 
gene expression are occurring directly as a result of the ASH1L SNP, since in K562 cells 







Figure 5.9: rtPCR analyses of wt K562 and KAX9 cell lines. Graphs show relative expression of genes 
normalised to actin β, for A – β-globin (HBB), B – γ-globin (HBG), C – α-globin (HBA) and D – KLF1. Error 
bars indicate 95% confidence intervals, calculated from three technical replicates for each of the two cell 
lines. Expression of the globin genes is significantly increased in KAX9 compared to K562, and KLF1 
expression is unchanged. 
 
If the cells are being induced to undergo differentiation, either as a direct result of the SNP, or 
due to stress associated with the genomic editing process (discussed in 5.3), then this could 
account for some of the observed changes, since b-actin levels have been shown to decrease 
during erythroblast development508. A relative increase in globin gene expression would be 
observed if the levels of b-actin RNA were reduced in the KAX9 sample, this could either be a 
direct effect of the ASH1L SNP, a decrease triggered by differentiation in response to stress, as 
discussed above, or even due to degradation of the RNA sample. RNA degradation impairs 
PCR efficiency, and can drastically affect PCR based quantification assays509. Quality of RNA 
samples should be assessed in future to rule this out as a potential cause of the observed 
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affects, this could be assayed using a variety of techniques, including agarose gel 
electrophoresis, NanoDrop, or more sophisticated analysis by Agilent’s Bioanalyzer509. 
With general upregulation of the globin genes, it is difficult to directly detect any changes in the 
levels of β-globin and γ-globin that may be occurring as a result of the ASH1L SNP. To account 
for this, relative expression levels were normalised to α-globin instead of actin (Figure 5.10). 
While α-globin expression was observed to change between the K562 wild type and KAX9 cells 
(Figure 5.9), and it is generally not appropriate to normalise to a gene with variable expression, 
we believe that it is informative in this case. Since expression was increased in each of the 
globin genes, analysis of the changes in expression relative to each other provides insight into 
changes in patterns of expression from the loci separately from the general increase in 
expression that was observed.  
It is worth noting that the other genes at the α-globin and β-globin loci were not assayed in 
these experiments, and may provide useful insight into the pattern of expression changes 
occurring as a result of the ASH1L SNP. If general disruption of transcriptional regulation is 
occurring at these loci, as described above, then it would be expected that the transcriptionally 
repressed z-globin at the α-globin locus, as well as e-globin and perhaps even d-globin at the β-
globin locus would also have increased expression relative to β-globin. 
When normalised to α-globin levels, it appears that relative expression of β-globin was 
increased in KAX9 compared to K562, whilst γ-globin levels were decreased. This is further 
demonstrated by the ratio of γ-globin:β-globin, which is reduced by approximately 50% in KAX9, 




Figure 5.10: rtPCR analyses of wt K562 and KAX9 cell lines, normalised to either α-globin or β-globin 
expression. A – β-globin normalised to α-globin, B – γ-globin normalised to α-globin, C – γ-globin 
normalised to β-globin. Error bars indicate 95% confidence intervals, calculated from three technical 
replicates for each of the two cell lines. Results indicate that relative to α-globin, β-globin increased and γ-
globin decreased in KAX9 compared to wt K562. The ratio of γ-globin to β-globin transcripts also 
decreased in KAX9 cells. 
 
 
One explanation for the increased expression of β-globin in proportion to γ-globin, rather than 
the reverse, which is hypothesised to occur in vivo, is that the wild type K562 cell line strongly 
expresses γ-globin expression, while adult human erythroid cells strongly express β-globin. 
Under these different regulatory states, transcription at the β-globin locus could be affected 
differently by the ASH1L SNP. This would suggest that rather than causing a specific reduction 
in β-globin expression, a more general disruption of transcriptional regulation is observed. This 
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5.6 KLF1 mutant K562 cell lines 
5.6.1 KLF1 CRISPR modified genotypes 
5.6.1.1 KLF1 SNP introduction 
The cell lines that survived the single cell sorting process were screened by Sanger sequencing 
over the KLF1 SNP site. Two cell lines were found to be homozygous for the KLF1 SNP 
(ssKS2-10 & ssKS2-29, Figure 5.11). 
Because of the nature of the SNP, and the fact that it is thought to interfere with transcriptional 
regulation through disruption of a DNA binding site, other cell lines with potentially disruptive 
genotypes were also selected to test this hypothesis. These include ssKS2-47, which was 
heterozygous for the SNP and the wild type allele, which is also shown in Figure 5.11. If 
transcriptional regulation is impaired on one allele, it would be expected that ssKS2-47 would 
present a phenotype similar to that observed in the homozygotes, but with a weaker effect size. 
 
Figure 5.11: Sanger sequencing trances of the KLF1 SNP site of K562 cell lines that incorporated the 
template sequence on at least one allele, and had no indel mutations on either allele. K562 shows the wild 
type untransfected sequence. ssKS2-10 and ssKS2-29 were homozygous for both the C to G PAM 
disruption (green box) and the C to G SNP of interest (red box). ssKS2-47 was heterozygous for both the 
PAM disruption and the KLF1 SNP. 
 
Three other heterozygous cell lines were also investigated: ssKS2-3, ssKS2-4 & ssKS2-45, all 
of which contained indel mutations (Figure 5.12). ssKS2-3 was heterozygous for the PAM 
disruption and SNP of interest, and the other allele contained a CT dinucleotide insertion 2bp 
downstream from the SNP site. This dinucleotide insertion is situated within the gRNA target 
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sequence, and likely disrupted gRNA binding, preventing repeat cleavage and incorporation of 
the target sequence. ssKS2-4 had the same dinucleotide insertion as was observed in ssKS2-3, 
but the other allele was wild type. ssKS2-4 was chosen due to the similarity in genotype with 
ssKS2-3, with the only difference being heterozygosity for the SNP of interest. It was thought 
that ssKS2-4 could be an informative control. 
 
Figure 5.12: Sanger sequencing trances of the KLF1 SNP site of three K562 cell lines that contained 
heterozygous indel mutations. K562 shows the wild type untransfected sequence. The green box shows 
the site of the C to G PAM disruption mutation. The red box shows the site of the C to G SNP of interest. 
Indel mutations prevent clear reading of the sequence from Sanger sequencing traces, since the two 
alleles are out of frame of each other. Therefore to fully characterise the genotypes of these cell lines, 
PCR amplicons were cloned and sequenced individually. (1) and (2) refer to two separate alleles for each 
cell line. ssKS2-3 and ssKS2-4 are both heterozygous for a dinucleotide insertion, and ssKS2-3 has the 
PAM disruption and SNP of interest on the other allele. ssKS2-45 is heterozygous for a 1bp deletion, and 
has the PAM disruption and SNP of interest on the other allele. 
 
ssKS2-45 was heterozygous for the PAM disruption and the SNP of interest, and the other 
allele contained a 1bp deletion of a cytosine 2bp downstream from the SNP site, and likely 
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disrupted gRNA binding similar to the mechanism suggested for the dinucleotide insertion in 
ssKS2-3. 
The three homozygous cell lines that were generated by co-transfection of the KS2 plasmid and 
Ligase IV siRNA were also investigated (KKL8, KKL11 & KKL17, Figure 5.13). Although none of 
these incorporated the template DNA, they each introduced indel mutations around the SNP 
site. KKL8 was homozygous for a 5bp deletion that covered the SNP site, starting immediately 
downstream of the site of the PAM disruption mutation. KKL11 was homozygous for the same 
CT dinucleotide insertion that was heterozygous in ssKS2-3 and ssKS2-4. KKL17 was 
homozygous for a 41bp deletion that extended 18bp upstream of the site of the PAM disruption 
mutation, and 19bp downstream of the SNP site. If the region is required for transcriptional 
regulation, the mutation in KKL17 would be expected to disrupt it.  
 
Figure 5.13: Sequences of the KLF1 SNP site of three K562 cell lines that contained homozygous indel 
mutations. K562 shows the wild type untransfected sequence. The green box/arrow shows the site of the 
C to G PAM disruption mutation. The red box/arrow shows the site of the C to G SNP of interest. A – 
MUSCLE alignment of the 4 sequences. B – Sanger sequencing traces. KKL8 was homozygous for a 5bp 
deletion removing the SNP site. KKL11 was homozygous for a 2bp insertion 2bp downstream of the SNP 




5.6.1.2 KLF1 PAM Disruption Only 
While successful K562 cell lines were generated containing the KLF1 SNP and the 
corresponding PAM site disruption, none of the KP2 plasmid transfections produced cell lines 
homozygous for the PAM disruption only. Two heterozygous cell lines were generated (ssKP2-3 
& ssKP2-4, Figure 5.14), both of which had indel mutations on the other allele. The ssKP2-3 
wild type allele also contained a cytosine insertion 1bp downstream from the SNP site, and 
ssKP2-4 was heterozygous for a 12bp deletion that covered the SNP site and the PAM site. 
These indel mutations both disrupt the gRNA binding sequence. While these may not be as 
relevant as homozygous controls, they could be informative when compared to the cell lines 




Figure 5.14: Sanger sequencing trances of the KLF1 SNP site of two candidate PAM disruption only 
controls. K562 shows the wild type untransfected sequence. The green box shows the site of the C to G 
PAM disruption mutation. Indel mutations prevent clear reading of the sequence from Sanger sequencing 
traces, since the two alleles are out of frame of each other. Therefore to fully characterise the genotypes of 
these cell lines, PCR amplicons were cloned and sequenced individually. (1) and (2) refer to two separate 
alleles for each cell line. ssKP2-3 is heterozygous for the PAM disruption and a 1bp insertion. ssKP2-4 is 




5.6.2 rtPCR Analysis of KLF1 mutant K562 cell lines 
5.6.2.1 KLF1 Expression in K562 KLF1 mutants 
The KLF1 intronic SNP does not appear to directly disrupt KLF1 expression in K562 cells 
(Figure 5.15). ssKS2-10 and ssKS2-29 were the two K562 cell lines homozygous for the SNP, 
while ssKS2-47 was heterozygous for the SNP and the wild type allele. Figure 5.15A shows 
rtPCR analysis of KLF1 in these three cell lines, none of which differ significantly from the wild 
type K562. Although not statistically significant, KLF1 expression actually appears to have 
increased in these cells. The changes in KLF1 expression observed in the other cell lines are 
more interesting, especially since these were included as controls to assess the effect size of 
the SNP.  
Of the three heterozygous cell lines shown in Figure 5.15B, ssKS2-3 and ssKS2-45 were almost 
completely depleted of KLF1 mRNA. As was described in 5.6.1.1, both of these cell lines were 
heterozygous for the KLF1 SNP and indel mutations, a 2bp insertion and a 1bp deletion 
respectively. ssKS2-4 was heterozygous for the same indel mutation as ssKS2-3, and was wild 
type on the other allele, meaning that the only difference between these cell lines was the 
presence of the KLF1 SNP on one allele. Given the clear difference in KLF1 expression levels 
between ssKS2-3 and ssKS2-4, this suggests that the SNP does have an effect, although why 
this is not observed in the absence of an indel mutation on the other allele is unclear. The same 
effect is observed in the ssKS2-45 cell line, where the KLF1 SNP appears to deplete KLF1 
expression when an indel occurs on the other allele. 
Figure 5.15C shows the KLF1 expression of the three cell lines that contained homozygous 
indel mutations. KKL8 had a 5bp deletion, KKL17 a 41bp deletion, and KKL11 had the same 
2bp insertion that was observed in ssKS2-3 and ssKS2-4. All three of the cell lines homozygous 
for indel mutations around the SNP site show significantly decreased expression of KLF1, 
further demonstrating that sequence disruption at this locus impaired KLF1 expression. 
KLF1 expression in the two PAM site disruption cell lines ssKP2-3 and ssKP2-4 are shown in 
Figure 5.15D. Both of these cell lines are heterozygous for the PAM disruption, and an indel 
mutation, a 1bp insertion in ssKP2-3 and a 12bp deletion in ssKP2-4. Reduction in KLF1 
expression was observed in both of these cell lines, but it was only statistically significant in 
ssKP2-3. Given the strength of the reduction in the other cell lines heterozygous for the KLF1 
SNP and indel mutations, this could suggest that the effect of the PAM disruption is lesser than 
that caused by the SNP. However this is not particularly clear, and while the difference in KLF1 
214 
 
expression between ssKP2-3 and ssKP2-4 is not statistically significant, the effect appears to 




Figure 5.15: KLF1 rtPCR analysis of wt K562 and cell lines containing different KLF1 mutant genotypes. 
Graphs show relative expression normalised to actin β, for A – Cell lines containing the KLF1 SNP with no 
indel mutations. ssKS2-10 & ssKS2-29 were homozygous, ssKS2-47 was heterozygous. B – Cell lines 
heterozygous for indel mutations. ssKS2-3 & ssKS2-45 were also heterozygous for the KLF1 SNP. C – 
Cell lines containing homozygous indel mutations. D – Cell lines heterozygous for the PAM site disruption 
and indel mutations. Error bars indicate 95% confidence intervals, calculated from three technical 
replicates for each of the cell lines. KLF1 expression is not reduced in cell lines containing only the KLF1 
SNPs, but is significantly reduced in cell lines containing homozygous indel mutations or heterozygous for 
indel mutations and the KLF1 SNP. ssKS2-3 and ssKS2-45 had extremely low KLF1 amplification, with 
levels the same as in the reverse transcriptase negative controls (not shown). 
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5.6.2.2 Globin gene expression in K562 KLF1 mutants 
Expression of α-globin, β-globin and γ-globin was assayed for each of the KLF1 mutant cell 
lines, the results of which are shown in Figure 5.16. 
For the cell lines containing the KLF1 SNP with no indel mutations, α-globin, β-globin and γ-
globin expression was significantly increased in all three cell lines, but the effect size for β-
globin and γ-globin expression was lesser in the heterozygous cell line ssKS2-47.  
Again, a strong effect was observed in the cell lines heterozygous for the KLF1 SNP and indel 
mutations. ssKS2-3 and ssKS2-45, which were shown to have greatly reduced expression of 
KLF1, were also found to have almost completely silenced expression of α-globin and γ-globin, 
but strongly increased expression of β-globin. While the loss of γ-globin in these cell lines can 
be explained by the fact that KLF1 is required to maintain the chromatin architecture at the β-
globin locus, and therefore expression is lost in its absence, the severity of the change in α-
globin expression is unexpected. KLF1 is a positive regulator of α-globin gene expression, 
binding at the promoter, but does not have the same effect on chromatin structure as is 
observed at the β-globin locus, e.g. Klf1 knockout mice don’t survive past early foetal stages 
due to severe β-thalassaemia, while α-globin expression still persists66,68,510–512. It has been 
suggested that this could be caused by the K562 cells in these clones losing their erythroid 
phenotype, causing the severe reduction in globin expression, contrary to what has been 
observed in the other K562 clones. Further investigation using KLF1 siRNA knockdowns, or 
using the CRISPR-Cas9 system to completely knock out KLF1 in these cells should inform as to 
whether the same effect is observed in response to loss of KLF1, or whether the effect 
observed in these cells is due to more widespread changes. Similarly, other erythroid marker 
genes should be tested in these cell lines, to investigate whether this effect is limited to the 
globin gene expression. The GATA family of transcription factors would be good candidates for 
this analysis, since they are key regulators of haematopoiesis, and since GATA1 is an upstream 
regulator of KLF152.  
The ssKS2-4 cell line, that previously showed no change in KLF1 expression, showed 
increased expression of β-globin and γ-globin, but β-globin  expression was approximately a 
quarter of that observed in ssKS2-3. Similarly, the three cell lines containing homozygous indel 




For the PAM site disruption cell lines, ssKP2-3 which had greatly reduced KLF1 expression, 
also showed strongly reduced α-globin and γ-globin expression, with an increase in β-globin 
levels, following the same pattern as ssKS2-3 and ssKS2-45. ssKP2-4, which showed no 
change in KLF1 levels, also showed no change in γ-globin expression, and had slight but 
significant reductions in levels of α-globin and β-globin. 
It is clear from these results that overall globin expression was increased in the majority of cell 
lines, compared to the wild type K562. Our initial hypothesis was that introduction of the KLF1 
SNP, as well as other sequence disruptions around the SNP site, would reduce KLF1 
expression, and in turn switch expression from β-globin to γ-globin. Since the levels of all three 
of the globin genes assayed were altered in most cell lines, it was decided to compare the ratio 
of γ-globin to β-globin, to estimate the change in proportion of globin transcripts as a result of 





Figure 5.16: Globin rtPCR analyses of wt K562 and cell lines containing different KLF1 mutant genotypes. 
Graphs show relative expression of genes normalised to actin β, for A – α-globin (HBA), B – β-globin 
(HBB) and C – γ-globin (HBG). Error bars indicate 95% confidence intervals, calculated from three 
technical replicates for each of the cell lines. Total globin gene expression appears to have increased in all 
cell lines, apart from ssKS2-3, ssKS2-45 and ssKP2-3, where HBA and HBG decreased, and HBB 






























































































































































































































Comparing the ratios of γ-globin to β-globin expression, it is clear that the two cell lines 
homozygous for the KLF1 SNP result in an increase in the proportion of β-globin transcription 
form the locus. Interestingly this appears to occur independently of any effect on KLF1 
expression. The heterozygous cell line ssKS2-47 was not significantly changed from wild type 
K562 cells. Similarly, the three cell lines containing homozygous indel mutations (KKL8, KKL11 
and KKL17) did not change significantly, despite the marked decrease in KLF1 expression 
observed in these cell lines. 
As was expected, given the clear loss and gain of γ-globin and β-globin expression respectively, 
the γ-globin:β-globin ratio was greatly reduced in ssKS2-3, ssKS2-45 and ssKP2-3 cells. 
Interestingly, ssKP2-4 was the only cell line to show an increase in the proportion of γ-globin 
transcripts. While KLF1 expression did appear to be reduced in ssKP2-4, it was not statistically 
significant. 
 
Figure 5.17: Globin rtPCR analyses of wt K562 and KLF1 mutant cell lines, showing γ-globin normalised to 
β-globin expression. Error bars indicate 95% confidence intervals, calculated from three technical 
replicates for each cell line. 
 
Similarly to the results from the cell line containing the ASH1L SNP (KAX9), the observed effect 
was the opposite of what was predicted. KLF1 is known to be a positive regulator of β-globin, 
and loss of expression was expected to result in down regulation of β-globin and increased 
expression of γ-globin. However, it is possible that the observed results are an artefact of the 
K562 pattern of globin expression, since γ-globin is already highly expressed in these cells. 
From the results generated by this study, it is therefore not possible to conclude whether the 













































































altered γ-globin:β-globin expression, but did not show any significant change in KLF1 
expression, whereas compound heterozygotes with indel mutations on the alternative allele 





5.7 Summary of the CRISPR Genomic Editing Results 
While the preliminary functional analyses performed on the cell lines generated by this work 
were inconclusive, the variants do appear to be having an effect on globin gene expression, and 
future work investigating these cell lines will provide more information. 
More importantly, the results from this chapter demonstrate that we have improved the 
efficiency of our CRISPR genomic editing pipeline, and that we are able to successfully 
introduce specific candidate variants into cell lines in vitro. This pipeline will therefore be used to 
perform functional analyses on the nine candidate genetic modifiers identified by the SCA 




6.1 Isolation of Nucleated Erythroid Progenitors 
6.1.1 In vitro expansion of erythroblasts is not appropriate for use in longitudinal studies 
Initial attempts to isolate nucleated erythroid progenitors from small volumes of peripheral blood 
relied on a two phase in vitro culture to expand the proerythroblast population and then induce 
them to differentiate, with the aim of collecting cells at the late basophilic to polychromatic 
erythroblast stage, when cells are expressing both GPA and CD71.  
In vitro cultures are commonly used in laboratories for testing the effects of drug treatments on 
erythroblastic populations. However, in these studies the treatment is also performed in vitro, 
whereas we intend to perform longitudinal drug treatment studies in vivo, and to collect blood 
samples at set time points throughout treatment, which would then be expanded in vitro for 
analysis. 
The in vitro culturing of erythroid progenitors from peripheral blood was found to be extremely 
unreliable for blood from both healthy donors and SCA patients, with many cultures not 
surviving past the transition into the second phase. The low success rate of these cultures is not 
necessarily problematic for certain types of studies, particularly those where experiments do not 
rely on patient samples and are able to be repeated with minimal inconvenience. However, for 
the purpose of processing small volumes of blood collected from severely anaemic patients at 
specific time points, as was intended for this study, where the effects of HU treatment on the 
methylome were to be investigated, the success rate of this technique was thought to be 
prohibitively low. 
In addition to the low culture success rates, there were also concerns regarding the influence 
the culture system itself could have on the methylome and transcriptome of the erythroblasts. 
Treating cells in vitro with SCF and erythropoietin has been shown to promote γ-globin 
expression over β-globin513,514, mimicking the effects observed under stress erythropoiesis. The 
glucocorticoid receptor, which is the target for dexamethasone, is also involved in induction of 
stress erythropoiesis in mice164. This could potentially complicate elucidating the mechanism of 
action of drugs such as HU in a treatment study, and it may be difficult to draw conclusions from 




6.1.2 CD71+GPA+ cells absent from healthy donors can be isolated from the peripheral 
blood of SCA patients, but lack a nucleus 
A large erythropoietic population was identified in the peripheral blood of SCA (HbSS) patients 
that was absent in the blood samples from healthy donors, as well as less severe SCD 
genotypes (HbSC). These cells were initially observed as a red coloured layer present during 
the isolation of PBMCs, and were identified by flow cytometry to represent a CD71+GPA+ 
population. 
Initial attempts to isolate this cell population using FACS were unsuccessful, with high rates of 
cell death, and a very low yield of DNA and RNA. This was improved through the use of a less 
stressful magnetic bead-based separation technique, depleting PBMC samples of CD45+ cells 
before enriching for CD71+ erythroblasts. The purity of the isolated population was not as high 
when using the magnet bead technique, since the specificity of the FACS process means that 
each cell is sorted on its individual fluorescence pattern, but the RNA yield was significantly 
increased. 
Since CD71 expression in vitro is lost by the end of the polychromatic erythroblast stage, and 
GPA expression starts at the basophilic erythroblast stage (Figure 1.6), this CD71+GPA+ 
population was thought to represent cells between these two stages. Upon further investigation 
it was discovered that these cells were at a much later stage than anticipated, and actually 
represented enucleated reticulocytes. While this explained why the DNA yield from these cells 
was consistently low despite testing several different DNA extraction techniques, it was 
unexpected. 
GPA and CD71 expression is observed on nucleated erythroblasts grown in vitro, and RNA-seq 
of erythroblasts at different stages of differentiation in vitro has demonstrated high CD71 and 
GPA expression at the late basophilic and polychromatic stages, with a marked reduction by the 
orthochromatic stage131,402. However, a cursory literature search into reticulocyte surface 
markers shows that CD71 is commonly used as a marker for immature reticulocytes, and that 
these cells are increased in SCA patients, likely as a result of stress erythropoiesis515–518.  
This suggests that there is discrepancy in surface expression patterns of GPA and CD71 on 
maturing erythroid progenitors grown in vitro and in vivo, and highlights the concerns mentioned 
in 6.1.1 about how the culture may alter erythroblastic development. This is supported by the 
fact that reticulocytes plated in an in vitro culture rapidly lose expression of CD71519.  
223 
 
Even with the CD71+GPA+ cells in vivo being more mature than anticipated, it is surprising that 
no DNA was extracted from this population, given that Walker et al. used the same isolation 
technique to investigate SCA patients before and after treatment with HU, and were able to 
extract DNA from these reticulocyte populations245. Due to the high numbers of cells isolated in 
that study, and the small amount of DNA required for the locus specific bisulphite sequencing 
that was performed, it is perhaps possible that enough DNA was extracted from a very small 
proportion of nucleated erythrocytes. Alternatively, with a purity of >90% after CD71 enrichment, 
this DNA could be provided by contamination of other haematopoietic lineages in the sample245. 
Overall, these results demonstrated that while the cell surface expression markers chosen to 
select for erythroid progenitors at a specific stage were correct for use for the in vitro cultured 
cells, they are not appropriate for the isolation of human erythroid progenitors differentiating in 
vivo. 
 
6.1.3 Isolation of early stage progenitors from the peripheral blood of SCA patients 
Due to the unexpected discovery that the CD71+GPA+ cells had already undergone enucleation, 
it was decided to instead attempt to isolate erythroid progenitors at a much earlier stage of 
development. CD34 is an early stage marker of haematopoietic cells that is lost before reaching 
the proerythroblast stage174. CD34+ cells were successfully isolated, but the total cell numbers 
obtained from 9ml of blood were too low for efficient extraction of DNA and RNA. 
Interestingly, two populations of CD34+ cells were identified, co-expressing either the early 
stage marker CD45 or the late stage marker GPA. This was unexpected given that GPA is 
normally expressed much further down the developmental pathway, after CD34 expression is 
lost. These CD34+GPA+ cells have been documented previously, and are believed to occur as a 
result of stress erythropoiesis, representing a population of progenitors undergoing accelerated 
differentiation, where CD34 downregulation does not occur520. 
Rather than enriching for markers of early stage differentiation, depletion of markers of late 
stage differentiation was found to be more effective. GPA-CD71+ cells were successfully 
isolated, almost all of which were co-expressed with either high or low levels of CD45 
expression, presumably representing the stages of erythroid development prior to the loss of 
CD45. The purity of the GPA-CD45+CD71+ population was lower than that of the CD34+ 
enriched samples, with approximately 83% purity compared to 97%, however the total number 
of cells was much greater, and DNA was successfully extracted from these cells.  
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Using the GPA depletion followed by CD71 enrichment, we were able to obtain suitable 
quantities of DNA from nucleated erythroid progenitor cells directly extracted from the peripheral 
blood of SCA patients, including one patient undergoing HU therapy. Although the reduction in 
purity may affect the sensitivity of downstream analyses, making it more difficult to detect 
smaller changes, we believe that this technique could be used in longitudinal studies and 
provide valuable insight into the mechanism of action of treatments such as HU in erythroid 





6.2 Identification of Candidate Genetic Modifiers of SCA by Whole 
Exome Sequencing 
In addition to epigenetic factors, genetic polymorphisms are known to influence the severity of 
the SCA phenotype, and we also set out to identify novel genetic modifiers by conducting a 
WES study. 
WES is a powerful tool for the identification of novel genetic variants either modifying or 
causative of disease phenotypes. A large number of variations from the reference genome are 
annotated within each individual, the majority of which occur in non-coding regions, since these 
are more tolerant of variation without influencing gene function. This is the case despite the fact 
that the commercially available exome capture kits specifically target protein-coding genes and 
ncRNA, and of the 2,798,560 variants that were annotated from 19 mild SCA exomes in this 
study, 2,662,432 occurred outside of ncRNA and non-protein coding sequences.  
 
6.2.1 Exome Variant Filtering Pipeline 
The remaining 136,128 candidate variants were pared down to 3,159 by the application of a 
series of filtering criteria, designed to remove variants that are unlikely to modify the SCA 
phenotype. These steps included the removal of genes commonly mutated in exome 
sequencing studies, as well as genes that were identified as not being expressed in 
haematopoietic tissues, as identified in publicly available gene expression data. The use of this 
pipeline greatly improved our ability to identify potential candidate variants, and removed many 
of the variants identified by the other analyses conducted in this study, that were thought to be 
false positive results, such as the variant in FSIP2 which was significantly associated with the 
mild SCA patient group, but is only expressed in spermatocytes. 
An imbalance in the representation of ncRNA in the final candidate variant list compared to the 
initial coding variant list was observed, making up 2,563 of the 3,159 variants. The fact that so 
many variants in ncRNAs remain post filtering, despite making up <1% of initial variants suggest 
that the ncRNA are not efficiently targeted by the filtering criteria. The proportion of ncRNA first 
noticeably increases after the filtering out of variants from the severe SCA exomes, rising from 
15.2% to 37.9% and 42.9%. This may be because ncRNA are more tolerant of genetic variation. 
If higher levels of ncRNA variation are observed between the US and the UK SCA populations, 
then that might explain why filtering using the severe US datasets is less effective than it is for 
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variants in the protein coding regions. Similarly, due to the small size of the UK severe SCA 
patient group, fewer of the specific ncRNA variants may be present in this control population. 
During the variant filtering process, two parallel candidate variant lists were generated, with the 
US severe SCA exome group consisting of either the SWiTCH exomes only, or both the 
SWiTCH and TWiTCH exomes. This was undertaken due to concerns about the definition of the 
‘severe’ phenotype group, with SWiTCH participants having already suffered a stroke, whereas 
TWiTCH participants were identified as being at risk for stroke. As such, the SWiTCH 
participants more closely matched the phenotype of the severe patient group recruited in the 
UK. The benefit of including the TWiTCH exomes was that it doubled the size of the severe 
cohort from 137 to 276 exomes, and reduced the final number of candidate variants from 3,159 
to 2,597. 
We believe that the additional filtering power provided by including the TWiTCH exome data 
was not worth sacrificing the strict clinical definition of the severe cohort, and two of the most 
interesting candidate variants identified were excluded when combined with the TWiTCH data. 
Even though one of the SCA patients from the UK severe group had not experienced a stroke, 
they were included based on the severity of the other symptoms at a young age, and based on 
the opinions of our clinical collaborators, whereas no clinical information was available for the 
individual TWiTCH participants. 
We demonstrated that using the variant filtering pipeline developed during this project we were 
able to detect seven putative genetic modifiers of the SCA phenotype, with biologically plausible 
mechanisms to influence the pathology of the disease. The major limitation of this analysis was 
highlighted by the fact that we were unable to directly detect the β0-thalassaemia mutation and 
the novel KLF1 variant due to the fact that they were only present in one patient, and we filtered 
out single occurrence variants. The small sample size of the mild SCA group is therefore the 
limiting factor for detecting rare variants. Both of these variants were identified by specifically 
investigating variants in known modifier genes before the filtering of single occurrences. 
The variant filtering pipeline was also used to generate a list of variants to identify commonly 
mutated genes in the mild SCA patient group. The utility of this analysis was limited, and 
highlighted the ability of ncRNA and some coding genes (such as MUC22) to tolerate large 
genetic variation. Of the protein coding genes containing a small number of variants that 
affected a large proportion of samples, none presented with a biologically plausible mechanism 
by which to affect SCA pathology. Since we were investigating modifier variants, and not 
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variants causative of a disease phenotype, we decided not to select for rare variants during the 
filtering process. The inclusion of common variants generates a high proportion of false positive 
‘hits’ in the analysed genes, and is likely to be one of the reasons why no plausible candidates 
were identified by this analysis. 
 
6.2.2 Differing genetic ancestry between the UK and the US SCA groups 
In the exome sequencing study, all of the mild patient group were recruited and sequenced from 
the cohort at King’s College Hospital in the UK, whereas the severe patient group consisted of 
132 patients recruited as part of the SWiTCH trial from centres across the USA, as well as five 
additional patients from King’s College Hospital. This means that as well as the two test groups 
being defined by severity of disease, they are also separated geographically. There is large 
genetic heterogeneity between different African populations521,522, which can be observed in the 
distribution of the different sickle haplotypes (Figure 1.8). Increased heterogeneity would be 
expected between populations of African ancestry living in the USA and those in the UK, with 
variation arising as the result of the different migration events of different African sub-
populations, as well as due to admixing with other populations in either the USA or the UK. 
The problem of genetic heterogeneity between populations within genetic association studies is 
common, and can be overcome by allelic clustering, stratifying test groups into smaller groups 
based on haplotype522. However, due to the small sample size of the mild group, stratification by 
haplotype was not performed, since any reduction in false positive association would be offset 
further by a reduction in sensitivity to detect associations if the mild group were segregated into 
even smaller subgroups. 
The way to overcome this problem is to vastly increase the number of patients in the exome 
cohort. Future work would benefit from expansion of the sample size for both the severe and 
mild patients within the UK, and also the inclusion of mild SCA patients from the USA. Aside 
from simply increasing the sample number, this would allow a balanced stratification of genetic 
association based on haplotype. 
With the observed association of variants based on genetic ancestry rather than by phenotypic 
severity, it was decided not to perform statistical testing on the candidate variants identified by 
the variant filtering pipeline. In this analysis, the severe exomes were used to generate a 
negative filtering list, where it was assumed that presence of a variant in the severe group 
meant that it was not protective of the severe SCA phenotype, but absence of a variant from the 
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severe group was not assumed to represent positive association with the mild group. Due to the 
design of this analysis, no false positive candidates were introduced as a result of the 
differences in genetic ancestry. While it would be possible to test the allelic imbalance of the 
candidate variants between the two groups using a Fisher’s Exact Test, the results of this test 
would be misleading, since as well as having artificially enriched for variants absent from the 
severe group, the statistical test would be biased by differences in genetic ancestry between the 
two groups. 
 
6.2.3 Statistical testing of association of variants with SCA phenotype groups 
Fisher’s Exact Tests for association of variants with either the 19 mild patients or the 5 severe 
patients recruited from King’s College Hospital only reached statistical significance for seven 
variants, all of which occurred in non-coding regions. This was likely due to the small sample 
size of each group. By including the exomes from the SWiTCH clinical trial in the severe group, 
2,442 variants reached statistical significance (Appendix 8). However, due to the clear bias 
generated by differences in genetic ancestry between the two groups, no candidate variants 
identified by this analysis were considered robust enough to warrant further investigation.   
For the statistical analyses investigating association of variants with either the SWiTCH exomes 
or the HUSTLE exomes, all patients were recruited from SCA populations within the USA, and 
so the bias introduced by differences in genetic ancestry is minimised. This analysis still 
considered the SWiTCH group to represent the severe SCA phenotype, but instead of being 
compared to a small mild group of 19 patients, the HUSTLE group was considered to be 
representative of the general SCA population, and had a much larger sample size of 140 
patients. Using this analysis 236 coding variants reached statistical significance (Appendix 9), 
and we were able to identify candidate variants in genes with biologically plausible mechanisms 
through which to influence the phenotypic severity of SCA.   
 
6.2.4 Candidate Modifier Genes and Variants 
Of the candidate variants identified by the variant filtering pipeline and the comparison of 
SWITCH and HUSTLE exomes, it was decided that seven warrant further investigation. The 
single occurrence variants in KLF1 and HBQ1 were also included, due to the established roles 
that KLF1 and the globin genes have in affecting the SCA phenotype. These nine variants fall 
into four distinct mechanistic groups: Nitric Oxide Signalling, Haematopoietic Regulation, 
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Altered Globin Gene Expression and Recovery from Ischaemic Injury. Future work in the 
laboratory will use CRISPR genomic editing to investigate the effects of these SNPs on gene 
function in vitro. 
 
6.2.4.1 Nitric Oxide Signalling: NMRAL1 
The heterozygous stopgain variant in NMRAL1 was observed in two mild SCA patients. 
NMRAL1 operates in a negative feedback loop with argininosuccinate synthetase, which is rate 
limiting for NO production. Increased expression of argininosuccinate synthetase upregulates 
expression of NMRAL1, which in turn inhibits argininosuccinate synthetase activity425. This 
presents a mechanism by which haploinsufficiency for NMRAL1 could increase 
argininosuccinate activity, in turn increasing NO production and resulting in a vasodilatory 
effect, which could reduce the frequency and severity of vaso-occlusive events. By this 
mechanism the heterozygous stopgain in NMRAL1 could achieve the same outcome targeted 
by arginine therapy262. 
RNAi mediated knockdown of NMRAL1 in HEK293T cells has previously demonstrated an 
increase in NO production425,523. CRISPR genomic editing could be used introduce this stopgain 
into a cell line expressing NMRAL1, allowing confirmation that the variant reduces NMRAL1 
production, and that this results in an increase in NO levels. Since the NMRAL1 variant was 
heterozygous in the mild SCA patients, ideally this mutation would also be introduced into the 
cell line in a heterozygous manner, to confirm that there is no compensation by the other allele. 
The role of NO in the pathophysiology of SCA is currently disputed, so while reconstituting the 
NMRAL1 mutation in a cell line may demonstrate its effect on NO levels, it would not validate its 
effect as a modifier of SCA23. To further investigate this, a SCA mouse model may be used, 
such as the one available from the Jackson Laboratory (www.jax.org -  strain: 003342)524. 
 
6.2.4.2 Haematopoietic Regulation: IGFBP2, FLT3, ETS2, MALAT1 & BAG1 
Variants were identified in five genes that influence the survival and proliferation potential of 
haematopoietic populations. The variants in IGFBP2, FLT3, ETS2 and MALAT1 were identified 
by the analysis using the variant filtering, and would be expected to ameliorate the phenotype 
severity of SCA. The variant in BAG1 was identified by the statistical analysis of variants in the 
SWiTCH and HUSTLE exome groups, and was significantly increased in the SWiTCH group, 
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representing patients that had experienced a stroke at a young age, and so is predicted to 
exacerbate the severity of symptoms. 
There are two main mechanisms by which altered regulation of erythropoiesis could affect 
symptomatic severity of SCA. The first is by altering normal steady state erythropoiesis, where 
increased erythropoietic potential would result in an increased number of sickling erythrocytes 
as well as increasing the concentration of cells in the blood, both of which could lead to an 
increase in vaso-occlusive events. Therefore variants that promote steady state erythropoiesis 
would be expected to increase severity, whereas those that reduce steady state erythropoiesis 
would be expected to ameliorate severity. 
The second mechanism is by altering stress erythropoiesis, where higher production of F-cells 
reduces the amount of sickling observed, and results in a reduction in vaso-occlusive events143. 
Therefore variants that promote stress erythropoiesis would be expected to ameliorate disease 
severity, whereas those that repress stress erythropoiesis would be expected to exacerbate 
phenotype severity. 
These two processes do not exist independently, and it is likely that variants affecting one will 
have an impact on the other. For example, a variant reducing steady state erythropoiesis will 
likely trigger an increase in stress erythropoiesis in response to hypoxia. 
While IGFBP2 also has an intracellular function, both IGFBP2 and FLT3 are targeted for 
secretion, and function as extra-cellular signalling molecules525. IGFBP2 promotes survival and 
expansion of haematopoietic stem cells in the bone marrow, and FLT3 is membrane bound 
tyrosine receptor kinase that stimulates expansion and migration from bone marrow into the 
peripheral blood117,429,437. The variants in IGFBP2 and FLT3 both occur in the N-terminal 
signalling peptide, required for secretion. Since the signal peptides are cleaved, these variants 
are unlikely to have an effect on function, but could interfere with secretion. Introducing these 
variants into cell lines will allow investigation into how localisation of the proteins is affected, and 
could be assayed using fluorescently tagged antibodies, either using fluorescent microscopy or 
in the case of the membrane protein FLT3, flow cytometry. 
ETS2 is a transcription factor important for lineage determination in a number of tissues at 
different stages throughout development, and in Megakaryocyte-Erythroid Progenitors its 
expression is thought to promote the megakaryocyte pathway over erythrocyte development526. 
When overexpressed in K562 cells, ETS2 increases expression of TAL1, but reduces 
expression of the erythroid specific transcription factor KLF1, and subsequently β-globin443. To 
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investigate the effect of the ETS2 variant in vitro, plasmids constitutively expressing either ETS2 
or the ETS2 mutant could be transfected into K562 cells, and expression of both KLF1 and the 
globin genes assayed by rtPCR. Given that loss of function of ETS2 would likely result in an 
increase in erythrocyte production, this variant would be expected to result in a gain of function 
in order to ameliorate the disease phenotype, perhaps enhancing the signal for cells to 
differentiate into megakaryocytes rather than erythrocytes. Alternatively, if a loss of function is 
observed, then it would be assumed that loss of ETS2 function allows greater erythrocyte 
expansion under conditions of stress erythropoiesis. 
MALAT1 is a ncRNA, and is thought to influence haematopoietic development through 
repression of B-MYB, a positive regulator of haematopoietic potential444,446,447. The effect of the 
MALAT1 variant after introduction into a cell line in vitro could be assayed by detecting B-MYB 
expression levels, including rt-PCR of differently spliced isoforms, since MALAT1 is known to 
affect serine/arginine splicing factors445. 
The BAG1 variant occurs in an arginine rich domain, which is only present in BAG1L and 
BAG1S, two of the four alternative splicing isoforms. BAG1L is the only isoform that is recruited 
to the nucleus, and it has been shown that BAG1L mutants lacking residues 17-50 show 
reduced nuclear localisation527. The variant in BAG1 changes glycine at position 45 to arginine, 
and since densely packed positively charged arginine and lysine residues are important for 
nuclear import, it’s possible that this variant could increase efficiency of nuclear localisation528. 
BAG1 markedly increases the anti-apoptotic activity of BCL2, and if nuclear localisation is 
increased as a result of this variant, then it is reasonable to expect that this anti-apoptotic effect 
would be increased as well529,530. Apoptosis plays an important role in regulating the rate of 
haematopoiesis, and limits the number of progenitor cells that reach full maturity, BCL2 plays an 
important role in this process, and overexpression in mice more than doubles the number of 
HSC in the bone marrow531. Interestingly the balance of BCL2 to BCL-X appears to influence 
lineage commitment, with higher BCL2 promoting the granulocyte lineages, and BLC-X 
promoting the erythroid lineage. This affect is thought to be mediated by RAF-1 expression 
levels532.    
Introduction of this variant into a cell line by CRISPR genomic editing will allow investigation into 
the effect that the variant has on intracellular localisation of BAG1. It would also be interesting to 
investigate whether the variant has an effect on survival, particularly when cultured in the 
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presence of pro-apoptotic factors. Quantification of RAF-1 expression in these cell lines could 
determine whether or not the BAG1 variant influences BCL2 directed lineage commitment. 
 
6.2.4.3 Altered Globin Gene Expression: KLF1 & HBQ1 
Variants were identified in two genes affecting globin gene expression and function. Variants in 
KLF1 and HBQ1 were exclusive to the mild SCA patient group, but each only occurred in a 
single patient, and so the presence of these variants in other mild SCA patients should be 
confirmed before laboratory investigation. 
The effect that altered expression from the globin gene loci can have on the phenotype severity 
of SCA is well established, and is described in 1.6. The main principle behind this mechanism is 
that polymerisation of haemoglobin only seems to occur in the HbS (α2βS2) tetramer, and 
increasing the abundance of other globins introduces competition for tetramer formation 
between the different subunits, diluting the intracellular concentration of HbS and in turn 
reducing rates of erythrocyte sickling. 
The KLF1 variant is a novel SNP identified in one of the mild SCA patients, and was not 
observed in any of the other SCA exomes or in dbSNP533. The SNP results in an arginine 
replacing the histidine at position 329, which is involved in coordination of the Zn2+ ion in one of 
the three zinc finger domains534. The variant was heterozygous, and so could exhibit an effect 
similar to haploinsufficiency for KLF1, which is known to increase γ-globin and ameliorate the 
SCA phenotype535. The patient in which this was observed also had the highest HbF% of all the 
patients investigated. This variant could be investigated by introducing the SNP into a cell line 
using CRISPR genomic editing, and assaying for changes in the γ-globin:β-globin expression 
ratio. 
HBQ1 encodes θ-globin, and due to the fact that expression from the gene is minimal, it seems 
unlikely that any variant affecting gene function would have an impact on SCA phenotype. 
However, the variant occurs approximately 90bp downstream from the transcription start site, 
and falls within binding sites for multiple transcription factors, including CTCF and 7BTB7A (as 
annotated by data from the ENCODE Consortium472,473), and could potentially disrupt regulation. 
Introducing this variant into a cell line using CRISPR will allow detection of any upregulation of 
HBQ1 expression, if this is not observed then it can be assumed that the SNP does not 
influence disease phenotype. An alternative strategy would be to directly assay the blood of this 
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patient, and to determine if abnormal levels of θ-globin are observed at the protein level in 
erythrocytes. 
 
6.2.4.4 Recovery from Ischaemic Injury: MYDGF 
Vaso-occlusive events are responsible for the most severe symptoms associated with SCA. 
While factors affecting the ischaemic response would not be expected to prevent these vaso-
occlusive events from occurring, the long term effects of these events could be ameliorated by 
an efficient response, reducing levels of cell death and tissue damage experienced by 
minimising the amount of time that affected areas remain starved of oxygen. Many SCA patients 
experience silent vaso-occlusive events in the brain, that occur in minor blood vessels and 
present with minimal phenotype, and are typically not diagnosed in the clinic 536–538. It is perhaps 
possible that impaired ischaemic repair pathways could increase the severity of these events, 
increasing cell death and the resultant inflammatory response to the extent where they become 
observable and present as an overt clinical stroke. 
The variant observed in MYDGF was significantly increased in the SWiTCH study group 
compared to the HUSTLE group, and so would be expected to increase severity of the SCA 
phenotype. MYDGF (Myeloid Derived Growth Factor) is a growth factor initially identified by its 
function in myocardial cell growth and survival following myocardial infarction, which stimulates 
its secretion by monocytes and macrophages466. Mice deficient for MYDGF have no discernible 
phenotype until myocardial infarction is induced, and then demonstrate increased scarring and 
reduced angiogenesis at the infarction site, as well as reduced systolic and diastolic function466. 
MYDGF mediated protection against cell death in mice was found to be dependent on the PI3K 
signalling pathway, and so the effect of the variant on MYDGF function could be investigated by 
introducing this SNP to a cell line in vitro using CRISPR, and assaying for PI3K activation by 
western blot for phosphorylation of PI3K as well as downstream targets BAD and BAX, 





6.3 Generation of Mutant K562 Cell Lines and Preliminary Testing of 
Variants in KLF1 and ASH1L using CRIPSR-Cas9 Genomic Editing 
We successfully introduced both the ASH1L and KLF1 SNPs into K562 cell lines in vitro, using 
CRISPR-Cas9 genomic editing.  
gRNA directed introduction of DSBs at the target sites by Cas9 was reliable, but survival rates 
of single cell K562 cultures were low, and template incorporation by the endogenous DNA 
repair pathways was inefficient. As a result this process took significantly longer than was 
anticipated, relying heavily on the stochastic chance of correct template incorporation on both 
alleles. This highlights some of the current limitations of CRISPR for genomic editing, firstly in 
that the endogenous repair machinery strongly favours the NHEJ pathway, and secondly that 
until correct template incorporation is much more efficient, cell populations must be expanded 
from a single cell in order to generate a genetically homogenous population.  
However, through optimisation of the CRISPR-Cas9 protocol, we increased efficiency of 
template uptake, and demonstrated that we are able to generate the desired mutations in cell 
lines in vitro. This CRISPR genomic editing pipeline will therefore be used in future to validate 
the candidate genetic modifiers identified by the exome sequencing study. 
While the work in this thesis was focussed on introducing variants into K562 cells, this 
technique could also be used in other cell lines. It would be particularly interesting to introduce 
variants of interest into HUDEP-2 cells, a recently established human erythroid progenitor cell 
line that can be induced to develop into terminally differentiated erythrocytes489. 
 
6.3.1 Low transfection efficiency and low survival rates of single cell K562 cultures 
Transfection efficiency was very low, and even nucleofection, which proved to be the most 
effective technique only resulted in 15% of cells taking up the 9.8kb Cas9 plasmid. It is not clear 
why this was the case, but ultimately it did not affect the results since a maximum of 288 cells 
from each transfection experiment were isolated by FACS. 
In order to improve the transfection efficiency in future experiments, more modern nucleofection 
protocols should be investigated. The Nucleofector™ 2b, which was used in this project, was 
first introduced in 2001, and uses a cuvette based system, with the current applied to a 500µl 
cell suspension. More modern nucleofection machines, such as the Neon® Transfection 
System (first introduced in 2006), and the 4D-Nucleofector™ (first introduced in 2010), work 
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with much smaller volumes of cell suspension, and increase both cell viability and transfection 
efficiency539. Comparing the Nucleofector™ protocols for K562 cell nucleofection, available on 
the Lonza Cell and Transfection Database, it appears that using the 4D-Nucleofector™ rather 
than the older Nucleofector™ 2b, increases efficiency from approximately 77% to >90%, and 
they report >95% cell viability540. It is worth noting that the plasmids used to test these protocols 
were approximately 2.5kb, and are much smaller than the plasmids used in our CRISPR-Cas9 
system. While the low transfection efficiency was not a major issue for the aims of this study, as 
mentioned above, it is possible that the additional stress associated with this nucleofection 
technique had an adverse effect on cell survival in the downstream stages of the process. 
After the transfection and FACS process, very few cell lines (170/1920) survived the single cell 
culture stage. It is believed that this was due to the stress involved in these processes, which 
could perhaps be avoided in future through the use of conditioned medium during the single cell 
culture phase, and by replacing the FACS process with serial dilutions to obtain single cell 
cultures instead398. However, while reducing the mechanical stress associated with FACS, the 
serial dilutions would not allow for selection based on expression of the GFP reporter, and also 
would not guarantee a single cell culture. Since the process assumes that the cells are evenly 
distributed throughout the medium, whereas in practice some aliquots would contain more than 
one cell, and others would contain none. Given the low transfection efficiency, this would mean 
that approximately only 15% of the cultures expanded would have taken up the plasmid, and 
any cells demonstrating two different genotypes could not be assumed to be heterozygous, but 
could represent two distinct cell populations within the same culture. 
If the transfection efficiency can be increased through the use of more modern nucleofection 
techniques, then serial dilution should be considered to increase cell viability. Even with the low 
number of clones that survived in this study, the genotype screening process was the rate 
limiting step, with PCR amplification and Sanger sequencing being carried out for each clone. 
With increased viability of single cell cultures, in the future it would be more efficient to introduce 
a pre-screening step to assess the genotypes of the transfected population prior to separation 
into single cell cultures, using a technique such as TIDE541. This would provide an accurate 
estimate as to whether or not the genome-editing process has generated the genotypes of 
interest for each transfection, and therefore whether the experiment is likely to yield the desired 
cell lines. Recognising extremely low success rates at this stage would avoid spending weeks 
expanding and sequencing unsuccessful single cell cultures, when the time could be better 
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spent optimising the CRISPR/Cas9 process. Additionally, the process of screening the 
individual clones could be streamlined, by initially performing restriction enzyme based analyses 
such as RFLP of RGEN on all clones, which would be faster than Sanger sequencing542. 
Individual clones that indicate a disruption of the recognition site could then be validated by 
sequencing. 
The survival rates of the cell lines varied depending on whether they were transfected with the 
plasmid only, or co-transfected with either siRNA or ssODN. Counter-intuitively, the cells 
transfected with only the plasmid had the lowest survival rates, whereas cells co-transfected 
with siRNA targeting Ligase IV or Ku70 had the highest rates of survival, despite the fact that 
both of these genes have been shown to have anti-apoptotic effects543,544. Due to the limitations 
on transfection volume, half as much plasmid was used when co-transfected with either siRNA 
or ssODN which may explain the observed effect, since K562 have previously been reported to 
demonstrate reduced viability after transfection with increasing plasmid concentrations545. 
Therefore lowering the plasmid concentration, while having an adverse effect on transfection 
efficiency, could increase survival in these cells. 
 
6.3.2 siRNA Knockdown of the NHEJ Pathway 
siRNA knockdown was performed on components of the NHEJ pathway in order to promote the 
HDR pathway for repair of the DSBs introduced by Cas9. Rates of HDR were still very low in 
these experiments, but was significantly increased in the knockdowns of Ligase IV, which 
generated three homozygous cell lines. However, none of these cell lines had incorporated the 
template sequence, and this was only achieved in the homozygous cell line generated by the 
Ku70 knockdown experiments. Despite the statistically significant increase in HDR, the rate at 
which it occurred was still very low, and due to the small sample size the test is quite unreliable, 
since introducing just one homozygous variant into the plasmid only group would be enough to 
completely remove any significance. 
The fact that HDR was found to be significantly increased in the Ligase IV knockdown but not 
the Ku70 knockdown could be due to an alternative NHEJ pathway that has recently been 
suggested. Fattah et al. found that NHEJ activity was lost in the absence of Ligase IV, but not 
Ku70, and that loss of Ku70 was sufficient to rescue NHEJ activity in the absence of Ligase 
IV501. They suggested that an alternative pathway compensates for the loss of the canonical 
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NHEJ pathway, but that it is unable to function in the presence of Ku70, which binds to the DSB, 
and could be out-competing this alternative pathway501. 
It is also possible that the small increase in HDR that was observed is the result of the 
inefficiencies of siRNA knock down, which only degraded approximately 50% of the Ligase IV 
transcripts. Knocking out as well as knocking down individual components of the NHEJ pathway 
has been investigated in silkworms, and demonstrated that full gene knockouts had a stronger 
effect on HDR frequency than siRNA knockdowns354. However, the advantage of using the 
siRNA knockdown technique is that its effect is transient, allowing the cells to recover after a 
short period of time. This allows us to reduce activity of the NHEJ pathway during the post 
transfection window, but does not lead to the long term genomic instability observed in stable 
knockouts, which would reduce the viability and reliability of our cell lines in the long term. 
 
6.3.3 Increasing Template Uptake 
ssODN templates were co-transfected alongside the plasmids in order to increase the 
intracellular copy number of the template sequence, as it was thought that this could be a 
limiting factor for template uptake. In the case of the plasmid only transfections, the template 
was present at a 1:1 ratio with the plasmid, and was therefore limited by the low transfection 
efficiencies observed. 
Co-transfecting with ssODN templates did not affect the rate of HDR, which remained at similar 
levels to those observed previously. However, the rate of template uptake was greatly 
increased, with 37.8% of cells either the heterozygous or homozygous for the SNP of interest, 
compared to 14.7% of the cells co-transfected with siRNA. Co-transfection with the ssODN 
templates generated two cell lines that were homozygous for the SNP of interest. 
Alternative techniques are available to increase template uptake, but were not tested in this 
project. These include the use of paired gRNA, which can be used to excise a large genomic 
fragment, forcing the cell to use the artificial template for repair. This is recommended for 
genomic editing of larger regions546. Using ssODNs with phosphorothioate modified ends can 
also greatly increase template incorporation, likely due to increased stability and protection from 
degradation547. Since the ssODNs used in this project were not protected from degradation by 
phosphorothioate modification, it is likely that the amount of intracellular ssODN template is 
reduced rapidly following nucleofection. Coupled with the fact that the gRNA and Cas9 were 
provided by a plasmid, and therefore must be generated within the cell after nucleofection, it is 
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possible that by the time Cas9 induced DSBs are introduced, the levels of template are already 
very low. This could be overcome by the direct nucleofection of Cas9/gRNA ribonucleoprotein 
complexes (RNPs) alongside the phosphorothioate modified ssODNs548,549. This might also 
address the low transfection efficiency observed with the large plasmids in this study.    
Interestingly, It has recently been observed that gRNA targeting the strand antisense to 
transcription result in increased rates of HDR compared to those targeting the transcribed 
strand340. Similarly, it has been shown that Cas9 releases the strand non-complementary to the 
gRNA earlier, and therefore ssODN templates complimentary to this strand (i.e. complementary 
to the gRNA), can bind at an earlier stage and increase rates of HDR470. In the same study, it 
was also demonstrated that asymmetric ssODN design can increase HDR efficiency, with 
homology arms of 36bp and 91bp on the PAM distal and proximal sides of the DSB 
respectively550.   
 
6.3.4 Is the ASH1L SNP likely to cause β-Thalassaemia in patients? 
It was hypothesised that introduction of the ASH1L SNP would reduce expression of β-globin in 
K562 cells, since the SNP was initially identified as a candidate causative mutation for β-
thalassaemia. However, the results presented here suggest that the SNP had the opposite 
effect, increasing expression of both α-globin and β-globin, whilst reducing expression of γ-
globin in the KAX9 cell line. If this SNP has the same effect in vivo, then it is unlikely to be 
causative of β-thalassaemia. 
However, it is possible that effect of the ASH1L SNP in vivo is less specific to the reduction of β-
globin expression, but instead has a more general effect disrupting regulation at the β-globin 
locus. Globin expression in K562 cells is more similar to that found at earlier stages of 
development, before the foetal globin to adult globin switch, with high levels of γ-globin 
expression, and low levels of β-globin. A possible model to explain the results observed could 
be that loss of targeted H3K4 tri-methylation at the γ-globin promoters disrupted the strength of 
the regulatory control, allowing increased transcription from the other promoters in the locus. 
This would account for the difference in our results compared to the effects previously observed 
in ASH1L shRNA knock downs carried out in human erythroid progenitor cells in vitro476. 
This model is further supported by the fact that ASH1L occupies the LCR in mice478, and is likely 
recruited to the promoter of the active globin gene by chromatin looping, meaning that 
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disruption of function would affect transcription of the globin gene that is being upregulated at 
each developmental stage, and would not necessarily be specific to either β-globin or γ-globin. 
It has also been found in K562 cells that H3K4 tri-methylation is associated with the active γ-
globin promoters, while H3K4 at the β-globin promoter is predominately mono-methylated, 
which also supports this explanation of the results551. 
To further understand the effects the ASH1L SNP has on β-globin expression in K562 cells, 
additional analyses will be carried out on the KAX9 cell line by the laboratory in the future, 
specifically using Chromatin Immunoprecipitation (ChIP) to assess any changes in ASH1L 
occupancy at the locus, as well as changes in H3K4 methylation patterns. Since little is known 
about the function of the serine rich domain in which the SNP is situated, it is not known 
whether to expect to observe a loss of recruitment of ASH1L to the locus, or whether occupancy 
will remain unchanged, but with catalytic activity impaired. 
 
6.3.5 Is the KLF1 SNP likely to affect HbF levels in patients? 
The analysis of the KLF1 mutant cell lines that were generated did not provide a clear answer to 
whether or not the KLF1 SNP affects KLF1 expression. Cell lines either homozygous or 
heterozygous for the SNP showed no significant change in KLF1 expression, which suggests 
that the mutation is unlikely to be influencing phenotype. However, when an insertion or deletion 
occurred on the other allele, a strong reduction in KLF1 expression was observed, but only in 
the presence of the SNP. Given both of these results, it seems that the KLF1 SNP is not 
sufficient to affect KLF1 expression on its own, but only when the alternative allele is impaired. 
KLF1 expression was also reduced in the case of homozygous insertions or deletions, 
suggesting that these were sufficient to reduce KLF1 expression. However, in the cell line with 
the wild type allele and the same insertion on the other allele, no change in KLF1 expression 
was observed, which could be explained by a compensatory mechanism, active on the wild type 
alleles but ineffective on alleles with the KLF1 SNP. A possible candidate for a feedback 
mechanism could be ZBTB7A, the binding site of which encompasses the site of the KLF1 SNP, 
and is itself positively regulated by KLF182,473,552. While a model such as this would explain the 
results in this study, no such mechanism has been documented elsewhere. Patients with KLF1 
haploinsufficiency caused by large scale deletion encompassing the entire KLF1 gene present 
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with high HbF expression, demonstrating that reduced KLF1 expression is not compensated for 
in these patients535. 
While the cell lines that were homozygous for insertions or deletions at the SNP site showed 
demonstrated a reduction in KLF1 expression, this did not correlate with changes in γ-
globin:β:globin ratio. Interestingly, KLF1 expression was reduced to approximately the same 
extent in the cell line with heterozygous insertion and PAM disruption (ssKP2-3), and in this cell 
line a strong reduction in γ-globin:β-globin was observed, similar to that observed in the cell 
lines where KLF1 was almost completely silenced. It is not clear why cells with similar KLF1 
expression levels would be discordant with regard to globin expression. 
Reduction of KLF1 is expected to reverse the γ-globin to β-globin switch, and so in the cell lines 
where KLF1 was almost completely depleted, it was initially surprising to observe such a strong 
effect in the opposite direction. However, this can be explained by the fact that low levels of 
KLF1 are known to be required for maintenance of the chromatin architecture at the globin loci, 
with the activation of β-globin occurring at higher KLF1 concentrations57,68. Therefore the 
complete loss of KLF1 explains the severe reduction of highly expressed α-globin and γ-globin. 
This has been observed previously in K562 cells following KLF1 knockdown57. Unfortunately 
this does not account for the increased expression of β-globin, which may be occurring as a 
result of destabilisation of the chromatin architecture at the locus, similar to what is 
hypothesised in the case of the KAX9 cell line containing the ASH1L SNP. 
The fact that KLF1 expression in K562 cells is minimal accounts at least in part for the 
phenotype of high γ-globin expression observed in these cell lines, especially since it has been 
shown that exogenous expression of KLF1 & BCL11A can rescue β-globin expression in K562 
cells492,493,553.  
This explains the high variability observed in the rtPCR experiments targeting KLF1 in Figure 
5.15, since at these low levels, even very minor fluctuations in transcript levels can result in 
large relative changes. The absence of KLF1 expression also provides an explanation for why a 
reduction in β-globin expression was not observed in the majority of cell lines containing the 
SNP. Since very low level KLF1 expression is required for maintenance of the chromatin 
architecture at the β-globin locus (1.3.1), this would also support the hypothesis that basal 
expression of KLF1 in K562 cells is maintaining expression of γ-globin, and that this is lost in 
the cell lines where KLF1 was completely ablated.  
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As well as being controlled at the transcriptional level, KLF1 is also subject to post-translational 
regulation, including SUMOylation, phosphorylation and ubiquitination554,555. This suggests that 
even the low levels of expression observed here may not accurately inform on the levels and 
functional activity of KLF1 protein in the cell. To accurately assess this, western blotting 
experiments should be conducted to inform on the affect that the KLF1 SNP has on protein 
levels, as well as ChIP experiments to inform on how this affects KLF1 binding activity at the 
globin loci. 
It could also be interesting to induce differentiation of these modified K562 cell lines by 
treatment with hemin. Induction of differentiation in K562 cells is accompanied by increase in 
expression of the globin genes, as well as KLF1, and it would be interesting to see if KLF1 
expression occurs to the same extent in cell lines with the SNP of interest506. 
As has been discussed, K562 cells are probably not the most useful cell system to model these 
SNPs in vitro, especially for KLF1. Now that we have successfully introduced the SNPs into 
K562 cells, and have improved the efficiency of the CRISPR-Cas9 pipeline in our laboratory, 
future work should focus on implementing this in more sensitive cell types. While this will likely 
require further optimisation of the technique, several potential ways to do this have been 
discussed in this chapter. This should probably focus on BEL-A initially, which is preferable to 
HUDEP-2 since it expresses b-globin without requiring differentiation, and is therefore a better 
model to study the impact of these SNPs on the regulation of adult haemoglobin490. The 
possibility of generating iPSCs from the patients in which the SNPs were initially identified 
should also be investigated, since it would be very informative to see if correcting the SNPs in 






6.4 Concluding Remarks 
Although we were unable to conduct our investigation into the effect that HU treatment has on 
the epigenome of SCA patients, we propose a technique by which CD45+CD71+GPA- erythroid 
progenitors can be isolated directly from the peripheral blood. This technique yields sufficient 
DNA to perform epigenomic analyses from small quantities of blood, and will allow future 
longitudinal studies investigating the mechanism of action of drugs such as HU in SCA patients 
in vivo. 
Through WES analyses, using the variant filtering pipeline that we developed as well as the 
statistical comparison of the SWiTCH and HUSTLE exome groups, we identified nine potential 
modifiers of SCA that warrant further investigation.  
Functional validation of genomic variants in vitro has been facilitated by recent advances in 
genomic editing technologies, and provides a powerful tool to test more specifically whether a 
given variant is likely to affect gene function. We demonstrated that we are able to use a 
CRISPR-Cas9 system to successfully introduce specific mutations into cell lines, and will use 
this for validation of the nine candidate variants identified by the WES analyses.  
The identification and validation of novel candidate variants affecting the phenotype severity, as 
well as mechanisms underlying the response to treatment, is crucial for advancing our 
understanding the complex pathophysiology of SCA, and may provide useful diagnostic 
indicators of risk for severe symptoms such as stroke. Particularly as Next Generation 
Sequencing techniques become cheaper and more easily available for use in the clinic, custom 
DNA capture arrays could be designed to sequence all known modifier genes in patients shortly 
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Full gene maps of the ASH1L and KLF1 genes (A & B respectively), adapted from the UCSC Genome Browser (http://genome.ucsc.edu - Assembly GRCh37/hg19380). PCR amplicons 
for template regions amplified for cloning into CRISPR-Cas9 plasmids are annotated. ASH1L gene spans a much larger area, and contains many exons. Structure of the KLF1 gene is 






CRISPR-Cas9 Plasmid Sequence. 20bp variable gRNA target sequence is highlighted in blue, with the 
conserved regions of the gRNA SDM primers highlighted in yellow. The BssHII restriction enzyme site 
used for template DNA insertion is shown in magenta. Cas9 sequence is shown in red in bold, and the 


















































































































































List of SDM primers used to substitute gRNA sequences into CRISPR-Cas9 plasmids. 10bp variable 




























XRCC6 & LIG4 siRNA and rtPCR Primer Sequences. siRNA were purchased from Origene. rtPCR primers 
for Ligase IV, XRCC6 and KLF1 were designed using Primer3Plus385, and rtPCR primers for Actin β, α-
globin, β-globin and γ-globin are the same as those used by Mabaera et al. (2007)550. 
 
siRNA Sequence Ref Number 
Ligase 4   
siLIG4-A AGCUCAUACUAAGAAUGAAGUAATT SR302689A 
siLIG4-B UCAAUAGACAAGUGUGAAUUACAAG SR302689B 
siLIG4-C AGAAUGGCCUAUGGAAUUAAAGAAA SR302689C 
   
XRCC6   
siXRCC6-A GCGCCAAAGUGAGCAGUAGCCAACA SR301689A 
siXRCC6-B GUUCUAUGGUACCGAGAAAGACAAA SR301689B 
siXRCC6-C CGAGGGCGAUGAAGAAGCAGAGGAA SR301689C 
    
    

































Primers used for Sanger sequencing over the site of the SNPs of interest in KLF1 and ASH1L. 
 












List of the 11 Fantom5 expression datasets used to generate the list of ‘haematopoietically silent’ genes. 
Fantom5 data - Tissue Sources 
Bone Marrow, Adult 
CD34 cells differentiated to erythrocyte lineage, Biological Replicate 1 
CD34 cells differentiated to erythrocyte lineage, Biological Replicate 2 
CD34+ stem cells - adult bone marrow derived 
Fetal Liver, Pool 1 
Peripheral Blood Mononuclear Cells, Donor 1 
Peripheral Blood Mononuclear Cells, Donor 2 
Peripheral Blood Mononuclear Cells, Donor 3 
Whole Blood (ribopure), donor 090309 
Whole Blood (ribopure), donor 090325 
Whole Blood (ribopure), donor 090612 
 
